While O O 0.9998465776443481
the O O 0.9999911785125732
elevations O O 0.9999860525131226
of O O 0.9999916553497314
the O O 0.9999943971633911
upper O O 0.999496579170227
lid O O 0.9986989498138428
margin O O 0.9999707937240601
in O O 0.9999994039535522
most O O 0.9999954700469971
subjects O O 0.9999048709869385
were O O 0.9999984502792358
not O O 0.9999980926513672
more O O 0.9999988079071045
than O O 0.9999973773956299
2 O O 0.9999116659164429
mm O O 0.9998389482498169
and O O 0.9999904632568359
did O O 0.9999988079071045
not O O 0.999998927116394
cause O O 0.9999991655349731
noticeable O O 0.9999964237213135
change O O 0.9999957084655762
in O O 0.9999996423721313
appearance O O 0.9999849796295166
, O O 0.9999978542327881
one O O 0.9999861717224121
subject O O 0.9999979734420776
suffered O O 0.9999994039535522
from O O 0.9999969005584717
mechanical O O 0.9992709755897522
entropion O O 0.6732065677642822
and O O 0.9998682737350464
marked O O 0.999967098236084
corneal O O 0.9993011951446533
abrasion O O 0.9921791553497314
3 O O 0.9992293119430542
hours O O 0.9999980926513672
after O O 0.9999984502792358
instillation O O 0.9995001554489136
of O O 0.999908447265625
the O O 0.9984902143478394
medication O O 0.9998898506164551
. O O 0.9999978542327881

This O O 0.9998737573623657
patient O O 0.9999815225601196
underwent O O 0.9999988079071045
a O O 0.9999923706054688
10 O O 0.9961097836494446
- O O 0.9998376369476318
month O O 0.9999780654907227
regimen O O 0.9994608759880066
of O O 0.9990612864494324
rifampin S-Chemical S-Chemical 0.7976537942886353
and O O 0.9784777164459229
isoniazid S-Chemical S-Chemical 0.8851456046104431
for O O 0.9999834299087524
pulmonary O O 0.9998692274093628
tuberculosis O O 0.999278724193573
and O O 0.9999880790710449
was O O 0.9999953508377075
discovered O O 0.9999977350234985
to O O 0.999997615814209
have O O 0.9999819993972778
developed O O 0.9999991655349731
signs O O 0.9999957084655762
of O O 0.999998927116394
severe O O 0.9999918937683105
renal O O 0.9999547004699707
failure O O 0.9999964237213135
five O O 0.9999958276748657
weeks O O 0.9999947547912598
after O O 0.9999995231628418
completion O O 0.9999978542327881
of O O 0.9999929666519165
therapy O O 0.9999432563781738
. O O 0.9999973773956299

Schizophrenia O O 0.9909554123878479
has O O 0.9999862909317017
been O O 0.9999992847442627
initially O O 0.9999974966049194
associated O O 0.9999977350234985
with O O 0.9999992847442627
dysfunction O O 0.9999703168869019
in O O 0.9999898672103882
dopamine S-Chemical S-Chemical 0.9962431192398071
neurotransmission O O 0.999845027923584
. O O 0.999997615814209

In O O 0.9998503923416138
the O O 0.9999910593032837
cohort O O 0.9914660453796387
the O O 0.9999791383743286
cumulative O O 0.9999901056289673
risk O O 0.9999983310699463
of O O 0.9999974966049194
bladder O O 0.9999150037765503
cancer O O 0.9999719858169556
after O O 0.9999978542327881
Wegener O O 0.9545539617538452
' O O 0.9986503720283508
s O O 0.9052714109420776
granulomatosis O O 0.9347293376922607
, O O 0.999718964099884
and O O 0.9999854564666748
the O O 0.9999947547912598
relative O O 0.9999682903289795
prevalence O O 0.9999964237213135
of O O 0.9999951124191284
a O O 0.9999902248382568
history O O 0.9999980926513672
of O O 0.9999971389770508
bladder O O 0.9996672868728638
cancer O O 0.9999182224273682
at O O 0.9999991655349731
the O O 0.9999995231628418
time O O 0.9999991655349731
of O O 0.9999988079071045
diagnosis O O 0.9999915361404419
of O O 0.9999301433563232
Wegener O O 0.9908560514450073
' O O 0.9997075200080872
s O O 0.9529418349266052
granulomatosis O O 0.9765368700027466
, O O 0.9999480247497559
were O O 0.9999912977218628
also O O 0.9999974966049194
estimated O O 0.9999985694885254
. O O 0.9999977350234985

This O O 0.9996333122253418
response O O 0.9999972581863403
was O O 0.9999988079071045
restricted O O 0.9999991655349731
to O O 0.9999945163726807
the O O 0.9996919631958008
striatum O O 0.9918627738952637
and O O 0.9999914169311523
contrasted O O 0.9999940395355225
sharply O O 0.9999984502792358
with O O 0.9999967813491821
unresponsive O O 0.995438277721405
eGFP O O 0.5758251547813416
- O O 0.9228196740150452
microglia O O 0.974779486656189
in O O 0.999990701675415
surrounding O O 0.9999079704284668
brain O O 0.999646782875061
areas O O 0.9990803003311157
that O O 0.9999642372131348
are O O 0.9999920129776001
not O O 0.9999985694885254
damaged O O 0.9999890327453613
by O O 0.9999977350234985
METH S-Chemical S-Chemical 0.9732632040977478
. O O 0.999993085861206

Six O O 0.989806592464447
- O O 0.9996639490127563
to O O 0.9999953508377075
9 O O 0.9910553693771362
- O O 0.9996902942657471
month O O 0.9999929666519165
old O O 0.9999285936355591
rats O O 0.9998125433921814
receiving O O 0.9999979734420776
prenatal O O 0.9213965535163879
dexamethasone S-Chemical S-Chemical 0.9907017946243286
on O O 0.9999657869338989
days O O 0.9999890327453613
17 O O 0.9995964169502258
and O O 0.9999598264694214
18 O O 0.99941086769104
of O O 0.9999732971191406
gestation O O 0.9997621178627014
had O O 0.9999983310699463
a O O 0.9999983310699463
17 O O 0.9998692274093628
% O O 0.999996542930603
reduction O O 0.9999958276748657
in O O 0.9999475479125977
glomeruli O O 0.6283354163169861
( O O 0.994388997554779
23 O O 0.9966199398040771
380 O O 0.9995119571685791
+ O O 0.999936580657959
/ O O 0.9999715089797974
- O O 0.9991933703422546
587 O O 0.9980925917625427
) O O 0.9999046325683594
compared O O 0.9999991655349731
with O O 0.9999934434890747
control O O 0.996964156627655
rats O O 0.9996581077575684
( O O 0.9999798536300659
P O O 0.990246057510376
< O O 0.9998960494995117
0 O O 0.9997420907020569
. O O 0.9999529123306274
05 O O 0.999713122844696
) O O 0.9999313354492188
. O O 0.9999990463256836

Kidney O O 0.9929728507995605
function O O 0.9999866485595703
and O O 0.9999969005584717
morphology O O 0.9990872144699097
after O O 0.9999967813491821
short O O 0.9890782237052917
- O O 0.9956483244895935
term O O 0.9997711777687073
combination O O 0.9990875720977783
therapy O O 0.9999569654464722
with O O 0.9998682737350464
cyclosporine B-Chemical B-Chemical 0.924204409122467
A E-Chemical E-Chemical 0.962422788143158
, O O 0.994649350643158
tacrolimus S-Chemical S-Chemical 0.9440377354621887
and O O 0.9992081522941589
sirolimus S-Chemical S-Chemical 0.9449012279510498
in O O 0.999925971031189
the O O 0.9999268054962158
rat O O 0.9996298551559448
. O O 0.9999978542327881

Iatrogenically O O 0.9997366070747375
induced O O 0.999984860420227
intractable O O 0.999736487865448
atrioventricular O O 0.9372125267982483
reentrant O O 0.9875271916389465
tachycardia O O 0.999228835105896
after O O 0.9999350309371948
verapamil S-Chemical S-Chemical 0.8213644027709961
and O O 0.9988765120506287
catheter O O 0.8948945999145508
ablation O O 0.9974682331085205
in O O 0.9999979734420776
a O O 0.9999878406524658
patient O O 0.9999704360961914
with O O 0.999993085861206
Wolff O O 0.9544270038604736
- O O 0.983883798122406
Parkinson O O 0.9991299510002136
- O O 0.9996294975280762
White O O 0.9997796416282654
syndrome O O 0.9999521970748901
and O O 0.9999910593032837
idiopathic O O 0.9989572763442993
dilated O O 0.9984210729598999
cardiomyopathy O O 0.9990649819374084
. O O 0.999996542930603

The O O 0.9999336004257202
normalized O O 0.993160605430603
reflex O O 0.9984554052352905
amplitude O O 0.9999563694000244
increased O O 0.9999992847442627
with O O 0.9999991655349731
an O O 0.9999945163726807
increase O O 0.999997615814209
in O O 0.9999974966049194
velocity O O 0.9990859031677246
at O O 0.9999977350234985
a O O 0.9999991655349731
given O O 0.9999902248382568
displacement O O 0.9999836683273315
, O O 0.9999985694885254
but O O 0.9999978542327881
remained O O 0.9999978542327881
constant O O 0.9999982118606567
with O O 0.9999997615814209
different O O 0.9999964237213135
displacements O O 0.9998282194137573
at O O 0.9999982118606567
a O O 0.999998927116394
given O O 0.9999780654907227
velocity O O 0.9999363422393799
. O O 0.9999982118606567

Plasma O O 0.9881893396377563
CGRP S-Chemical S-Chemical 0.9622660279273987
concentration O O 0.9999814033508301
increased O O 0.9999973773956299
significantly O O 0.9999985694885254
( O O 0.9999797344207764
P O O 0.9986681938171387
< O O 0.999983549118042
0 O O 0.9999504089355469
. O O 0.9999798536300659
01 O O 0.9998773336410522
) O O 0.9999783039093018
during O O 0.9999997615814209
the O O 0.9999984502792358
migraine O O 0.9996838569641113
attack O O 0.9999806880950928
and O O 0.9999985694885254
returned O O 0.9999986886978149
to O O 0.9999978542327881
baseline O O 0.9999456405639648
after O O 0.9999995231628418
the O O 0.9999978542327881
cessation O O 0.9999972581863403
of O O 0.9999923706054688
the O O 0.9999773502349854
migraine O O 0.9997879862785339
. O O 0.9999984502792358

Therefore O O 0.9998661279678345
, O O 0.9999926090240479
like O O 0.9999231100082397
VPA S-Chemical S-Chemical 0.948351263999939
, O O 0.9999938011169434
the O O 0.9999887943267822
finding O O 0.9999933242797852
that O O 0.9999783039093018
VPU S-Chemical S-Chemical 0.9435948133468628
could O O 0.9999856948852539
drastically O O 0.9999914169311523
reduce O O 0.9993482232093811
pilocarpine S-Chemical S-Chemical 0.9965163469314575
- O O 0.9973021745681763
induced O O 0.9999707937240601
increases O O 0.9999889135360718
in O O 0.9998921155929565
glutamate S-Chemical S-Chemical 0.914035439491272
and O O 0.9983564019203186
aspartate S-Chemical S-Chemical 0.9559640288352966
should O O 0.9999547004699707
account O O 0.9999616146087646
, O O 0.9999958276748657
at O O 0.9999994039535522
least O O 0.9999995231628418
partly O O 0.9999991655349731
, O O 0.9999972581863403
for O O 0.9999988079071045
its O O 0.9999799728393555
anticonvulsant O O 0.921276867389679
activity O O 0.9993602633476257
observed O O 0.9999856948852539
in O O 0.9998995065689087
pilocarpine S-Chemical S-Chemical 0.9968806505203247
- O O 0.9966751337051392
induced O O 0.9999905824661255
seizure O O 0.9998960494995117
in O O 0.9999984502792358
experimental O O 0.9998946189880371
animals O O 0.9994078874588013
. O O 0.9999983310699463

Perinatal O O 0.9980022311210632
risk O O 0.9999748468399048
factors O O 0.9999980926513672
of O O 0.9999877214431763
infants O O 0.9995860457420349
with O O 0.9999992847442627
hearing O O 0.9991045594215393
loss O O 0.9999960660934448
were O O 0.9999994039535522
compared O O 0.9999990463256836
with O O 0.9999980926513672
those O O 0.9999977350234985
of O O 0.9999949932098389
two O O 0.9999734163284302
control O O 0.9905083179473877
groups O O 0.9998867511749268
matched O O 0.999998927116394
for O O 0.9999983310699463
gestation O O 0.999954342842102
and O O 0.9999960660934448
birth O O 0.9998950958251953
weight O O 0.9999834299087524
and O O 0.9999972581863403
for O O 0.9999992847442627
perinatal O O 0.9998619556427002
complications O O 0.9999902248382568
. O O 0.9999994039535522

To O O 0.9999818801879883
the O O 0.9999986886978149
best O O 0.9999947547912598
of O O 0.9999959468841553
our O O 0.9999980926513672
knowledge O O 0.9999947547912598
, O O 0.9999985694885254
this O O 0.9999891519546509
constitutes O O 0.9999994039535522
the O O 0.9999995231628418
first O O 0.999932050704956
report O O 0.9999394416809082
of O O 0.9997045397758484
HBV O O 0.6566139459609985
lamivudine S-Chemical S-Chemical 0.9231854677200317
- O O 0.9962567090988159
resistant O O 0.9999287128448486
strains O O 0.9994680285453796
in O O 0.9999872446060181
therapy O O 0.9980326294898987
- O O 0.9973617196083069
na S-Chemical S-Chemical 0.4503340721130371
ve O O 0.9730193614959717
HBV O O 0.9882864356040955
- O O 0.9978833794593811
HIV O O 0.9949310421943665
co O O 0.9578589797019958
- O O 0.9829844236373901
infected O O 0.9996428489685059
patients O O 0.9999288320541382
. O O 0.999997615814209

Following O O 0.9999513626098633
intervention O O 0.9999991655349731
, O O 0.9999992847442627
7 O O 0.9996769428253174
out O O 0.9999988079071045
of O O 0.9999969005584717
21 O O 0.999984622001648
affected O O 0.9999653100967407
patients O O 0.9999748468399048
recovered O O 0.9999986886978149
, O O 0.9999964237213135
10 O O 0.9998899698257446
remained O O 0.9999961853027344
stable O O 0.9999724626541138
and O O 0.9999957084655762
4 O O 0.9923107624053955
demonstrated O O 0.9999966621398926
aggravation O O 0.9998499155044556
. O O 0.9999977350234985

The O O 0.999871015548706
ratio O O 0.9999786615371704
of O O 0.9998483657836914
cimetidine S-Chemical S-Chemical 0.9801170229911804
clearance O O 0.9996423721313477
to O O 0.999915361404419
creatinine S-Chemical S-Chemical 0.9824543595314026
clearance O O 0.9996688365936279
( O O 0.9998695850372314
Rc O O 0.8877249956130981
) O O 0.9982888102531433
averaged O O 0.9999977350234985
4 O O 0.999392032623291
. O O 0.9999940395355225
8 O O 0.9999643564224243
+ O O 0.9999916553497314
/ O O 0.9999938011169434
- O O 0.9998733997344971
2 O O 0.999886155128479
. O O 0.9999876022338867
0 O O 0.9991937279701233
, O O 0.9999823570251465
indicating O O 0.9999986886978149
net O O 0.9981239438056946
tubular O O 0.9993745684623718
secretion O O 0.9996480941772461
for O O 0.9999582767486572
cimetidine S-Chemical S-Chemical 0.9960326552391052
. O O 0.9999872446060181

Animal O O 0.9998745918273926
and O O 0.9999992847442627
clinical O O 0.999980092048645
studies O O 0.9999669790267944
have O O 0.9999703168869019
suggested O O 0.999995231628418
that O O 0.9998117089271545
N B-Chemical B-Chemical 0.9746084809303284
- I-Chemical I-Chemical 0.9928990602493286
methyl I-Chemical I-Chemical 0.9953271150588989
- I-Chemical I-Chemical 0.9983878135681152
D I-Chemical I-Chemical 0.9361528158187866
- I-Chemical I-Chemical 0.9941776990890503
aspartate E-Chemical E-Chemical 0.9767348170280457
( O O 0.9945852160453796
NMDA S-Chemical S-Chemical 0.9812511205673218
) O O 0.9971386194229126
antagonists O O 0.9918549060821533
, O O 0.9998791217803955
such O O 0.9999713897705078
as O O 0.9992901086807251
ketamine S-Chemical S-Chemical 0.9991365075111389
, O O 0.9998562335968018
may O O 0.9999347925186157
be O O 0.9999967813491821
effective O O 0.9999884366989136
in O O 0.9999995231628418
improving O O 0.9999955892562866
opioid O O 0.989812433719635
analgesia O O 0.9995903372764587
in O O 0.9999994039535522
difficult O O 0.9999957084655762
pain O O 0.9998311996459961
syndromes O O 0.9999086856842041
, O O 0.9999961853027344
such O O 0.999998927116394
as O O 0.9999992847442627
neuropathic O O 0.9999680519104004
pain O O 0.9999805688858032
. O O 0.9999992847442627

Neurologic O O 0.9998798370361328
effects O O 0.9999983310699463
of O O 0.9999606609344482
subarachnoid O S-Chemical 0.35222044587135315
administration O O 0.9989362359046936
of O O 0.9996798038482666
2 B-Chemical B-Chemical 0.8959782719612122
- I-Chemical I-Chemical 0.9855432510375977
chloroprocaine I-Chemical I-Chemical 0.7523137927055359
- I-Chemical I-Chemical 0.9146190881729126
CE E-Chemical E-Chemical 0.9495153427124023
, O O 0.9976400136947632
bupivacaine S-Chemical S-Chemical 0.9868494272232056
, O O 0.9997100234031677
and O O 0.9998688697814941
low O O 0.9924044013023376
pH O O 0.9429624676704407
normal O O 0.9994018077850342
saline O O 0.9954200983047485
in O O 0.999985933303833
dogs O O 0.9994359612464905
. O O 0.9999984502792358

Further O O 0.999992847442627
studies O O 0.9999843835830688
are O O 0.9999995231628418
needed O O 0.9999995231628418
in O O 0.9999990463256836
order O O 0.9999996423721313
to O O 0.9999992847442627
establish O O 0.9999719858169556
a O O 0.9999982118606567
potential O O 0.9999862909317017
negative O O 0.9999840259552002
effect O O 0.999997615814209
of O O 0.9999947547912598
maternal O O 0.9997689127922058
smoking S-Chemical S-Chemical 0.8144558072090149
on O O 0.9999529123306274
the O O 0.9999388456344604
neonate O O 0.9955933690071106
' O O 0.9999089241027832
s O O 0.9981607794761658
hearing O O 0.9994264841079712
acuity O O 0.9998592138290405
. O O 0.9999979734420776

INTERPRETATION O O 0.9989784955978394
: O O 0.999948263168335
Tranexamic B-Chemical B-Chemical 0.6540457010269165
acid E-Chemical E-Chemical 0.9845640659332275
retains O O 0.9998574256896973
its O O 0.999994158744812
convulsive O O 0.999086856842041
action O O 0.9998514652252197
within O O 0.9999935626983643
FS O O 0.9656964540481567
. O O 0.9999915361404419

In O O 0.9998797178268433
both O O 0.9999902248382568
types O O 0.9997783303260803
, O O 0.9999392032623291
purinoceptor O S-Chemical 0.35282331705093384
desensitization O O 0.9982965588569641
with O O 0.9999681711196899
alpha B-Chemical B-Chemical 0.6423953175544739
, I-Chemical I-Chemical 0.9508526921272278
beta I-Chemical I-Chemical 0.9287880063056946
- I-Chemical I-Chemical 0.9068235754966736
methylene I-Chemical I-Chemical 0.4744451642036438
adenosine I-Chemical I-Chemical 0.31463268399238586
- I-Chemical I-Chemical 0.606099545955658
5 I-Chemical I-Chemical 0.8075249791145325
' I-Chemical I-Chemical 0.9104443788528442
- I-Chemical I-Chemical 0.9840488433837891
triphosphate E-Chemical E-Chemical 0.9657163023948669
( O O 0.9975427389144897
alpha B-Chemical B-Chemical 0.9276826977729797
, I-Chemical I-Chemical 0.5886406302452087
beta I-Chemical I-Chemical 0.6936797499656677
- I-Chemical I-Chemical 0.9423569440841675
meATP E-Chemical E-Chemical 0.9005506038665771
) O O 0.9976529479026794
caused O O 0.9999979734420776
further O O 0.9999974966049194
reductions O O 0.9999979734420776
at O O 0.9999955892562866
low O O 0.999933123588562
frequencies O O 0.9983798265457153
( O O 0.9999510049819946
< O O 0.9998948574066162
10 O O 0.9994515776634216
Hz O O 0.9982176423072815
) O O 0.9999182224273682
. O O 0.9999979734420776

OBJECTIVE O O 0.9995759129524231
: O O 0.999996542930603
To O O 0.9999958276748657
examine O O 0.9999812841415405
the O O 0.9999953508377075
effect O O 0.9999915361404419
of O O 0.9991927742958069
raloxifene S-Chemical S-Chemical 0.9998452663421631
on O O 0.9999887943267822
major O O 0.9999955892562866
adverse O O 0.9999774694442749
events O O 0.9999845027923584
that O O 0.9999901056289673
occur O O 0.9999862909317017
with O O 0.9999977350234985
postmenopausal O O 0.9972990155220032
estrogen S-Chemical S-Chemical 0.9744691848754883
therapy O O 0.9998461008071899
or O O 0.9998613595962524
tamoxifen S-Chemical S-Chemical 0.9968228340148926
. O O 0.9999884366989136

The O O 0.999638557434082
half O O 0.9998915195465088
- O O 0.9998235106468201
life O O 0.9999833106994629
( O O 0.9999756813049316
t1 O O 0.9998972415924072
/ O O 0.9999744892120361
2 O O 0.9997758269309998
) O O 0.999950647354126
of O O 0.9997730851173401
cocaine S-Chemical S-Chemical 0.991963267326355
is O O 0.9999783039093018
relatively O O 0.9999992847442627
short O O 0.9999970197677612
, O O 0.9999921321868896
but O O 0.9999972581863403
some O O 0.9999961853027344
of O O 0.9999940395355225
the O O 0.9999983310699463
consequences O O 0.9999991655349731
of O O 0.9999879598617554
its O O 0.9992569088935852
use O O 0.9999113082885742
, O O 0.9999934434890747
such O O 0.9999985694885254
as O O 0.9999979734420776
seizures O O 0.999747097492218
and O O 0.9999970197677612
strokes O O 0.9997196793556213
, O O 0.9999921321868896
can O O 0.9999984502792358
occur O O 0.9999994039535522
hours O O 0.9999992847442627
after O O 0.9999988079071045
exposure O O 0.999983549118042
. O O 0.9999926090240479

In O O 0.9999475479125977
contrast O O 0.9999914169311523
with O O 0.9999996423721313
the O O 0.9999855756759644
literature O O 0.999964714050293
, O O 0.9999986886978149
serum O O 0.9999324083328247
levels O O 0.9999762773513794
of O O 0.9999470710754395
angiogenesis O O 0.9923219084739685
factors O O 0.9999967813491821
did O O 0.9999986886978149
not O O 0.9999988079071045
change O O 0.9999961853027344
significantly O O 0.9999988079071045
by O O 0.9999983310699463
pegylated B-Chemical B-Chemical 0.9107045531272888
interferon E-Chemical E-Chemical 0.8579403758049011
and O O 0.9871878623962402
ribavirin S-Chemical S-Chemical 0.9978899359703064
therapy O O 0.999966025352478
. O O 0.9999980926513672

According O O 0.9999101161956787
to O O 0.9999982118606567
intention O O 0.9999828338623047
- O O 0.9998722076416016
to O O 0.9999898672103882
- O O 0.9994295239448547
treat O O 0.9997504353523254
, O O 0.9999943971633911
the O O 0.9999920129776001
overall O O 0.9998561143875122
response O O 0.9999923706054688
rate O O 0.9999814033508301
was O O 0.9999984502792358
71 O O 0.9998718500137329
. O O 0.9999971389770508
4 O O 0.9999661445617676
% O O 0.9999971389770508
( O O 0.9999895095825195
95 O O 0.9999749660491943
% O O 0.9999958276748657
CI O O 0.9969367980957031
, O O 0.9999865293502808
53 O O 0.999945878982544
. O O 0.99998939037323
7 O O 0.9998947381973267
- O O 0.9998419284820557
85 O O 0.9999371767044067
. O O 0.9999935626983643
4 O O 0.9999785423278809
% O O 0.9999951124191284
) O O 0.999954104423523
. O O 0.9999971389770508

FINDINGS O O 0.9992693066596985
: O O 0.9999983310699463
A O O 0.9999786615371704
temporal O O 0.9999806880950928
relationship O O 0.999998927116394
was O O 0.9999995231628418
found O O 0.9999992847442627
between O O 0.9999984502792358
topical O O 0.9976750016212463
papaverine S-Chemical S-Chemical 0.9796196222305298
and O O 0.999923586845398
BAEP O O 0.870750904083252
changes O O 0.9999103546142578
leading O O 0.9999960660934448
to O O 0.9999984502792358
complete O O 0.9999666213989258
waveform O O 0.9995984435081482
loss O O 0.9999980926513672
. O O 0.9999990463256836

Significant O O 0.9999688863754272
disfiguring O O 0.9996354579925537
changes O O 0.9999932050704956
occur O O 0.9999983310699463
as O O 0.9999996423721313
a O O 0.9999996423721313
result O O 0.9999996423721313
of O O 0.9999957084655762
bone O O 0.9972540736198425
, O O 0.9998999834060669
cartilage O S-Chemical 0.47700145840644836
, O O 0.9998486042022705
and O O 0.99998939037323
soft O O 0.9949936270713806
tissue O O 0.998426079750061
hypertrophy O O 0.9995430707931519
, O O 0.9999964237213135
including O O 0.9999982118606567
the O O 0.999990701675415
thickening O O 0.9998383522033691
of O O 0.9998944997787476
the O O 0.9998342990875244
skin O O 0.9998175501823425
, O O 0.9999942779541016
coarsening O O 0.9999692440032959
of O O 0.9999526739120483
facial O O 0.9997665286064148
features O O 0.999846339225769
, O O 0.9999672174453735
and O O 0.9998693466186523
cutis O O 0.9797407388687134
verticis O O 0.996268093585968
gyrata O O 0.9827864170074463
. O O 0.9999972581863403

Statins S-Chemical S-Chemical 0.552306592464447
can O O 0.9999476671218872
cause O O 0.9999983310699463
a O O 0.999987006187439
necrotizing O O 0.994458794593811
myopathy O O 0.9966195821762085
and O O 0.9997536540031433
hyperCKaemia O O 0.9925876259803772
which O O 0.9998531341552734
is O O 0.9999531507492065
reversible O O 0.9999256134033203
on O O 0.9999933242797852
cessation O O 0.9999048709869385
of O O 0.99992835521698
the O O 0.9985461235046387
drug O O 0.9997696280479431
. O O 0.9999958276748657

BACKGROUND O O 0.9956949949264526
: O O 0.9991555213928223
Cyclooxygenase O S-Chemical 0.7106232047080994
( O O 0.9936116337776184
COX O S-Chemical 0.6515071988105774
) O O 0.8894786238670349
inhibitors O O 0.9906601309776306
are O O 0.9999960660934448
one O O 0.9999850988388062
of O O 0.9999943971633911
the O O 0.9999983310699463
most O O 0.9999978542327881
often O O 0.9999442100524902
ingested O O 0.9997954964637756
drugs O O 0.9996002316474915
during O O 0.9999979734420776
pregnancy O O 0.9999949932098389
. O O 0.9999991655349731

CONCLUSION O O 0.9999544620513916
: O O 0.9999984502792358
Toxic O O 0.9982650876045227
hepatitis O O 0.9763178825378418
is O O 0.999969482421875
a O O 0.9999986886978149
potential O O 0.9999685287475586
adverse O O 0.9999542236328125
effect O O 0.9999878406524658
of O O 0.9999282360076904
antithyroid O O 0.6107708811759949
drugs O O 0.9022906422615051
which O O 0.9997649788856506
warrants O O 0.9999853372573853
, O O 0.9999825954437256
as O O 0.9999804496765137
for O O 0.9999923706054688
haematological O O 0.999893307685852
disturbances O O 0.9999507665634155
, O O 0.9999980926513672
a O O 0.9999960660934448
pre O O 0.9963022470474243
- O O 0.9996871948242188
therapeutic O O 0.9996609687805176
determination O O 0.9999901056289673
and O O 0.9999988079071045
a O O 0.999998927116394
careful O O 0.9998795986175537
follow O O 0.9999772310256958
- O O 0.9997287392616272
up O O 0.9999890327453613
of O O 0.9999712705612183
relevant O O 0.999980092048645
biological O O 0.9998444318771362
markers O O 0.999919056892395
. O O 0.9999988079071045

BACKGROUND O O 0.9979848861694336
: O O 0.9998828172683716
Methamphetamine S-Chemical S-Chemical 0.9955524802207947
is O O 0.9999895095825195
a O O 0.999995231628418
very O O 0.9998244643211365
addictive O O 0.9994434714317322
, O O 0.9999951124191284
powerful O O 0.9881302118301392
stimulant O O 0.9598655700683594
that O O 0.9999349117279053
increases O O 0.9999793767929077
wakefulness O O 0.9988675117492676
and O O 0.999996542930603
physical O O 0.999946117401123
activity O O 0.9999244213104248
and O O 0.9999734163284302
can O O 0.9999910593032837
produce O O 0.999993085861206
other O O 0.999997615814209
effects O O 0.9999935626983643
such O O 0.9999988079071045
as O O 0.9999992847442627
cardiac O O 0.9989266991615295
dysrhythmias O O 0.9996837377548218
, O O 0.9999827146530151
hypertension O O 0.9996886253356934
, O O 0.999992847442627
hallucinations O O 0.9999592304229736
, O O 0.9999963045120239
and O O 0.9999979734420776
violent O O 0.999988317489624
behavior O O 0.9999943971633911
. O O 0.9999991655349731

Suxamethonium B-Chemical B-Chemical 0.991888701915741
chloride E-Chemical E-Chemical 0.9212437868118286
( O O 0.9966298937797546
Sch S-Chemical S-Chemical 0.6780050992965698
) O O 0.9921267032623291
was O O 0.9999921321868896
administered O O 0.9999992847442627
i O O 0.999690055847168
. O O 0.9999756813049316
v O O 0.9996582269668579
. O O 0.999990701675415
to O O 0.9999964237213135
36 O O 0.9997636675834656
adult O O 0.9999724626541138
males O O 0.9998347759246826
at O O 0.9999959468841553
six O O 0.9999594688415527
rates O O 0.9999791383743286
: O O 0.9999933242797852
0 O O 0.99864262342453
. O O 0.999994158744812
25 O O 0.9999310970306396
mg O O 0.999962329864502
s O O 0.9816420078277588
- O O 0.9908191561698914
1 O O 0.9990153312683105
to O O 0.9999760389328003
20 O O 0.9998694658279419
mg O O 0.9999014139175415
s O O 0.9896804690361023
- O O 0.9901453852653503
1 O O 0.995220959186554
. O O 0.9999240636825562

Effects O O 0.9999600648880005
of O O 0.9999735355377197
pallidal O O 0.5517711043357849
neurotensin S-Chemical S-Chemical 0.33423298597335815
on O O 0.9724647402763367
haloperidol S-Chemical S-Chemical 0.9831069707870483
- O O 0.9965143799781799
induced O O 0.9999580383300781
parkinsonian O O 0.9925296902656555
catalepsy O O 0.996290922164917
: O O 0.9999955892562866
behavioral O O 0.9999724626541138
and O O 0.9999972581863403
electrophysiological O O 0.9999513626098633
studies O O 0.99998939037323
. O O 0.9999990463256836

Dobutamine S-Chemical S-Chemical 0.5209051966667175
stress O O 0.9972104430198669
echocardiography O O 0.990067720413208
: O O 0.9999910593032837
a O O 0.9999948740005493
sensitive O O 0.9999607801437378
indicator O O 0.9999849796295166
of O O 0.9999961853027344
diminished O O 0.9999605417251587
myocardial O O 0.9977890253067017
function O O 0.9998304843902588
in O O 0.9999954700469971
asymptomatic O O 0.9871568083763123
doxorubicin S-Chemical S-Chemical 0.9845227003097534
- O O 0.9971771240234375
treated O O 0.9999542236328125
long O O 0.9988059997558594
- O O 0.997205913066864
term O O 0.999881386756897
survivors O O 0.9998908042907715
of O O 0.999995231628418
childhood O O 0.999658465385437
cancer O O 0.999953031539917
. O O 0.9999992847442627

The O O 0.9998854398727417
number O O 0.999995231628418
of O O 0.9999979734420776
previous O O 0.9999974966049194
manic O O 0.9986162185668945
episodes O O 0.9999767541885376
did O O 0.9999988079071045
not O O 0.9999990463256836
affect O O 0.9999985694885254
the O O 0.9999971389770508
probability O O 0.9999990463256836
of O O 0.9999959468841553
switching O O 0.9999699592590332
, O O 0.9999974966049194
whereas O O 0.9999996423721313
a O O 0.9999966621398926
high O O 0.9999948740005493
score O O 0.9998990297317505
on O O 0.9999865293502808
the O O 0.9997673630714417
hyperthymia O O 0.977920651435852
component O O 0.9998071789741516
of O O 0.9999691247940063
the O O 0.999630331993103
Semistructured O O 0.9624785780906677
Affective O O 0.9965409636497498
Temperament O O 0.9964622855186462
Interview O O 0.9998747110366821
was O O 0.9999984502792358
associated O O 0.9999990463256836
with O O 0.9999998807907104
a O O 0.9999996423721313
greater O O 0.9999991655349731
risk O O 0.9999985694885254
of O O 0.9999984502792358
switching O O 0.999964714050293
( O O 0.9999663829803467
p O O 0.999016523361206
= O O 0.9999722242355347
. O O 0.9999645948410034
008 O O 0.9995249509811401
) O O 0.9999402761459351
. O O 0.9999983310699463

Dopamine S-Chemical S-Chemical 0.8868539929389954
turnover O O 0.9993085861206055
ratios O O 0.9999312162399292
( O O 0.9998863935470581
DOPAC S-Chemical O 0.8520078063011169
: O O 0.9983968138694763
DA S-Chemical O 0.7178736329078674
and O O 0.999051034450531
HVA S-Chemical O 0.6939056515693665
: O O 0.9964246153831482
DA S-Chemical S-Chemical 0.6190837025642395
) O O 0.999896764755249
were O O 0.9999990463256836
found O O 0.999998927116394
to O O 0.9999994039535522
be O O 0.999998927116394
lower O O 0.9999986886978149
in O O 0.9999980926513672
those O O 0.9999932050704956
animals O O 0.9995681643486023
exposed O O 0.9999988079071045
to O O 0.9999972581863403
the O O 0.9998648166656494
exploratory O O 0.9992015957832336
box O O 0.9997045397758484
when O O 0.999994158744812
compared O O 0.9999985694885254
to O O 0.9999953508377075
their O O 0.9999899864196777
home O O 0.9998778104782104
cage O O 0.9989460110664368
counterparts O O 0.9999744892120361
. O O 0.9999991655349731

Fragments O O 0.9996181726455688
of O O 0.9998952150344849
necrotic O O 0.9953212141990662
endothelial O O 0.9985839128494263
cells O O 0.9996497631072998
were O O 0.9999967813491821
in O O 0.9999979734420776
the O O 0.9999806880950928
vascular O O 0.9996390342712402
lumens O O 0.9994385838508606
and O O 0.9999943971633911
in O O 0.9999984502792358
these O O 0.999996542930603
there O O 0.9999980926513672
was O O 0.9999983310699463
loosening O O 0.9999568462371826
and O O 0.9999946355819702
breaking O O 0.9999871253967285
of O O 0.9997832179069519
tight O O 0.9986374974250793
cellular O O 0.999919056892395
junctions O O 0.9999749660491943
. O O 0.999998927116394

Only O O 0.9970190525054932
1 O O 0.9467573165893555
prolactinoma O O 0.9746800065040588
was O O 0.9998470544815063
discovered O O 0.9999939203262329
. O O 0.999996542930603

Subsequently O O 0.9999692440032959
, O O 0.9999991655349731
acute O O 0.9997583031654358
cardiac O O 0.9999215602874756
arrest O O 0.9999818801879883
and O O 0.9999984502792358
fatal O O 0.9998401403427124
subarachnoid O O 0.9361705780029297
hemorrhage O O 0.9996532201766968
occurred O O 0.9999983310699463
. O O 0.9999978542327881

For O O 0.9997770190238953
three O O 0.9999853372573853
patients O O 0.9999854564666748
, O O 0.9999991655349731
the O O 0.9999951124191284
decision O O 0.9999849796295166
was O O 0.9999996423721313
made O O 0.9999996423721313
not O O 0.9999998807907104
to O O 0.9999984502792358
proceed O O 0.9999895095825195
with O O 0.9999948740005493
angiography O O 0.9976739287376404
after O O 0.9999995231628418
positive O O 0.9999934434890747
preangiographic O O 0.9997482895851135
testing O O 0.9999730587005615
. O O 0.9999982118606567

We O O 0.9996665716171265
believe O O 0.9999974966049194
the O O 0.9999978542327881
results O O 0.999998927116394
of O O 0.9999986886978149
those O O 0.9999978542327881
studies O O 0.9999732971191406
may O O 0.9999982118606567
have O O 0.999998927116394
been O O 0.9999998807907104
affected O O 0.9999996423721313
by O O 0.9999997615814209
residual O O 0.9999735355377197
confounding O O 0.9999009370803833
. O O 0.9999967813491821

Portal O O 0.9836878776550293
plasma O O 0.9966251850128174
concentrations O O 0.999805748462677
of O O 0.9999450445175171
neither O O 0.999783456325531
arginine B-Chemical S-Chemical 0.459634393453598
vasopressin E-Chemical O 0.5186783075332642
nor O O 0.9974560141563416
oxytocin S-Chemical S-Chemical 0.7651585340499878
are O O 0.9998489618301392
significantly O O 0.9999991655349731
altered O O 0.9999970197677612
in O O 0.9999988079071045
this O O 0.9999890327453613
paradigm O O 0.9999746084213257
. O O 0.9999973773956299

METHODS O O 0.9989317059516907
: O O 0.9999945163726807
All O O 0.9999077320098877
PD O O 0.9678298234939575
patients O O 0.9998860359191895
in O O 0.9999990463256836
the O O 0.9999678134918213
Amiens O O 0.988063395023346
area O O 0.9998337030410767
treated O O 0.9999991655349731
with O O 0.999983549118042
pergolide S-Chemical S-Chemical 0.7464034557342529
were O O 0.9999704360961914
invited O O 0.9999995231628418
to O O 0.9999990463256836
attend O O 0.999991774559021
a O O 0.9999982118606567
cardiologic O O 0.9997661709785461
assessment O O 0.9999973773956299
including O O 0.9999990463256836
transthoracic O O 0.9979454874992371
echocardiography O O 0.9998157620429993
. O O 0.9999982118606567

There O O 0.9999711513519287
were O O 0.9999995231628418
no O O 0.9999997615814209
clinically O O 0.9999992847442627
important O O 0.9999990463256836
changes O O 0.9999977350234985
in O O 0.9999995231628418
laboratory O O 0.9999866485595703
parameters O O 0.9999021291732788
. O O 0.9999985694885254

Procainamide S-Chemical S-Chemical 0.9784744381904602
- O O 0.9980953335762024
induced O O 0.9999501705169678
polymorphous O O 0.9932234287261963
ventricular O O 0.9985525012016296
tachycardia O O 0.9994950294494629
. O O 0.999996542930603

Prospective O O 0.9999668598175049
study O O 0.9999881982803345
of O O 0.9999949932098389
the O O 0.9999955892562866
long O O 0.9999890327453613
- O O 0.999721109867096
term O O 0.9999799728393555
effects O O 0.9999892711639404
of O O 0.9997267127037048
somatostatin O S-Chemical 0.7686124444007874
analog O O 0.4400578439235687
( O O 0.9343854784965515
octreotide S-Chemical S-Chemical 0.9459080696105957
) O O 0.9990867376327515
on O O 0.9999611377716064
gallbladder O O 0.9814930558204651
function O O 0.9997301697731018
and O O 0.9999785423278809
gallstone O O 0.9807799458503723
formation O O 0.9998072981834412
in O O 0.9999951124191284
Chinese O O 0.9927502870559692
acromegalic O O 0.9874239563941956
patients O O 0.9997839331626892
. O O 0.9999983310699463

CONCLUSION O O 0.9999561309814453
: O O 0.9999986886978149
This O O 0.9999967813491821
study O O 0.9999915361404419
demonstrates O O 0.9999949932098389
that O O 0.999863862991333
cinacalcet S-Chemical S-Chemical 0.9254328012466431
is O O 0.9999302625656128
a O O 0.9999942779541016
strong O O 0.9989751577377319
inhibitor O O 0.9993500113487244
of O O 0.9997220635414124
CYP2D6 O O 0.6271122097969055
. O O 0.9999823570251465

The O O 0.9996708631515503
anti O O 0.9994668364524841
- O O 0.9995678067207336
dementia O O 0.9998292922973633
effects O O 0.9999954700469971
of O O 0.9998507499694824
s B-Chemical B-Chemical 0.9658789038658142
- I-Chemical I-Chemical 0.9939314126968384
limonene E-Chemical E-Chemical 0.9351614713668823
and O O 0.9977890253067017
s B-Chemical B-Chemical 0.9161302447319031
- I-Chemical I-Chemical 0.9768937230110168
perillyl I-Chemical I-Chemical 0.8765652775764465
alcohol E-Chemical E-Chemical 0.8887695670127869
were O O 0.9998898506164551
observed O O 0.9999912977218628
using O O 0.9999920129776001
the O O 0.9999444484710693
passive O O 0.9995318651199341
avoidance O O 0.9996939897537231
test O O 0.9998897314071655
( O O 0.999963641166687
PA O O 0.995563268661499
) O O 0.9999430179595947
and O O 0.9999951124191284
the O O 0.9999945163726807
open O O 0.9992522597312927
field O O 0.9999145269393921
habituation O O 0.9998103976249695
test O O 0.9999396800994873
( O O 0.9999866485595703
OFH O O 0.9970448613166809
) O O 0.9999490976333618
. O O 0.9999980926513672

In O O 0.9998822212219238
21 O O 0.9997950196266174
patients O O 0.999977707862854
an O O 0.9999971389770508
alternative O O 0.9999842643737793
cause O O 0.9999899864196777
of O O 0.999922513961792
proteinuria O O 0.9689282774925232
was O O 0.9999774694442749
either O O 0.9999969005584717
obvious O O 0.9999420642852783
or O O 0.9999960660934448
insufficient O O 0.9999985694885254
data O O 0.9986420273780823
was O O 0.9999943971633911
available O O 0.9999990463256836
to O O 0.9999995231628418
be O O 0.9999948740005493
conclusive O O 0.9999985694885254
. O O 0.9999986886978149

Accumulation O O 0.9997830986976624
of O O 0.9990469813346863
atracurium S-Chemical S-Chemical 0.8258203268051147
in O O 0.9994763731956482
the O O 0.9999445676803589
intravenous O O 0.9997559189796448
line O O 0.9999911785125732
led O O 0.9999945163726807
to O O 0.9999977350234985
recurarization O O 0.9999463558197021
after O O 0.9999991655349731
flushing O O 0.9999301433563232
the O O 0.9999262094497681
line O O 0.9999938011169434
in O O 0.9999979734420776
the O O 0.999990701675415
recovery O O 0.9999886751174927
room O O 0.9999908208847046
. O O 0.9999985694885254

Assessment O O 0.9999734163284302
of O O 0.9999943971633911
a O O 0.999985933303833
new O O 0.9999852180480957
non O O 0.9998776912689209
- O O 0.9999042749404907
invasive O O 0.9998941421508789
index O O 0.9998435974121094
of O O 0.9999785423278809
cardiac O O 0.9988285899162292
performance O O 0.999974250793457
for O O 0.9999979734420776
detection O O 0.999884843826294
of O O 0.9995647072792053
dobutamine S-Chemical S-Chemical 0.9968806505203247
- O O 0.9978277087211609
induced O O 0.9999948740005493
myocardial O O 0.9997429251670837
ischemia O O 0.9986391663551331
. O O 0.9999970197677612

One O O 0.9994837045669556
of O O 0.9999862909317017
the O O 0.9999867677688599
twins O O 0.9997261166572571
developed O O 0.9999980926513672
complete O O 0.9993956089019775
heart O O 0.9998483657836914
block O O 0.9999011754989624
and O O 0.9999825954437256
dilated O O 0.9996583461761475
cardiomyopathy O O 0.9992176294326782
related O O 0.9999958276748657
to O O 0.99986732006073
lopinavir B-Chemical B-Chemical 0.9763447046279907
/ I-Chemical I-Chemical 0.9344511032104492
ritonavir E-Chemical E-Chemical 0.9551001191139221
therapy O O 0.999096155166626
, O O 0.9999911785125732
a O O 0.9999796152114868
boosted O O 0.9991348385810852
protease O O 0.99118971824646
- O O 0.9968175888061523
inhibitor O O 0.9982013702392578
agent O O 0.9919191598892212
, O O 0.999970555305481
while O O 0.9999964237213135
the O O 0.9999966621398926
other O O 0.9999595880508423
twin O O 0.9986312985420227
developed O O 0.9999984502792358
mild O O 0.9998069405555725
bradycardia O O 0.9970260262489319
. O O 0.9999971389770508

These O O 0.999942421913147
observations O O 0.999964714050293
suggest O O 0.999997615814209
that O O 0.999980092048645
rigidity O O 0.997234046459198
should O O 0.9999951124191284
be O O 0.9999985694885254
prevented O O 0.9999983310699463
when O O 0.9998928308486938
alfentanil S-Chemical S-Chemical 0.9651901125907898
, O O 0.9997517466545105
and O O 0.9999102354049683
, O O 0.999974250793457
presumably O O 0.9999926090240479
, O O 0.999994158744812
other O O 0.9999878406524658
opiates O O 0.9904935956001282
, O O 0.9999357461929321
are O O 0.9999681711196899
used O O 0.9999982118606567
in O O 0.999998927116394
the O O 0.9999730587005615
anesthetic O O 0.9998030066490173
management O O 0.9999910593032837
of O O 0.9999805688858032
patients O O 0.9999808073043823
with O O 0.999998927116394
ICP O O 0.9918798804283142
problems O O 0.9999868869781494
. O O 0.9999990463256836

Because O O 0.9997873902320862
each O O 0.9999529123306274
patient O O 0.999808132648468
was O O 0.9999942779541016
tumor O O 0.9996603727340698
- O O 0.9995526671409607
free O O 0.9998934268951416
or O O 0.9999963045120239
had O O 0.9999927282333374
only O O 0.999994158744812
a O O 0.999987006187439
small O O 0.9998099207878113
tumor O O 0.9999103546142578
at O O 0.9999986886978149
the O O 0.9999982118606567
onset O O 0.9999985694885254
of O O 0.9999949932098389
this O O 0.9999744892120361
syndrome O O 0.9999707937240601
, O O 0.9999983310699463
the O O 0.9999616146087646
thrombotic O O 0.9869023561477661
microangiopathy O O 0.9930566549301147
may O O 0.9999845027923584
have O O 0.9999959468841553
been O O 0.9999992847442627
induced O O 0.9999986886978149
by O O 0.9999991655349731
chemotherapy O O 0.9969933032989502
. O O 0.9999961853027344

Additional O O 0.9999761581420898
studies O O 0.9999644756317139
of O O 0.9999887943267822
these O O 0.9999797344207764
murine O O 0.9589529633522034
strains O O 0.9993415474891663
may O O 0.9999991655349731
be O O 0.9999997615814209
useful O O 0.9999996423721313
for O O 0.9999997615814209
investigating O O 0.9999918937683105
genetic O O 0.9996745586395264
influences O O 0.9992170333862305
on O O 0.9998914003372192
cocaine S-Chemical S-Chemical 0.9980600476264954
- O O 0.9979556798934937
induced O O 0.9999607801437378
seizures O O 0.9999645948410034
. O O 0.9999990463256836

The O O 0.9999721050262451
first O O 0.999987006187439
patient O O 0.9999876022338867
died O O 0.9999979734420776
without O O 0.9999995231628418
a O O 0.999998927116394
diagnosis O O 0.9999896287918091
; O O 0.9999995231628418
the O O 0.999998927116394
second O O 0.9999872446060181
patient O O 0.9999915361404419
had O O 0.9999994039535522
a O O 0.9999991655349731
dramatic O O 0.9999428987503052
recovery O O 0.9999932050704956
following O O 0.9999996423721313
the O O 0.9999979734420776
administration O O 0.9999932050704956
of O O 0.9994077682495117
vitamin B-Chemical B-Chemical 0.9998452663421631
B6 E-Chemical E-Chemical 0.9870453476905823
. O O 0.9999226331710815

Contact O O 0.9995538592338562
with O O 0.9999808073043823
the O O 0.9946913123130798
skin O O 0.9867146611213684
can O O 0.999930739402771
result O O 0.9999988079071045
in O O 0.9999990463256836
percutaneous O O 0.9994656443595886
absorption O O 0.9998620748519897
of O O 0.9997901320457458
the O O 0.99891197681427
substance O O 0.9986452460289001
that O O 0.9999020099639893
inhibits O O 0.9996519088745117
aldehyde S-Chemical O 0.4969615638256073
dehydrogenase O O 0.4842195510864258
and O O 0.9955936074256897
can O O 0.9999514818191528
induce O O 0.9999406337738037
acetaldehyde S-Chemical O 0.9118998646736145
syndrome O O 0.9998264908790588
in O O 0.9999992847442627
case O O 0.9999865293502808
of O O 0.9998705387115479
alcohol S-Chemical S-Chemical 0.9967789053916931
use O O 0.9996844530105591
. O O 0.9999985694885254

METHODS O O 0.9968693852424622
: O O 0.9999967813491821
A O O 0.9999102354049683
Phase O O 0.9997794032096863
II O O 0.9996241331100464
study O O 0.9999860525131226
of O O 0.9999750852584839
the O O 0.9998792409896851
combination O O 0.9999518394470215
of O O 0.9993019104003906
cisplatin S-Chemical S-Chemical 0.9621809124946594
plus O O 0.9963998794555664
amifostine S-Chemical S-Chemical 0.9840646386146545
was O O 0.9999849796295166
conducted O O 0.9999971389770508
in O O 0.9999991655349731
patients O O 0.9999980926513672
with O O 0.9999996423721313
progressive O O 0.9998749494552612
metastatic O O 0.9998636245727539
breast O O 0.9997370839118958
carcinoma O O 0.9997513890266418
who O O 0.9999946355819702
had O O 0.9999957084655762
received O O 0.9999951124191284
one O O 0.9984115362167358
, O O 0.9999563694000244
but O O 0.9999960660934448
not O O 0.9999983310699463
more O O 0.9999897480010986
than O O 0.9999947547912598
one O O 0.9999208450317383
, O O 0.9999730587005615
chemotherapy O O 0.997282862663269
regimen O O 0.9997052550315857
for O O 0.9999994039535522
metastatic O O 0.9999381303787231
disease O O 0.9999535083770752
. O O 0.9999994039535522

NX O S-Chemical 0.8290239572525024
+ O O 0.9988407492637634
HP O S-Chemical 0.8316071629524231
caused O O 0.9999911785125732
a O O 0.9999969005584717
further O O 0.9999958276748657
rise O O 0.9999988079071045
in O O 0.9999990463256836
blood O O 0.9982927441596985
pressure O O 0.9998049139976501
in O O 0.9999265670776367
Li S-Chemical S-Chemical 0.9478399157524109
- O O 0.9948050379753113
pretreated O O 0.9999858140945435
rats O O 0.999657392501831
. O O 0.999997615814209

Reversible O O 0.9999105930328369
inferior O O 0.9946529865264893
colliculus O O 0.670390784740448
lesion O O 0.9131224751472473
in O O 0.9983867406845093
metronidazole S-Chemical S-Chemical 0.9782635569572449
- O O 0.9967558979988098
induced O O 0.9999376535415649
encephalopathy O O 0.9992151260375977
: O O 0.999992847442627
magnetic O O 0.9964948296546936
resonance O O 0.9999600648880005
findings O O 0.9999094009399414
on O O 0.9999890327453613
diffusion O O 0.9687573909759521
- O O 0.997368335723877
weighted O O 0.9998173117637634
and O O 0.9999703168869019
fluid O O 0.9994602799415588
attenuated O O 0.9987074136734009
inversion O O 0.9991562366485596
recovery O O 0.9999634027481079
imaging O O 0.999954342842102
. O O 0.999998927116394

It O O 0.9998308420181274
has O O 0.9999985694885254
been O O 0.9999997615814209
consistently O O 0.9999959468841553
shown O O 0.9999967813491821
that O O 0.9999334812164307
ecstasy S-Chemical S-Chemical 0.9857062697410583
users O O 0.9992539286613464
display O O 0.9999208450317383
impairments O O 0.999984860420227
in O O 0.9999996423721313
learning O O 0.999873161315918
and O O 0.9999977350234985
memory O O 0.9999803304672241
performance O O 0.9999983310699463
. O O 0.999998927116394

The O O 0.9999234676361084
effects O O 0.9999988079071045
of O O 0.9999634027481079
METH S-Chemical S-Chemical 0.9176448583602905
in O O 0.9999843835830688
CX3CR1 O O 0.945027232170105
knockout O O 0.9990736246109009
mice O O 0.9997599720954895
were O O 0.9999995231628418
not O O 0.9999979734420776
gender O O 0.9996153116226196
- O O 0.999887228012085
dependent O O 0.9999910593032837
and O O 0.9999983310699463
did O O 0.9999977350234985
not O O 0.9999971389770508
extend O O 0.999994158744812
beyond O O 0.9999978542327881
the O O 0.9999353885650635
striatum O O 0.9952327609062195
. O O 0.9999973773956299

Captopril S-Chemical S-Chemical 0.5517213940620422
may O O 0.9998338222503662
, O O 0.9999947547912598
by O O 0.9999986886978149
the O O 0.9999918937683105
same O O 0.9999759197235107
mechanism O O 0.9998469352722168
, O O 0.9999947547912598
reduce O O 0.9999927282333374
the O O 0.9999895095825195
increase O O 0.999991774559021
in O O 0.9999974966049194
glomerular O O 0.9233102798461914
filtration O O 0.9945423603057861
that O O 0.9999171495437622
is O O 0.9999665021896362
known O O 0.9999982118606567
to O O 0.9999974966049194
occur O O 0.9999939203262329
after O O 0.9999994039535522
an O O 0.9999935626983643
injection O O 0.9999573230743408
of O O 0.9998182654380798
thrombin O O 0.6694265604019165
, O O 0.9979541301727295
thereby O O 0.9999991655349731
diminishing O O 0.9999881982803345
the O O 0.9999754428863525
aggregation O O 0.9999638795852661
of O O 0.9998781681060791
fibrin O O 0.5253387093544006
monomers O O 0.8455338478088379
in O O 0.9997249245643616
the O O 0.9996159076690674
glomeruli O O 0.9707373976707458
, O O 0.9999810457229614
with O O 0.9999982118606567
the O O 0.9999986886978149
result O O 0.9999985694885254
that O O 0.999998927116394
less O O 0.9998284578323364
fibrin O S-Chemical 0.7734281420707703
will O O 0.9996997117996216
be O O 0.9998132586479187
deposited O O 0.9999330043792725
and O O 0.9999889135360718
thus O O 0.9999971389770508
less O O 0.999997615814209
kidney O O 0.9990622401237488
damage O O 0.9998499155044556
will O O 0.9999943971633911
be O O 0.9999879598617554
produced O O 0.9999920129776001
. O O 0.9999967813491821

Testosterone S-Chemical S-Chemical 0.9291458129882812
replacement O O 0.9999967813491821
in O O 0.9999898672103882
castrated O O 0.9409185647964478
DS O O 0.7987948656082153
rats O O 0.9976173043251038
increased O O 0.9999949932098389
BP O O 0.9073344469070435
, O O 0.9999231100082397
renal O O 0.9999525547027588
injury O O 0.9999845027923584
, O O 0.9999935626983643
and O O 0.9999891519546509
upregulation O O 0.9998501539230347
of O O 0.9999492168426514
renal O O 0.9881975054740906
angiotensinogen O O 0.899358868598938
associated O O 0.9998950958251953
with O O 0.9999947547912598
HS O O 0.860366702079773
diet O O 0.997795581817627
. O O 0.9999988079071045

Subsequent O O 0.9998094439506531
amantadine S-Chemical S-Chemical 0.9927575588226318
treatments O O 0.9999594688415527
produced O O 0.9999899864196777
enhancement O O 0.9999706745147705
of O O 0.9999542236328125
motility O O 0.9987014532089233
from O O 0.9999920129776001
corresponding O O 0.9998692274093628
control O O 0.9998328685760498
in O O 0.9999959468841553
all O O 0.9999805688858032
mouse O O 0.9985972046852112
strains O O 0.999951958656311
with O O 0.9999991655349731
the O O 0.9999192953109741
BALB O O 0.9969885945320129
/ O O 0.9999041557312012
C O O 0.9862544536590576
mice O O 0.9992775321006775
being O O 0.9999964237213135
the O O 0.9999991655349731
least O O 0.9999985694885254
sensitive O O 0.9999845027923584
. O O 0.9999985694885254

A O O 0.9956087470054626
47 O O 0.9986395239830017
- O O 0.9999421834945679
year O O 0.9999974966049194
- O O 0.9999557733535767
old O O 0.9999480247497559
patient O O 0.9999639987945557
suffering O O 0.9999990463256836
from O O 0.9999995231628418
coronary O O 0.9999330043792725
artery O O 0.999977707862854
disease O O 0.9999650716781616
was O O 0.999998927116394
admitted O O 0.9999985694885254
to O O 0.9999964237213135
the O O 0.9998584985733032
CCU O O 0.9970909357070923
in O O 0.9999992847442627
shock O O 0.9999892711639404
with O O 0.9999971389770508
III O O 0.8906928896903992
. O O 0.999988317489624

Mazindol S-Chemical S-Chemical 0.8890907168388367
did O O 0.9999953508377075
not O O 0.9999961853027344
benefit O O 0.9999947547912598
strength O O 0.9999982118606567
at O O 0.9999998807907104
any O O 0.9999998807907104
point O O 0.9999996423721313
in O O 1.0
the O O 0.999997615814209
study O O 0.9999942779541016
. O O 0.9999986886978149

Cardiac O O 0.9950496554374695
toxicity O O 0.9996702671051025
observed O O 0.9999959468841553
in O O 0.9999982118606567
association O O 0.9999927282333374
with O O 0.9999985694885254
high O O 0.999954342842102
- O O 0.998206377029419
dose O O 0.9998241066932678
cyclophosphamide S-Chemical S-Chemical 0.9819685816764832
- O O 0.995297372341156
based O O 0.9999643564224243
chemotherapy O O 0.996758759021759
for O O 0.9999980926513672
metastatic O O 0.9998387098312378
breast O O 0.9997401833534241
cancer O O 0.9999228715896606
. O O 0.9999992847442627

Four O O 0.9981380701065063
compounds O O 0.9995571970939636
known O O 0.9999991655349731
to O O 0.9999947547912598
increase O O 0.9999504089355469
QT O O 0.9446927309036255
interval O O 0.9985660910606384
and O O 0.9999873638153076
cause O O 0.9999207258224487
TDP O O 0.976599395275116
were O O 0.9999966621398926
investigated O O 0.9999926090240479
: O O 0.9997311234474182
terfenadine S-Chemical S-Chemical 0.9743401408195496
, O O 0.9991451501846313
terodiline S-Chemical S-Chemical 0.9654129147529602
, O O 0.998414158821106
cisapride S-Chemical S-Chemical 0.9940978288650513
and O O 0.9987919926643372
E4031 S-Chemical S-Chemical 0.9542840123176575
. O O 0.9999908208847046

Cardioprotective O O 0.9996174573898315
effect O O 0.999962329864502
of O O 0.99972003698349
salvianolic B-Chemical B-Chemical 0.9965901374816895
acid I-Chemical I-Chemical 0.754722535610199
A E-Chemical E-Chemical 0.99289870262146
on O O 0.9921417236328125
isoproterenol S-Chemical S-Chemical 0.9974349141120911
- O O 0.9961636066436768
induced O O 0.9999884366989136
myocardial O O 0.9998553991317749
infarction O O 0.9999241828918457
in O O 0.9999921321868896
rats O O 0.9995427131652832
. O O 0.9999977350234985

CONCLUSIONS O O 0.9998056292533875
: O O 0.9999887943267822
Prilocaine S-Chemical S-Chemical 0.9252578616142273
may O O 0.9999822378158569
be O O 0.999997615814209
preferable O O 0.9999980926513672
to O O 0.9999426603317261
lidocaine S-Chemical S-Chemical 0.9987988471984863
for O O 0.9999904632568359
short O O 0.9999027252197266
surgical O O 0.9998243451118469
procedures O O 0.9998854398727417
because O O 0.9999980926513672
it O O 0.9999793767929077
has O O 0.9999955892562866
a O O 0.9999980926513672
similar O O 0.9999904632568359
duration O O 0.9999822378158569
of O O 0.999993085861206
action O O 0.9999322891235352
but O O 0.9999982118606567
a O O 0.9999997615814209
lower O O 0.9999984502792358
incidence O O 0.9999796152114868
of O O 0.9999439716339111
TNSs O O 0.938634991645813
. O O 0.9999909400939941

Concomitant O O 0.9823233485221863
curcumin S-Chemical S-Chemical 0.918332040309906
administration O O 0.9999626874923706
prevented O O 0.9999983310699463
the O O 0.9999691247940063
cognitive O O 0.9999626874923706
impairment O O 0.999982476234436
and O O 0.9999982118606567
decreased O O 0.9999986886978149
the O O 0.9999916553497314
increased O O 0.9999847412109375
oxidative O O 0.9996225833892822
stress O O 0.9999665021896362
induced O O 0.9999961853027344
by O O 0.9999990463256836
these O O 0.9996365308761597
antiepileptic O O 0.9964839220046997
drugs O O 0.9997543692588806
. O O 0.9999978542327881

There O O 0.9999722242355347
was O O 0.9999997615814209
no O O 1.0
significant O O 0.9999966621398926
difference O O 0.9999986886978149
between O O 0.9999986886978149
occupancy O O 0.9935076236724854
levels O O 0.9999637603759766
obtained O O 0.9999858140945435
with O O 0.9999178647994995
haloperidol S-Chemical S-Chemical 0.9756075143814087
or O O 0.9992256164550781
risperidone S-Chemical S-Chemical 0.9986687898635864
. O O 0.9999805688858032

The O O 0.9999572038650513
epidemiological O O 0.9994186162948608
studies O O 0.9999444484710693
that O O 0.9999901056289673
assessed O O 0.9999911785125732
the O O 0.9999761581420898
risk O O 0.9999959468841553
of O O 0.9999972581863403
venous O O 0.9926462173461914
thromboembolism O O 0.988905668258667
( O O 0.9998395442962646
VTE O O 0.9877393841743469
) O O 0.9998832941055298
associated O O 0.9999890327453613
with O O 0.999996542930603
newer O O 0.9971123933792114
oral B-Chemical B-Chemical 0.5435059070587158
contraceptives E-Chemical E-Chemical 0.9666747450828552
( O O 0.9991039633750916
OC S-Chemical S-Chemical 0.3990250527858734
) O O 0.9975785613059998
did O O 0.9999895095825195
not O O 0.9999963045120239
distinguish O O 0.999984622001648
between O O 0.9999951124191284
patterns O O 0.9998492002487183
of O O 0.9999489784240723
OC S-Chemical S-Chemical 0.40972745418548584
use O O 0.9995810389518738
, O O 0.9999984502792358
namely O O 0.9999973773956299
first O O 0.9999653100967407
- O O 0.9997860789299011
time O O 0.9999557733535767
users O O 0.9999300241470337
, O O 0.9999921321868896
repeaters O O 0.9999172687530518
and O O 0.9999939203262329
switchers O O 0.9998462200164795
. O O 0.9999979734420776

Oral B-Chemical B-Chemical 0.6407129764556885
contraceptives E-Chemical E-Chemical 0.8960764408111572
and O O 0.9999610185623169
the O O 0.9999957084655762
risk O O 0.9999990463256836
of O O 0.9999990463256836
myocardial O O 0.9999769926071167
infarction O O 0.9999935626983643
. O O 0.9999988079071045

The O O 0.9999871253967285
aim O O 0.9999985694885254
of O O 0.9999991655349731
this O O 0.9999911785125732
study O O 0.9999852180480957
was O O 0.9999998807907104
to O O 0.9999966621398926
examine O O 0.9998185038566589
further O O 0.9999982118606567
the O O 0.9999935626983643
renal O O 0.999403715133667
function O O 0.9999936819076538
, O O 0.9999980926513672
including O O 0.9999980926513672
morphological O O 0.9989233613014221
analysis O O 0.9999533891677856
of O O 0.9999814033508301
the O O 0.9999539852142334
kidneys O O 0.9996354579925537
of O O 0.9999572038650513
male O O 0.9991512298583984
Sprague O O 0.9949642419815063
- O O 0.9993283748626709
Dawley O O 0.9996795654296875
rats O O 0.9999433755874634
treated O O 0.9999932050704956
with O O 0.9999850988388062
either O O 0.993669331073761
cyclosporine B-Chemical B-Chemical 0.7108744978904724
A E-Chemical E-Chemical 0.9411937594413757
( O O 0.9928905963897705
CsA S-Chemical O 0.41070082783699036
) O O 0.8304226994514465
, O O 0.9868908524513245
tacrolimus S-Chemical S-Chemical 0.943693995475769
( O O 0.9981558918952942
FK506 S-Chemical S-Chemical 0.9417479038238525
) O O 0.9961686730384827
or O O 0.9996167421340942
SRL S-Chemical S-Chemical 0.9485594034194946
as O O 0.9999629259109497
monotherapies O O 0.9940537810325623
or O O 0.9999886751174927
in O O 0.9999983310699463
different O O 0.9999942779541016
combinations O O 0.9999725818634033
. O O 0.9999991655349731

All O O 0.9999032020568848
patients O O 0.9999839067459106
were O O 0.9999988079071045
on O O 0.9999985694885254
a O O 0.9999431371688843
regular O O 0.9940909743309021
transfusion O O 0.9970471262931824
- O O 0.9979597330093384
chelation O O 0.9360975623130798
program O O 0.9999834299087524
maintaining O O 0.9999877214431763
a O O 0.999961256980896
mean O O 0.9995301961898804
hemoglobin O O 0.9782217144966125
level O O 0.999990701675415
of O O 0.9999899864196777
9 O O 0.9991845488548279
. O O 0.9999781847000122
5 O O 0.9998794794082642
gr O O 0.9998030066490173
/ O O 0.9999746084213257
dl O O 0.9994283318519592
. O O 0.9999951124191284

Magnetic O O 0.9981781244277954
resonance O O 0.9998598098754883
volumetry O O 0.9986116886138916
of O O 0.9998039603233337
the O O 0.9986522793769836
cerebellum O O 0.8891677856445312
in O O 0.9999829530715942
epileptic O O 0.998843789100647
patients O O 0.9998965263366699
after O O 0.9999723434448242
phenytoin S-Chemical S-Chemical 0.905911386013031
overdosages O O 0.9965233206748962
. O O 0.9999908208847046

The O O 0.9996623992919922
histology O O 0.9983231425285339
comprised O O 0.999996542930603
squamous O O 0.9945342540740967
carcinoma O O 0.9906759262084961
( O O 0.9994606375694275
11 O O 0.9806982278823853
) O O 0.9972068667411804
, O O 0.9998613595962524
adenocarcinoma O O 0.9675955176353455
( O O 0.9979257583618164
1 O O 0.9771562814712524
) O O 0.9973626732826233
, O O 0.999974250793457
mixed O O 0.9977174997329712
histology O O 0.9861966967582703
( O O 0.9993749260902405
2 O O 0.9813634157180786
) O O 0.9971998929977417
, O O 0.999946117401123
bronchio O O 0.8850117921829224
- O O 0.9222192764282227
alveolar O O 0.9673022031784058
carcinoma O O 0.9866547584533691
( O O 0.9992744326591492
1 O O 0.9939616322517395
) O O 0.9992491602897644
and O O 0.9999873638153076
large O O 0.9974260926246643
cell O O 0.9996383190155029
undifferentiated O O 0.9997678399085999
carcinoma O O 0.9949837923049927
( O O 0.999667763710022
1 O O 0.9945092797279358
) O O 0.9995163679122925
. O O 0.9999963045120239

Following O O 0.9999290704727173
discontinuation O O 0.9999973773956299
of O O 0.9999581575393677
SNP S-Chemical S-Chemical 0.6981346607208252
, O O 0.9999754428863525
blood O O 0.9966675639152527
pressure O O 0.999915361404419
in O O 0.9999970197677612
the O O 0.9999834299087524
control O O 0.9984472393989563
animals O O 0.9994458556175232
rebounded O O 0.9999974966049194
to O O 0.9999611377716064
94 O O 0.9973371624946594
torr O O 0.9977026581764221
, O O 0.9999659061431885
as O O 0.9999805688858032
compared O O 0.9999940395355225
with O O 0.9999732971191406
78 O O 0.9966731071472168
torr O O 0.9989733695983887
in O O 0.9999409914016724
the O O 0.9992201328277588
saralasin S-Chemical S-Chemical 0.8746182322502136
- O O 0.996697187423706
treated O O 0.9999666213989258
rats O O 0.9995778203010559
. O O 0.9999974966049194

This O O 0.9997017979621887
was O O 0.9999990463256836
preceded O O 0.9999995231628418
by O O 0.9999985694885254
altered O O 0.9998238682746887
nephrin O O 0.595189094543457
expression O O 0.9989708662033081
, O O 0.999998927116394
supporting O O 0.9999973773956299
its O O 0.9999985694885254
pivotal O O 0.9999845027923584
role O O 0.9999996423721313
in O O 0.9999982118606567
podocyte O O 0.5951042771339417
morphology O O 0.9919805526733398
. O O 0.9999972581863403

Previous O O 0.9999836683273315
studies O O 0.9999324083328247
have O O 0.9999585151672363
demonstrated O O 0.9999927282333374
that O O 0.999852180480957
Rg1 S-Chemical S-Chemical 0.8872284889221191
might O O 0.9999839067459106
be O O 0.9999984502792358
a O O 0.9999967813491821
useful O O 0.9998844861984253
agent O O 0.9988083839416504
for O O 0.9999959468841553
the O O 0.999963641166687
prevention O O 0.9999796152114868
and O O 0.9999978542327881
treatment O O 0.9999969005584717
of O O 0.9999961853027344
the O O 0.9999970197677612
adverse O O 0.9999902248382568
effects O O 0.9999971389770508
of O O 0.9999077320098877
morphine S-Chemical S-Chemical 0.9991206526756287
. O O 0.9999830722808838

Five O O 0.9989150762557983
females O O 0.9996761083602905
and O O 0.9999884366989136
6 O O 0.9977506995201111
males O O 0.9995872378349304
, O O 0.9999641180038452
21 O O 0.9994896650314331
- O O 0.9997606873512268
59 O O 0.9999499320983887
years O O 0.9999979734420776
of O O 0.9999996423721313
age O O 0.9999910593032837
, O O 0.9999986886978149
were O O 0.9999992847442627
examined O O 0.9999986886978149
with O O 0.9999973773956299
a O O 0.9999161958694458
1 O O 0.959277331829071
. O O 0.9984846711158752
5 O O 0.9664254784584045
- O O 0.9687591195106506
T O O 0.9905321598052979
whole O O 0.9991324543952942
- O O 0.9986326098442078
body O O 0.999459445476532
system O O 0.999828577041626
using O O 0.9999834299087524
a O O 0.9998751878738403
circular O O 0.9956744313240051
polarized O O 0.993014931678772
head O O 0.9992865920066833
coil O O 0.9982228875160217
. O O 0.9999953508377075

Cerebral O O 0.9995695948600769
haemorrhage O O 0.999974250793457
induced O O 0.9999971389770508
by O O 0.9999425411224365
warfarin S-Chemical S-Chemical 0.9704786539077759
- O O 0.9966669678688049
the O O 0.9999852180480957
influence O O 0.999957799911499
of O O 0.9999592304229736
drug O O 0.9983319640159607
- O O 0.9984910488128662
drug O O 0.9992884397506714
interactions O O 0.9998832941055298
. O O 0.9999984502792358

Its O O 0.9998984336853027
role O O 0.9999992847442627
in O O 0.9999996423721313
the O O 0.9999760389328003
therapy O O 0.9999819993972778
of O O 0.9999657869338989
glomerulonephritis O O 0.8126354217529297
, O O 0.9990758895874023
autoimmunity O O 0.9992865920066833
, O O 0.9999963045120239
cystic O O 0.9988071918487549
renal O O 0.9998196959495544
diseases O O 0.9999744892120361
and O O 0.999998927116394
renal O O 0.9997978806495667
cancer O O 0.9999498128890991
is O O 0.9999991655349731
under O O 0.9999994039535522
investigation O O 0.999997615814209
. O O 0.9999982118606567

Dental O O 0.999554455280304
patients O O 0.9999072551727295
abusing O O 0.9998125433921814
methamphetamine S-Chemical S-Chemical 0.9958227872848511
can O O 0.9999891519546509
present O O 0.9999991655349731
with O O 0.9999992847442627
poor O O 0.9998131394386292
oral O O 0.9909875988960266
hygiene O O 0.9990710020065308
, O O 0.9999833106994629
xerostomia O O 0.9880071878433228
, O O 0.9999867677688599
rampant O O 0.9973629117012024
caries O O 0.9878947138786316
( O O 0.9999603033065796
" O O 0.9980509281158447
meth O O 0.9845459461212158
mouth O O 0.987128734588623
" O O 0.9990917444229126
) O O 0.9998794794082642
, O O 0.9999793767929077
and O O 0.9999934434890747
excessive O O 0.999934196472168
tooth O O 0.9996320009231567
wear O O 0.9993605017662048
. O O 0.9999980926513672

CONCLUSIONS O O 0.9999258518218994
: O O 0.9999992847442627
Currently O O 0.9999850988388062
accepted O O 0.999933123588562
intravitreal O O 0.9827200174331665
antibiotic O O 0.8834167122840881
regimens O O 0.9932546019554138
may O O 0.999997615814209
cause O O 0.9999967813491821
retinal O O 0.9994682669639587
toxicity O O 0.9997881054878235
and O O 0.9999964237213135
macular O O 0.99993896484375
ischaemia O O 0.9993993043899536
. O O 0.9999983310699463

The O O 0.9994035959243774
serum O O 0.9959964752197266
creatinine S-Chemical S-Chemical 0.9518157243728638
levels O O 0.9999653100967407
of O O 0.999964714050293
patients O O 0.9999639987945557
in O O 0.9999991655349731
the O O 0.999984622001648
mild O O 0.9996563196182251
- O O 0.9993895292282104
type O O 0.9995819926261902
chronic O O 0.995591402053833
FK506 S-Chemical S-Chemical 0.5163319110870361
nephropathy O O 0.8170244097709656
group O O 0.9945715069770813
, O O 0.999950647354126
which O O 0.9999786615371704
included O O 0.9999922513961792
7 O O 0.9957700371742249
episode O O 0.9993844032287598
biopsies O O 0.9983119964599609
, O O 0.999991774559021
were O O 0.9999979734420776
statistically O O 0.9999988079071045
higher O O 0.9999990463256836
than O O 0.9999977350234985
those O O 0.9999977350234985
in O O 0.9999985694885254
the O O 0.9999939203262329
minimum O O 0.999975323677063
- O O 0.9994839429855347
type O O 0.9996893405914307
chronic O O 0.9926621913909912
FK506 S-Chemical S-Chemical 0.7367774844169617
- O O 0.8048091530799866
nephropathy O O 0.7472666501998901
group O O 0.9916442036628723
( O O 0.9999172687530518
P O O 0.9884544014930725
< O O 0.9998036026954651
0 O O 0.9996854066848755
. O O 0.9999454021453857
001 O O 0.9993798732757568
) O O 0.9999494552612305
. O O 0.9999991655349731

Estrogens O O 0.8684669137001038
protect O O 0.9997970461845398
ovariectomized O O 0.9512975215911865
rats O O 0.9968852400779724
from O O 0.9999959468841553
hippocampal O O 0.9980223178863525
injury O O 0.9999772310256958
induced O O 0.999996542930603
by O O 0.9999858140945435
kainic B-Chemical B-Chemical 0.9988256096839905
acid E-Chemical E-Chemical 0.973939836025238
- O O 0.9770912528038025
induced O O 0.9997895359992981
status O O 0.9995782971382141
epilepticus O O 0.9817942380905151
( O O 0.9986773133277893
SE O O 0.9565934538841248
) O O 0.998981773853302
. O O 0.9999973773956299

The O O 0.9999008178710938
increased O O 0.9996757507324219
nicotine S-Chemical S-Chemical 0.996766209602356
exposure O O 0.9999520778656006
from O O 0.9999897480010986
the O O 0.9997465014457703
lozenge O O 0.9983142614364624
has O O 0.9999984502792358
raised O O 0.999998927116394
questions O O 0.9999899864196777
about O O 0.9999980926513672
the O O 0.9999979734420776
relative O O 0.9999841451644897
safety O O 0.999988317489624
of O O 0.9999626874923706
the O O 0.9990320205688477
lozenge O O 0.9703763127326965
and O O 0.9998505115509033
gum O O 0.6832162737846375
. O O 0.9997889399528503

Carbonic O O 0.5577062964439392
anhydrase O O 0.752112090587616
inhibitors O O 0.8909273743629456
can O O 0.9998786449432373
cause O O 0.9999611377716064
nephrolithiasis O O 0.9977741837501526
. O O 0.9999977350234985

We O O 0.9993705153465271
report O O 0.9999822378158569
QTLs O O 0.9872410297393799
identified O O 0.9999970197677612
using O O 0.9999719858169556
a O O 0.9994344115257263
B6 O O 0.9230630993843079
( O O 0.9990618824958801
host O O 0.9942898750305176
) O O 0.9994334578514099
x O O 0.9622781872749329
A O O 0.978266179561615
/ O O 0.9996793270111084
J O O 0.9923173189163208
( O O 0.9999343156814575
donor O O 0.9994757771492004
) O O 0.9998884201049805
CSS O O 0.9763913750648499
panel O O 0.9999634027481079
to O O 0.9999939203262329
localize O O 0.9921225905418396
genes O O 0.9994686245918274
involved O O 0.9999984502792358
in O O 0.9999982118606567
susceptibility O O 0.9999878406524658
to O O 0.999927282333374
pilocarpine S-Chemical S-Chemical 0.9975618124008179
- O O 0.9951587319374084
induced O O 0.9999586343765259
seizures O O 0.9999637603759766
. O O 0.9999991655349731

The O O 0.9995980858802795
ASEX O O 0.7444246411323547
score O O 0.9988603591918945
and O O 0.9999665021896362
CGI O O 0.9337692856788635
- O O 0.9933741688728333
SF O O 0.9936071634292603
score O O 0.9998427629470825
were O O 0.999997615814209
correlated O O 0.9999914169311523
( O O 0.9999874830245972
P O O 0.9970623850822449
= O O 0.9999854564666748
0 O O 0.9998838901519775
. O O 0.9999693632125854
003 O O 0.9994097948074341
) O O 0.9999576807022095
. O O 0.9999986886978149

We O O 0.9989163875579834
used O O 0.999998927116394
an O O 0.9998617172241211
in O O 0.9999662637710571
vitro O O 0.9988864064216614
model O O 0.9999469518661499
of O O 0.9999731779098511
chemotherapy O O 0.9940453767776489
induced O O 0.999977707862854
peripheral O O 0.998196542263031
neuropathy O O 0.9983047246932983
that O O 0.9999794960021973
closely O O 0.9999926090240479
mimic O O 0.9999815225601196
the O O 0.9999449253082275
in O O 0.9999686479568481
vivo O O 0.9972967505455017
condition O O 0.9999662637710571
by O O 0.9999991655349731
exposing O O 0.9999831914901733
primary O O 0.9985755681991577
cultures O O 0.9996391534805298
of O O 0.9999557733535767
dorsal O O 0.9988030195236206
root O O 0.9920431971549988
ganglion O O 0.9782887697219849
( O O 0.9998224377632141
DRG O O 0.9594389796257019
) O O 0.9995008707046509
sensory O O 0.9999130964279175
neurons O O 0.999581515789032
to O O 0.99994957447052
paclitaxel S-Chemical S-Chemical 0.9151009917259216
and O O 0.9983727335929871
cisplatin S-Chemical S-Chemical 0.9829440712928772
, O O 0.9999185800552368
two O O 0.9983041286468506
widely O O 0.9991509914398193
used O O 0.9999144077301025
and O O 0.9999715089797974
highly O O 0.9999698400497437
effective O O 0.9991937279701233
chemotherapeutic O O 0.999030351638794
drugs O O 0.9996329545974731
. O O 0.9999982118606567

Other O O 0.9999749660491943
possible O O 0.9999948740005493
causes O O 0.9999957084655762
of O O 0.9999986886978149
rapidly O O 0.9999874830245972
progressive O O 0.999100923538208
glomerulonephritis O O 0.9498223662376404
were O O 0.9999960660934448
investigated O O 0.9999994039535522
and O O 0.9999996423721313
ruled O O 0.9999955892562866
out O O 0.9999943971633911
. O O 0.9999939203262329

These O O 0.9999653100967407
results O O 0.9999986886978149
suggest O O 0.9999992847442627
that O O 0.9999972581863403
endothelial O O 0.9914148449897766
cells O O 0.9996713399887085
treated O O 0.9999845027923584
simultaneously O O 0.9999814033508301
with O O 0.9999774694442749
EPO O O 0.5465672612190247
and O O 0.9742133021354675
IL O O 0.8317418098449707
- O O 0.874903678894043
3 O O 0.8306854963302612
have O O 0.9999057054519653
a O O 0.9999992847442627
negative O O 0.99993896484375
effect O O 0.9999972581863403
on O O 0.9999974966049194
erythroid O O 0.8393869996070862
cell O O 0.9716081023216248
production O O 0.9999260902404785
. O O 0.9999992847442627

METHODS O O 0.9986048340797424
: O O 0.9999974966049194
We O O 0.9999734163284302
sent O O 0.9999973773956299
a O O 0.9999346733093262
questionnaire O O 0.9999494552612305
concerning O O 0.9999988079071045
complications O O 0.9997795224189758
of O O 0.9996358156204224
indocyanine B-Chemical B-Chemical 0.8402366042137146
green E-Chemical E-Chemical 0.8308722972869873
to O O 0.9997079968452454
32 O O 0.9972000122070312
institutions O O 0.9999784231185913
in O O 0.9999977350234985
Japan O O 0.9992722868919373
, O O 0.9999984502792358
which O O 0.9999948740005493
were O O 0.9999986886978149
selected O O 0.9999990463256836
on O O 0.9999990463256836
the O O 0.9999997615814209
basis O O 0.9999994039535522
of O O 0.999995231628418
the O O 0.9999878406524658
client O O 0.9994638562202454
list O O 0.9999675750732422
from O O 0.9999960660934448
the O O 0.9997416138648987
Topcon O O 0.9821538925170898
Company O O 0.9986281394958496
, O O 0.999980092048645
which O O 0.9997652173042297
manufactures O O 0.99996018409729
the O O 0.999560534954071
indocyanine B-Chemical O 0.8503101468086243
green E-Chemical O 0.8520269393920898
fundus O O 0.9817700982093811
camera O O 0.9996587038040161
. O O 0.9999974966049194

In O O 0.9999065399169922
all O O 0.9999886751174927
clones O O 0.9991075396537781
with O O 0.9999969005584717
combined O O 0.9994091987609863
immune O O 0.994122326374054
escape O O 0.9909911155700684
and O O 0.9999395608901978
LAM S-Chemical S-Chemical 0.4853164851665497
resistance O O 0.9984192848205566
mutations O O 0.9998987913131714
, O O 0.999998927116394
the O O 0.9996657371520996
nucleotide S-Chemical O 0.7776566743850708
analogues O O 0.9939059615135193
adefovir S-Chemical O 0.5776824355125427
and O O 0.997908353805542
tenofovir S-Chemical S-Chemical 0.7292371392250061
remained O O 0.9999806880950928
effective O O 0.9999926090240479
in O O 0.9999995231628418
suppressing O O 0.9999526739120483
viral O O 0.9997791647911072
replication O O 0.9999513626098633
in O O 0.9999959468841553
vitro O O 0.999376118183136
. O O 0.9999967813491821

Brain O O 0.997028648853302
natriuretic O O 0.9247230887413025
peptide O O 0.6652414202690125
is O O 0.9989482760429382
a O O 0.9999953508377075
predictor O O 0.9999485015869141
of O O 0.9996126294136047
anthracycline S-Chemical S-Chemical 0.9875558018684387
- O O 0.9961531758308411
induced O O 0.9999504089355469
cardiotoxicity O O 0.9997057318687439
. O O 0.9999980926513672

These O O 0.9999316930770874
differences O O 0.9999887943267822
may O O 0.9999996423721313
be O O 0.9999996423721313
caused O O 0.9999970197677612
by O O 0.9999234676361084
timolol S-Chemical S-Chemical 0.9981381893157959
- O O 0.9931280612945557
induced O O 0.9996601343154907
bradycardia O O 0.9966997504234314
and O O 0.9999840259552002
a O O 0.9999891519546509
compensatory O O 0.9998457431793213
increase O O 0.9999831914901733
in O O 0.9999985694885254
end O O 0.9998682737350464
- O O 0.9993426203727722
diastolic O O 0.9990468621253967
volume O O 0.9994756579399109
. O O 0.9999982118606567

Nitro B-Chemical B-Chemical 0.6301034092903137
- I-Chemical I-Chemical 0.7250908613204956
L I-Chemical I-Chemical 0.774050772190094
- I-Chemical I-Chemical 0.9623928666114807
arginine I-Chemical I-Chemical 0.6110488176345825
methyl I-Chemical I-Chemical 0.8525851368904114
ester E-Chemical E-Chemical 0.9953097701072693
: O O 0.99960857629776
a O O 0.9999911785125732
potential O O 0.9997896552085876
protector O O 0.9983343482017517
against O O 0.9999572038650513
gentamicin S-Chemical O 0.8803454041481018
ototoxicity O O 0.9973956346511841
. O O 0.9999953508377075

Organophosphate S-Chemical S-Chemical 0.9700555801391602
- O O 0.9987395405769348
induced O O 0.9999412298202515
convulsions O O 0.9998056292533875
and O O 0.9999958276748657
prevention O O 0.9999867677688599
of O O 0.9999953508377075
neuropathological O O 0.9999295473098755
damages O O 0.9999656677246094
. O O 0.9999986886978149

We O O 0.9996566772460938
studied O O 0.9999977350234985
a O O 0.9999915361404419
patient O O 0.9999610185623169
with O O 0.9999995231628418
no O O 0.9999978542327881
prior O O 0.9999967813491821
history O O 0.9999992847442627
of O O 0.9999996423721313
neuromuscular O O 0.9998993873596191
disease O O 0.9999672174453735
who O O 0.9999942779541016
became O O 0.9999971389770508
virtually O O 0.9999948740005493
quadriplegic O O 0.999019980430603
after O O 0.9999939203262329
parenteral O O 0.9666633605957031
magnesium S-Chemical S-Chemical 0.9728890061378479
administration O O 0.9999814033508301
for O O 0.9999969005584717
preeclampsia O O 0.9978653788566589
. O O 0.9999973773956299

High O O 0.999825656414032
doses O O 0.9999940395355225
of O O 0.9992806315422058
atropine S-Chemical S-Chemical 0.9970055222511292
( O O 0.9994499087333679
up O O 0.9982442855834961
to O O 0.9999338388442993
50 O O 0.9995933175086975
mg O O 0.9996563196182251
per O O 0.9999426603317261
24 O O 0.9998072981834412
hours O O 0.9998595714569092
) O O 0.9997498393058777
, O O 0.9996951818466187
adrenaline S-Chemical S-Chemical 0.988471508026123
and O O 0.9996505975723267
dopamine S-Chemical S-Chemical 0.9982193112373352
were O O 0.999995231628418
necessary O O 0.9999978542327881
. O O 0.9999984502792358

Electrical O O 0.9995377063751221
recordings O O 0.999815046787262
from O O 0.999991774559021
the O O 0.9998206496238708
hippocampus O O 0.9939562678337097
showed O O 0.9999971389770508
a O O 0.999997615814209
rhythmic O O 0.998809814453125
progression O O 0.9999829530715942
in O O 0.9999949932098389
EEG O O 0.9739219546318054
frequency O O 0.999954342842102
and O O 0.9999860525131226
voltage O O 0.9999574422836304
with O O 0.999998927116394
clinical O O 0.9999618530273438
seizure O O 0.999873161315918
expression O O 0.9999860525131226
. O O 0.9999994039535522

Total O O 0.9997512698173523
cell O O 0.9778046011924744
yields O O 0.9979177117347717
from O O 0.9999262094497681
DES S-Chemical S-Chemical 0.9544804692268372
- O O 0.9975226521492004
treated O O 0.9999806880950928
pituitaries O O 0.9993371367454529
increased O O 0.9999992847442627
from O O 0.9999927282333374
1 O O 0.999578058719635
. O O 0.9999842643737793
3 O O 0.9999313354492188
times O O 0.9999986886978149
control O O 0.9997721314430237
yields O O 0.9995697140693665
at O O 0.9999966621398926
8 O O 0.9999202489852905
days O O 0.999998927116394
of O O 0.9999984502792358
treatment O O 0.9999983310699463
to O O 0.9999972581863403
58 O O 0.9997370839118958
. O O 0.999997615814209
9 O O 0.999946117401123
times O O 0.9999990463256836
control O O 0.9998915195465088
values O O 0.9999854564666748
by O O 0.9999990463256836
day O O 0.9999239444732666
150 O O 0.998771607875824
. O O 0.9999982118606567

These O O 0.9999641180038452
results O O 0.9999988079071045
provide O O 0.9999995231628418
evidence O O 0.9999984502792358
for O O 0.9999997615814209
a O O 0.9999997615814209
possible O O 0.9999983310699463
mechanistic O O 0.9999797344207764
role O O 0.9999983310699463
of O O 0.99998939037323
oxidative O O 0.9990468621253967
and O O 0.9999676942825317
nitrosative O O 0.8777926564216614
stress O O 0.989837110042572
and O O 0.999386191368103
NFkappaB O O 0.9138217568397522
in O O 0.9999932050704956
the O O 0.9999783039093018
alterations O O 0.9999897480010986
induced O O 0.9999972581863403
by O O 0.9999918937683105
cocaine S-Chemical S-Chemical 0.9990369081497192
. O O 0.9999868869781494

The O O 0.9999516010284424
times O O 0.9999980926513672
to O O 0.9999991655349731
first O O 0.9996531009674072
fasciculation O O 0.998273491859436
, O O 0.9999632835388184
twitch O O 0.9180044531822205
suppression O O 0.9988184571266174
and O O 0.9999760389328003
tetanus O O 0.8676143288612366
suppression O O 0.9995681643486023
were O O 0.9999995231628418
inversely O O 0.9999998807907104
related O O 0.999998927116394
to O O 0.9999978542327881
the O O 0.9998892545700073
infusion O O 0.9999799728393555
rates O O 0.9999659061431885
. O O 0.9999988079071045

The O O 0.9999765157699585
present O O 0.9999452829360962
study O O 0.9999967813491821
was O O 0.9999998807907104
designed O O 0.9999998807907104
to O O 0.9999995231628418
investigate O O 0.999995231628418
the O O 0.9999792575836182
hypothesis O O 0.9999783039093018
that O O 0.9999607801437378
calcium S-Chemical S-Chemical 0.9890192151069641
channel O O 0.9996628761291504
blockers O O 0.9996485710144043
in O O 0.9999938011169434
general O O 0.9950339794158936
induce O O 0.9999810457229614
cardiovascular O O 0.999976634979248
malformations O O 0.9999212026596069
indicating O O 0.9999994039535522
a O O 0.9999921321868896
pharmacologic O O 0.9994927644729614
class O O 0.9999314546585083
effect O O 0.9999891519546509
. O O 0.9999983310699463

The O O 0.999962568283081
results O O 0.9999994039535522
of O O 0.9999991655349731
detailed O O 0.9999738931655884
laboratory O O 0.9999344348907471
tests O O 0.9999949932098389
and O O 0.9999995231628418
evaluations O O 0.9999938011169434
of O O 0.9999978542327881
various O O 0.9999613761901855
quantitative O O 0.9998188614845276
and O O 0.9999982118606567
qualitative O O 0.9998354911804199
tolerability O O 0.9996892213821411
parameters O O 0.9998201727867126
were O O 0.9999998807907104
not O O 0.9999998807907104
indicative O O 0.9999998807907104
of O O 0.9999979734420776
toxic O O 0.9995591044425964
effects O O 0.999983549118042
. O O 0.9999985694885254

Prenatal O O 0.9925885200500488
protein O O 0.8297483921051025
deprivation O O 0.9991180300712585
alters O O 0.999937891960144
dopamine S-Chemical S-Chemical 0.996670663356781
- O O 0.9980074763298035
mediated O O 0.999966025352478
behaviors O O 0.9999688863754272
and O O 0.9999909400939941
dopaminergic O O 0.9301427602767944
and O O 0.9991657733917236
glutamatergic O O 0.798197865486145
receptor O O 0.9930777549743652
binding O O 0.9998836517333984
. O O 0.9999988079071045

TCR S-Chemical S-Chemical 0.405582994222641
protected O O 0.9993213415145874
against O O 0.9999942779541016
pathological O O 0.999889612197876
changes O O 0.9999854564666748
induced O O 0.9999967813491821
by O O 0.9999604225158691
isoproterenol S-Chemical S-Chemical 0.9981100559234619
in O O 0.9999593496322632
rat O O 0.9993320107460022
heart O O 0.999963641166687
. O O 0.9999980926513672

It O O 0.9999079704284668
is O O 0.9999964237213135
recommended O O 0.9999997615814209
that O O 0.999998927116394
further O O 0.9999895095825195
studies O O 0.9999772310256958
and O O 0.9999986886978149
investigations O O 0.9999635219573975
are O O 0.999998927116394
undertaken O O 0.9999959468841553
in O O 0.9999985694885254
the O O 0.9999963045120239
effort O O 0.9999980926513672
to O O 0.9999992847442627
minimize O O 0.9999945163726807
such O O 0.999998927116394
severe O O 0.999991774559021
side O O 0.999963641166687
effects O O 0.9999948740005493
. O O 0.9999986886978149

Every O O 0.9997480511665344
patient O O 0.9998680353164673
was O O 0.999992847442627
screened O O 0.9999936819076538
for O O 0.9999535083770752
testosterone S-Chemical S-Chemical 0.9954347014427185
and O O 0.9997588992118835
451 O O 0.9527844786643982
were O O 0.9999746084213257
screened O O 0.999992847442627
for O O 0.9999910593032837
prolactin O O 0.9895639419555664
on O O 0.9999680519104004
the O O 0.9999955892562866
basis O O 0.9999982118606567
of O O 0.9999985694885254
low O O 0.9999748468399048
sexual O O 0.999901533126831
desire O O 0.9989964365959167
, O O 0.9998641014099121
gynecomastia O S-Chemical 0.5437062978744507
or O O 0.9991169571876526
testosterone S-Chemical S-Chemical 0.9990171194076538
less O O 0.9999760389328003
than O O 0.9999850988388062
4 O O 0.9987512826919556
ng O O 0.9997778534889221
. O O 0.9999977350234985
/ O O 0.9999946355819702
ml O O 0.9995336532592773
. O O 0.999985933303833

In O O 0.9998922348022461
view O O 0.999998927116394
of O O 0.9999958276748657
the O O 0.9999983310699463
potentially O O 0.9999982118606567
widespread O O 0.9999768733978271
use O O 0.9999954700469971
of O O 0.9999834299087524
these O O 0.9993231296539307
compounds O O 0.9991759657859802
, O O 0.9999980926513672
there O O 0.9999982118606567
is O O 0.9999992847442627
an O O 0.9999994039535522
urgent O O 0.9999961853027344
need O O 0.9999985694885254
to O O 0.9999992847442627
develop O O 0.9999939203262329
safer O O 0.9999186992645264
alternatives O O 0.9997082352638245
. O O 0.9999973773956299

Six O O 0.9974097609519958
patients O O 0.9999700784683228
( O O 0.9999957084655762
12 O O 0.9999710321426392
% O O 0.999997615814209
) O O 0.9999886751174927
had O O 0.9999991655349731
World O O 0.9988234639167786
Health O O 0.9999923706054688
Organization O O 0.999993085861206
Grade O O 0.9997484087944031
3 O O 0.9884815216064453
- O O 0.9910089373588562
4 O O 0.9927513599395752
neutropenia O O 0.9830476641654968
, O O 0.9999490976333618
2 O O 0.9931733012199402
patients O O 0.9996020197868347
( O O 0.9999816417694092
4 O O 0.9999459981918335
% O O 0.9999951124191284
) O O 0.999955415725708
had O O 0.9999856948852539
Grade O O 0.9983786344528198
3 O O 0.981966495513916
- O O 0.9808565378189087
4 O O 0.9830001592636108
thrombocytopenia O O 0.9980142116546631
, O O 0.9999852180480957
and O O 0.999969482421875
2 O O 0.9949224591255188
patients O O 0.9998445510864258
( O O 0.9999836683273315
4 O O 0.9999409914016724
% O O 0.9999951124191284
) O O 0.9999440908432007
had O O 0.9999914169311523
Grade O O 0.9918253421783447
3 O O 0.9916862845420837
neurotoxicity O O 0.9994915723800659
. O O 0.999997615814209

His O O 0.9999017715454102
medical O O 0.9999524354934692
history O O 0.9999973773956299
was O O 0.9999997615814209
unremarkable O O 0.9999991655349731
, O O 0.9999990463256836
except O O 0.9999982118606567
for O O 0.9999995231628418
minor O O 0.9999947547912598
fractures O O 0.9999972581863403
of O O 0.9999887943267822
the O O 0.999972939491272
fingers O O 0.9999035596847534
and O O 0.9999905824661255
foot O O 0.9999475479125977
. O O 0.9999977350234985

Of O O 0.9998138546943665
24 O O 0.9999390840530396
evaluable O O 0.9999934434890747
patients O O 0.9999866485595703
, O O 0.9999985694885254
two O O 0.999987006187439
achieved O O 0.9999988079071045
a O O 0.9999985694885254
complete O O 0.9999759197235107
remission O O 0.9999964237213135
and O O 0.999997615814209
one O O 0.9999728202819824
achieved O O 0.9999996423721313
a O O 0.9999984502792358
partial O O 0.9998055100440979
remission O O 0.9999910593032837
for O O 0.9999970197677612
an O O 0.9999942779541016
overall O O 0.999976396560669
response O O 0.9999918937683105
rate O O 0.9999942779541016
of O O 0.9999980926513672
12 O O 0.9999051094055176
. O O 0.9999982118606567
5 O O 0.9999703168869019
% O O 0.9999980926513672
( O O 0.9999948740005493
95 O O 0.999980092048645
% O O 0.9999984502792358
confidence O O 0.9997972846031189
interval O O 0.9999767541885376
: O O 0.9999960660934448
2 O O 0.9996501207351685
. O O 0.9999860525131226
6 O O 0.9998859167098999
- O O 0.999839186668396
32 O O 0.9999510049819946
. O O 0.9999942779541016
4 O O 0.9999791383743286
% O O 0.9999958276748657
) O O 0.9999597072601318
. O O 0.9999980926513672

TEM O S-Chemical 0.898824155330658
revealed O O 0.9999818801879883
extensive O O 0.9998223185539246
elastolysis O O 0.9820063710212708
in O O 0.9999755620956421
the O O 0.9999779462814331
arterial O O 0.9996129870414734
wall O O 0.999940037727356
of O O 0.999686598777771
D B-Chemical B-Chemical 0.665300726890564
- I-Chemical I-Chemical 0.9270852208137512
pen E-Chemical E-Chemical 0.9629753232002258
- O O 0.978029727935791
treated O O 0.9998334646224976
rats O O 0.9996021389961243
, O O 0.9999886751174927
consistent O O 0.9999943971633911
with O O 0.9999960660934448
an O O 0.999974250793457
inhibitory O O 0.9997661709785461
effect O O 0.9999778270721436
on O O 0.9999926090240479
crosslink O O 0.9696186184883118
formation O O 0.9997833371162415
. O O 0.999998927116394

RATIONALE O O 0.9987479448318481
: O O 0.9999449253082275
gamma B-Chemical B-Chemical 0.9007756114006042
- I-Chemical I-Chemical 0.9271580576896667
Vinyl I-Chemical I-Chemical 0.7751970291137695
GABA E-Chemical E-Chemical 0.9024455547332764
( O O 0.998310923576355
GVG S-Chemical S-Chemical 0.7194884419441223
) O O 0.9837307929992676
irreversibly O O 0.9997026324272156
inhibits O O 0.9997450709342957
GABA S-Chemical S-Chemical 0.6016904711723328
- O O 0.97906094789505
transaminase O O 0.9167031049728394
. O O 0.9999918937683105

Sulpiride S-Chemical S-Chemical 0.9249373078346252
induced O O 0.9999977350234985
only O O 0.9998849630355835
SOCS O O 0.558037519454956
- O O 0.8010205626487732
1 O O 0.9626348614692688
in O O 0.9999676942825317
the O O 0.9999957084655762
medial O O 0.9997922778129578
preoptic O O 0.9972242116928101
area O O 0.999213457107544
, O O 0.9999940395355225
where O O 0.9999831914901733
GnRH O O 0.980797290802002
neurons O O 0.9991222023963928
are O O 0.9999929666519165
regulated O O 0.9999872446060181
, O O 0.9999918937683105
but O O 0.9999929666519165
in O O 0.9999957084655762
the O O 0.9999734163284302
arcuate O O 0.9915157556533813
nucleus O O 0.9984216690063477
and O O 0.9998500347137451
choroid O O 0.8960710167884827
plexus O O 0.953493595123291
, O O 0.9977599382400513
PRL O O 0.9779999852180481
- O O 0.9927698969841003
R O O 0.9980776309967041
, O O 0.9998425245285034
SOCS O O 0.9783343076705933
- O O 0.984153687953949
3 O O 0.9827661514282227
, O O 0.9995381832122803
and O O 0.9998955726623535
CIS O O 0.9914484024047852
mRNA O O 0.9978474378585815
levels O O 0.9999788999557495
were O O 0.9999947547912598
also O O 0.999996542930603
induced O O 0.9999974966049194
. O O 0.9999991655349731

The O O 0.9999492168426514
advantage O O 0.9999997615814209
of O O 0.9999966621398926
standard O O 0.9981966614723206
dose O O 0.9999798536300659
over O O 0.9999246597290039
low O O 0.9996744394302368
dose O O 0.9998902082443237
was O O 0.9999758005142212
replicated O O 0.9999961853027344
in O O 0.9999983310699463
phase O O 0.9997367262840271
B O O 0.9975981116294861
. O O 0.9999945163726807

Similar O O 0.999971866607666
mechanisms O O 0.9999618530273438
may O O 0.9999991655349731
be O O 0.9999992847442627
involved O O 0.9999997615814209
in O O 0.9999995231628418
the O O 0.9999895095825195
pathogenesis O O 0.9996743202209473
of O O 0.999992847442627
cluster O O 0.9997109770774841
headache O O 0.9997467398643494
. O O 0.999998927116394

Acute O O 0.9996121525764465
hepatitis O O 0.984741747379303
attack O O 0.9997240900993347
after O O 0.9999946355819702
exposure O O 0.9999393224716187
to O O 0.9999001026153564
telithromycin S-Chemical S-Chemical 0.984805166721344
. O O 0.9999710321426392

The O O 0.9999297857284546
similarity O O 0.9999951124191284
between O O 0.999998927116394
the O O 0.9999796152114868
histologic O O 0.9981755018234253
appearances O O 0.9999241828918457
of O O 0.9999122619628906
busulfan S-Chemical S-Chemical 0.7169961333274841
cystitis O O 0.7287669777870178
and O O 0.999078631401062
both O O 0.9996286630630493
radiation O O 0.9893683791160583
and O O 0.9996802806854248
cyclophosphamide S-Chemical S-Chemical 0.9846173524856567
- O O 0.9983885288238525
induced O O 0.9998784065246582
cystitis O O 0.9979096055030823
is O O 0.9999959468841553
discussed O O 0.9999990463256836
and O O 0.9999980926513672
the O O 0.9999958276748657
world O O 0.9999163150787354
literature O O 0.9998914003372192
reviewed O O 0.9999977350234985
. O O 0.9999964237213135

Patients O O 0.9997410178184509
without O O 0.999991774559021
proteinuria O O 0.9906070232391357
had O O 0.9999972581863403
increased O O 0.9999959468841553
renal O O 0.999572217464447
function O O 0.999969482421875
( O O 0.9999949932098389
median O O 0.9997679591178894
42 O O 0.9997615218162537
. O O 0.9999853372573853
5 O O 0.9998705387115479
vs O O 0.9999500513076782
. O O 0.9999575614929199
64 O O 0.9998747110366821
. O O 0.9999881982803345
1 O O 0.9997542500495911
, O O 0.9999551773071289
p O O 0.9998829364776611
= O O 0.9999929666519165
0 O O 0.999930739402771
. O O 0.999968409538269
25 O O 0.9997089505195618
) O O 0.9999401569366455
, O O 0.9999983310699463
whereas O O 0.9999996423721313
patients O O 0.9999808073043823
who O O 0.9999990463256836
developed O O 0.9999980926513672
high O O 0.9999113082885742
- O O 0.999170184135437
grade O O 0.9983478784561157
proteinuria O O 0.9711551666259766
showed O O 0.9999885559082031
decreased O O 0.9999631643295288
renal O O 0.9993777275085449
function O O 0.9999480247497559
at O O 0.9999982118606567
the O O 0.9999996423721313
end O O 0.9999984502792358
of O O 0.9999979734420776
follow O O 0.9999940395355225
- O O 0.9995346069335938
up O O 0.9999480247497559
( O O 0.9999871253967285
median O O 0.9998753070831299
39 O O 0.9998456239700317
. O O 0.9999867677688599
6 O O 0.9998457431793213
vs O O 0.9999576807022095
. O O 0.9999634027481079
29 O O 0.9998949766159058
. O O 0.9999872446060181
2 O O 0.9998469352722168
, O O 0.9999676942825317
p O O 0.999925971031189
= O O 0.9999942779541016
0 O O 0.9999419450759888
. O O 0.9999667406082153
125 O O 0.9997217059135437
) O O 0.9999600648880005
. O O 0.9999986886978149

The O O 0.9999572038650513
fifth O O 0.9999920129776001
case O O 0.9999955892562866
had O O 0.9999980926513672
features O O 0.9999908208847046
of O O 0.9999786615371704
thrombotic O O 0.9752265214920044
microangiopathy O O 0.9898051023483276
related O O 0.9999780654907227
to O O 0.9999959468841553
an O O 0.9993988275527954
antiphospholipid O O 0.9895889759063721
syndrome O O 0.9998229146003723
in O O 0.9999977350234985
a O O 0.9999896287918091
patient O O 0.9999629259109497
with O O 0.9999991655349731
systemic O O 0.9996256828308105
lupus O O 0.9664533138275146
erythematosus O O 0.9967431426048279
. O O 0.9999983310699463

Effect O O 0.9997920393943787
of O O 0.9998255372047424
adriamycin S-Chemical S-Chemical 0.9767995476722717
combined O O 0.9999737739562988
with O O 0.9999964237213135
whole O O 0.9996820688247681
body O O 0.9999253749847412
hyperthermia O O 0.9991687536239624
on O O 0.9999890327453613
tumor O O 0.9994290471076965
and O O 0.999987006187439
normal O O 0.9999560117721558
tissues O O 0.9995349645614624
. O O 0.9999983310699463

Epinephrine S-Chemical S-Chemical 0.9863649606704712
has O O 0.9999836683273315
a O O 0.9999984502792358
proven O O 0.9999746084213257
role O O 0.9999996423721313
in O O 0.9999998807907104
cardiac O O 0.9999569654464722
arrest O O 0.9999854564666748
in O O 0.9999996423721313
prehospital O O 0.9997500777244568
care O O 0.9998831748962402
; O O 0.9999985694885254
however O O 0.9999988079071045
, O O 0.9999842643737793
use O O 0.9999843835830688
by O O 0.9999936819076538
paramedics O S-Chemical 0.7313470840454102
in O O 0.9999887943267822
patients O O 0.9999845027923584
with O O 0.9999995231628418
suspected O O 0.999985933303833
allergic O O 0.9997720122337341
reaction O O 0.99997878074646
and O O 0.9999959468841553
severe O O 0.999907374382019
hypertension O O 0.9996156692504883
should O O 0.9999985694885254
be O O 0.9999996423721313
viewed O O 0.9999995231628418
with O O 0.9999994039535522
caution O O 0.9999371767044067
. O O 0.9999979734420776

The O O 0.9999477863311768
girl O O 0.9999818801879883
died O O 0.9999991655349731
seven O O 0.9999945163726807
days O O 0.9999982118606567
, O O 0.9999991655349731
the O O 0.9999991655349731
man O O 0.9999902248382568
four O O 0.9999945163726807
weeks O O 0.9999982118606567
after O O 0.9999964237213135
intrathecal O O 0.8490365147590637
injection O O 0.999147891998291
of O O 0.9984889030456543
vincristine S-Chemical S-Chemical 0.995430588722229
. O O 0.999941349029541

Of O O 0.9997701048851013
the O O 0.9999912977218628
nonepisode O O 0.9956412315368652
biopsies O O 0.9960647225379944
, O O 0.9999532699584961
7 O O 0.9123514294624329
and O O 0.9884335398674011
4 O O 0.9926612377166748
biopsies O O 0.9956858158111572
showed O O 0.9999938011169434
minimal O O 0.9998151659965515
- O O 0.9979573488235474
type O O 0.9982888102531433
and O O 0.99998939037323
mild O O 0.9998189806938171
- O O 0.999150276184082
type O O 0.9995848536491394
chronic O O 0.9939849972724915
FK506 S-Chemical S-Chemical 0.8474491238594055
nephropathy O O 0.9979493021965027
, O O 0.9999963045120239
respectively O O 0.9999990463256836
. O O 0.9999988079071045

The O O 0.9999024868011475
narrow O O 0.9937307834625244
therapeutic O O 0.999721109867096
window O O 0.9999276399612427
observed O O 0.9999675750732422
with O O 0.9998514652252197
haloperidol S-Chemical S-Chemical 0.9896161556243896
may O O 0.9999821186065674
also O O 0.9999953508377075
apply O O 0.9999973773956299
to O O 0.9999957084655762
other O O 0.9999524354934692
neuroleptics O O 0.9923305511474609
used O O 0.9999996423721313
in O O 0.9999990463256836
Alzheimer O O 0.9956602454185486
' O O 0.9995064735412598
s O O 0.9997320771217346
disease O O 0.9999297857284546
patients O O 0.9999771118164062
with O O 0.9999994039535522
psychosis O O 0.9998910427093506
and O O 0.9999986886978149
disruptive O O 0.9999890327453613
behaviors O O 0.9999698400497437
. O O 0.9999991655349731

Both O O 0.9996932744979858
compounds O O 0.9932228326797485
are O O 0.9999948740005493
metabolised O O 0.9999741315841675
in O O 0.9999991655349731
the O O 0.999998927116394
same O O 0.9999978542327881
way O O 0.9999898672103882
as O O 0.999941349029541
1 B-Chemical B-Chemical 0.5129479169845581
- I-Chemical I-Chemical 0.8307979106903076
bromo I-Chemical I-Chemical 0.9441902041435242
- I-Chemical I-Chemical 0.975960373878479
1 I-Chemical I-Chemical 0.9804539084434509
- I-Chemical I-Chemical 0.996429979801178
chloro I-Chemical I-Chemical 0.9970850348472595
- I-Chemical I-Chemical 0.9992527365684509
2 I-Chemical I-Chemical 0.9961972236633301
, I-Chemical I-Chemical 0.9979023933410645
2 I-Chemical I-Chemical 0.9978413581848145
, I-Chemical I-Chemical 0.9993053674697876
2 I-Chemical I-Chemical 0.9992721676826477
- I-Chemical I-Chemical 0.9996601343154907
trifluoroethane E-Chemical E-Chemical 0.9180902242660522
( O O 0.9804830551147461
halothane S-Chemical S-Chemical 0.9332627654075623
) O O 0.998935878276825
to O O 0.99998939037323
form O O 0.9999521970748901
reactive O O 0.9994725584983826
trifluoroacetyl S-Chemical O 0.5603876709938049
halide O O 0.6876545548439026
intermediates O O 0.9845796823501587
, O O 0.999937891960144
which O O 0.9999651908874512
have O O 0.9999909400939941
been O O 0.9999992847442627
implicated O O 0.999998927116394
in O O 0.999998927116394
the O O 0.9999768733978271
hepatotoxicity O O 0.9996230602264404
of O O 0.999659538269043
halothane S-Chemical S-Chemical 0.9738315939903259
. O O 0.9999840259552002

DNA O O 0.9551963806152344
analysis O O 0.9999760389328003
revealed O O 0.9999991655349731
low O O 0.9999904632568359
amounts O O 0.9999964237213135
of O O 0.9999887943267822
a O O 0.99993896484375
4 O O 0.9861482381820679
. O O 0.9998065829277039
8 O O 0.9996711015701294
kb O O 0.9980984330177307
mtDNA O O 0.9890921115875244
deletion O O 0.999958872795105
but O O 0.9999978542327881
with O O 0.9999996423721313
no O O 0.9999992847442627
differences O O 0.9999971389770508
in O O 0.9999991655349731
frequency O O 0.9999266862869263
or O O 0.9999958276748657
quantity O O 0.9999936819076538
in O O 0.9999980926513672
the O O 0.999991774559021
control O O 0.9999526739120483
and O O 0.9999947547912598
experimental O O 0.9998354911804199
groups O O 0.9999731779098511
. O O 0.999998927116394

Intracerebral O O 0.9965214729309082
hemorrhage O O 0.9997336268424988
is O O 0.9999890327453613
associated O O 0.9999946355819702
with O O 0.9999992847442627
more O O 0.9999964237213135
inflammation O O 0.9996801614761353
than O O 0.9999964237213135
ischemic O O 0.9999244213104248
stroke O O 0.9999334812164307
. O O 0.9999995231628418

This O O 0.9998573064804077
experiment O O 0.9999490976333618
is O O 0.9999994039535522
discussed O O 0.9999995231628418
with O O 0.9999996423721313
regard O O 0.9999991655349731
to O O 0.999998927116394
the O O 0.9999558925628662
hypothesis O O 0.9999821186065674
that O O 0.999976634979248
ultrasound O O 0.491414874792099
production O O 0.9950860142707825
is O O 0.999996542930603
the O O 0.9999961853027344
acoustic O O 0.9997957348823547
by O O 0.9999842643737793
- O O 0.9991939663887024
product O O 0.9997552037239075
of O O 0.9999773502349854
a O O 0.9999819993972778
physiological O O 0.9988922476768494
maneuver O O 0.9995242357254028
that O O 0.9999731779098511
compensates O O 0.9999725818634033
for O O 0.9998836517333984
clonidine S-Chemical S-Chemical 0.9903821349143982
' O O 0.9995180368423462
s O O 0.9981935620307922
detrimental O O 0.9999845027923584
effects O O 0.9999858140945435
on O O 0.999997615814209
cardiovascular O O 0.999964714050293
function O O 0.999944806098938
. O O 0.999998927116394

Adult O O 0.9997014403343201
rats O O 0.999681830406189
given O O 0.999971866607666
dexamethasone S-Chemical S-Chemical 0.9940396547317505
on O O 0.9999445676803589
days O O 0.9999890327453613
15 O O 0.9996862411499023
and O O 0.9999575614929199
16 O O 0.9993430972099304
of O O 0.9999616146087646
gestation O O 0.9998130202293396
had O O 0.9999933242797852
more O O 0.9999927282333374
glomeruli O S-Chemical 0.5143494009971619
with O O 0.9999115467071533
glomerulosclerosis O O 0.9491075277328491
than O O 0.9999855756759644
control O O 0.9935731291770935
rats O O 0.9996159076690674
. O O 0.9999984502792358

Neuroinflammation O O 0.9990013241767883
and O O 0.9999984502792358
behavioral O O 0.9999767541885376
abnormalities O O 0.9999871253967285
after O O 0.9999992847442627
neonatal O O 0.9977757334709167
terbutaline S-Chemical S-Chemical 0.9949870109558105
treatment O O 0.9999874830245972
in O O 0.999995231628418
rats O O 0.9980389475822449
: O O 0.9999963045120239
implications O O 0.9999992847442627
for O O 0.9999984502792358
autism O O 0.9942411184310913
. O O 0.9999979734420776

A O O 0.998548686504364
policy O O 0.9999911785125732
of O O 0.9999948740005493
unrestricted O O 0.9999080896377563
prescription O O 0.9992895126342773
of O O 0.9980720281600952
appetite B-Chemical B-Chemical 0.9875774383544922
suppressants E-Chemical E-Chemical 0.9912644624710083
may O O 0.9999910593032837
lead O O 0.9999996423721313
to O O 0.9999992847442627
a O O 0.9999971389770508
high O O 0.9999969005584717
incidence O O 0.9999951124191284
of O O 0.9999958276748657
associated O O 0.9999786615371704
primary O O 0.9998866319656372
pulmonary O O 0.9995375871658325
hypertension O O 0.9999105930328369
. O O 0.9999990463256836

METHODS O O 0.9942231774330139
: O O 0.999995231628418
The O O 0.9999918937683105
expression O O 0.9998401403427124
of O O 0.999849796295166
MRP2 O O 0.7497804760932922
and O O 0.9996193647384644
Pgp O O 0.913963258266449
in O O 0.9999452829360962
brain O O 0.9992571473121643
and O O 0.9999710321426392
liver O O 0.9988954067230225
sections O O 0.9999269247055054
of O O 0.9998155236244202
TR O O 0.8585581183433533
( O O 0.9871000051498413
- O O 0.974639356136322
) O O 0.9950843453407288
rats O O 0.9996798038482666
and O O 0.9999803304672241
normal O O 0.9997168183326721
Wistar O O 0.8214299082756042
rats O O 0.9965864419937134
was O O 0.9999966621398926
determined O O 0.9999992847442627
with O O 0.9999948740005493
immunohistochemistry O O 0.9964827299118042
, O O 0.999991774559021
by O O 0.9999942779541016
using O O 0.9999747276306152
a O O 0.9998199343681335
novel O O 0.9998459815979004
, O O 0.9999902248382568
highly O O 0.9999154806137085
selective O O 0.9973672032356262
monoclonal O O 0.9960673451423645
MRP2 O O 0.9915062785148621
antibody O O 0.9974619150161743
and O O 0.9999738931655884
the O O 0.9999557733535767
monoclonal O O 0.9894298911094666
Pgp O O 0.9886139631271362
antibody O O 0.9955750703811646
C219 O O 0.9068188667297363
, O O 0.9999748468399048
respectively O O 0.9999979734420776
. O O 0.9999988079071045

Proximal O O 0.9994901418685913
muscle O O 0.9575696587562561
weakness O O 0.9998955726623535
has O O 0.9999948740005493
developed O O 0.9999988079071045
during O O 0.9999991655349731
her O O 0.9999605417251587
follow O O 0.9999922513961792
- O O 0.9997933506965637
up O O 0.9999645948410034
. O O 0.9999794960021973

The O O 0.9989835619926453
ocular O O 0.8064175844192505
myasthenia O O 0.9569056630134583
associated O O 0.9999163150787354
with O O 0.9999896287918091
combination O O 0.999087929725647
therapy O O 0.9999594688415527
of O O 0.9999072551727295
pegylated B-Chemical B-Chemical 0.5229558944702148
IFN I-Chemical I-Chemical 0.48776689171791077
alpha I-Chemical I-Chemical 0.6306133270263672
- I-Chemical I-Chemical 0.8153717517852783
2b E-Chemical E-Chemical 0.733604907989502
and O O 0.9590240120887756
ribavirin S-Chemical S-Chemical 0.9756970405578613
for O O 0.9999072551727295
CHC O O 0.7415863871574402
is O O 0.9999618530273438
very O O 0.9999953508377075
rarely O O 0.9999959468841553
reported O O 0.9999982118606567
; O O 0.9999983310699463
therefore O O 0.9999978542327881
, O O 0.9999986886978149
we O O 0.9999897480010986
present O O 0.9999979734420776
this O O 0.999998927116394
case O O 0.9999992847442627
with O O 0.9999998807907104
a O O 0.999997615814209
review O O 0.9999980926513672
of O O 0.9999972581863403
the O O 0.9999985694885254
various O O 0.9999977350234985
eye O O 0.9998764991760254
complications O O 0.99997878074646
of O O 0.9999737739562988
IFN S-Chemical S-Chemical 0.9607242345809937
therapy O O 0.9999595880508423
. O O 0.9999979734420776

Urgent O O 0.9999299049377441
fasciotomies O O 0.9904711246490479
were O O 0.9999984502792358
performed O O 0.9999992847442627
and O O 0.9999977350234985
the O O 0.9999949932098389
patient O O 0.9999371767044067
made O O 0.9999946355819702
an O O 0.9999963045120239
uneventful O O 0.9999796152114868
recovery O O 0.9999939203262329
with O O 0.9999996423721313
the O O 0.9999973773956299
withdrawal O O 0.9999936819076538
of O O 0.9998138546943665
simvastatin S-Chemical S-Chemical 0.9849768877029419
. O O 0.9999665021896362

Only O O 0.9990645051002502
2 O O 0.9903136491775513
patients O O 0.9998152852058411
of O O 0.9999812841415405
our O O 0.9999943971633911
retrospective O O 0.9998996257781982
study O O 0.9999829530715942
experienced O O 0.9999994039535522
a O O 0.9999960660934448
mild O O 0.9999581575393677
or O O 0.9999938011169434
severe O O 0.9999523162841797
neutropenia O O 0.9991340041160583
. O O 0.9999977350234985

The O O 0.999977707862854
aims O O 0.9999986886978149
of O O 0.9999991655349731
this O O 0.9999963045120239
study O O 0.9999960660934448
were O O 0.9999998807907104
to O O 0.9999995231628418
confirm O O 0.9999972581863403
our O O 0.9999982118606567
previous O O 0.9999980926513672
findings O O 0.9999969005584717
in O O 0.9999998807907104
a O O 0.999998927116394
separate O O 0.9999891519546509
cohort O O 0.9997060894966125
of O O 0.999977707862854
patients O O 0.9999898672103882
and O O 0.9999990463256836
to O O 0.9999990463256836
determine O O 0.9999790191650391
the O O 0.9999985694885254
time O O 0.9999984502792358
course O O 0.9999990463256836
of O O 0.9999967813491821
the O O 0.9999967813491821
cardiovascular O O 0.9999879598617554
consequences O O 0.9999992847442627
of O O 0.9999994039535522
stopping O O 0.999165415763855
selegiline S-Chemical S-Chemical 0.9981866478919983
in O O 0.9999891519546509
the O O 0.9999961853027344
expectation O O 0.9999980926513672
that O O 0.9999984502792358
this O O 0.9999327659606934
might O O 0.9999978542327881
shed O O 0.999997615814209
light O O 0.9999985694885254
on O O 0.9999973773956299
the O O 0.9999856948852539
mechanisms O O 0.9999104738235474
by O O 0.9999958276748657
which O O 0.9999719858169556
the O O 0.9998887777328491
drug O O 0.9998509883880615
causes O O 0.9999955892562866
orthostatic O O 0.9989444613456726
hypotension O O 0.9998834133148193
. O O 0.9999983310699463

Severe O O 0.9999152421951294
complications O O 0.9999953508377075
of O O 0.9999927282333374
antianginal O O 0.9961131811141968
drug O O 0.9998476505279541
therapy O O 0.9999741315841675
in O O 0.9999991655349731
a O O 0.9999747276306152
patient O O 0.9999088048934937
identified O O 0.9999980926513672
as O O 0.9999973773956299
a O O 0.9999927282333374
poor O O 0.9985321760177612
metabolizer O O 0.9931846261024475
of O O 0.9989559650421143
metoprolol S-Chemical S-Chemical 0.9756871461868286
, O O 0.9986065030097961
propafenone S-Chemical S-Chemical 0.9721695780754089
, O O 0.998910665512085
diltiazem S-Chemical S-Chemical 0.895024836063385
, O O 0.9964154958724976
and O O 0.9958105087280273
sparteine S-Chemical S-Chemical 0.9978830218315125
. O O 0.9999810457229614

Topiramate S-Chemical S-Chemical 0.9733331203460693
prevented O O 0.9999986886978149
all O O 0.9999948740005493
the O O 0.9999954700469971
alterations O O 0.9999958276748657
observed O O 0.9999985694885254
, O O 0.9999985694885254
showing O O 0.9999949932098389
novel O O 0.9999263286590576
neuroprotective O O 0.9997913241386414
properties O O 0.9999843835830688
. O O 0.999998927116394

To O O 0.9999425411224365
clarify O O 0.999976396560669
the O O 0.9999901056289673
mechanisms O O 0.9999691247940063
of O O 0.9999498128890991
FK B-Chemical B-Chemical 0.9767621159553528
506 E-Chemical E-Chemical 0.9951416254043579
- O O 0.9896296858787537
induced O O 0.9999752044677734
hypertension O O 0.9999290704727173
, O O 0.9999985694885254
we O O 0.999816358089447
studied O O 0.9999986886978149
the O O 0.9999947547912598
chronic O O 0.9998559951782227
effects O O 0.9999920129776001
of O O 0.9999028444290161
FK B-Chemical B-Chemical 0.9618968367576599
506 E-Chemical E-Chemical 0.9974576830863953
on O O 0.9998464584350586
the O O 0.9999316930770874
synthesis O O 0.9992559552192688
of O O 0.9996435642242432
endothelin O O 0.9363275170326233
- O O 0.9801715612411499
1 O O 0.9673792719841003
( O O 0.8710851073265076
ET O O 0.8640764355659485
- O O 0.9317249655723572
1 O O 0.9251213073730469
) O O 0.5761309266090393
, O O 0.9993278980255127
the O O 0.9999984502792358
expression O O 0.9999194145202637
of O O 0.9999629259109497
mRNA O O 0.9969838261604309
of O O 0.999947190284729
ET O O 0.9487603902816772
- O O 0.9577031135559082
1 O O 0.964677095413208
and O O 0.9917470216751099
endothelin O O 0.5165513157844543
- O O 0.9453661441802979
converting O O 0.9952542781829834
enzyme O O 0.9805285334587097
- O O 0.9755492210388184
1 O O 0.9609916806221008
( O O 0.9958633184432983
ECE O O 0.9644819498062134
- O O 0.961013913154602
1 O O 0.9478194713592529
) O O 0.9954029321670532
, O O 0.9999791383743286
the O O 0.9999841451644897
endothelial O O 0.9878727197647095
nitric B-Chemical B-Chemical 0.7797590494155884
oxide E-Chemical E-Chemical 0.9969845414161682
synthase O O 0.9318286180496216
( O O 0.9975979924201965
eNOS O O 0.9340735077857971
) O O 0.9976614713668823
activity O O 0.9998328685760498
, O O 0.9999810457229614
and O O 0.9999908208847046
the O O 0.9999964237213135
expression O O 0.9998201727867126
of O O 0.9999030828475952
mRNA O O 0.9962397813796997
of O O 0.9998127818107605
eNOS O O 0.9721294641494751
and O O 0.9995566010475159
C O O 0.8619019389152527
- O O 0.9160622954368591
type O O 0.9832198023796082
natriuretic O O 0.9932718873023987
peptide O O 0.8894988894462585
( O O 0.9988030195236206
CNP O O 0.9334737062454224
) O O 0.999605119228363
in O O 0.9999926090240479
rat O O 0.9914448857307434
blood O O 0.9991700649261475
vessels O O 0.9991216063499451
. O O 0.999998927116394

RESULTS O O 0.9998942613601685
: O O 0.9999984502792358
He O O 0.9996747970581055
was O O 0.9999943971633911
treated O O 0.9999995231628418
with O O 0.999998927116394
intravenous O O 0.9997641444206238
administration O O 0.9998655319213867
of O O 0.999602735042572
corticosteroids O S-Chemical 0.518600583076477
and O O 0.981408417224884
glycerin S-Chemical S-Chemical 0.8359873294830322
for O O 0.9998983144760132
6 O O 0.999468982219696
days O O 0.9999986886978149
after O O 0.9999996423721313
the O O 0.9999842643737793
injection O O 0.9999988079071045
. O O 0.9999980926513672

RESULTS O O 0.9999430179595947
: O O 0.9999995231628418
We O O 0.9999337196350098
found O O 0.9999926090240479
PTCR O O 0.9506680369377136
in O O 0.9999963045120239
14 O O 0.9998052716255188
of O O 0.9999542236328125
15 O O 0.9999510049819946
cases O O 0.9998756647109985
of O O 0.9999628067016602
TG O O 0.5338298082351685
, O O 0.9979649782180786
in O O 0.999995231628418
7 O O 0.9918545484542847
transplant O O 0.9999476671218872
biopsy O O 0.9981993436813354
specimens O O 0.9956905245780945
without O O 0.9999926090240479
TG O O 0.8808022141456604
, O O 0.9997084736824036
and O O 0.999993085861206
in O O 0.9999972581863403
13 O O 0.9998667240142822
of O O 0.9999547004699707
143 O O 0.9992793202400208
native O O 0.9997515082359314
kidney O O 0.9966272711753845
biopsy O O 0.9980940222740173
specimens O O 0.9977854490280151
. O O 0.9999979734420776

Causes O O 0.9999402761459351
of O O 0.9999990463256836
death O O 0.999996542930603
, O O 0.9999994039535522
with O O 0.9999996423721313
special O O 0.9999914169311523
reference O O 0.9999961853027344
to O O 0.9999980926513672
cerebral O O 0.9998327493667603
haemorrhage O O 0.9999109506607056
, O O 0.9999972581863403
among O O 0.9999969005584717
240 O O 0.9999512434005737
patients O O 0.9998822212219238
with O O 0.9999988079071045
pathologically O O 0.9999160766601562
verified O O 0.999970555305481
Parkinson O O 0.993248462677002
' O O 0.9995600581169128
s O O 0.9985185265541077
disease O O 0.999962568283081
were O O 0.9999995231628418
investigated O O 0.9999994039535522
using O O 0.9999902248382568
the O O 0.9998064637184143
Annuals O O 0.9955763816833496
of O O 0.9999778270721436
the O O 0.9999407529830933
Pathological O O 0.9998206496238708
Autopsy O O 0.9999140501022339
Cases O O 0.999951958656311
in O O 0.999996542930603
Japan O O 0.999705970287323
from O O 0.9999991655349731
1981 O O 0.9999994039535522
to O O 0.9999991655349731
1985 O O 0.9999905824661255
. O O 0.999998927116394

This O O 0.9998657703399658
unwanted O O 0.999925971031189
effect O O 0.9999934434890747
on O O 0.9999984502792358
postural O O 0.9954686164855957
blood O O 0.9960730075836182
pressure O O 0.9998759031295776
was O O 0.9999994039535522
not O O 0.9999997615814209
the O O 0.9999997615814209
result O O 0.9999992847442627
of O O 0.9999995231628418
underlying O O 0.9999850988388062
autonomic O O 0.9998898506164551
failure O O 0.999997615814209
. O O 0.9999986886978149

Encephalopathy O O 0.9956318140029907
induced O O 0.9999926090240479
by O O 0.9998970031738281
levetiracetam S-Chemical S-Chemical 0.9580877423286438
added O O 0.9998927116394043
to O O 0.9999066591262817
valproate S-Chemical O 0.5352900624275208
. O O 0.9999268054962158

A O O 0.9991697072982788
case O O 0.9999914169311523
of O O 0.9998155236244202
a O O 0.9974619150161743
busulfan S-Chemical S-Chemical 0.9846957325935364
- O O 0.9948828220367432
induced O O 0.9997486472129822
hemorrhage O O 0.9996618032455444
cystitis O O 0.9843021631240845
is O O 0.9999774694442749
reported O O 0.9999988079071045
. O O 0.9999953508377075

Twenty O O 0.9939753413200378
- O O 0.9996647834777832
five O O 0.9999611377716064
women O O 0.9999420642852783
were O O 0.9999942779541016
given O O 0.9999545812606812
raloxifene B-Chemical B-Chemical 0.5024555921554565
hydrochloride E-Chemical E-Chemical 0.9862448573112488
( O O 0.9988150596618652
60 O O 0.9943049550056458
mg O O 0.9982435703277588
/ O O 0.9998656511306763
day O O 0.9991299510002136
) O O 0.9983025789260864
plus O O 0.999612033367157
calcium S-Chemical S-Chemical 0.9984835982322693
( O O 0.999148964881897
500 O O 0.9923399686813354
mg O O 0.9965463280677795
/ O O 0.9999316930770874
day O O 0.9997981190681458
) O O 0.9998480081558228
. O O 0.9999963045120239

Mean O O 0.9990980625152588
urinary O O 0.9943385720252991
protein O O 0.9945015907287598
of O O 0.9998666048049927
patients O O 0.9999568462371826
who O O 0.9999936819076538
returned O O 0.9999934434890747
to O O 0.9999665021896362
dialysis O O 0.9965253472328186
was O O 0.9999959468841553
1 O O 0.9993925094604492
. O O 0.9999681711196899
26 O O 0.999819815158844
( O O 0.9999895095825195
0 O O 0.9999202489852905
. O O 0.9999771118164062
5 O O 0.9999287128448486
to O O 0.9999843835830688
3 O O 0.9998953342437744
. O O 0.9999724626541138
5 O O 0.9998807907104492
) O O 0.999962568283081
g O O 0.9999316930770874
/ O O 0.9999918937683105
d O O 0.9998939037322998
before O O 0.9999982118606567
and O O 0.9999954700469971
4 O O 0.9997379183769226
. O O 0.9999816417694092
7 O O 0.9996935129165649
( O O 0.9999942779541016
3 O O 0.9999635219573975
to O O 0.9999822378158569
12 O O 0.9998791217803955
) O O 0.9999421834945679
g O O 0.9999555349349976
/ O O 0.9999963045120239
d O O 0.999843955039978
after O O 0.9999961853027344
conversion O O 0.9999661445617676
( O O 0.9999727010726929
P O O 0.9918875098228455
= O O 0.9999085664749146
. O O 0.9999043941497803
01 O O 0.9991469383239746
) O O 0.9998728036880493
. O O 0.9999974966049194

The O O 0.999240517616272
antinociception O O 0.9836481809616089
produced O O 0.9999887943267822
by O O 0.9999926090240479
( O O 0.9993953704833984
+ O O 0.9999246597290039
/ O O 0.9999208450317383
- O O 0.9989532232284546
) O O 0.9989822506904602
- O O 0.9978753328323364
PG B-Chemical B-Chemical 0.9617388248443604
- I-Chemical I-Chemical 0.9700302481651306
9 E-Chemical E-Chemical 0.9139864444732666
was O O 0.9997691512107849
prevented O O 0.9999994039535522
by O O 0.9999995231628418
the O O 0.9999107122421265
unselective O O 0.9873433113098145
muscarinic O O 0.743465006351471
antagonist O O 0.9592739343643188
atropine S-Chemical S-Chemical 0.9897785782814026
, O O 0.999795138835907
the O O 0.9974568486213684
M1 O O 0.501960039138794
- O O 0.8569177985191345
selective O O 0.9971985816955566
antagonists O O 0.9889219999313354
pirenzepine S-Chemical S-Chemical 0.9704218506813049
and O O 0.9991052746772766
dicyclomine S-Chemical S-Chemical 0.937231183052063
and O O 0.999636173248291
the O O 0.9989849925041199
acetylcholine S-Chemical S-Chemical 0.9322585463523865
depletor O O 0.9986231327056885
hemicholinium B-Chemical O 0.7505941390991211
- I-Chemical O 0.7585739493370056
3 E-Chemical O 0.7867788672447205
, O O 0.753865122795105
but O O 0.9984286427497864
not O O 0.99998939037323
by O O 0.9999963045120239
the O O 0.9995588660240173
opioid O O 0.9538352489471436
antagonist O O 0.9431630373001099
naloxone S-Chemical S-Chemical 0.9875484704971313
, O O 0.9997979998588562
the O O 0.9991840720176697
gamma B-Chemical O 0.7027285695075989
- I-Chemical O 0.888982355594635
aminobutyric I-Chemical O 0.9723380208015442
acidB E-Chemical O 0.8654563426971436
antagonist O O 0.9945507645606995
3 B-Chemical B-Chemical 0.5423500537872314
- I-Chemical I-Chemical 0.8180909156799316
aminopropyl I-Chemical I-Chemical 0.897879421710968
- I-Chemical I-Chemical 0.971561849117279
diethoxy I-Chemical I-Chemical 0.9502037763595581
- I-Chemical I-Chemical 0.9849576950073242
methyl I-Chemical I-Chemical 0.9848048686981201
- I-Chemical I-Chemical 0.9953494668006897
phosphinic I-Chemical I-Chemical 0.9737052321434021
acid E-Chemical E-Chemical 0.971247136592865
, O O 0.9994425177574158
the O O 0.999442994594574
H3 O O 0.8419626951217651
agonist O O 0.9860617518424988
R B-Chemical O 0.8503740429878235
- I-Chemical O 0.7943888306617737
( I-Chemical O 0.9718590378761292
alpha I-Chemical O 0.7967594861984253
) I-Chemical O 0.9317936897277832
- I-Chemical O 0.9252083897590637
methylhistamine E-Chemical S-Chemical 0.7020173072814941
, O O 0.9998725652694702
the O O 0.9969856142997742
D2 O O 0.9535977840423584
antagonist O O 0.992711067199707
quinpirole S-Chemical S-Chemical 0.9612899422645569
, O O 0.9997885823249817
the O O 0.9966272115707397
5 B-Chemical O 0.5831254124641418
- I-Chemical O 0.8003217577934265
hydroxytryptamine4 E-Chemical O 0.6454287767410278
antagonist O O 0.8109734654426575
2 B-Chemical B-Chemical 0.561606764793396
- I-Chemical I-Chemical 0.7482024431228638
methoxy I-Chemical I-Chemical 0.5818631649017334
- I-Chemical I-Chemical 0.6910351514816284
4 I-Chemical I-Chemical 0.7424860596656799
- I-Chemical I-Chemical 0.9194419980049133
amino I-Chemical I-Chemical 0.9630509614944458
- I-Chemical I-Chemical 0.9931644797325134
5 I-Chemical I-Chemical 0.992017388343811
- I-Chemical I-Chemical 0.9991833567619324
chlorobenzoic I-Chemical I-Chemical 0.9933526515960693
acid I-Chemical I-Chemical 0.681000828742981
2 I-Chemical I-Chemical 0.8754453063011169
- I-Chemical I-Chemical 0.9570056200027466
( I-Chemical I-Chemical 0.8244476318359375
diethylamino I-Chemical I-Chemical 0.9384017586708069
) I-Chemical I-Chemical 0.935836672782898
ethyl I-Chemical I-Chemical 0.8923539519309998
ester E-Chemical I-Chemical 0.7847987413406372
hydrochloride O E-Chemical 0.5817333459854126
, O O 0.9985993504524231
the O O 0.9962244033813477
5 B-Chemical B-Chemical 0.7562599778175354
- I-Chemical I-Chemical 0.9156549572944641
hydroxytryptamin1A E-Chemical E-Chemical 0.7393461465835571
antagonist O O 0.5437101125717163
1 B-Chemical B-Chemical 0.47278642654418945
- I-Chemical I-Chemical 0.8748704791069031
( I-Chemical I-Chemical 0.6109371781349182
2 I-Chemical I-Chemical 0.8310644030570984
- I-Chemical I-Chemical 0.984899640083313
methoxyphenyl I-Chemical I-Chemical 0.9862648844718933
) I-Chemical I-Chemical 0.9932036399841309
- I-Chemical I-Chemical 0.9971404075622559
4 I-Chemical I-Chemical 0.9894870519638062
- I-Chemical I-Chemical 0.9988194108009338
[ I-Chemical I-Chemical 0.9963020086288452
4 I-Chemical I-Chemical 0.9944682121276855
- I-Chemical I-Chemical 0.9995149374008179
( I-Chemical I-Chemical 0.9966285824775696
2 I-Chemical I-Chemical 0.9985247254371643
- I-Chemical I-Chemical 0.9997860789299011
phthalimido I-Chemical I-Chemical 0.9933106899261475
) I-Chemical I-Chemical 0.9963878393173218
butyl I-Chemical I-Chemical 0.994746208190918
] I-Chemical I-Chemical 0.9965335130691528
piperazine E-Chemical I-Chemical 0.8210316300392151
hydrobromide O E-Chemical 0.7360736131668091
and O O 0.9953550100326538
the O O 0.9992213249206543
polyamines O O 0.8590561747550964
depletor O O 0.9960055947303772
reserpine S-Chemical S-Chemical 0.910977840423584
. O O 0.9999775886535645

This O O 0.9998276233673096
observation O O 0.9999675750732422
, O O 0.9999971389770508
along O O 0.9999978542327881
with O O 0.9999988079071045
the O O 0.9999977350234985
rapid O O 0.9999860525131226
rate O O 0.9999977350234985
of O O 0.9999969005584717
decline O O 0.999983549118042
in O O 0.9999964237213135
red O O 0.9787799119949341
cell O O 0.9992939233779907
mass O O 0.9999208450317383
parameters O O 0.9970088601112366
of O O 0.9998940229415894
affected O O 0.9986070990562439
dogs O O 0.999261200428009
, O O 0.9999923706054688
suggests O O 0.9999977350234985
that O O 0.9999951124191284
a O O 0.9995971322059631
hemolytic O O 0.9866800904273987
component O O 0.9998761415481567
complicated O O 0.999996542930603
the O O 0.9999679327011108
red O O 0.9977878332138062
cell O O 0.9996787309646606
production O O 0.999902606010437
problem O O 0.9999923706054688
and O O 0.9999974966049194
that O O 0.9999978542327881
multiple O O 0.999879002571106
toxicologic O O 0.9995118379592896
mechanisms O O 0.99997878074646
contributed O O 0.9999998807907104
to O O 0.9999983310699463
the O O 0.9998422861099243
cytopenia O O 0.9942209720611572
. O O 0.9999960660934448

During O O 0.9999836683273315
the O O 0.9999974966049194
study O O 0.9999949932098389
, O O 0.999994158744812
vitamin B-Chemical B-Chemical 0.9998750686645508
B12 E-Chemical E-Chemical 0.953972578048706
and O O 0.9990233182907104
folate S-Chemical S-Chemical 0.9286496043205261
levels O O 0.9999794960021973
were O O 0.9999985694885254
significantly O O 0.9999998807907104
higher O O 0.9999996423721313
in O O 0.9999966621398926
group O O 0.999894380569458
II O O 0.9964333772659302
patients O O 0.9999915361404419
; O O 0.9999995231628418
however O O 0.9999997615814209
, O O 0.9999995231628418
no O O 0.9999991655349731
differences O O 0.9999988079071045
in O O 0.9999891519546509
hemoglobin O O 0.8323098421096802
, O O 0.9018896222114563
hematocrit O S-Chemical 0.6859038472175598
, O O 0.9996416568756104
mean O O 0.998197615146637
corpuscular O O 0.9919163584709167
volume O O 0.9973466396331787
, O O 0.9999911785125732
and O O 0.9998903274536133
white O O 0.997464656829834
- O O 0.9992033839225769
cell O O 0.9990895986557007
, O O 0.999885082244873
neutrophil O S-Chemical 0.4689709544181824
and O O 0.9993465542793274
platelet O O 0.9716296195983887
counts O O 0.9998730421066284
were O O 0.9999982118606567
observed O O 0.9999978542327881
between O O 0.9999980926513672
groups O O 0.9999884366989136
at O O 0.9999983310699463
3 O O 0.9998127818107605
, O O 0.9999849796295166
6 O O 0.9998482465744019
, O O 0.9999650716781616
9 O O 0.9997285008430481
and O O 0.999976634979248
12 O O 0.9999575614929199
months O O 0.9999973773956299
. O O 0.9999994039535522

Tolerance O O 0.9998676776885986
and O O 0.9999986886978149
antiviral O O 0.9997836947441101
effect O O 0.9999542236328125
of O O 0.999835729598999
ribavirin S-Chemical S-Chemical 0.9954850673675537
in O O 0.9999791383743286
patients O O 0.9999909400939941
with O O 0.9999985694885254
Argentine O O 0.9942207336425781
hemorrhagic O O 0.9992154836654663
fever O O 0.99969482421875
. O O 0.9999991655349731

BACKGROUND O O 0.9996761083602905
: O O 0.9999990463256836
Recent O O 0.9999992847442627
evidence O O 0.9999635219573975
suggests O O 0.9999986886978149
that O O 0.9999964237213135
transient O O 0.9991598129272461
neurologic O O 0.9999278783798218
symptoms O O 0.9998922348022461
( O O 0.9999791383743286
TNSs O O 0.9936748147010803
) O O 0.9999481439590454
frequently O O 0.9999830722808838
follow O O 0.9999921321868896
lidocaine S-Chemical S-Chemical 0.7583910226821899
spinal O O 0.9977543950080872
anesthesia O O 0.9993852376937866
but O O 0.9999792575836182
are O O 0.9999969005584717
infrequent O O 0.9999974966049194
with O O 0.9999771118164062
bupivacaine S-Chemical S-Chemical 0.9979225993156433
. O O 0.9999871253967285

Comparison O O 0.9998970031738281
of O O 0.9999960660934448
the O O 0.9999946355819702
subjective O O 0.9999525547027588
effects O O 0.9999967813491821
and O O 0.9999916553497314
plasma O O 0.9979222416877747
concentrations O O 0.9998708963394165
following O O 0.9999935626983643
oral O O 0.9656549692153931
and O O 0.9998401403427124
i O O 0.9997120499610901
. O O 0.9999693632125854
m O O 0.9982156753540039
. O O 0.999993085861206
administration O O 0.9999713897705078
of O O 0.9995824694633484
flunitrazepam S-Chemical S-Chemical 0.9971843361854553
in O O 0.9999659061431885
volunteers O O 0.9997643828392029
. O O 0.9999984502792358

Clinical O O 0.9999624490737915
and O O 0.9999995231628418
histopathologic O O 0.9996896982192993
examination O O 0.9999923706054688
of O O 0.9999778270721436
renal O O 0.9974516034126282
allografts O O 0.9976723790168762
treated O O 0.9999927282333374
with O O 0.999884843826294
tacrolimus S-Chemical S-Chemical 0.8638148307800293
( O O 0.9890634417533875
FK506 S-Chemical S-Chemical 0.9557462930679321
) O O 0.9994631409645081
for O O 0.9999961853027344
at O O 0.9999974966049194
least O O 0.9999996423721313
one O O 0.9999990463256836
year O O 0.9999994039535522
. O O 0.9999990463256836

RESULT O O 0.9992052912712097
( O O 0.9988957643508911
S O O 0.9917170405387878
) O O 0.999599277973175
: O O 0.9999898672103882
A O O 0.9997766613960266
36 O O 0.9997994303703308
- O O 0.9999693632125854
year O O 0.9999988079071045
- O O 0.9999709129333496
old O O 0.9998927116394043
Chinese O O 0.9942662119865417
woman O O 0.9997395873069763
developed O O 0.9999990463256836
central O O 0.9998003840446472
retinal O O 0.9994744658470154
vein O O 0.9947966933250427
occlusion O O 0.999984622001648
after O O 0.9999990463256836
eight O O 0.9999762773513794
courses O O 0.999971866607666
of O O 0.9999661445617676
CC S-Chemical S-Chemical 0.7355692386627197
. O O 0.9999581575393677

The O O 0.9998971223831177
recreational O O 0.9996708631515503
use O O 0.999976396560669
of O O 0.9993645548820496
cocaine S-Chemical S-Chemical 0.993800699710846
is O O 0.9999228715896606
on O O 0.9999842643737793
the O O 0.999996542930603
increase O O 0.9999958276748657
. O O 0.9999986886978149

Although O O 0.9999520778656006
there O O 0.9999994039535522
was O O 0.9999995231628418
a O O 0.9999984502792358
discrepancy O O 0.9999966621398926
between O O 0.9999992847442627
the O O 0.9999903440475464
amount O O 0.9999897480010986
of O O 0.9999316930770874
cTnI O O 0.9534451961517334
and O O 0.9996447563171387
cTnT O O 0.9374711513519287
after O O 0.9997358918190002
DOX S-Chemical S-Chemical 0.9958265423774719
, O O 0.9999868869781494
probably O O 0.9999992847442627
due O O 0.999998927116394
to O O 0.9999932050704956
heterogeneity O O 0.9854898452758789
in O O 0.9999785423278809
cross O O 0.9929087162017822
- O O 0.9986710548400879
reactivities O O 0.9999227523803711
of O O 0.9997621178627014
mAbs O O 0.9802525043487549
to O O 0.9999951124191284
various O O 0.9986615180969238
cTnI O O 0.9826341271400452
and O O 0.9999383687973022
cTnT O O 0.9768403768539429
forms O O 0.999931812286377
, O O 0.9999961853027344
it O O 0.9999980926513672
is O O 0.9999994039535522
likely O O 0.9999996423721313
that O O 0.9999899864196777
cTnT O O 0.9613124132156372
in O O 0.9998859167098999
rats O O 0.9997089505195618
after O O 0.9999697208404541
DOX S-Chemical S-Chemical 0.9960591793060303
indicates O O 0.9999954700469971
cell O O 0.9982390403747559
damage O O 0.9999730587005615
determined O O 0.9999988079071045
by O O 0.9999984502792358
the O O 0.9999947547912598
magnitude O O 0.9999916553497314
of O O 0.9999977350234985
injury O O 0.9999840259552002
induced O O 0.9999933242797852
and O O 0.9999932050704956
that O O 0.9999816417694092
cTnT O O 0.8545463681221008
should O O 0.9999310970306396
be O O 0.9999986886978149
a O O 0.999998927116394
useful O O 0.9999649524688721
marker O O 0.9998801946640015
for O O 0.9999985694885254
the O O 0.9999922513961792
prediction O O 0.999994158744812
of O O 0.9999943971633911
experimentally O O 0.9999786615371704
induced O O 0.9998797178268433
cardiotoxicity O O 0.9986370205879211
and O O 0.9999969005584717
possibly O O 0.9999964237213135
for O O 0.9999942779541016
cardioprotective O O 0.9998787641525269
experiments O O 0.9999253749847412
. O O 0.9999982118606567

The O O 0.9998806715011597
development O O 0.9999957084655762
of O O 0.9999691247940063
psychosis O O 0.9913135170936584
related O O 0.9999945163726807
to O O 0.9999853372573853
antiepileptic O O 0.9605293273925781
drug O O 0.9987943172454834
treatment O O 0.9999059438705444
is O O 0.9999940395355225
usually O O 0.999998927116394
attributed O O 0.9999991655349731
to O O 0.9999986886978149
the O O 0.9999829530715942
interaction O O 0.9999873638153076
between O O 0.999998927116394
the O O 0.9998486042022705
epileptic O O 0.9987850785255432
brain O O 0.9978546500205994
substratum O O 0.9885810017585754
and O O 0.9999463558197021
the O O 0.9995939135551453
antiepileptic O O 0.9933803081512451
drugs O O 0.9994807839393616
. O O 0.9999980926513672

He O O 0.9978660941123962
bought O O 0.9999665021896362
25 O O 0.9917623996734619
g O O 0.9657310247421265
of O O 0.9794713854789734
carbachol S-Chemical S-Chemical 0.9972169399261475
as O O 0.9999289512634277
pure O O 0.9984257221221924
substance O O 0.9998164772987366
in O O 0.9999986886978149
a O O 0.9999779462814331
pharmacy O O 0.9997038245201111
, O O 0.9999964237213135
and O O 0.9999961853027344
the O O 0.9999935626983643
father O O 0.9998615980148315
was O O 0.9999791383743286
administered O O 0.9999982118606567
400 O O 0.9998453855514526
to O O 0.9999924898147583
500 O O 0.99986732006073
mg O O 0.9986082911491394
. O O 0.9999793767929077

Diseases O O 0.9993522763252258
of O O 0.9999808073043823
peripheral O O 0.9998261332511902
nerves O O 0.9999170303344727
as O O 0.9999973773956299
seen O O 0.999997615814209
in O O 0.9999985694885254
the O O 0.9999884366989136
Nigerian O O 0.9996306896209717
African O O 0.9998695850372314
. O O 0.9999977350234985

Most O O 0.9998843669891357
patients O O 0.99996018409729
showed O O 0.9999990463256836
improvement O O 0.999998927116394
in O O 0.9999995231628418
individual O O 0.9999544620513916
parameters O O 0.9998459815979004
and O O 0.9999992847442627
global O O 0.9999972581863403
score O O 0.9999927282333374
of O O 0.9999959468841553
quality O O 0.9999991655349731
of O O 0.9999921321868896
life O O 0.9999973773956299
. O O 0.9999994039535522

The O O 0.9999115467071533
effect O O 0.9999979734420776
of O O 0.9999946355819702
treatment O O 0.9999961853027344
with O O 0.9999704360961914
gum B-Chemical B-Chemical 0.9989468455314636
Arabic E-Chemical E-Chemical 0.9831105470657349
on O O 0.9995191097259521
gentamicin S-Chemical S-Chemical 0.498208224773407
nephrotoxicity O O 0.9794803857803345
in O O 0.9999645948410034
rats O O 0.9965959191322327
: O O 0.9999972581863403
a O O 0.9999984502792358
preliminary O O 0.9999948740005493
study O O 0.9999808073043823
. O O 0.999998927116394

This O O 0.9998759031295776
data O O 0.9999529123306274
suggests O O 0.9999988079071045
that O O 0.9999752044677734
E2 S-Chemical S-Chemical 0.5740319490432739
modifies O O 0.9999428987503052
the O O 0.9999816417694092
expression O O 0.9983198046684265
of O O 0.9994502663612366
CD36 O O 0.7340456247329712
at O O 0.9999945163726807
the O O 0.9999946355819702
level O O 0.9999951124191284
of O O 0.9999663829803467
protein O O 0.9579786658287048
expression O O 0.9968343377113342
in O O 0.9999676942825317
monocyte O O 0.6442775130271912
- O O 0.8748572468757629
derived O O 0.9985916018486023
macrophages O O 0.9983215928077698
resulting O O 0.9999967813491821
in O O 0.9999966621398926
reduced O O 0.9999016523361206
cholesteryl B-Chemical B-Chemical 0.8066653609275818
ester E-Chemical E-Chemical 0.98084557056427
accumulation O O 0.9992883801460266
following O O 0.9999901056289673
ritonavir S-Chemical S-Chemical 0.9884594082832336
treatment O O 0.9999939203262329
. O O 0.9999985694885254

Trifluoroacetyl S-Chemical S-Chemical 0.7892580628395081
- O O 0.9786954522132874
adducted O O 0.9995061159133911
proteins O O 0.9975658655166626
were O O 0.9999938011169434
detected O O 0.9999966621398926
in O O 0.999998927116394
surviving O O 0.9999749660491943
hepatocytes O O 0.9969274401664734
. O O 0.9999985694885254

This O O 0.9998944997787476
case O O 0.9999986886978149
illustrates O O 0.9999992847442627
a O O 0.9999967813491821
number O O 0.9999916553497314
of O O 0.999998927116394
problems O O 0.9999951124191284
that O O 0.9999915361404419
may O O 0.9999985694885254
be O O 0.9999992847442627
encountered O O 0.9999986886978149
in O O 0.9999995231628418
women O O 0.9999639987945557
with O O 0.9999992847442627
eating O O 0.9975318908691406
disorders O O 0.9999698400497437
in O O 0.9999997615814209
pregnancy O O 0.9999958276748657
, O O 0.9999985694885254
including O O 0.9999992847442627
prolonged O O 0.9999918937683105
and O O 0.9999980926513672
recurrent O O 0.9999949932098389
metabolic O O 0.9995096921920776
disturbances O O 0.9999750852584839
and O O 0.9999977350234985
diuretic O O 0.9998013377189636
abuse O O 0.9999309778213501
. O O 0.9999991655349731

No O O 0.9999674558639526
systemic O O 0.9997422099113464
side O O 0.9998171925544739
- O O 0.9998961687088013
effects O O 0.9999927282333374
were O O 0.9999969005584717
observed O O 0.9999969005584717
. O O 0.9999921321868896

Haloperidol S-Chemical S-Chemical 0.9659721851348877
administration O O 0.9999876022338867
( O O 0.9999938011169434
one O O 0.9999334812164307
dose O O 0.9999891519546509
of O O 0.9999828338623047
12 O O 0.9991961121559143
mg O O 0.9998379945755005
/ O O 0.9999799728393555
kg O O 0.9998359680175781
once O O 0.9999972581863403
a O O 0.9999898672103882
week O O 0.9999022483825684
s O O 0.9974094033241272
. O O 0.9999226331710815
c O O 0.9986419081687927
. O O 0.9999394416809082
) O O 0.9999231100082397
for O O 0.9999889135360718
4 O O 0.999659538269043
weeks O O 0.9999833106994629
caused O O 0.9999995231628418
an O O 0.9999980926513672
increase O O 0.9999991655349731
in O O 0.9999994039535522
vacuous O O 0.9881095290184021
chewing O O 0.977948784828186
, O O 0.9999737739562988
tongue O O 0.992130696773529
protrusion O O 0.9997733235359192
and O O 0.9999990463256836
duration O O 0.9999954700469971
of O O 0.9999970197677612
facial O O 0.9998923540115356
twitching O O 0.9996176958084106
observed O O 0.9999978542327881
in O O 0.9999995231628418
four O O 0.999985933303833
weekly O O 0.9999284744262695
evaluations O O 0.9999908208847046
. O O 0.9999991655349731

1 O O 0.8531608581542969
. O O 0.9997267127037048

Treatment O O 0.9999518394470215
with O O 0.9999850988388062
Ato S-Chemical S-Chemical 0.9842876195907593
improved O O 0.9999988079071045
endothelial O O 0.996541440486908
function O O 0.9999337196350098
, O O 0.9999951124191284
reduced O O 0.9999216794967651
superoxide S-Chemical S-Chemical 0.9937461614608765
production O O 0.9999384880065918
and O O 0.9999973773956299
reduced O O 0.9999650716781616
SBP O O 0.8765690326690674
in O O 0.9984025359153748
Dex S-Chemical S-Chemical 0.9989929795265198
- O O 0.9985576272010803
treated O O 0.9999769926071167
SD O O 0.9918102622032166
rats O O 0.9998078942298889
. O O 0.9999988079071045

Long O O 0.9999098777770996
term O O 0.9999966621398926
audiological O O 0.9999017715454102
evaluation O O 0.999996542930603
of O O 0.9998784065246582
beta O O 0.5895284414291382
- O O 0.6280876398086548
thalassemic O O 0.8635596632957458
patients O O 0.9979270696640015
. O O 0.9999979734420776

Optimal O O 0.9968293309211731
control O O 0.9999361038208008
of O O 0.9999921321868896
the O O 0.9999649524688721
absences O O 0.9999361038208008
was O O 0.9999972581863403
achieved O O 0.9999983310699463
with O O 0.9998626708984375
sodium B-Chemical B-Chemical 0.9934524297714233
valproate E-Chemical E-Chemical 0.9364349842071533
, O O 0.9967654943466187
lamotrigine S-Chemical S-Chemical 0.9852659106254578
, O O 0.9993150234222412
or O O 0.9947891235351562
ethosuximide S-Chemical S-Chemical 0.9648419618606567
alone O O 0.9948150515556335
or O O 0.9999452829360962
in O O 0.9999911785125732
combination O O 0.9999948740005493
. O O 0.9999979734420776

Glucocorticoid O S-Chemical 0.6650976538658142
- O O 0.9884235262870789
induced O O 0.9998342990875244
hypertension O O 0.9972453117370605
( O O 0.9997730851173401
GC O O 0.5496747493743896
- O O 0.622342586517334
HT O O 0.6597219705581665
) O O 0.9951569437980652
in O O 0.9999881982803345
the O O 0.9999078512191772
rat O O 0.9989595413208008
is O O 0.9999967813491821
associated O O 0.9999982118606567
with O O 0.9999984502792358
nitric B-Chemical B-Chemical 0.9783318042755127
oxide E-Chemical E-Chemical 0.9950827360153198
- O O 0.9517739415168762
redox O O 0.796888530254364
imbalance O O 0.9996601343154907
. O O 0.9999985694885254

RESULTS O O 0.9999356269836426
: O O 0.9999994039535522
Nine O O 0.9999959468841553
hundred O O 0.9999985694885254
one O O 0.9999622106552124
patients O O 0.9999661445617676
were O O 0.9999990463256836
randomized O O 0.9999926090240479
to O O 0.9999984502792358
treatment O O 0.999997615814209
, O O 0.9999983310699463
447 O O 0.9998544454574585
who O O 0.9999990463256836
received O O 0.9999972581863403
the O O 0.9989989399909973
lozenge O O 0.789903998374939
and O O 0.9973425269126892
454 O O 0.9941124320030212
who O O 0.9999966621398926
received O O 0.999996542930603
the O O 0.9991850256919861
gum O O 0.8106887936592102
( O O 0.9983275532722473
safety O O 0.999826967716217
population O O 0.9999001026153564
) O O 0.9999574422836304
. O O 0.9999979734420776

NX O S-Chemical 0.9197121262550354
caused O O 0.9999972581863403
an O O 0.999987006187439
additive O O 0.9999041557312012
deterioration O O 0.9999958276748657
in O O 0.9999935626983643
GFR O O 0.668136477470398
which O O 0.9992377758026123
, O O 0.9999886751174927
however O O 0.9999969005584717
, O O 0.9999798536300659
was O O 0.9999936819076538
ameliorated O O 0.9999902248382568
by O O 0.9999785423278809
HP O S-Chemical 0.8029143214225769
. O O 0.9999343156814575

Rabbit O O 0.9969732761383057
syndrome O O 0.9994053840637207
, O O 0.9999343156814575
antidepressant S-Chemical S-Chemical 0.7227224707603455
use O O 0.9984511137008667
, O O 0.9999934434890747
and O O 0.9999961853027344
cerebral O O 0.9993786811828613
perfusion O O 0.9898237586021423
SPECT O O 0.9920617341995239
scan O O 0.9998894929885864
findings O O 0.9999905824661255
. O O 0.9999992847442627

Analysis O O 0.999935507774353
was O O 0.9999990463256836
performed O O 0.9999992847442627
on O O 0.9999903440475464
61 O O 0.9994823932647705
women O O 0.9999363422393799
with O O 0.9999967813491821
chemotherapy O O 0.9872418642044067
- O O 0.9995455145835876
responsive O O 0.9999932050704956
metastatic O O 0.9990045428276062
breast O O 0.9983813762664795
cancer O O 0.9999645948410034
receiving O O 0.9999672174453735
96 O O 0.8127558827400208
- O O 0.8162112832069397
h O O 0.8647800087928772
infusional O O 0.9866163730621338
cyclophosphamide S-Chemical S-Chemical 0.9882100820541382
as O O 0.9999825954437256
part O O 0.999981164932251
of O O 0.9999940395355225
a O O 0.9999946355819702
triple O O 0.9995796084403992
sequential O O 0.9999405145645142
high O O 0.9999336004257202
- O O 0.99886155128479
dose O O 0.9999595880508423
regimen O O 0.9975699782371521
to O O 0.9999955892562866
assess O O 0.9999662637710571
association O O 0.9999868869781494
between O O 0.9999984502792358
presence O O 0.9999932050704956
of O O 0.9999886751174927
peritransplant O O 0.9895108342170715
congestive O O 0.999819815158844
heart O O 0.9999501705169678
failure O O 0.9999351501464844
( O O 0.9999558925628662
CHF O O 0.9965100884437561
) O O 0.9999271631240845
and O O 0.9999959468841553
the O O 0.9999949932098389
following O O 0.999993085861206
pretreatment O O 0.9999785423278809
characteristics O O 0.9999597072601318
: O O 0.999997615814209
presence O O 0.9999949932098389
of O O 0.9999626874923706
electrocardiogram O O 0.9053418636322021
( O O 0.9984034895896912
EKG O O 0.9111599922180176
) O O 0.9983065128326416
abnormalities O O 0.9999690055847168
, O O 0.9999982118606567
age O O 0.9999648332595825
, O O 0.9999954700469971
hypertension O O 0.9999496936798096
, O O 0.999998927116394
prior O O 0.9999878406524658
cardiac O O 0.9999147653579712
history O O 0.9999971389770508
, O O 0.9999978542327881
smoking O O 0.9049472212791443
, O O 0.9998095631599426
diabetes O O 0.9986020922660828
mellitus O O 0.9995113611221313
, O O 0.9999972581863403
prior O O 0.9999895095825195
use O O 0.9999954700469971
of O O 0.9999490976333618
anthracyclines S-Chemical O 0.5474411845207214
, O O 0.9999188184738159
and O O 0.9999961853027344
left O O 0.9995280504226685
- O O 0.9996647834777832
sided O O 0.9999866485595703
chest O O 0.999656081199646
irradiation O O 0.9993014335632324
. O O 0.9999985694885254

METHODS O O 0.9944673776626587
: O O 0.999997615814209
Retrospective O O 0.9999911785125732
review O O 0.9999945163726807
of O O 0.9999945163726807
medical O O 0.999956488609314
records O O 0.9999762773513794
of O O 0.9999842643737793
236 O O 0.9999080896377563
patients O O 0.9999775886535645
with O O 0.9999978542327881
hyperthyroidism O O 0.6197779178619385
admitted O O 0.9997299313545227
in O O 0.9999958276748657
our O O 0.9999858140945435
department O O 0.9999922513961792
( O O 0.9999909400939941
in O O 0.9999921321868896
- O O 0.9992777705192566
or O O 0.9999516010284424
out O O 0.9999285936355591
- O O 0.9993712306022644
patients O O 0.999925971031189
) O O 0.9999895095825195
from O O 0.9999990463256836
1986 O O 0.9999967813491821
to O O 0.9999994039535522
1992 O O 0.9999905824661255
. O O 0.9999979734420776

None O O 0.9998981952667236
of O O 0.999993085861206
the O O 0.9999983310699463
patients O O 0.9999867677688599
complained O O 0.9999990463256836
of O O 0.9999986886978149
subjective O O 0.9999889135360718
hearing O O 0.9999758005142212
loss O O 0.9999978542327881
. O O 0.9999988079071045

Toxic O O 0.9990622401237488
peripheral O O 0.9987701773643494
neuropathy O O 0.9996627569198608
is O O 0.9999942779541016
still O O 0.9999990463256836
a O O 0.9999991655349731
significant O O 0.9999916553497314
limiting O O 0.9999347925186157
factor O O 0.9999979734420776
for O O 0.9999972581863403
chemotherapy O O 0.9981520771980286
with O O 0.9999445676803589
paclitaxel S-Chemical S-Chemical 0.9766279458999634
( O O 0.998583197593689
PAC S-Chemical S-Chemical 0.9636433720588684
) O O 0.9988460540771484
, O O 0.999955415725708
although O O 0.9998769760131836
glutamate S-Chemical S-Chemical 0.9898982048034668
and O O 0.9999070167541504
its O O 0.999510645866394
closely O O 0.9992558360099792
related O O 0.9941471815109253
amino B-Chemical B-Chemical 0.9894044399261475
acid E-Chemical I-Chemical 0.5248676538467407
glutamine S-Chemical E-Chemical 0.7745564579963684
were O O 0.9999237060546875
claimed O O 0.9999902248382568
to O O 0.9999874830245972
ameliorate O O 0.9982295632362366
PAC S-Chemical O 0.7805342674255371
neurotoxicity O O 0.9998416900634766
. O O 0.9999986886978149

Jaundice O O 0.9738852977752686
occurred O O 0.9999991655349731
after O O 0.9999994039535522
administration O O 0.9999855756759644
of O O 0.9993576407432556
troleandomycin S-Chemical S-Chemical 0.9910701513290405
for O O 0.9998656511306763
7 O O 0.9985030889511108
days O O 0.9999915361404419
and O O 0.9999954700469971
was O O 0.9999988079071045
associated O O 0.9999983310699463
with O O 0.9999926090240479
hypereosinophilia O O 0.876317024230957
. O O 0.9999860525131226

This O O 0.9997856020927429
case O O 0.9999947547912598
documents O O 0.9999936819076538
acute O O 0.9991862177848816
drug O O 0.9998334646224976
- O O 0.9996463060379028
related O O 0.9999700784683228
vanishing O O 0.9994800686836243
bile O O 0.9977272152900696
duct O O 0.9993470311164856
syndrome O O 0.9999256134033203
in O O 0.9999982118606567
the O O 0.9999830722808838
pediatric O O 0.9986811280250549
age O O 0.9995869994163513
group O O 0.9999675750732422
and O O 0.999994158744812
suggests O O 0.9999974966049194
shared O O 0.9995918869972229
immune O O 0.9993220567703247
mechanisms O O 0.9999618530273438
in O O 0.9999990463256836
the O O 0.9999673366546631
pathogenesis O O 0.9996083378791809
of O O 0.9999759197235107
both O O 0.9999287128448486
Stevens O O 0.9899861216545105
- O O 0.9972707629203796
Johnson O O 0.9996535778045654
syndrome O O 0.9999759197235107
and O O 0.9999982118606567
vanishing O O 0.9992380142211914
bile O O 0.9989811778068542
duct O O 0.9995219707489014
syndrome O O 0.9999392032623291
. O O 0.9999983310699463

Clinical O O 0.9999366998672485
examination O O 0.9999978542327881
and O O 0.9999998807907104
continued O O 0.9999828338623047
vigilance O O 0.9999116659164429
for O O 0.9999985694885254
neurologic O O 0.9999247789382935
deterioration O O 0.999994158744812
after O O 0.9999991655349731
epidural O O 0.9632587432861328
steroid S-Chemical S-Chemical 0.9914935827255249
injections O O 0.9999876022338867
is O O 0.999998927116394
important O O 0.9999994039535522
. O O 0.9999971389770508

Based O O 0.9999552965164185
on O O 0.9999991655349731
clinical O O 0.9999926090240479
data O O 0.9999512434005737
, O O 0.9999972581863403
indicating O O 0.999969482421875
that O O 0.9997151494026184
chloroacetaldehyde S-Chemical S-Chemical 0.9478482604026794
( O O 0.9994128942489624
CAA S-Chemical S-Chemical 0.934045672416687
) O O 0.9988620281219482
is O O 0.9999896287918091
an O O 0.9999982118606567
important O O 0.9999728202819824
metabolite O O 0.9980546236038208
of O O 0.9998831748962402
oxazaphosphorine O S-Chemical 0.7908511757850647
cytostatics O O 0.9848859906196594
, O O 0.9999946355819702
an O O 0.999895453453064
experimental O O 0.9992445707321167
study O O 0.999785840511322
was O O 0.9999990463256836
carried O O 0.9999996423721313
out O O 0.9999984502792358
in O O 0.9999986886978149
order O O 0.9999971389770508
to O O 0.9999991655349731
elucidate O O 0.9999796152114868
the O O 0.9999921321868896
role O O 0.9999973773956299
of O O 0.9999492168426514
CAA S-Chemical S-Chemical 0.7121052145957947
in O O 0.9999964237213135
the O O 0.9999966621398926
development O O 0.9999992847442627
of O O 0.9999980926513672
hemorrhagic O O 0.9988675117492676
cystitis O O 0.9994097948074341
. O O 0.9999980926513672

Atrial O O 0.9991193413734436
fibrillation O O 0.9999511241912842
is O O 0.9999964237213135
associated O O 0.9999983310699463
with O O 0.9999998807907104
substantial O O 0.9999970197677612
morbidity O O 0.9998568296432495
and O O 0.9999955892562866
mortality O O 0.9999771118164062
. O O 0.9999991655349731

A O O 0.9906954765319824
63 O O 0.9991581439971924
- O O 0.9999700784683228
year O O 0.9999988079071045
- O O 0.9999773502349854
old O O 0.9999727010726929
male O O 0.9997749924659729
experienced O O 0.9999994039535522
sudden O O 0.9999479055404663
diplopia O O 0.9995784163475037
after O O 0.9999984502792358
9 O O 0.9999222755432129
weeks O O 0.999998927116394
of O O 0.9999980926513672
administration O O 0.9999849796295166
of O O 0.9999312162399292
pegylated B-Chemical B-Chemical 0.9554078578948975
interferon I-Chemical E-Chemical 0.8735097646713257
( I-Chemical O 0.9888231754302979
IFN I-Chemical O 0.7930849194526672
) I-Chemical O 0.9810887575149536
alpha I-Chemical B-Chemical 0.6210905313491821
- I-Chemical I-Chemical 0.7717017531394958
2b E-Chemical E-Chemical 0.8880452513694763
and O O 0.9875022172927856
ribavirin S-Chemical S-Chemical 0.9652934074401855
for O O 0.9999897480010986
chronic O O 0.999257504940033
hepatitis O O 0.9872627854347229
C O O 0.9697096347808838
( O O 0.9997779726982117
CHC O O 0.9879191517829895
) O O 0.9999263286590576
. O O 0.9999969005584717

This O O 0.9997949004173279
effect O O 0.9999924898147583
was O O 0.9999995231628418
more O O 0.9999996423721313
relevant O O 0.9999973773956299
in O O 0.9999994039535522
patients O O 0.9999922513961792
treated O O 0.9999992847442627
with O O 0.999998927116394
higher O O 0.9999456405639648
doses O O 0.9999902248382568
. O O 0.9999979734420776

Extrapyramidal O O 0.9482024908065796
side O O 0.9991468191146851
effects O O 0.9999921321868896
with O O 0.9999711513519287
risperidone S-Chemical S-Chemical 0.9894501566886902
and O O 0.9994354844093323
haloperidol S-Chemical S-Chemical 0.9920195937156677
at O O 0.9999682903289795
comparable O O 0.9999250173568726
D2 O O 0.9633440375328064
receptor O O 0.999693751335144
occupancy O O 0.9997265934944153
levels O O 0.999988317489624
. O O 0.9999991655349731

A O O 0.9998643398284912
large O O 0.9998244643211365
group O O 0.9999865293502808
of O O 0.9999773502349854
patients O O 0.999969482421875
with O O 0.9999995231628418
suspected O O 0.9999872446060181
allergic O O 0.9994993209838867
reactions O O 0.9999830722808838
to O O 0.9999703168869019
beta B-Chemical B-Chemical 0.9096093773841858
- I-Chemical I-Chemical 0.975193202495575
lactam E-Chemical E-Chemical 0.9905722737312317
antibiotics O O 0.9130357503890991
was O O 0.9999923706054688
evaluated O O 0.9999980926513672
. O O 0.9999967813491821

Here O O 0.9998295307159424
we O O 0.9999910593032837
present O O 0.9999980926513672
a O O 0.9999991655349731
case O O 0.9999961853027344
of O O 0.9999815225601196
withdrawal O O 0.9998955726623535
- O O 0.9998914003372192
emergent O O 0.9900458455085754
RS O O 0.7582443952560425
, O O 0.9994144439697266
which O O 0.9999842643737793
is O O 0.9999982118606567
the O O 0.9999996423721313
first O O 0.9999985694885254
of O O 0.9999991655349731
its O O 0.9999996423721313
kind O O 0.9999988079071045
to O O 0.9999998807907104
be O O 0.9999985694885254
reported O O 0.9999988079071045
. O O 0.9999954700469971

In O O 0.9999475479125977
these O O 0.9999980926513672
individuals O O 0.99997878074646
, O O 0.9999992847442627
side O O 0.9999277591705322
effects O O 0.9999972581863403
are O O 0.9999983310699463
most O O 0.9999985694885254
likely O O 0.9999977350234985
generated O O 0.9999808073043823
superficially O O 0.999993085861206
in O O 0.9999955892562866
the O O 0.9999831914901733
skin O O 0.9998006224632263
. O O 0.9999986886978149

Rats O O 0.9924507737159729
were O O 0.9999982118606567
treated O O 0.9999986886978149
with O O 0.9999916553497314
the O O 0.9981757402420044
vehicle O O 0.9991969466209412
( O O 0.9999678134918213
2 O O 0.9991483688354492
mL O O 0.9994863271713257
/ O O 0.999971866607666
kg O O 0.9998080134391785
of O O 0.9998505115509033
distilled O O 0.6458404064178467
water O O 0.7636289596557617
and O O 0.9968281388282776
5 O O 0.9995543360710144
% O O 0.9999873638153076
w O O 0.9986155033111572
/ O O 0.9999086856842041
v O O 0.9983550906181335
cellulose O S-Chemical 0.38417497277259827
, O O 0.9756072759628296
10 O O 0.998039186000824
days O O 0.9999463558197021
) O O 0.999852180480957
, O O 0.999904990196228
gum B-Chemical B-Chemical 0.9689680933952332
Arabic E-Chemical E-Chemical 0.7401289343833923
( O O 0.9913120865821838
2 O O 0.9973777532577515
mL O O 0.9992697834968567
/ O O 0.9999533891677856
kg O O 0.9995409250259399
of O O 0.9998419284820557
a O O 0.999922513961792
10 O O 0.9996084570884705
% O O 0.9999886751174927
w O O 0.9986622333526611
/ O O 0.9999169111251831
v O O 0.9986366629600525
aqueous O O 0.9146019220352173
suspension O O 0.9921711683273315
of O O 0.9988133907318115
gum B-Chemical B-Chemical 0.9688775539398193
Arabic E-Chemical I-Chemical 0.9456826448440552
powder O E-Chemical 0.9168171882629395
, O O 0.593838632106781
orally O O 0.9649036526679993
for O O 0.9997289776802063
10 O O 0.9995504021644592
days O O 0.9999642372131348
) O O 0.999908447265625
, O O 0.9999499320983887
or O O 0.9998618364334106
gum B-Chemical O 0.8933820128440857
Arabic E-Chemical O 0.5036909580230713
concomitantly O O 0.9893835186958313
with O O 0.9999606609344482
GM S-Chemical S-Chemical 0.8854018449783325
( O O 0.9995287656784058
80mg O O 0.9964748024940491
/ O O 0.9999076128005981
kg O O 0.9993888139724731
/ O O 0.9999581575393677
day O O 0.9998852014541626
intramuscularly O O 0.9999725818634033
, O O 0.9999879598617554
during O O 0.999998927116394
the O O 0.999998927116394
last O O 0.999998927116394
six O O 0.9999896287918091
days O O 0.9999982118606567
of O O 0.9999960660934448
the O O 0.9999904632568359
treatment O O 0.9999942779541016
period O O 0.9999983310699463
) O O 0.9999827146530151
. O O 0.999997615814209

Although O O 0.9983173608779907
interleukin O O 0.7604449987411499
3 O O 0.691656768321991
( O O 0.8817324638366699
IL O O 0.5982427000999451
- O O 0.5708945989608765
3 O O 0.7453068494796753
) O O 0.5720461010932922
and O O 0.9937475919723511
erythropoietin O O 0.44332894682884216
( O O 0.9910388588905334
EPO O O 0.5232880711555481
) O O 0.9911810159683228
are O O 0.9999932050704956
known O O 0.9999990463256836
to O O 0.9999954700469971
act O O 0.999963641166687
synergistically O O 0.9999140501022339
on O O 0.9999948740005493
hematopoietic O O 0.9954134821891785
cell O O 0.9990090131759644
proliferation O O 0.9999675750732422
in O O 0.9999947547912598
vitro O O 0.9843714833259583
, O O 0.9998629093170166
injection O O 0.9999266862869263
of O O 0.999940037727356
IGF O O 0.9802516102790833
- O O 0.9920114874839783
IL O O 0.9953402280807495
- O O 0.9972687363624573
3 O O 0.9843267798423767
and O O 0.9987144470214844
EPO O O 0.9786441922187805
in O O 0.9998830556869507
AZT S-Chemical S-Chemical 0.6648933291435242
- O O 0.9963781237602234
treated O O 0.9999661445617676
mice O O 0.9996145963668823
resulted O O 0.9999994039535522
in O O 0.9999979734420776
a O O 0.9999932050704956
reduction O O 0.9999980926513672
of O O 0.9999661445617676
red O O 0.9771914482116699
cells O O 0.9983349442481995
and O O 0.999993085861206
an O O 0.9999961853027344
increase O O 0.999995231628418
of O O 0.999980092048645
plasma O O 0.9989302754402161
EPO O O 0.7713784575462341
levels O O 0.9998613595962524
as O O 0.9999953508377075
compared O O 0.9999972581863403
to O O 0.9999938011169434
animals O O 0.9970687031745911
treated O O 0.9999973773956299
with O O 0.9999936819076538
IGF O O 0.7732099294662476
- O O 0.8741286396980286
IL O O 0.9524637460708618
- O O 0.968117356300354
3 O O 0.957622766494751
or O O 0.9988588094711304
EPO O O 0.9782111048698425
alone O O 0.9998161196708679
. O O 0.9999982118606567

In O O 0.999835729598999
linear O O 0.9999644756317139
regression O O 0.9998923540115356
analyses O O 0.9999890327453613
the O O 0.9999834299087524
CGI O O 0.8880940675735474
- O O 0.9900998473167419
SF O O 0.9786204099655151
score O O 0.9996156692504883
was O O 0.999996542930603
not O O 0.9999994039535522
affected O O 0.9999991655349731
significantly O O 0.9999997615814209
by O O 0.9999998807907104
the O O 0.9999967813491821
duration O O 0.9999904632568359
of O O 0.9999494552612305
SD O O 0.7403980493545532
, O O 0.9990553259849548
type O O 0.9997960925102234
of O O 0.9998681545257568
SSRI S-Chemical S-Chemical 0.8019565343856812
used O O 0.9999856948852539
and O O 0.9999816417694092
age O O 0.9999392032623291
. O O 0.999998927116394

Angioedema O O 0.9841432571411133
following O O 0.9999973773956299
the O O 0.9999939203262329
intravenous O O 0.9999207258224487
administration O O 0.9999687671661377
of O O 0.9983581900596619
metoprolol S-Chemical S-Chemical 0.9995453953742981
. O O 0.9999575614929199

We O O 0.9997605681419373
conclude O O 0.9999926090240479
that O O 0.9999816417694092
in O O 0.9997463822364807
streptozotocin S-Chemical S-Chemical 0.8862989544868469
- O O 0.978449285030365
diabetic O O 0.995017945766449
rats O O 0.9997476935386658
with O O 0.999997615814209
an O O 0.9999814033508301
increased O O 0.999527096748352
urinary O O 0.9966731071472168
albumin O O 0.889830470085144
excretion O O 0.9977937936782837
, O O 0.9999970197677612
a O O 0.9999672174453735
reduced O O 0.9808452129364014
heparan B-Chemical B-Chemical 0.8847129940986633
sulphate E-Chemical E-Chemical 0.61048823595047
charge O O 0.5078966617584229
barrier O O 0.8491616249084473
/ O O 0.9841516017913818
density O O 0.9994694590568542
is O O 0.9999934434890747
found O O 0.9999984502792358
at O O 0.9999934434890747
the O O 0.99980229139328
lamina O O 0.9912047982215881
rara O O 0.9961637258529663
externa O O 0.9987801909446716
of O O 0.9996663331985474
the O O 0.9997449517250061
glomerular O O 0.9971645474433899
basement O O 0.9995418787002563
membrane O O 0.9993588328361511
. O O 0.9999978542327881

The O O 0.9985699653625488
gamma B-Chemical B-Chemical 0.9013864398002625
- I-Chemical I-Chemical 0.8966097235679626
aminobutyric I-Chemical I-Chemical 0.838752031326294
acid E-Chemical E-Chemical 0.9810082912445068
- O O 0.9903006553649902
transmitted O O 0.9999556541442871
thalamocortical O O 0.9921320080757141
circuitry O O 0.9986453652381897
accounts O O 0.9999531507492065
for O O 0.9999991655349731
a O O 0.9999992847442627
major O O 0.9999960660934448
part O O 0.9999910593032837
of O O 0.9999940395355225
the O O 0.9999938011169434
underlying O O 0.9999040365219116
neurophysiology O O 0.9996957778930664
of O O 0.999982476234436
the O O 0.9999794960021973
absence O O 0.9998412132263184
epilepsy O O 0.9997925162315369
. O O 0.9999985694885254

This O O 0.999929666519165
study O O 0.9999932050704956
assessed O O 0.9999990463256836
the O O 0.9999932050704956
ability O O 0.9999773502349854
of O O 0.9998953342437744
IH636 B-Chemical B-Chemical 0.5443201065063477
grape I-Chemical I-Chemical 0.6988816857337952
seed I-Chemical I-Chemical 0.7290032505989075
proanthocyanidin I-Chemical I-Chemical 0.3899243474006653
extract E-Chemical E-Chemical 0.6448360681533813
( O O 0.985630214214325
GSPE S-Chemical O 0.83624666929245
) O O 0.9985999464988708
to O O 0.9999665021896362
prevent O O 0.9990647435188293
acetaminophen S-Chemical S-Chemical 0.7077771425247192
( O O 0.9984126091003418
AAP S-Chemical S-Chemical 0.9835110902786255
) O O 0.9949396848678589
- O O 0.9992828965187073
induced O O 0.9999228715896606
nephrotoxicity O O 0.9940662384033203
, O O 0.9998445510864258
amiodarone S-Chemical S-Chemical 0.9635372161865234
( O O 0.9988611936569214
AMI S-Chemical S-Chemical 0.9613947868347168
) O O 0.9950029253959656
- O O 0.9991756081581116
induced O O 0.9999905824661255
lung O O 0.9996447563171387
toxicity O O 0.9995951056480408
, O O 0.9999279975891113
and O O 0.9995871186256409
doxorubicin S-Chemical S-Chemical 0.7013331651687622
( O O 0.9885272979736328
DOX S-Chemical S-Chemical 0.9855813384056091
) O O 0.9953225255012512
- O O 0.999476969242096
induced O O 0.9999686479568481
cardiotoxicity O O 0.9997255206108093
in O O 0.9999963045120239
mice O O 0.9999265670776367
. O O 0.9999991655349731

The O O 0.99996018409729
present O O 0.9998800754547119
study O O 0.9999927282333374
aimed O O 0.9999992847442627
to O O 0.9999994039535522
investigate O O 0.999995231628418
the O O 0.9999966621398926
effects O O 0.9999990463256836
of O O 0.999976634979248
pallidal O O 0.7797597646713257
neurotensin S-Chemical S-Chemical 0.6332891583442688
on O O 0.8063161969184875
haloperidol S-Chemical S-Chemical 0.9904534816741943
- O O 0.9957737326622009
induced O O 0.9999839067459106
parkinsonian O O 0.999117910861969
symptoms O O 0.9999735355377197
. O O 0.9999990463256836

It O O 0.9994916915893555
may O O 0.9999979734420776
even O O 0.9999994039535522
present O O 0.9999972581863403
in O O 0.9999986886978149
patients O O 0.9999644756317139
who O O 0.9999967813491821
have O O 0.9999850988388062
tolerated O O 0.9999891519546509
this O O 0.9998842477798462
medicine O O 0.9998272061347961
well O O 0.9999961853027344
in O O 0.9999998807907104
the O O 0.9999995231628418
past O O 0.999997615814209
. O O 0.9999977350234985

These O O 0.9994242191314697
ecstasy S-Chemical S-Chemical 0.8243951201438904
- O O 0.9949553608894348
specific O O 0.9999592304229736
effects O O 0.9999914169311523
may O O 0.9999994039535522
be O O 0.9999996423721313
related O O 0.9999992847442627
to O O 0.9999985694885254
the O O 0.9999750852584839
vulnerability O O 0.9999933242797852
of O O 0.9998750686645508
isocortical O O 0.9628581404685974
and O O 0.9993001222610474
allocortical O O 0.9800528883934021
regions O O 0.997710108757019
to O O 0.9999982118606567
the O O 0.9999308586120605
neurotoxic O O 0.9995688796043396
effects O O 0.9999935626983643
of O O 0.9998993873596191
ecstasy S-Chemical S-Chemical 0.9886045455932617
. O O 0.9999886751174927

In O O 0.9999374151229858
the O O 0.9999983310699463
seventh O O 0.9999921321868896
patient O O 0.999985933303833
, O O 0.9999990463256836
a O O 0.9999920129776001
permanent O O 0.9992339611053467
ventricular O O 0.9987534284591675
pacemaker O O 0.9945366382598877
was O O 0.9999912977218628
inserted O O 0.9999974966049194
and O O 0.9999971389770508
, O O 0.9999980926513672
despite O O 0.9999984502792358
continuation O O 0.999987006187439
of O O 0.9997921586036682
procainamide S-Chemical S-Chemical 0.9842331409454346
therapy O O 0.999829888343811
, O O 0.9999740123748779
polymorphous O O 0.8346329927444458
ventricular O O 0.9960286617279053
tachycardia O O 0.9995808005332947
did O O 0.999993085861206
not O O 0.9999942779541016
reoccur O O 0.9997658133506775
. O O 0.9999978542327881

PATIENT O O 0.9983748197555542
( O O 0.9975353479385376
S O O 0.9879167675971985
) O O 0.9992668032646179
: O O 0.9999815225601196
A O O 0.9996669292449951
36 O O 0.9997808337211609
- O O 0.9999654293060303
year O O 0.9999990463256836
- O O 0.9999792575836182
old O O 0.999922513961792
woman O O 0.999946117401123
referred O O 0.9999996423721313
from O O 0.9999985694885254
the O O 0.9999804496765137
infertility O O 0.9993569254875183
clinic O O 0.9999196529388428
for O O 0.9999994039535522
blurred O O 0.9998143315315247
vision O O 0.9999619722366333
. O O 0.999998927116394

All O O 0.999588668346405
four O O 0.9997871518135071
recovered O O 0.999994158744812
completely O O 0.9999961853027344
without O O 0.9999982118606567
neurological O O 0.9998049139976501
sequelae O O 0.9974796175956726
following O O 0.9999966621398926
the O O 0.9999896287918091
withdrawal O O 0.9999935626983643
of O O 0.9999885559082031
the O O 0.9999879598617554
offending O O 0.9997460246086121
agents O O 0.9996330738067627
. O O 0.9999940395355225

Finally O O 0.9999887943267822
, O O 0.9999990463256836
moral O O 0.9997900128364563
issues O O 0.999990701675415
relating O O 0.9999992847442627
to O O 0.9999954700469971
the O O 0.9999297857284546
testing O O 0.9999650716781616
of O O 0.9999247789382935
potential O O 0.9976620674133301
cocaine S-Chemical S-Chemical 0.9966212511062622
users O O 0.999919056892395
will O O 0.9999964237213135
be O O 0.9999991655349731
addressed O O 0.9999990463256836
. O O 0.9999966621398926

Although O O 0.9997442364692688
MHb O O 0.707973301410675
formers O O 0.9930729269981384
are O O 0.9999834299087524
generally O O 0.9999747276306152
applied O O 0.999982476234436
as O O 0.9999856948852539
treatments O O 0.9999322891235352
for O O 0.9999973773956299
CN O O 0.9808845520019531
poisoning O O 0.9997871518135071
, O O 0.9999985694885254
it O O 0.9999761581420898
has O O 0.9999979734420776
been O O 0.9999992847442627
proposed O O 0.9999978542327881
that O O 0.9999932050704956
a O O 0.9999939203262329
stable O O 0.99996018409729
, O O 0.9999969005584717
long O O 0.9999803304672241
- O O 0.9998276233673096
acting O O 0.9994379878044128
MHb O O 0.9270572066307068
former O O 0.9995070695877075
could O O 0.999990701675415
serve O O 0.9999861717224121
as O O 0.9999972581863403
a O O 0.9999847412109375
CN O O 0.9115269780158997
pretreatment O O 0.9999125003814697
. O O 0.999998927116394

Uni O O 0.7554273009300232
- O O 0.9877288341522217
and O O 0.9999703168869019
multivariate O O 0.9849693775177002
analyses O O 0.9988114833831787
were O O 0.9999964237213135
used O O 0.9999994039535522
to O O 0.9999954700469971
test O O 0.9999144077301025
the O O 0.9999940395355225
influence O O 0.9999802112579346
of O O 0.9999915361404419
the O O 0.9999886751174927
clinical O O 0.9998677968978882
variables O O 0.9999676942825317
: O O 0.9999992847442627
age O O 0.9999203681945801
, O O 0.9999961853027344
sex O O 0.9998865127563477
, O O 0.9999918937683105
stroke O O 0.9994331002235413
, O O 0.9999873638153076
myocardiopathy O O 0.9715606570243835
( O O 0.9996600151062012
MP O O 0.9878088235855103
) O O 0.9998703002929688
, O O 0.9999964237213135
duration O O 0.999993085861206
of O O 0.9999951124191284
the O O 0.9998964071273804
test O O 0.999893307685852
, O O 0.9999855756759644
mitral O O 0.9550243020057678
regurgitation O O 0.9971785545349121
( O O 0.9998931884765625
MR O O 0.9817626476287842
) O O 0.9995954632759094
and O O 0.9999802112579346
the O O 0.9999270439147949
MZ S-Chemical O 0.645578145980835
dose O O 0.9999586343765259
. O O 0.9999978542327881

These O O 0.9999566078186035
findings O O 0.9999933242797852
demonstrate O O 0.9999973773956299
that O O 0.9999984502792358
some O O 0.99997878074646
neuroactive O O 0.9977667331695557
steroids S-Chemical S-Chemical 0.9887640476226807
attenuate O O 0.9997231364250183
convulsant O O 0.9965020418167114
and O O 0.9999840259552002
sensitizing O O 0.999703586101532
properties O O 0.9999281167984009
of O O 0.9996732473373413
cocaine S-Chemical S-Chemical 0.9930425882339478
and O O 0.999942421913147
add O O 0.9999409914016724
to O O 0.9999939203262329
a O O 0.999955415725708
growing O O 0.9997648596763611
literature O O 0.9996721744537354
on O O 0.9999977350234985
their O O 0.9999836683273315
potential O O 0.9995942711830139
use O O 0.9999954700469971
in O O 0.9999996423721313
the O O 0.9999895095825195
modulation O O 0.9999858140945435
of O O 0.9999942779541016
effects O O 0.9999947547912598
of O O 0.9999690055847168
drugs O O 0.9987192153930664
of O O 0.9999661445617676
abuse O O 0.9997852444648743
. O O 0.9999985694885254

Compared O O 0.9999556541442871
with O O 0.9999954700469971
control O O 0.9984031319618225
patients O O 0.9998469352722168
, O O 0.9999865293502808
CRF O O 0.7795441150665283
and O O 0.9996674060821533
ESRD O O 0.8196412920951843
patients O O 0.9991700649261475
had O O 0.9999995231628418
higher O O 0.9999979734420776
preoperative O O 0.9991770386695862
serum O O 0.999679684638977
creatinine S-Chemical S-Chemical 0.9954755902290344
levels O O 0.9999815225601196
, O O 0.9999995231628418
a O O 0.9999995231628418
greater O O 0.999998927116394
percentage O O 0.9999978542327881
of O O 0.999995231628418
patients O O 0.9999933242797852
with O O 0.9999990463256836
hepatorenal O O 0.9310387372970581
syndrome O O 0.9997655749320984
, O O 0.9999990463256836
higher O O 0.9999876022338867
percentage O O 0.9999628067016602
requirement O O 0.9999841451644897
for O O 0.9999967813491821
dialysis O O 0.9978845715522766
in O O 0.9999984502792358
the O O 0.9999982118606567
first O O 0.999996542930603
3 O O 0.9999241828918457
months O O 0.999991774559021
postoperatively O O 0.9999972581863403
, O O 0.9999940395355225
and O O 0.999996542930603
a O O 0.9999986886978149
higher O O 0.9999936819076538
1 O O 0.9963704347610474
- O O 0.9998520612716675
year O O 0.9999954700469971
serum O O 0.9996688365936279
creatinine S-Chemical S-Chemical 0.9950234889984131
. O O 0.9999945163726807

Under O O 0.9999126195907593
anesthesia O O 0.9998635053634644
, O O 0.9999971389770508
the O O 0.9999170303344727
superior O O 0.9959805011749268
temporal O O 0.9999197721481323
gyrus O O 0.9963898062705994
of O O 0.9998714923858643
adult O O 0.9974274039268494
macaque O O 0.9741697907447815
monkeys O O 0.9942724704742432
was O O 0.9999885559082031
exposed O O 0.9999969005584717
, O O 0.9999972581863403
and O O 0.9999946355819702
the O O 0.9999833106994629
tonotopic O O 0.9947999715805054
organization O O 0.9995658993721008
of O O 0.9997314810752869
A1 O O 0.7114797234535217
was O O 0.9997225403785706
mapped O O 0.9999896287918091
using O O 0.999991774559021
conventional O O 0.9986352324485779
microelectrode O O 0.9919438362121582
recording O O 0.9999215602874756
techniques O O 0.999942421913147
. O O 0.9999985694885254

Before O O 0.9998656511306763
treatment O O 0.9999969005584717
all O O 0.9999890327453613
patients O O 0.9998630285263062
had O O 0.9999986886978149
a O O 0.9999908208847046
cardiac O O 0.9996242523193359
evaluation O O 0.9999972581863403
and O O 0.9999992847442627
during O O 0.9999967813491821
treatment O O 0.9999951124191284
serial O O 0.9998966455459595
ECG O O 0.9900000691413879
recordings O O 0.999864935874939
were O O 0.999998927116394
performed O O 0.9999990463256836
. O O 0.9999983310699463

The O O 0.9999804496765137
most O O 0.9999948740005493
common O O 0.999955415725708
primary O O 0.994662880897522
tumor O O 0.9977738261222839
site O O 0.9999204874038696
was O O 0.999998927116394
the O O 0.9999977350234985
head O O 0.9999892711639404
and O O 0.9999983310699463
neck O O 0.999996542930603
. O O 0.9999977350234985

To O O 0.9999836683273315
our O O 0.9999935626983643
knowledge O O 0.9999971389770508
, O O 0.9999991655349731
this O O 0.9999963045120239
is O O 0.9999996423721313
the O O 0.9999997615814209
first O O 0.9999927282333374
report O O 0.9999884366989136
of O O 0.9999593496322632
a O O 0.9998681545257568
pseudo O O 0.900855541229248
- O O 0.9811769723892212
allergy O O 0.9997432827949524
caused O O 0.9999954700469971
by O O 0.9999736547470093
paramethasone S-Chemical S-Chemical 0.9984714388847351
. O O 0.9999642372131348

METHODS O O 0.9971938133239746
: O O 0.9999967813491821
A O O 0.9999874830245972
review O O 0.9999969005584717
of O O 0.9999921321868896
admissions O O 0.9999938011169434
during O O 0.9999997615814209
a O O 0.9999973773956299
6 O O 0.997565746307373
- O O 0.9999494552612305
year O O 0.9999979734420776
period O O 0.9999996423721313
revealed O O 0.9999990463256836
14 O O 0.9998277425765991
patients O O 0.9999518394470215
with O O 0.9999877214431763
cocaine S-Chemical S-Chemical 0.9632372856140137
- O O 0.997718095779419
related O O 0.999984860420227
aneurysms O O 0.9999046325683594
. O O 0.9999983310699463

Increasing O O 0.9999529123306274
doses O O 0.9999949932098389
of O O 0.9997702240943909
catecholamines S-Chemical S-Chemical 0.8120808601379395
, O O 0.9987576007843018
sedatives O O 0.9904131293296814
, O O 0.9999861717224121
and O O 0.9999068975448608
muscle O O 0.9827030897140503
relaxants O O 0.9940114617347717
administered O O 0.9999901056289673
through O O 0.999997615814209
a O O 0.9998656511306763
central O O 0.9991412162780762
venous O O 0.9972630739212036
catheter O O 0.9985044002532959
were O O 0.9999982118606567
ineffective O O 0.9999984502792358
. O O 0.999998927116394

NIN O S-Chemical 0.3285467326641083
- O O 0.9548313617706299
induced O O 0.9996610879898071
midpontine O S-Chemical 0.6936431527137756
activation O O 0.9980113506317139
may O O 0.9999959468841553
correspond O O 0.9999960660934448
to O O 0.9999946355819702
activation O O 0.9995736479759216
of O O 0.9998846054077148
the O O 0.999402642250061
dorsomedial O O 0.991359531879425
pontine O O 0.8116596341133118
nuclei O O 0.9419095516204834
and O O 0.99964439868927
the O O 0.9997014403343201
nucleus O O 0.9971219897270203
reticularis O O 0.9804345965385437
tegmenti O O 0.9515395164489746
pontis O O 0.9708488583564758
, O O 0.9998125433921814
structures O O 0.9999185800552368
known O O 0.9999995231628418
to O O 0.999997615814209
participate O O 0.9999958276748657
in O O 0.999997615814209
the O O 0.9999839067459106
generation O O 0.9999703168869019
of O O 0.9999313354492188
multidirectional O O 0.9994407296180725
saccades O O 0.9975747466087341
and O O 0.9999920129776001
smooth O O 0.9998074173927307
pursuit O O 0.9999445676803589
eye O O 0.9991890788078308
movements O O 0.999971866607666
. O O 0.9999988079071045

BMCs O O 0.9610059857368469
obtained O O 0.9999682903289795
from O O 0.9996123909950256
green O O 0.6426350474357605
fluorescent O O 0.9817143678665161
protein O O 0.9731119871139526
( O O 0.9995877146720886
GFP O O 0.9678240418434143
) O O 0.9997169375419617
transgenic O O 0.9951808452606201
mice O O 0.9610732793807983
or O O 0.9998526573181152
rats O O 0.9901899695396423
were O O 0.9999885559082031
transplanted O O 0.9999910593032837
intravenously O O 0.9999760389328003
after O O 0.9999992847442627
induction O O 0.9999679327011108
of O O 0.9999467134475708
status O O 0.9939109086990356
epilepticus O O 0.9867371916770935
( O O 0.9988399147987366
SE O O 0.9633479714393616
) O O 0.9993979930877686
. O O 0.9999982118606567

An O O 0.999427318572998
80 O O 0.9912728667259216
- O O 0.9984252452850342
yr O O 0.9997276663780212
- O O 0.9996836185455322
old O O 0.9995337724685669
man O O 0.999640941619873
developed O O 0.9999991655349731
acute O O 0.9998693466186523
hepatitis O O 0.9988717436790466
shortly O O 0.9999973773956299
after O O 0.9999972581863403
ingesting O O 0.9990148544311523
oral O O 0.723476231098175
ceftriaxone S-Chemical S-Chemical 0.9985617995262146
. O O 0.9999731779098511

However O O 0.9999730587005615
, O O 0.9999991655349731
future O O 0.9999974966049194
investigations O O 0.9999881982803345
are O O 0.9999994039535522
necessary O O 0.9999996423721313
to O O 0.9999992847442627
exactly O O 0.9999628067016602
analyze O O 0.9998831748962402
the O O 0.9999663829803467
biochemical O O 0.9994731545448303
mechanisms O O 0.999920129776001
by O O 0.9999946355819702
which O O 0.9999252557754517
PDTC S-Chemical S-Chemical 0.893507719039917
exerted O O 0.9999934434890747
its O O 0.9999916553497314
beneficial O O 0.9999263286590576
effects O O 0.999996542930603
in O O 0.9999980926513672
the O O 0.9999349117279053
piriform O O 0.9341845512390137
cortex O O 0.9966356158256531
. O O 0.9999966621398926

The O O 0.9998912811279297
onset O O 0.9999945163726807
of O O 0.9999923706054688
all O O 0.9999934434890747
manifestations O O 0.9999762773513794
( O O 0.9999850988388062
except O O 0.9999682903289795
toxic O O 0.9967564940452576
encephalopathy O O 0.9990389347076416
) O O 0.9999433755874634
was O O 0.9999948740005493
usually O O 0.9999995231628418
subacute O O 0.998701810836792
, O O 0.9999960660934448
with O O 0.9999994039535522
subsequent O O 0.9999988079071045
partial O O 0.999987006187439
recovery O O 0.9999977350234985
. O O 0.9999988079071045

Subjects O O 0.9998595714569092
were O O 0.9999983310699463
receiving O O 0.9999858140945435
desferrioxamine S-Chemical S-Chemical 0.8889797925949097
( O O 0.9939332604408264
DFO S-Chemical S-Chemical 0.9732444286346436
) O O 0.9965607523918152
chelation O O 0.9232659339904785
treatment O O 0.9999934434890747
with O O 0.9999985694885254
a O O 0.9999884366989136
mean O O 0.9999536275863647
daily O O 0.9998509883880615
dose O O 0.9999940395355225
of O O 0.9999680519104004
50 O O 0.9861344695091248
- O O 0.9963996410369873
60 O O 0.999794065952301
mg O O 0.999948263168335
/ O O 0.999983549118042
kg O O 0.9999133348464966
, O O 0.9999407529830933
5 O O 0.9851422905921936
- O O 0.9962298274040222
6 O O 0.9998084902763367
days O O 0.9999988079071045
a O O 0.9999972581863403
week O O 0.9999991655349731
during O O 0.9999997615814209
the O O 0.9999994039535522
first O O 0.9999986886978149
six O O 0.9999896287918091
years O O 0.9999992847442627
of O O 0.9999994039535522
the O O 0.9999958276748657
study O O 0.9999685287475586
, O O 0.9999911785125732
which O O 0.9999879598617554
was O O 0.9999874830245972
then O O 0.9999963045120239
reduced O O 0.9999946355819702
to O O 0.9999841451644897
40 O O 0.9988510608673096
- O O 0.9994962215423584
50 O O 0.9998809099197388
mg O O 0.9999430179595947
/ O O 0.9999819993972778
kg O O 0.9999226331710815
for O O 0.9999910593032837
the O O 0.9999985694885254
following O O 0.9999983310699463
eight O O 0.9999845027923584
years O O 0.9999970197677612
. O O 0.9999991655349731

Ketamine S-Chemical S-Chemical 0.9922187328338623
reduced O O 0.9999951124191284
both O O 0.9999741315841675
the O O 0.9998805522918701
area O O 0.9993174076080322
of O O 0.9997178912162781
brush O O 0.9256709814071655
- O O 0.994047999382019
evoked O O 0.9999405145645142
and O O 0.9998315572738647
punctate O O 0.8970680236816406
- O O 0.9963363409042358
evoked O O 0.9999691247940063
hyperalgesia O O 0.9980301260948181
significantly O O 0.9999961853027344
and O O 0.9999809265136719
it O O 0.9999947547912598
tended O O 0.9999973773956299
to O O 0.9999915361404419
reduce O O 0.9998904466629028
brush O O 0.9937361478805542
- O O 0.9999099969863892
evoked O O 0.9999984502792358
pain O O 0.9999583959579468
. O O 0.9999984502792358

The O O 0.9999842643737793
most O O 0.9999985694885254
commonly O O 0.9999847412109375
reported O O 0.9999955892562866
toxic O O 0.9952292442321777
effects O O 0.999984622001648
of O O 0.9998751878738403
capecitabine S-Chemical S-Chemical 0.992745041847229
are O O 0.9999719858169556
diarrhea O O 0.9986382126808167
, O O 0.9999924898147583
nausea O O 0.9999479055404663
, O O 0.9999966621398926
vomiting O O 0.9997631907463074
, O O 0.9999772310256958
stomatitis O O 0.9963906407356262
and O O 0.9999939203262329
hand O O 0.9978293776512146
- O O 0.9996999502182007
foot O O 0.9997881054878235
syndrome O O 0.99994957447052
. O O 0.9999983310699463

The O O 0.9989050626754761
co O O 0.594617486000061
- O O 0.8842500448226929
administration O O 0.9998661279678345
of O O 0.9999203681945801
aspirin S-Chemical S-Chemical 0.6014679670333862
with O O 0.9948996901512146
N B-Chemical B-Chemical 0.9938014149665833
- I-Chemical I-Chemical 0.9956687688827515
[ I-Chemical I-Chemical 0.995524525642395
4 I-Chemical I-Chemical 0.9753807187080383
- I-Chemical I-Chemical 0.9995062351226807
( I-Chemical I-Chemical 0.9983322024345398
5 I-Chemical I-Chemical 0.9980428218841553
- I-Chemical I-Chemical 0.9997519850730896
nitro I-Chemical I-Chemical 0.9982878565788269
- I-Chemical I-Chemical 0.9995251893997192
2 I-Chemical I-Chemical 0.9987503290176392
- I-Chemical I-Chemical 0.9996802806854248
furyl I-Chemical I-Chemical 0.9950225353240967
) I-Chemical I-Chemical 0.996353030204773
- I-Chemical I-Chemical 0.9979426264762878
2 I-Chemical I-Chemical 0.9971221089363098
- I-Chemical I-Chemical 0.9994717240333557
thiazolyl I-Chemical I-Chemical 0.9520313143730164
] I-Chemical I-Chemical 0.971054196357727
- I-Chemical I-Chemical 0.9858323335647583
formamide E-Chemical E-Chemical 0.881153404712677
( O O 0.9904541969299316
FANFT S-Chemical S-Chemical 0.7276215553283691
) O O 0.9978715181350708
to O O 0.9999864101409912
rats O O 0.9990491271018982
resulted O O 0.9999978542327881
in O O 0.9999985694885254
a O O 0.9999971389770508
reduced O O 0.9999076128005981
incidence O O 0.9998075366020203
of O O 0.9998002648353577
FANFT S-Chemical S-Chemical 0.9675061106681824
- O O 0.9983721375465393
induced O O 0.9999903440475464
bladder O O 0.9991084933280945
carcinomas O O 0.9995019435882568
but O O 0.999996542930603
a O O 0.9999974966049194
concomitant O O 0.9976270794868469
induction O O 0.999970555305481
of O O 0.9999163150787354
forestomach O O 0.9573987126350403
tumors O O 0.999448835849762
. O O 0.9999983310699463

Recurrence O O 0.9999672174453735
rates O O 0.9999947547912598
were O O 0.9999992847442627
31 O O 0.9999021291732788
. O O 0.9999973773956299
4 O O 0.9999767541885376
% O O 0.9999961853027344
with O O 0.9999644756317139
rizatriptan S-Chemical S-Chemical 0.9864565134048462
and O O 0.9997612833976746
15 O O 0.9932308197021484
. O O 0.9999836683273315
3 O O 0.9999090433120728
% O O 0.9999881982803345
with O O 0.9998365640640259
ergotamine S-Chemical S-Chemical 0.9563210010528564
/ O O 0.9899700284004211
caffeine S-Chemical S-Chemical 0.9983820915222168
. O O 0.9999918937683105

Accumulation O O 0.9998475313186646
of O O 0.9997921586036682
drugs O O 0.998672366142273
was O O 0.9999972581863403
not O O 0.999998927116394
reflected O O 0.999998927116394
in O O 0.9999997615814209
prolonged O O 0.9999933242797852
behavioral O O 0.9999810457229614
impairment O O 0.9999890327453613
. O O 0.9999990463256836

Results O O 0.9999659061431885
indicate O O 0.9999960660934448
that O O 0.9999657869338989
GSPE S-Chemical S-Chemical 0.8566983938217163
preexposure O O 0.9999366998672485
prior O O 0.9999995231628418
to O O 0.9999537467956543
AAP S-Chemical S-Chemical 0.7900545001029968
, O O 0.9993470311164856
AMI S-Chemical S-Chemical 0.749975323677063
and O O 0.9994102716445923
DOX S-Chemical S-Chemical 0.993252694606781
, O O 0.9999915361404419
provided O O 0.9999972581863403
near O O 0.999997615814209
complete O O 0.9999861717224121
protection O O 0.99998939037323
in O O 0.9999994039535522
terms O O 0.999998927116394
of O O 0.9999923706054688
serum O O 0.999812662601471
chemistry O O 0.9991437196731567
changes O O 0.9998834133148193
( O O 0.9999406337738037
ALT O O 0.960529625415802
, O O 0.999258816242218
BUN O O 0.927432656288147
and O O 0.999630331993103
CPK O O 0.890502393245697
) O O 0.9997803568840027
, O O 0.9999945163726807
and O O 0.9999971389770508
significantly O O 0.9999997615814209
reduced O O 0.9999983310699463
DNA O O 0.993324339389801
fragmentation O O 0.9999902248382568
. O O 0.9999994039535522

Use O O 0.9991647005081177
of O O 0.9988378882408142
antithymocyte B-Chemical B-Chemical 0.8530709743499756
globulin E-Chemical E-Chemical 0.9647839069366455
may O O 0.9999532699584961
be O O 0.9999948740005493
the O O 0.9999960660934448
optimal O O 0.9997377991676331
treatment O O 0.9999861717224121
of O O 0.9998677968978882
D B-Chemical B-Chemical 0.7641535401344299
- I-Chemical I-Chemical 0.973013699054718
penicillamine E-Chemical E-Chemical 0.987412691116333
- O O 0.9826818108558655
induced O O 0.9999527931213379
aplastic O O 0.9989073276519775
anemia O O 0.999906063079834
. O O 0.9999977350234985

Since O O 0.999962568283081
the O O 0.9999949932098389
incidence O O 0.9999831914901733
and O O 0.999998927116394
severity O O 0.9999983310699463
of O O 0.9999973773956299
specific O O 0.9999785423278809
adverse O O 0.9999620914459229
effects O O 0.9999951124191284
differ O O 0.9999983310699463
among O O 0.9999991655349731
the O O 0.9999897480010986
various O O 0.999957799911499
atypicals O O 0.9992930889129639
, O O 0.9999990463256836
the O O 0.9999898672103882
clinician O O 0.9994995594024658
should O O 0.9999986886978149
carefully O O 0.9999961853027344
consider O O 0.9999984502792358
which O O 0.9999914169311523
side O O 0.9998538494110107
effects O O 0.9999890327453613
are O O 0.9999969005584717
most O O 0.9999992847442627
likely O O 0.9999997615814209
to O O 0.9999994039535522
lead O O 0.9999990463256836
to O O 0.9999988079071045
the O O 0.9999834299087524
individual O O 0.9998995065689087
' O O 0.9999892711639404
s O O 0.9970198273658752
dissatisfaction O O 0.9999418258666992
and O O 0.9999954700469971
noncompliance O O 0.9999123811721802
before O O 0.9999995231628418
choosing O O 0.9998376369476318
an O O 0.9992855191230774
antipsychotic O O 0.9986710548400879
for O O 0.9999885559082031
a O O 0.999994158744812
particular O O 0.9999910593032837
patient O O 0.9999634027481079
. O O 0.9999986886978149

A O O 0.9798540472984314
nonregenerative O O 0.999052107334137
anemia O O 0.9994338154792786
was O O 0.9999988079071045
the O O 0.9999996423721313
most O O 0.9999973773956299
compromising O O 0.9998238682746887
of O O 0.9998714923858643
the O O 0.9997969269752502
cytopenias O O 0.933756411075592
and O O 0.9999784231185913
occurred O O 0.9999983310699463
in O O 0.9999995231628418
approximately O O 0.9999977350234985
50 O O 0.9999685287475586
% O O 0.9999973773956299
of O O 0.9999046325683594
dogs O O 0.9987516403198242
receiving O O 0.9999761581420898
400 O O 0.9852303862571716
- O O 0.997320830821991
500 O O 0.9998160004615784
mg O O 0.999588668346405
/ O O 0.9998341798782349
kg O O 0.9981162548065186
cefonicid S-Chemical S-Chemical 0.9232574105262756
or O O 0.9927669763565063
540 O O 0.7935863733291626
- O O 0.8364614248275757
840 O O 0.9773362278938293
mg O O 0.9985272884368896
/ O O 0.9996455907821655
kg O O 0.9984512329101562
cefazedone S-Chemical S-Chemical 0.9980415105819702
. O O 0.9999786615371704

ACE B-Chemical O 0.6869712471961975
inhibitor E-Chemical O 0.8872583508491516
and O O 0.9973862767219543
angiotensin B-Chemical S-Chemical 0.9263362884521484
- I-Chemical O 0.6259123682975769
releasing I-Chemical O 0.9872941374778748
blocker E-Chemical O 0.9981223940849304
( O O 0.999610960483551
ARB S-Chemical O 0.7753674983978271
) O O 0.9969159364700317
therapy O O 0.9997711777687073
reduced O O 0.9999829530715942
proteinuria O O 0.9318380355834961
development O O 0.9999774694442749
. O O 0.9999991655349731

While O O 0.9996098875999451
the O O 0.9999912977218628
involvement O O 0.999995231628418
of O O 0.9998421669006348
metronidazole S-Chemical S-Chemical 0.9727289080619812
in O O 0.9999878406524658
the O O 0.9999492168426514
aetiology O O 0.9994633793830872
of O O 0.9999071359634399
the O O 0.999910831451416
haemolytic O O 0.9972532391548157
- O O 0.9990610480308533
uraemic O O 0.9960963129997253
syndrome O O 0.9995263814926147
is O O 0.999988317489624
not O O 0.9999924898147583
established O O 0.999971866607666
firmly O O 0.9999574422836304
, O O 0.9999977350234985
the O O 0.9999896287918091
action O O 0.9997451901435852
of O O 0.9999383687973022
this O O 0.9997987151145935
drug O O 0.9999306201934814
in O O 0.999992847442627
sensitizing O O 0.9985033273696899
tissues O O 0.9974660873413086
to O O 0.9999945163726807
oxidation O O 0.9954387545585632
injury O O 0.9999676942825317
and O O 0.9999961853027344
the O O 0.9999979734420776
reported O O 0.9999969005584717
evidence O O 0.999962329864502
of O O 0.9998948574066162
oxidation O O 0.9979324340820312
changes O O 0.9999858140945435
in O O 0.999996542930603
the O O 0.9999357461929321
haemolytic O O 0.9958322644233704
- O O 0.9988044500350952
uraemic O O 0.9984765648841858
syndrome O O 0.9999276399612427
suggest O O 0.9999985694885254
a O O 0.9999986886978149
possible O O 0.9999707937240601
link O O 0.9999954700469971
between O O 0.9999818801879883
metronidazole S-Chemical S-Chemical 0.9981885552406311
treatment O O 0.999950647354126
and O O 0.9999963045120239
some O O 0.9999943971633911
cases O O 0.9998762607574463
of O O 0.9999740123748779
the O O 0.999924898147583
haemolytic O O 0.998519241809845
- O O 0.9990044236183167
uraemic O O 0.9988619089126587
syndrome O O 0.9998152852058411
. O O 0.9999972581863403

Eating O O 0.9970439076423645
disorders O O 0.9999785423278809
and O O 0.9999974966049194
the O O 0.9999955892562866
associated O O 0.9999717473983765
behavioural O O 0.999815046787262
problems O O 0.9999932050704956
and O O 0.9999953508377075
drug O O 0.9999634027481079
abuse O O 0.9999065399169922
are O O 0.9999979734420776
uncommon O O 0.9999868869781494
in O O 0.9999995231628418
pregnancy O O 0.9999961853027344
. O O 0.999998927116394

The O O 0.9999347925186157
patients O O 0.9999730587005615
were O O 0.9999992847442627
randomly O O 0.9999995231628418
allocated O O 0.9999991655349731
to O O 0.9999991655349731
one O O 0.999992847442627
of O O 0.9999971389770508
three O O 0.9999721050262451
groups O O 0.9999936819076538
; O O 0.9999996423721313
those O O 0.9999991655349731
in O O 0.9999984502792358
group O O 0.9999300241470337
A O O 0.9890556335449219
( O O 0.9999754428863525
n O O 0.9980772733688354
= O O 0.9999836683273315
10 O O 0.9997137188911438
) O O 0.9999732971191406
were O O 0.9999994039535522
subjected O O 0.9999997615814209
to O O 0.9999971389770508
controlled O O 0.9987977743148804
hypotension O O 0.9959206581115723
alone O O 0.9999568462371826
, O O 0.9999979734420776
those O O 0.9999982118606567
in O O 0.9999980926513672
group O O 0.9999160766601562
B O O 0.9956717491149902
( O O 0.9999446868896484
n O O 0.9975512623786926
= O O 0.9999744892120361
10 O O 0.9995424747467041
) O O 0.9998807907104492
to O O 0.9999929666519165
haemodilution O S-Chemical 0.5854266881942749
alone O O 0.9953708052635193
and O O 0.9999861717224121
those O O 0.9999974966049194
in O O 0.9999970197677612
group O O 0.9999163150787354
C O O 0.9924295544624329
( O O 0.9999268054962158
n O O 0.9980219602584839
= O O 0.9999756813049316
10 O O 0.9994795918464661
) O O 0.9999295473098755
to O O 0.9999984502792358
both O O 0.9999216794967651
controlled O O 0.9985673427581787
hypotension O O 0.9994101524353027
and O O 0.999976396560669
haemodilution O O 0.9991194605827332
. O O 0.9999979734420776

CONCLUSIONS O O 0.9996871948242188
: O O 0.9999849796295166
Alprazolam S-Chemical S-Chemical 0.9012698531150818
caused O O 0.9999910593032837
side O O 0.9995887875556946
- O O 0.9998090863227844
effects O O 0.9999972581863403
and O O 0.999998927116394
adverse O O 0.999994158744812
effects O O 0.9999970197677612
during O O 0.9999982118606567
treatment O O 0.9999984502792358
but O O 0.9999985694885254
many O O 0.9999977350234985
patients O O 0.9999076128005981
were O O 0.9999995231628418
willing O O 0.9999979734420776
to O O 0.9999977350234985
accept O O 0.9999933242797852
these O O 0.9999929666519165
. O O 0.9999920129776001

Macrophage O O 0.619312584400177
- O O 0.8334675431251526
migration O O 0.993006706237793
inhibition O O 0.9942883253097534
( O O 0.9998539686203003
MIF O O 0.9926437735557556
) O O 0.9997968077659607
test O O 0.9999390840530396
with O O 0.9999772310256958
ampicillin S-Chemical S-Chemical 0.9120302796363831
was O O 0.9999648332595825
positive O O 0.9999973773956299
. O O 0.9999980926513672

Reduced O O 0.999915599822998
size O O 0.9998862743377686
of O O 0.9999403953552246
capillary O O 0.9362740516662598
lumen O O 0.9057920575141907
and O O 0.9997352957725525
occlusion O O 0.9998536109924316
were O O 0.9999992847442627
caused O O 0.9999992847442627
by O O 0.9999988079071045
swollen O O 0.9760513305664062
endothelial O O 0.997677743434906
cells O O 0.9996242523193359
which O O 0.9999734163284302
had O O 0.9999884366989136
luminal S-Chemical O 0.9837648272514343
protrusions O O 0.9970988035202026
and O O 0.99996018409729
swollen O O 0.9901860952377319
microvilli O O 0.9209554195404053
. O O 0.9999834299087524

Antitumor O O 0.9932329654693604
activity O O 0.9998482465744019
was O O 0.9999972581863403
studied O O 0.9999936819076538
using O O 0.9999879598617554
a O O 0.9998237490653992
tumor O O 0.9986826777458191
growth O O 0.9998899698257446
delay O O 0.9997337460517883
assay O O 0.9995643496513367
. O O 0.9999982118606567

In O O 0.999922513961792
male O O 0.9998863935470581
animals O O 0.9998934268951416
, O O 0.9999978542327881
repeated O O 0.9989323019981384
apomorphine S-Chemical S-Chemical 0.9975935816764832
treatment O O 0.9999936819076538
induced O O 0.9999990463256836
a O O 0.9999967813491821
gradual O O 0.9999700784683228
development O O 0.9999969005584717
of O O 0.9999967813491821
aggressive O O 0.9997822642326355
behavior O O 0.9999927282333374
as O O 0.9999991655349731
evidenced O O 0.9999994039535522
by O O 0.9999997615814209
the O O 0.999998927116394
increased O O 0.9999969005584717
intensity O O 0.9999898672103882
of O O 0.9999935626983643
aggressiveness O O 0.9999573230743408
and O O 0.9999992847442627
shortened O O 0.9999983310699463
latency O O 0.9999814033508301
before O O 0.9999997615814209
the O O 0.9999983310699463
first O O 0.9999940395355225
attack O O 0.9999741315841675
toward O O 0.9999988079071045
the O O 0.9999896287918091
opponent O O 0.9999463558197021
. O O 0.9999978542327881

Recurrent O O 0.9999698400497437
reversible O O 0.9999971389770508
acute O O 0.9999502897262573
renal O O 0.9998366832733154
failure O O 0.9999938011169434
from O O 0.9999765157699585
amphotericin S-Chemical S-Chemical 0.9678868055343628
. O O 0.9999793767929077

When O O 0.9996905326843262
they O O 0.999987006187439
do O O 0.9999892711639404
occur O O 0.9999955892562866
they O O 0.9999978542327881
are O O 0.9999964237213135
often O O 0.9999969005584717
unrecognized O O 0.9999980926513672
because O O 0.9999997615814209
of O O 0.999997615814209
denial O O 0.9999716281890869
but O O 0.9999960660934448
when O O 0.9999983310699463
significant O O 0.9999924898147583
may O O 0.9999990463256836
pose O O 0.9999996423721313
a O O 0.9999988079071045
risk O O 0.9999992847442627
to O O 0.9999995231628418
both O O 0.9999982118606567
the O O 0.9999927282333374
mother O O 0.999941349029541
and O O 0.999997615814209
her O O 0.9999877214431763
fetus O O 0.9999492168426514
. O O 0.9999958276748657

Here O O 0.9997257590293884
, O O 0.9999972581863403
we O O 0.9999915361404419
present O O 0.9999969005584717
a O O 0.9999991655349731
similar O O 0.9999957084655762
incident O O 0.9999804496765137
in O O 0.9999996423721313
a O O 0.9999971389770508
severely O O 0.9999682903289795
depressed O O 0.9999126195907593
patient O O 0.9999563694000244
who O O 0.9999964237213135
received O O 0.9999979734420776
electroconvulsive O O 0.9796434044837952
therapy O O 0.9997970461845398
( O O 0.9999399185180664
ECT O O 0.9983677268028259
) O O 0.9999246597290039
. O O 0.9999973773956299

Thus O O 0.9981618523597717
, O O 0.9999629259109497
FS O O 0.7065402269363403
containing O O 0.9984945058822632
47 O O 0.9944548010826111
. O O 0.9999868869781494
5 O O 0.9998387098312378
mg O O 0.9997143149375916
/ O O 0.9998892545700073
ml O O 0.9754148721694946
tAMCA S-Chemical S-Chemical 0.9670844078063965
evoked O O 0.9999948740005493
generalized O O 0.9992849230766296
seizures O O 0.9997512698173523
in O O 0.9999972581863403
all O O 0.999982476234436
tested O O 0.9997004270553589
rats O O 0.999018669128418
( O O 0.9999661445617676
n O O 0.9971143007278442
= O O 0.9999668598175049
6 O O 0.9993106126785278
) O O 0.9999421834945679
while O O 0.9999985694885254
the O O 0.9999982118606567
lowest O O 0.9992560744285583
concentration O O 0.9998443126678467
of O O 0.9995898604393005
tAMCA S-Chemical S-Chemical 0.9563450217247009
( O O 0.9994704127311707
0 O O 0.9970369338989258
. O O 0.9999364614486694
5 O O 0.9998832941055298
mg O O 0.9999336004257202
/ O O 0.9999761581420898
ml O O 0.999659538269043
) O O 0.9997721314430237
only O O 0.9999958276748657
evoked O O 0.9999991655349731
brief O O 0.999947190284729
episodes O O 0.9999643564224243
of O O 0.9999407529830933
jerk O O 0.9852677583694458
- O O 0.9993388056755066
correlated O O 0.9999935626983643
convulsive O O 0.9997617602348328
potentials O O 0.9999744892120361
in O O 0.9999978542327881
1 O O 0.9996030926704407
of O O 0.9997351765632629
6 O O 0.9991067051887512
rats O O 0.9998024106025696
. O O 0.9999977350234985

METHODS O O 0.9979023933410645
: O O 0.9999961853027344
In O O 0.9999996423721313
this O O 0.999995231628418
study O O 0.9999984502792358
, O O 0.9999986886978149
we O O 0.9997946619987488
evaluated O O 0.9999990463256836
the O O 0.9999942779541016
performance O O 0.9999983310699463
of O O 0.999941349029541
dopamine S-Chemical S-Chemical 0.7029455304145813
beta O O 0.9368381500244141
- O O 0.9302825331687927
hydroxylase O O 0.8820921182632446
knockout O O 0.9598723649978638
( O O 0.9995033740997314
Dbh O O 0.8504959940910339
- O O 0.9115736484527588
/ O O 0.9911121726036072
- O O 0.994034469127655
) O O 0.9991660118103027
mice O O 0.9983322024345398
, O O 0.9999731779098511
which O O 0.9999316930770874
lack O O 0.9994134902954102
norepinephrine S-Chemical S-Chemical 0.9541581273078918
( O O 0.998813271522522
NE S-Chemical S-Chemical 0.7925800681114197
) O O 0.9940217137336731
, O O 0.9999607801437378
in O O 0.9999923706054688
the O O 0.9999854564666748
elevated O O 0.9986487030982971
plus O O 0.999453604221344
maze O O 0.9977433681488037
( O O 0.9998972415924072
EPM O O 0.9677273631095886
) O O 0.9996621608734131
to O O 0.999995231628418
examine O O 0.9998940229415894
the O O 0.9999936819076538
contribution O O 0.9999949932098389
of O O 0.9999576807022095
noradrenergic O O 0.9850277900695801
signaling O O 0.9988253712654114
to O O 0.9998928308486938
cocaine S-Chemical S-Chemical 0.9978360533714294
- O O 0.9979301691055298
induced O O 0.9999791383743286
anxiety O O 0.9999821186065674
. O O 0.9999992847442627

Two O O 0.9996985197067261
groups O O 0.9999921321868896
of O O 0.9999963045120239
22 O O 0.9999750852584839
similar O O 0.9999871253967285
patients O O 0.9999006986618042
were O O 0.9999986886978149
studied O O 0.9999954700469971
: O O 0.9999747276306152
one O O 0.9990167617797852
group O O 0.9999644756317139
received O O 0.9999988079071045
6 O O 0.995010256767273
mL O O 0.9797545075416565
prilocaine S-Chemical S-Chemical 0.9561241865158081
2 O O 0.9979549646377563
% O O 0.9999605417251587
; O O 0.9999767541885376
and O O 0.9999806880950928
the O O 0.9999978542327881
other O O 0.9999914169311523
received O O 0.999995231628418
3 O O 0.9950332641601562
mL O O 0.967958390712738
bupivacaine S-Chemical S-Chemical 0.9890233278274536
0 O O 0.9964371919631958
. O O 0.9999814033508301
5 O O 0.9998816251754761
% O O 0.9999895095825195
. O O 0.999988317489624

Labetalol S-Chemical S-Chemical 0.8618429899215698
administration O O 0.9999816417694092
was O O 0.9999990463256836
not O O 0.9999996423721313
associated O O 0.9999986886978149
with O O 0.9999998807907104
any O O 0.9999985694885254
of O O 0.9999958276748657
these O O 0.9999964237213135
findings O O 0.9999905824661255
. O O 0.9999983310699463

A O O 0.9999350309371948
good O O 0.9996787309646606
agreement O O 0.999997615814209
was O O 0.9999994039535522
found O O 0.9999996423721313
between O O 0.9999994039535522
two O O 0.9999865293502808
independent O O 0.9994232654571533
observers O O 0.9998201727867126
( O O 0.9999855756759644
interclass O O 0.995806097984314
correlation O O 0.9998014569282532
coefficient O O 0.99928218126297
0 O O 0.9993426203727722
. O O 0.9999271631240845
72 O O 0.9993334412574768
) O O 0.9999072551727295
. O O 0.9999973773956299

As O O 0.9996609687805176
wider O O 0.9990441203117371
use O O 0.9999802112579346
confirms O O 0.9999974966049194
their O O 0.9999923706054688
safety O O 0.9999295473098755
profile O O 0.9999860525131226
, O O 0.9999988079071045
they O O 0.9999915361404419
will O O 0.9999979734420776
gain O O 0.9999994039535522
increasing O O 0.9999939203262329
importance O O 0.9999979734420776
in O O 0.9999995231628418
the O O 0.9999862909317017
therapeutic O O 0.9998230338096619
approach O O 0.9999872446060181
to O O 0.9999949932098389
hypercholesterolaemia O O 0.9835193753242493
and O O 0.9999732971191406
its O O 0.999997615814209
consequences O O 0.9999978542327881
. O O 0.9999994039535522

This O O 0.9997966885566711
observation O O 0.9999858140945435
suggests O O 0.9999971389770508
that O O 0.9999856948852539
increased O O 0.9999868869781494
susceptibility O O 0.9999880790710449
to O O 0.9999058246612549
Warfarin S-Chemical S-Chemical 0.9945762157440186
- O O 0.9981511235237122
induced O O 0.9999796152114868
artery O O 0.996404767036438
calcification O O 0.9991509914398193
could O O 0.999997615814209
be O O 0.9999991655349731
related O O 0.9999994039535522
to O O 0.9999984502792358
higher O O 0.9999510049819946
serum O O 0.9965112805366516
phosphate S-Chemical S-Chemical 0.8054943084716797
levels O O 0.9999499320983887
. O O 0.9999985694885254

Twenty O O 0.9941930174827576
- O O 0.9993353486061096
three O O 0.9999535083770752
h O O 0.9887723326683044
postoperatively O O 0.9999843835830688
he O O 0.9999433755874634
developed O O 0.9999990463256836
a O O 0.9999967813491821
brief O O 0.999279797077179
self O O 0.9999436140060425
- O O 0.9999843835830688
limited O O 0.9999922513961792
seizure O O 0.999936580657959
. O O 0.9999983310699463

Stratification O O 0.9999021291732788
of O O 0.9999831914901733
patients O O 0.9999842643737793
by O O 0.9999997615814209
sex O O 0.9996931552886963
, O O 0.9999978542327881
age O O 0.9999791383743286
, O O 0.9999990463256836
extent O O 0.9999957084655762
of O O 0.9999951124191284
concurrent O O 0.9998021721839905
smoking O S-Chemical 0.8689164519309998
, O O 0.99996018409729
extent O O 0.9999825954437256
of O O 0.999990701675415
product O O 0.9991219639778137
use O O 0.9999508857727051
, O O 0.9999988079071045
and O O 0.9999983310699463
severity O O 0.9999918937683105
of O O 0.9999974966049194
adverse O O 0.9999861717224121
events O O 0.9999816417694092
revealed O O 0.9999997615814209
no O O 0.9999971389770508
clinically O O 0.9999977350234985
significant O O 0.9999961853027344
differences O O 0.9999966621398926
between O O 0.9999994039535522
the O O 0.9999477863311768
lozenge O O 0.9778795838356018
and O O 0.9999645948410034
gum O O 0.5246162414550781
. O O 0.9995624423027039

A O O 0.9999030828475952
lesser O O 0.9999353885650635
degree O O 0.9999582767486572
of O O 0.9999957084655762
orthostatic O O 0.9967617988586426
hypotension O O 0.999910831451416
occurred O O 0.9999996423721313
with O O 0.9999997615814209
standing O O 0.9998388290405273
. O O 0.9999852180480957

A O O 0.9997603297233582
delayed O O 0.9998571872711182
complication O O 0.9999946355819702
in O O 0.9999996423721313
nine O O 0.999994158744812
patients O O 0.9999767541885376
has O O 0.9999996423721313
been O O 0.9999997615814209
unilateral O O 0.999946117401123
loss O O 0.9999977350234985
of O O 0.9999936819076538
vision O O 0.9991275668144226
secondary O O 0.9999700784683228
to O O 0.9999983310699463
a O O 0.9994469285011292
retinal O O 0.9590917825698853
vasculitis O O 0.9931522607803345
. O O 0.9999961853027344

RESULTS O O 0.9999352693557739
: O O 0.9999994039535522
The O O 0.9999983310699463
patients O O 0.9999905824661255
in O O 0.9999996423721313
the O O 0.9999843835830688
study O O 0.9998775720596313
group O O 0.9999935626983643
were O O 0.9999997615814209
significantly O O 0.9999998807907104
younger O O 0.9999994039535522
than O O 0.9999985694885254
the O O 0.9999958276748657
patients O O 0.9999879598617554
in O O 0.9999994039535522
the O O 0.9999932050704956
control O O 0.9995923638343811
group O O 0.9999592304229736
( O O 0.9999867677688599
P O O 0.9960857629776001
< O O 0.9999573230743408
0 O O 0.9998534917831421
. O O 0.9999762773513794
002 O O 0.9997467398643494
) O O 0.9999592304229736
. O O 0.9999992847442627

RESULTS O O 0.9999394416809082
: O O 0.9999995231628418
We O O 0.999994158744812
observed O O 0.9999986886978149
a O O 0.9999996423721313
significant O O 0.9999985694885254
decrease O O 0.9999924898147583
in O O 0.9999939203262329
haptoglobin O O 0.7576647996902466
levels O O 0.999804675579071
at O O 0.9999974966049194
the O O 0.9999996423721313
end O O 0.9999986886978149
of O O 0.9999946355819702
the O O 0.9999953508377075
treatment O O 0.9999983310699463
period O O 0.9999997615814209
. O O 0.9999994039535522

Pretreatment O O 0.9998014569282532
with O O 0.9999977350234985
the O O 0.9963209629058838
D2 O O 0.873230516910553
agonist O O 0.9867892861366272
PHNO S-Chemical S-Chemical 0.8595715761184692
enhanced O O 0.9994508624076843
nicotine S-Chemical S-Chemical 0.9995002746582031
- O O 0.9982041120529175
induced O O 0.9999638795852661
hyperactivity O O 0.9999505281448364
, O O 0.9999982118606567
whereas O O 0.9999979734420776
the O O 0.9995970129966736
D1 O O 0.9321889281272888
agonist O O 0.9988358616828918
SKF B-Chemical B-Chemical 0.9501414895057678
38393 E-Chemical E-Chemical 0.9970197081565857
had O O 0.9999339580535889
no O O 0.9999977350234985
effect O O 0.9999932050704956
. O O 0.9999977350234985

Modafinil S-Chemical S-Chemical 0.8982282876968384
was O O 0.9999747276306152
associated O O 0.9999977350234985
with O O 0.9999996423721313
increased O O 0.9999973773956299
daytime O O 0.9981387853622437
sleep O O 0.9993232488632202
latency O O 0.9999730587005615
, O O 0.999996542930603
as O O 0.9999964237213135
measured O O 0.9999991655349731
by O O 0.9999994039535522
the O O 0.9999841451644897
Multiple O O 0.9999369382858276
Sleep O O 0.9965161085128784
Latency O O 0.9998683929443359
Test O O 0.9995973706245422
, O O 0.9999948740005493
and O O 0.9999980926513672
a O O 0.9999995231628418
nearly O O 0.9999966621398926
significant O O 0.9999983310699463
decrease O O 0.9999978542327881
in O O 0.9999995231628418
subjective O O 0.9999755620956421
daytime O O 0.9998420476913452
sleepiness O O 0.9999191761016846
. O O 0.9999992847442627

SDRR O O 0.704850435256958
was O O 0.9999212026596069
reduced O O 0.9999988079071045
only O O 0.999998927116394
by O O 0.9999649524688721
alpha B-Chemical B-Chemical 0.903799831867218
- I-Chemical I-Chemical 0.9630182981491089
methyldopa E-Chemical E-Chemical 0.9717425107955933
. O O 0.9999252557754517

Long O O 0.9994065761566162
- O O 0.9993516802787781
term O O 0.9997900128364563
use O O 0.9999732971191406
of O O 0.9999761581420898
these O O 0.9978128671646118
drugs O O 0.9996174573898315
was O O 0.9999964237213135
associated O O 0.999997615814209
with O O 0.9999996423721313
female O O 0.999832034111023
sex O O 0.9995142221450806
and O O 0.9999970197677612
use O O 0.9999969005584717
of O O 0.9999865293502808
a O O 0.9999735355377197
higher O O 0.9999734163284302
number O O 0.9999138116836548
of O O 0.9999731779098511
drugs O O 0.99947589635849
with O O 0.9999970197677612
effects O O 0.9999450445175171
on O O 0.9999943971633911
the O O 0.9997478127479553
CNS O O 0.9812396764755249
, O O 0.9999353885650635
which O O 0.9999840259552002
tended O O 0.9999991655349731
to O O 0.9999974966049194
be O O 0.9999934434890747
related O O 0.9999955892562866
to O O 0.9999986886978149
diagnosed O O 0.9999518394470215
dementia O O 0.9998980760574341
. O O 0.9999990463256836

Allergic O O 0.9983100891113281
manifestations O O 0.999962329864502
such O O 0.9999977350234985
as O O 0.9999697208404541
rash O O 0.8617560267448425
and O O 0.998788058757782
eosinophilia O O 0.9563350081443787
were O O 0.9999938011169434
rare O O 0.9999885559082031
. O O 0.9999988079071045

Mitochondrial O O 0.9822145104408264
radiocalcium S-Chemical S-Chemical 0.5856180787086487
uptakes O O 0.9984613656997681
were O O 0.9999978542327881
significantly O O 0.9999996423721313
decreased O O 0.9999985694885254
in O O 0.9999953508377075
animals O O 0.9987847208976746
pretreated O O 0.9999974966049194
with O O 0.999976396560669
acetylsalicylic B-Chemical B-Chemical 0.943086564540863
acid E-Chemical E-Chemical 0.9922722578048706
or O O 0.9981403350830078
dipyridamole S-Chemical S-Chemical 0.9941664934158325
or O O 0.9997298121452332
when O O 0.9983820915222168
hydrocortisone S-Chemical S-Chemical 0.9318282604217529
was O O 0.9999498128890991
added O O 0.999975323677063
to O O 0.9999746084213257
the O O 0.9973394274711609
epinephrine S-Chemical S-Chemical 0.9092880487442017
infusion O O 0.9994891881942749
( O O 0.9999512434005737
2 O O 0.9929227828979492
, O O 0.9994922876358032
682 O O 0.9990203380584717
, O O 0.9998832941055298
2 O O 0.9990070462226868
, O O 0.9997426867485046
803 O O 0.9990862607955933
, O O 0.9998958110809326
and O O 0.9999278783798218
3 O O 0.9986521601676941
, O O 0.9998553991317749
424 O O 0.9997017979621887
counts O O 0.9999220371246338
per O O 0.9999905824661255
minute O O 0.9999580383300781
per O O 0.9999926090240479
gram O O 0.9998372793197632
of O O 0.9999675750732422
dried O O 0.9931415915489197
fraction O O 0.9999387264251709
, O O 0.9999874830245972
respectively O O 0.9999972581863403
) O O 0.9999784231185913
. O O 0.9999984502792358

In O O 0.9997645020484924
vitro O O 0.9909048676490784
, O O 0.9998822212219238
gamma B-Chemical B-Chemical 0.8335398435592651
- I-Chemical I-Chemical 0.8762729167938232
HCH E-Chemical E-Chemical 0.8266260027885437
, O O 0.9957531690597534
pentylenetetrazol S-Chemical S-Chemical 0.9695312976837158
and O O 0.9997448325157166
picrotoxin S-Chemical S-Chemical 0.8990580439567566
were O O 0.9999805688858032
shown O O 0.9999938011169434
to O O 0.9999879598617554
inhibit O O 0.9985682964324951
3H B-Chemical O 0.6918155550956726
- I-Chemical O 0.6900509595870972
TBOB E-Chemical O 0.48792049288749695
binding O O 0.9990543723106384
in O O 0.9999932050704956
mouse O O 0.9975220561027527
whole O O 0.9998984336853027
brain O O 0.9998756647109985
, O O 0.9999939203262329
with O O 0.9999942779541016
IC50 O O 0.9891893863677979
values O O 0.9999881982803345
of O O 0.9999949932098389
4 O O 0.9982934594154358
. O O 0.9999799728393555
6 O O 0.9994656443595886
, O O 0.9998397827148438
404 O O 0.9980092644691467
and O O 0.9999586343765259
9 O O 0.999591052532196
. O O 0.9999868869781494
4 O O 0.999809205532074
microM O O 0.9956798553466797
, O O 0.9999935626983643
respectively O O 0.9999992847442627
. O O 0.9999992847442627

Further O O 0.9999916553497314
work O O 0.9999905824661255
is O O 0.9999985694885254
warranted O O 0.9999966621398926
on O O 0.9999986886978149
the O O 0.9999977350234985
effect O O 0.9999986886978149
of O O 0.99998939037323
the O O 0.9998904466629028
treatments O O 0.9999289512634277
on O O 0.9999983310699463
renal O O 0.999599039554596
functional O O 0.9999426603317261
aspects O O 0.9999909400939941
in O O 0.9999991655349731
models O O 0.9999876022338867
of O O 0.9999983310699463
chronic O O 0.9998190999031067
renal O O 0.9995520710945129
failure O O 0.9999923706054688
, O O 0.9999974966049194
and O O 0.9999963045120239
on O O 0.9999961853027344
the O O 0.9999918937683105
mechanism O O 0.9999769926071167
( O O 0.9999819993972778
s O O 0.9989668130874634
) O O 0.999985933303833
involved O O 0.9999986886978149
. O O 0.9999911785125732

Terbutaline S-Chemical S-Chemical 0.8826127052307129
, O O 0.9997978806495667
a O O 0.9955118298530579
beta2 O O 0.936882495880127
- O O 0.9754898548126221
adrenoceptor O O 0.9282137155532837
agonist O O 0.9395241141319275
used O O 0.9999969005584717
to O O 0.9999971389770508
arrest O O 0.999964714050293
preterm O O 0.9998045563697815
labor O O 0.9991220831871033
, O O 0.9999912977218628
has O O 0.9999927282333374
been O O 0.9999996423721313
associated O O 0.9999978542327881
with O O 0.9999995231628418
increased O O 0.9999843835830688
concordance O O 0.9999620914459229
for O O 0.9999979734420776
autism O O 0.9957072734832764
in O O 0.9999986886978149
dizygotic O O 0.9877854585647583
twins O O 0.9982749223709106
. O O 0.999997615814209

Nitroglycerin S-Chemical S-Chemical 0.5033472180366516
has O O 0.9994937181472778
been O O 0.9999988079071045
shown O O 0.9999854564666748
to O O 0.9999935626983643
reduce O O 0.9998792409896851
ST O O 0.9337963461875916
- O O 0.9793640971183777
segment O O 0.9993902444839478
elevation O O 0.9999692440032959
during O O 0.9999997615814209
acute O O 0.9997010827064514
myocardial O O 0.9998252987861633
infarction O O 0.9999243021011353
, O O 0.9999974966049194
an O O 0.9999938011169434
effect O O 0.999983549118042
potentiated O O 0.9999892711639404
in O O 0.9999970197677612
the O O 0.9999721050262451
dog O O 0.9980201721191406
by O O 0.9999856948852539
agents O O 0.9785032868385315
that O O 0.9998487234115601
reverse O O 0.9972565770149231
nitroglycerin S-Chemical S-Chemical 0.9701533913612366
- O O 0.9958029389381409
induced O O 0.9999686479568481
hypotension O O 0.999900221824646
. O O 0.9999984502792358

Desferrioxamine S-Chemical S-Chemical 0.9739708304405212
withdrawal O O 0.9999358654022217
resulted O O 0.9999997615814209
in O O 0.9999996423721313
a O O 0.999998927116394
complete O O 0.9999611377716064
recovery O O 0.9999957084655762
of O O 0.9999977350234985
visual O O 0.9999294281005859
function O O 0.999977707862854
in O O 0.9999977350234985
1 O O 0.9985285997390747
patient O O 0.9999253749847412
and O O 0.999994158744812
partial O O 0.9999903440475464
recovery O O 0.9999920129776001
in O O 0.999997615814209
3 O O 0.9668952226638794
, O O 0.9996541738510132
and O O 0.9999953508377075
a O O 0.9999992847442627
complete O O 0.9999877214431763
reversal O O 0.9999994039535522
of O O 0.9999990463256836
hearing O O 0.9998630285263062
loss O O 0.9999978542327881
in O O 0.9999985694885254
3 O O 0.9984149932861328
patients O O 0.9999719858169556
and O O 0.9999974966049194
partial O O 0.9999974966049194
recovery O O 0.9999973773956299
in O O 0.9999990463256836
3 O O 0.9928701519966125
. O O 0.9999908208847046

Although O O 0.9999516010284424
the O O 0.9999948740005493
explanation O O 0.9999899864196777
for O O 0.9999986886978149
the O O 0.9999964237213135
association O O 0.9999903440475464
between O O 0.9999985694885254
artery O O 0.9924308657646179
calcification O O 0.9975597858428955
and O O 0.9999889135360718
growth O O 0.9996260404586792
status O O 0.9999160766601562
cannot O O 0.9999979734420776
be O O 0.9999974966049194
determined O O 0.9999985694885254
from O O 0.9999980926513672
the O O 0.9999972581863403
present O O 0.9999948740005493
study O O 0.9999972581863403
, O O 0.9999996423721313
there O O 0.9999996423721313
was O O 0.9999998807907104
a O O 0.999998927116394
relationship O O 0.9999964237213135
between O O 0.9999995231628418
higher O O 0.9999488592147827
serum O O 0.9879812598228455
phosphate S-Chemical S-Chemical 0.8224024176597595
and O O 0.9999417066574097
susceptibility O O 0.9999955892562866
to O O 0.9999955892562866
artery O O 0.9898753762245178
calcification O O 0.9996426105499268
, O O 0.9999977350234985
with O O 0.9999990463256836
30 O O 0.9999438524246216
% O O 0.9999988079071045
higher O O 0.9999983310699463
levels O O 0.9999809265136719
of O O 0.9999784231185913
serum O O 0.9592286348342896
phosphate S-Chemical S-Chemical 0.746895432472229
in O O 0.999984860420227
young O O 0.999772846698761
, O O 0.999955415725708
ad O O 0.9938907623291016
libitum O O 0.96640944480896
- O O 0.9954858422279358
fed O O 0.9949682354927063
rats O O 0.999747097492218
compared O O 0.9999978542327881
with O O 0.9999786615371704
either O O 0.9998636245727539
of O O 0.9998993873596191
the O O 0.9999549388885498
groups O O 0.9996975660324097
that O O 0.9999589920043945
was O O 0.9999494552612305
resistant O O 0.9999902248382568
to O O 0.9998080134391785
Warfarin S-Chemical S-Chemical 0.9972763657569885
- O O 0.9976876974105835
induced O O 0.9999880790710449
artery O O 0.9979956150054932
calcification O O 0.9998146891593933
, O O 0.9999922513961792
ie O O 0.9997311234474182
, O O 0.9999860525131226
the O O 0.9999876022338867
10 O O 0.9869776368141174
- O O 0.998906135559082
month O O 0.9999690055847168
- O O 0.9997867941856384
old O O 0.9972852468490601
rats O O 0.999380350112915
and O O 0.9999731779098511
the O O 0.9999791383743286
restricted O O 0.999915599822998
- O O 0.9990548491477966
diet O O 0.9995678067207336
, O O 0.9999417066574097
growth O O 0.9991463422775269
- O O 0.9995038509368896
inhibited O O 0.9999780654907227
young O O 0.9999172687530518
rats O O 0.9996128678321838
. O O 0.9999983310699463

Peripheral O O 0.9988234639167786
neuropathy O O 0.9999171495437622
occurred O O 0.9999992847442627
in O O 0.9999988079071045
12 O O 0.9997071623802185
patients O O 0.9999524354934692
and O O 0.999969482421875
pancreatitis O O 0.9997355341911316
in O O 0.9999979734420776
six O O 0.999922513961792
. O O 0.9999942779541016

Its O O 0.9997783303260803
activity O O 0.9999653100967407
is O O 0.9999983310699463
believed O O 0.9999997615814209
to O O 0.9999992847442627
be O O 0.9999984502792358
due O O 0.9999910593032837
modulation O O 0.9998949766159058
of O O 0.9999525547027588
the O O 0.9998188614845276
tumour O O 0.998762845993042
milieu O O 0.9959688186645508
, O O 0.9999916553497314
including O O 0.9999933242797852
downregulation O O 0.999517560005188
of O O 0.9999271631240845
angiogenesis O O 0.9930589199066162
and O O 0.9999922513961792
inflammatory O O 0.9998770952224731
cytokines O O 0.9952706694602966
. O O 0.9999978542327881

The O O 0.9999146461486816
administration O O 0.9999902248382568
of O O 0.9999675750732422
pharmacologic O O 0.9858919978141785
doses O O 0.999950647354126
of O O 0.9993884563446045
pyridoxine B-Chemical B-Chemical 0.49456116557121277
hydrochloride E-Chemical E-Chemical 0.9895275235176086
led O O 0.9999929666519165
to O O 0.9999991655349731
a O O 0.9999973773956299
disappearance O O 0.9999954700469971
of O O 0.9999971389770508
symptoms O O 0.9999855756759644
. O O 0.999998927116394

BACKGROUND O O 0.9992272853851318
: O O 0.99998939037323
Although O O 0.9999901056289673
intravitreal O O 0.9972921013832092
aminoglycosides S-Chemical S-Chemical 0.5249902606010437
have O O 0.9999797344207764
substantially O O 0.9999985694885254
improved O O 0.9999982118606567
visual O O 0.9997928738594055
prognosis O O 0.9999003410339355
in O O 0.9999884366989136
endophthalmitis O O 0.9811904430389404
, O O 0.9999895095825195
macular O O 0.9997736811637878
infarction O O 0.9998377561569214
may O O 0.9999991655349731
impair O O 0.9999991655349731
full O O 0.9999979734420776
visual O O 0.9999790191650391
recovery O O 0.9999946355819702
. O O 0.9999994039535522

Zyban S-Chemical S-Chemical 0.9170324802398682
caused O O 0.9999983310699463
significant O O 0.9999949932098389
neurological O O 0.9999771118164062
and O O 0.9999985694885254
cardiovascular O O 0.9999914169311523
toxicity O O 0.9999402761459351
in O O 0.9999967813491821
overdose O O 0.9991317391395569
. O O 0.9999977350234985

Hunt O O 0.9818307757377625
and O O 0.9999821186065674
Hess O O 0.9789140224456787
grade O O 0.9999266862869263
( O O 0.9999716281890869
P O O 0.9952155351638794
< O O 0.9999575614929199
0 O O 0.9998542070388794
. O O 0.9999698400497437
005 O O 0.9995056390762329
) O O 0.9999157190322876
and O O 0.9999949932098389
age O O 0.9999629259109497
( O O 0.9999861717224121
P O O 0.9956985712051392
< O O 0.9999637603759766
0 O O 0.9998674392700195
. O O 0.9999825954437256
007 O O 0.9995235204696655
) O O 0.9999579191207886
were O O 0.9999998807907104
significant O O 0.9999991655349731
predictors O O 0.9999974966049194
of O O 0.9999991655349731
outcome O O 0.9999959468841553
for O O 0.9999979734420776
the O O 0.999994158744812
patients O O 0.9999825954437256
with O O 0.999992847442627
cocaine S-Chemical S-Chemical 0.9761442542076111
- O O 0.9982209801673889
related O O 0.9999808073043823
aneurysms O O 0.9998902082443237
. O O 0.999998927116394

Illness O O 0.9996751546859741
occurred O O 0.9999996423721313
within O O 0.9999974966049194
1 O O 0.9418808817863464
- O O 0.9814196825027466
- O O 0.9985573887825012
9 O O 0.9999585151672363
weeks O O 0.9999996423721313
of O O 0.9999996423721313
commencement O O 0.999998927116394
of O O 0.9999967813491821
therapy O O 0.9999872446060181
in O O 0.9999985694885254
9 O O 0.9982433319091797
patients O O 0.9999758005142212
, O O 0.9999984502792358
the O O 0.9999994039535522
remaining O O 0.9999969005584717
3 O O 0.9992275238037109
patients O O 0.9999454021453857
having O O 0.9999957084655762
received O O 0.9999983310699463
the O O 0.999862790107727
drug O O 0.9998956918716431
for O O 0.9999973773956299
13 O O 0.9999306201934814
months O O 0.9999936819076538
, O O 0.9999982118606567
15 O O 0.9999676942825317
months O O 0.9999979734420776
and O O 0.9999966621398926
7 O O 0.9999393224716187
years O O 0.9999986886978149
before O O 0.9999998807907104
experiencing O O 0.999998927116394
symptoms O O 0.9999878406524658
. O O 0.9999985694885254

Replication O O 0.9996347427368164
- O O 0.9998871088027954
competent O O 0.9996484518051147
HBV O O 0.9969202280044556
strains O O 0.9998183846473694
with O O 0.9999641180038452
sG145R O O 0.8495832085609436
or O O 0.9989035129547119
sP120T O O 0.898211658000946
and O O 0.9991652965545654
LAM S-Chemical S-Chemical 0.4180494248867035
resistance O O 0.9879550933837891
( O O 0.9999136924743652
rtM204I O O 0.9169191122055054
or O O 0.9996744394302368
rtL180M O O 0.8834671378135681
/ O O 0.9960330128669739
rtM204V O O 0.9796090722084045
) O O 0.9998564720153809
were O O 0.9999953508377075
generated O O 0.9999727010726929
on O O 0.9999643564224243
an O O 0.9993879795074463
HBeAg S-Chemical O 0.7089698910713196
- O O 0.9821532368659973
positive O O 0.9999600648880005
and O O 0.9999955892562866
an O O 0.9998801946640015
HBeAg S-Chemical O 0.6200457215309143
- O O 0.9757516384124756
negative O O 0.9999125003814697
background O O 0.999984622001648
with O O 0.9999961853027344
precore O O 0.988283097743988
( O O 0.9995446801185608
PC O O 0.9368156790733337
) O O 0.9994226694107056
and O O 0.9999886751174927
basal O O 0.9980422258377075
core O O 0.9988824725151062
promoter O O 0.998734176158905
( O O 0.9998973608016968
BCP O O 0.9875778555870056
) O O 0.9997708201408386
mutants O O 0.9994539618492126
. O O 0.9999990463256836

Depressed O O 0.999731719493866
mood O O 0.9999167919158936
was O O 0.9999994039535522
more O O 0.9999995231628418
common O O 0.999997615814209
among O O 0.9999985694885254
patients O O 0.9999790191650391
and O O 0.9999960660934448
was O O 0.9999984502792358
associated O O 0.9999978542327881
with O O 0.9999998807907104
certain O O 0.9999984502792358
sexual O O 0.9999829530715942
difficulties O O 0.999997615814209
, O O 0.999998927116394
but O O 0.9999979734420776
not O O 0.9999983310699463
with O O 0.9999984502792358
impotence O O 0.9991831183433533
. O O 0.9999960660934448

Therefore O O 0.9996860027313232
, O O 0.9997969269752502
TAM S-Chemical S-Chemical 0.9821053743362427
- O O 0.9979015588760376
induced O O 0.9999672174453735
hemolysis O O 0.9996328353881836
results O O 0.9999971389770508
from O O 0.9999985694885254
a O O 0.999992847442627
structural O O 0.999836802482605
perturbation O O 0.9997403025627136
of O O 0.9999176263809204
red O O 0.9877349734306335
cell O O 0.9988048076629639
membrane O O 0.9986510872840881
, O O 0.9999947547912598
leading O O 0.9999948740005493
to O O 0.9999963045120239
changes O O 0.9999889135360718
in O O 0.999994158744812
the O O 0.9999587535858154
framework O O 0.9999805688858032
of O O 0.9999581575393677
the O O 0.9996048808097839
erythrocyte O O 0.9898945689201355
membrane O O 0.9983136653900146
and O O 0.9999446868896484
its O O 0.9998729228973389
cytoskeleton O O 0.7775247693061829
caused O O 0.9999784231185913
by O O 0.999997615814209
its O O 0.9999854564666748
high O O 0.9999302625656128
partition O O 0.9991812109947205
in O O 0.9999827146530151
the O O 0.9998883008956909
membrane O O 0.9986909031867981
. O O 0.9999977350234985

Monitoring O O 0.9998810291290283
consisted O O 0.9999970197677612
of O O 0.999929666519165
airflow O O 0.9967709183692932
detection O O 0.9999969005584717
by O O 0.9999997615814209
a O O 0.9991698265075684
carbon B-Chemical B-Chemical 0.9932158589363098
dioxide E-Chemical E-Chemical 0.9988747239112854
analyser O O 0.9992590546607971
, O O 0.9999967813491821
chest O O 0.9993851184844971
wall O O 0.999887228012085
movement O O 0.9999701976776123
detected O O 0.9999980926513672
by O O 0.9999972581863403
pneumatic O O 0.9590858817100525
capsules O O 0.995157778263092
, O O 0.9999921321868896
and O O 0.9999966621398926
continuous O O 0.9995099306106567
electrocardiograph O O 0.9988295435905457
recorded O O 0.9999878406524658
with O O 0.9999936819076538
a O O 0.9997840523719788
Holter O O 0.9983685612678528
ambulatory O O 0.9999295473098755
monitor O O 0.9999057054519653
. O O 0.9999977350234985

The O O 0.9999591112136841
beneficial O O 0.9999302625656128
effect O O 0.9999963045120239
of O O 0.9998743534088135
Adriamycin S-Chemical S-Chemical 0.8404059410095215
appears O O 0.9999487400054932
obvious O O 0.9999712705612183
and O O 0.9999902248382568
might O O 0.9999978542327881
be O O 0.9999988079071045
related O O 0.9999988079071045
to O O 0.9999973773956299
the O O 0.9998540878295898
drug O O 0.9995090961456299
itself O O 0.9999239444732666
, O O 0.9999974966049194
the O O 0.9999980926513672
early O O 0.9999971389770508
and O O 0.9999973773956299
repeated O O 0.99997878074646
instillations O O 0.9996429681777954
after O O 0.999988317489624
TUR O O 0.5543285608291626
, O O 0.9961068034172058
or O O 0.9999849796295166
both O O 0.9999903440475464
. O O 0.9999909400939941

Our O O 0.999925971031189
results O O 0.9999978542327881
demonstrate O O 0.9999972581863403
that O O 0.9999954700469971
both O O 0.997078537940979
cisplatin S-Chemical S-Chemical 0.9963397979736328
and O O 0.9990440011024475
paclitaxel S-Chemical S-Chemical 0.9988569021224976
cause O O 0.999987006187439
early O O 0.9999935626983643
mitochondrial O O 0.9999730587005615
impairment O O 0.9999918937683105
with O O 0.9999998807907104
loss O O 0.9999947547912598
of O O 0.999932050704956
membrane O O 0.9951319694519043
potential O O 0.9999387264251709
and O O 0.9999942779541016
induction O O 0.9999806880950928
of O O 0.999931812286377
autophagic O O 0.9981563687324524
vacuoles O O 0.978184700012207
in O O 0.9999959468841553
neurons O O 0.9990403056144714
. O O 0.9999982118606567

The O O 0.9998779296875
drug O O 0.9997702240943909
was O O 0.999996542930603
still O O 0.9999972581863403
present O O 0.9999988079071045
in O O 0.9999996423721313
measurable O O 0.9999911785125732
quantities O O 0.9999710321426392
after O O 0.9999994039535522
24 O O 0.9998239874839783
h O O 0.9978803396224976
even O O 0.9999977350234985
with O O 0.9999986886978149
the O O 0.9999982118606567
smallest O O 0.9999699592590332
dose O O 0.9999864101409912
. O O 0.999995231628418

Diclofenac B-Chemical B-Chemical 0.9468656182289124
sodium E-Chemical E-Chemical 0.9745165109634399
( O O 0.9966404438018799
Voltarol S-Chemical S-Chemical 0.8239519596099854
, O O 0.8244933485984802
Geigy O O 0.7743844389915466
Pharmaceuticals O O 0.452614963054657
) O O 0.9829680323600769
is O O 0.9999748468399048
a O O 0.9999953508377075
non O O 0.999605119228363
- O O 0.9992390871047974
steroidal O O 0.9819374084472656
anti O O 0.9992386102676392
- O O 0.9986855387687683
inflammatory O O 0.999535322189331
derivative O O 0.9994425177574158
of O O 0.9997925162315369
phenylacetic B-Chemical B-Chemical 0.607835590839386
acid E-Chemical E-Chemical 0.9921533465385437
. O O 0.9999605417251587

Finally O O 0.999962568283081
, O O 0.9999961853027344
the O O 0.9999916553497314
contribution O O 0.9999974966049194
of O O 0.9999908208847046
a O O 0.9999841451644897
primary O O 0.999565064907074
, O O 0.9999943971633911
thrombotic O O 0.9992419481277466
effect O O 0.9999672174453735
of O O 0.9996424913406372
cocaine S-Chemical S-Chemical 0.992668092250824
has O O 0.9999707937240601
not O O 0.9999979734420776
been O O 0.9999979734420776
excluded O O 0.9999735355377197
. O O 0.9999959468841553

The O O 0.9998759031295776
convulsant O O 0.9777961373329163
activity O O 0.9995810389518738
of O O 0.9987861514091492
bupivacaine S-Chemical S-Chemical 0.987037181854248
was O O 0.9999748468399048
not O O 0.9999977350234985
significantly O O 0.9999996423721313
modified O O 0.9999916553497314
but O O 0.9999104738235474
calcium S-Chemical S-Chemical 0.9650299549102783
channel O O 0.9995719790458679
blockers O O 0.9998339414596558
decreased O O 0.9999990463256836
the O O 0.9999978542327881
time O O 0.9999958276748657
of O O 0.999993085861206
latency O O 0.9998847246170044
to O O 0.9999916553497314
obtain O O 0.9953232407569885
bupivacaine S-Chemical S-Chemical 0.9940592050552368
- O O 0.9981338381767273
induced O O 0.9999837875366211
convulsions O O 0.9998924732208252
; O O 0.9999974966049194
this O O 0.9999791383743286
effect O O 0.9999874830245972
was O O 0.9999994039535522
less O O 0.9999996423721313
pronounced O O 0.9999737739562988
with O O 0.9999701976776123
bepridil S-Chemical S-Chemical 0.9291248321533203
. O O 0.999985933303833

Cell O O 0.9786508083343506
extracts O O 0.9966709017753601
were O O 0.9999912977218628
harvested O O 0.9999039173126221
, O O 0.9999904632568359
and O O 0.999988317489624
lipid O O 0.9967554211616516
or O O 0.999988317489624
total O O 0.9998375177383423
RNA O O 0.9398455023765564
was O O 0.9999842643737793
isolated O O 0.9999827146530151
. O O 0.9999986886978149

In O O 0.99998939037323
the O O 0.9999994039535522
present O O 0.9999938011169434
paper O O 0.9999804496765137
the O O 0.9999961853027344
authors O O 0.9999569654464722
describe O O 0.9999916553497314
2 O O 0.9982814788818359
female O O 0.9999330043792725
patients O O 0.9999600648880005
who O O 0.9999988079071045
developed O O 0.9999986886978149
incontinence O O 0.9996334314346313
secondary O O 0.9999806880950928
to O O 0.9999960660934448
the O O 0.9984367489814758
selective O O 0.993066668510437
serotonin S-Chemical S-Chemical 0.8403540253639221
reuptake O O 0.6496122479438782
inhibitors O O 0.75557941198349
paroxetine S-Chemical S-Chemical 0.9948261380195618
and O O 0.9996008276939392
sertraline S-Chemical S-Chemical 0.892745316028595
, O O 0.9999330043792725
as O O 0.999994158744812
well O O 0.9999980926513672
as O O 0.9999990463256836
a O O 0.9999988079071045
third O O 0.9999947547912598
who O O 0.9999974966049194
developed O O 0.9999992847442627
this O O 0.9999908208847046
side O O 0.9998830556869507
effect O O 0.9999775886535645
on O O 0.9999402761459351
venlafaxine S-Chemical S-Chemical 0.9987285733222961
. O O 0.9999871253967285

T O O 0.4694449305534363
- O O 0.7400001883506775
cell O O 0.96865314245224
stimulation O O 0.999549925327301
by O O 0.9999946355819702
therapeutic O O 0.9966819882392883
concentration O O 0.9999357461929321
of O O 0.9994398951530457
ticlopidine S-Chemical S-Chemical 0.9899278283119202
was O O 0.9999691247940063
demonstrated O O 0.9999961853027344
in O O 0.9999860525131226
vitro O O 0.9982483386993408
in O O 0.9999951124191284
the O O 0.999984622001648
patients O O 0.9999810457229614
, O O 0.9999967813491821
but O O 0.9999958276748657
not O O 0.9999969005584717
in O O 0.9999990463256836
healthy O O 0.9998916387557983
controls O O 0.9999456405639648
. O O 0.9999988079071045

Routine O O 0.9983810186386108
EKG O O 0.946427583694458
monitoring O O 0.9999279975891113
during O O 0.9999980926513672
infusional O O 0.9957026839256287
cyclophosphamide S-Chemical S-Chemical 0.9905316829681396
did O O 0.9999961853027344
not O O 0.9999847412109375
predict O O 0.999930739402771
CHF O O 0.9703404903411865
development O O 0.9999964237213135
. O O 0.9999991655349731

Systolic O O 0.9821236729621887
blood O O 0.9814836382865906
pressure O O 0.9981241822242737
( O O 0.9999017715454102
SBP O O 0.9923176765441895
) O O 0.9999147653579712
was O O 0.9999970197677612
measured O O 0.9999985694885254
on O O 0.9999979734420776
alternate O O 0.9999865293502808
days O O 0.9999978542327881
using O O 0.9999974966049194
the O O 0.9999129772186279
tail O O 0.9994947910308838
- O O 0.9993550181388855
cuff O O 0.997890293598175
method O O 0.9997201561927795
. O O 0.999997615814209

The O O 0.9999308586120605
potential O O 0.9999269247055054
toxic O O 0.9970706701278687
effects O O 0.9999932050704956
should O O 0.9999973773956299
be O O 0.9999984502792358
considered O O 0.9999983310699463
when O O 0.9999856948852539
prescribing O O 0.9998273253440857
it O O 0.9956687688827515
as O O 0.9999943971633911
a O O 0.999990701675415
smoking O O 0.9546321034431458
cessation O O 0.9997460246086121
aid O O 0.9998519420623779
. O O 0.9999991655349731

After O O 0.9997194409370422
withdrawal O O 0.9999455213546753
of O O 0.9990689158439636
octreotide S-Chemical S-Chemical 0.9891989827156067
in O O 0.9998911619186401
10 O O 0.9994475245475769
patients O O 0.9999406337738037
without O O 0.9999957084655762
gallstones O O 0.9995501637458801
, O O 0.9999958276748657
8 O O 0.986473798751831
patients O O 0.9997921586036682
assessed O O 0.9999961853027344
had O O 0.9999899864196777
return O O 0.999988317489624
of O O 0.9999834299087524
normal O O 0.9998940229415894
gallbladder O O 0.9940333962440491
contractility O O 0.9998968839645386
within O O 0.9999994039535522
1 O O 0.9998984336853027
month O O 0.9999988079071045
. O O 0.999998927116394

17beta B-Chemical B-Chemical 0.9901632070541382
- I-Chemical I-Chemical 0.994168758392334
Estradiol E-Chemical E-Chemical 0.9445171356201172
did O O 0.9999421834945679
not O O 0.9999946355819702
alter O O 0.9999920129776001
the O O 0.9999966621398926
onset O O 0.9999806880950928
of O O 0.9999802112579346
first O O 0.9989762306213379
clonus O O 0.9246666431427002
in O O 0.9999805688858032
ovariectomized O O 0.9604777693748474
rats O O 0.9966572523117065
but O O 0.9999794960021973
accelerated O O 0.9999959468841553
it O O 0.999906063079834
in O O 0.9999958276748657
males O O 0.9998552799224854
. O O 0.9999983310699463

Suxamethonium S-Chemical S-Chemical 0.9785112738609314
causes O O 0.9999940395355225
prolonged O O 0.9996792078018188
apnea O O 0.9846184849739075
in O O 0.9999955892562866
patients O O 0.9999855756759644
in O O 0.999997615814209
whom O O 0.9996532201766968
pseudocholinesterase O O 0.6859993934631348
enzyme O O 0.7024719715118408
gets O O 0.9830857515335083
deactivated O O 0.9995100498199463
by O O 0.9999839067459106
organophosphorus B-Chemical O 0.4206118583679199
( I-Chemical O 0.9494274258613586
OP I-Chemical S-Chemical 0.5699205994606018
) I-Chemical O 0.8646653294563293
poisons E-Chemical O 0.9950683116912842
. O O 0.9999988079071045

At O O 0.9999288320541382
this O O 0.9999998807907104
point O O 0.9999997615814209
it O O 0.9999991655349731
was O O 0.9999985694885254
assumed O O 0.9999995231628418
that O O 0.9999963045120239
the O O 0.999458372592926
cytochrome O O 0.7626396417617798
P450 O O 0.9068055748939514
/ O O 0.9959589838981628
CCl4 S-Chemical O 0.9785593152046204
toxic O O 0.9950574636459351
state O O 0.9990106821060181
was O O 0.9999943971633911
both O O 0.9999988079071045
maximal O O 0.9999661445617676
and O O 0.9999972581863403
stable O O 0.9999735355377197
. O O 0.9999971389770508

Flestolol S-Chemical S-Chemical 0.9717017412185669
: O O 0.9998879432678223
an O O 0.9999687671661377
ultra O O 0.9996935129165649
- O O 0.9998401403427124
short O O 0.9999291896820068
- O O 0.9996522665023804
acting O O 0.9990288019180298
beta O O 0.9654632806777954
- O O 0.9950776696205139
adrenergic O O 0.9943860769271851
blocking O O 0.999297022819519
agent O O 0.9992296695709229
. O O 0.9999878406524658

These O O 0.9999107122421265
children O O 0.9999418258666992
were O O 0.9999996423721313
older O O 0.9999898672103882
and O O 0.9999986886978149
were O O 0.9999995231628418
more O O 0.9999997615814209
likely O O 0.9999998807907104
to O O 0.9999997615814209
have O O 0.9999982118606567
undergone O O 0.9999974966049194
recent O O 0.9999938011169434
bowel O O 0.9998146891593933
surgery O O 0.9999947547912598
than O O 0.9999986886978149
are O O 0.9999972581863403
other O O 0.9999969005584717
children O O 0.9997377991676331
with O O 0.9999995231628418
this O O 0.9999843835830688
condition O O 0.999977707862854
. O O 0.9999992847442627

In O O 0.9999384880065918
the O O 0.9999980926513672
present O O 0.9999731779098511
experiment O O 0.9965925812721252
calcitonin S-Chemical S-Chemical 0.9970280528068542
decreased O O 0.9999936819076538
locomotor O O 0.8332356810569763
activity O O 0.9993164539337158
when O O 0.999983549118042
locally O O 0.9998869895935059
injected O O 0.9998428821563721
into O O 0.9999960660934448
the O O 0.9999443292617798
same O O 0.999942421913147
sites O O 0.9998430013656616
where O O 0.9999817609786987
it O O 0.9999834299087524
decreases O O 0.9999939203262329
food O O 0.9972435235977173
intake O O 0.9999488592147827
. O O 0.9999990463256836

Patients O O 0.9998923540115356
likely O O 0.9999998807907104
to O O 0.9999994039535522
have O O 0.9999784231185913
both O O 0.9999699592590332
raised O O 0.9975722432136536
trough O O 0.9994403719902039
- O O 0.9995588660240173
concentrations O O 0.9999821186065674
and O O 0.9999988079071045
mental O O 0.999974250793457
confusion O O 0.9999762773513794
are O O 0.9999995231628418
those O O 0.9999991655349731
with O O 0.9999991655349731
both O O 0.9999957084655762
severe O O 0.9999792575836182
renal O O 0.9999281167984009
and O O 0.9999974966049194
hepatic O O 0.9994961023330688
dysfunction O O 0.9999849796295166
. O O 0.999998927116394

BACKGROUND O O 0.9988019466400146
: O O 0.9999527931213379
Fibrin O B-Chemical 0.9047460556030273
sealants O E-Chemical 0.6321864128112793
( O O 0.9884402751922607
FS O O 0.9372065663337708
) O O 0.9988973140716553
derived O O 0.9998558759689331
from O O 0.9999715089797974
human O O 0.99639493227005
plasma O O 0.9990649819374084
are O O 0.9999406337738037
frequently O O 0.9999266862869263
used O O 0.9999986886978149
in O O 0.9999985694885254
neurosurgery O O 0.9999504089355469
. O O 0.9999992847442627

The O O 0.9999113082885742
addition O O 0.9999892711639404
of O O 0.9998511075973511
1 O O 0.9113829135894775
mM O O 0.9620947241783142
adenosine S-Chemical S-Chemical 0.9897856116294861
to O O 0.9999226331710815
the O O 0.9996563196182251
myocardial O O 0.9986912608146667
cell O O 0.9976153373718262
cultures O O 0.9997194409370422
markedly O O 0.9999979734420776
increases O O 0.9999994039535522
the O O 0.999963641166687
ATP S-Chemical S-Chemical 0.8277913331985474
concentration O O 0.9999097585678101
through O O 0.9999996423721313
a O O 0.9999788999557495
pathway O O 0.9997627139091492
reportedly O O 0.9999973773956299
leading O O 0.9999974966049194
to O O 0.9999982118606567
a O O 0.9999963045120239
compartmentalized O O 0.9996277093887329
ATP S-Chemical O 0.9881458282470703
pool O O 0.999957799911499
. O O 0.9999990463256836

RESULTS O O 0.9999101161956787
: O O 0.9999990463256836
Six O O 0.9999386072158813
of O O 0.9999866485595703
30 O O 0.9999865293502808
patients O O 0.999954342842102
( O O 0.9999936819076538
20 O O 0.9999669790267944
% O O 0.9999959468841553
) O O 0.9999802112579346
without O O 0.9999983310699463
prior O O 0.999953031539917
chemotherapy O O 0.9974296689033508
achieved O O 0.9999983310699463
a O O 0.9999817609786987
partial O O 0.999637246131897
response O O 0.9999780654907227
( O O 0.9999390840530396
PR O O 0.9951320886611938
) O O 0.9998955726623535
( O O 0.9999878406524658
95 O O 0.9997931122779846
% O O 0.9999932050704956
confidence O O 0.9937641024589539
interval O O 0.9991569519042969
[ O O 0.9967067837715149
CI O O 0.9862404465675354
] O O 0.9998237490653992
, O O 0.999994158744812
8 O O 0.9999805688858032
% O O 0.9999990463256836
to O O 0.9999988079071045
39 O O 0.9999746084213257
% O O 0.999996542930603
) O O 0.9999518394470215
. O O 0.9999978542327881

The O O 0.999619722366333
pH O O 0.7454457879066467
adjustment O O 0.9997991919517517
of O O 0.9999490976333618
standard O O 0.9610357284545898
lidocaine S-Chemical S-Chemical 0.9922205805778503
can O O 0.9999783039093018
be O O 0.9999949932098389
accomplished O O 0.9999986886978149
easily O O 0.9999940395355225
in O O 0.9999984502792358
the O O 0.9999809265136719
catheterization O O 0.9988133907318115
laboratory O O 0.9999312162399292
before O O 0.999996542930603
injection O O 0.9999732971191406
and O O 0.9999948740005493
results O O 0.999998927116394
in O O 0.9999997615814209
a O O 0.9999966621398926
reduction O O 0.999998927116394
of O O 0.9999899864196777
the O O 0.9999818801879883
pain O O 0.9997785687446594
occurring O O 0.9999964237213135
during O O 0.9999995231628418
the O O 0.9999935626983643
infiltration O O 0.9999940395355225
of O O 0.9999438524246216
tissues O O 0.9989860653877258
. O O 0.9999978542327881

Components O O 0.9989323019981384
of O O 0.9998592138290405
lemon O O 0.5944750905036926
essential O O 0.9450321197509766
oil O O 0.974027693271637
attenuate O O 0.9906339645385742
dementia O O 0.9997510313987732
induced O O 0.999993085861206
by O O 0.999984860420227
scopolamine S-Chemical S-Chemical 0.99836665391922
. O O 0.9999872446060181

Sirolimus S-Chemical S-Chemical 0.8952791690826416
is O O 0.9999279975891113
a O O 0.9999902248382568
novel O O 0.9924740195274353
immunosuppressant O O 0.9957143664360046
with O O 0.9999966621398926
potent O O 0.999582827091217
antiproliferative O O 0.9995031356811523
actions O O 0.9998316764831543
through O O 0.9999994039535522
its O O 0.9999918937683105
ability O O 0.9999833106994629
to O O 0.9999933242797852
inhibit O O 0.9998475313186646
the O O 0.9998326301574707
raptor O O 0.9918442368507385
- O O 0.9996811151504517
containing O O 0.9999583959579468
mammalian O O 0.985813558101654
target O O 0.9999094009399414
of O O 0.9994437098503113
rapamycin S-Chemical S-Chemical 0.5702069997787476
protein O O 0.7216794490814209
kinase O O 0.9508368372917175
. O O 0.9999865293502808

In O O 0.9998939037322998
contrast O O 0.9999549388885498
, O O 0.9999896287918091
monkeys O O 0.9816942811012268
with O O 0.9999953508377075
long O O 0.9991528987884521
- O O 0.9975860118865967
term O O 0.9989330172538757
MPTP S-Chemical S-Chemical 0.5559302568435669
exposure O O 0.9999821186065674
, O O 0.9999983310699463
slow O O 0.9999514818191528
symptom O O 0.9992383718490601
progression O O 0.9999361038208008
and O O 0.9999949932098389
/ O O 0.9998972415924072
or O O 0.999997615814209
long O O 0.9999963045120239
symptom O O 0.9998239874839783
duration O O 0.9999840259552002
prior O O 0.9999992847442627
to O O 0.999995231628418
initiation O O 0.9993195533752441
of O O 0.9994377493858337
levodopa S-Chemical S-Chemical 0.9674971699714661
therapy O O 0.9999432563781738
were O O 0.9999994039535522
more O O 0.9999995231628418
resistant O O 0.9999988079071045
to O O 0.9999972581863403
developing O O 0.9995158910751343
LIDs O O 0.9826192855834961
( O O 0.9999747276306152
e O O 0.9938637018203735
. O O 0.9999293088912964
g O O 0.9945328235626221
. O O 0.9998302459716797
, O O 0.9997124075889587
dyskinesia O O 0.7890206575393677
developed O O 0.9999916553497314
no O O 0.9999959468841553
sooner O O 0.9999996423721313
than O O 0.9999977350234985
146 O O 0.99996018409729
days O O 0.9999985694885254
of O O 0.9999918937683105
chronic O O 0.9943156838417053
levodopa S-Chemical S-Chemical 0.9497997760772705
administration O O 0.9998452663421631
) O O 0.9999663829803467
. O O 0.9999971389770508

Effect O O 0.9996521472930908
of O O 0.9995244741439819
nifedipine S-Chemical S-Chemical 0.9964665174484253
on O O 0.9999582767486572
renal O O 0.9997784495353699
function O O 0.9999758005142212
in O O 0.9999986886978149
liver O O 0.9986955523490906
transplant O O 0.9999325275421143
recipients O O 0.9998841285705566
receiving O O 0.9999842643737793
tacrolimus S-Chemical S-Chemical 0.9815011024475098
. O O 0.999984622001648

RESULTS O O 0.999908447265625
: O O 0.9999994039535522
272 O O 0.9999140501022339
cases O O 0.9999881982803345
of O O 0.9999926090240479
confusion O O 0.9999536275863647
were O O 0.9999991655349731
reported O O 0.9999991655349731
with O O 0.999995231628418
valproic B-Chemical B-Chemical 0.9848245978355408
acid E-Chemical E-Chemical 0.9830299019813538
: O O 0.9995879530906677
153 O O 0.9997215867042542
women O O 0.9999918937683105
and O O 0.999995231628418
119 O O 0.9999682903289795
men O O 0.9999474287033081
. O O 0.9999984502792358

The O O 0.9998403787612915
area O O 0.9999265670776367
under O O 0.9999983310699463
the O O 0.9999524354934692
curve O O 0.9998998641967773
was O O 0.999997615814209
537 O O 0.9997302889823914
+ O O 0.9999643564224243
/ O O 0.9999836683273315
- O O 0.9999133348464966
149 O O 0.9999330043792725
ng O O 0.9998704195022583
/ O O 0.9999819993972778
ml O O 0.9995651841163635
x O O 0.9966776371002197
hours O O 0.9997561573982239
, O O 0.9999454021453857
volume O O 0.9997026324272156
of O O 0.9998499155044556
distribution O O 0.9994188547134399
( O O 0.9998261332511902
Vd O O 0.993370771408081
) O O 0.999582827091217
3504 O O 0.9982649683952332
+ O O 0.9999573230743408
/ O O 0.9999783039093018
- O O 0.9998062252998352
644 O O 0.9996920824050903
l O O 0.999702513217926
/ O O 0.9999749660491943
m2 O O 0.9993725419044495
, O O 0.999930739402771
and O O 0.9999876022338867
total O O 0.9998965263366699
clearance O O 0.9999425411224365
( O O 0.999968409538269
ClT O O 0.9819241166114807
) O O 0.9998036026954651
was O O 0.9999958276748657
204 O O 0.9992768168449402
+ O O 0.9999774694442749
39 O O 0.9998875856399536
. O O 0.9999927282333374
3 O O 0.9999241828918457
l O O 0.9998937845230103
/ O O 0.9999922513961792
hour O O 0.9999785423278809
/ O O 0.9999914169311523
m2 O O 0.9996899366378784
. O O 0.9999922513961792

Simvastatin S-Chemical S-Chemical 0.9761723279953003
- O O 0.9990806579589844
induced O O 0.999995231628418
bilateral O O 0.9999619722366333
leg O O 0.998170018196106
compartment O O 0.9997878670692444
syndrome O O 0.9998482465744019
and O O 0.99992835521698
myonecrosis O O 0.9955096244812012
associated O O 0.9999773502349854
with O O 0.9999922513961792
hypothyroidism O O 0.9029663801193237
. O O 0.9999665021896362

4 O O 0.8201737403869629
. O O 0.999700665473938

Pneumonitis O O 0.9684237837791443
, O O 0.9999873638153076
bilateral O O 0.9997125267982483
pleural O O 0.9930851459503174
effusions O O 0.9995434880256653
, O O 0.9999983310699463
echocardiographic O O 0.9991074204444885
evidence O O 0.9999940395355225
of O O 0.9999750852584839
cardiac O O 0.9955279231071472
tamponade O O 0.9079806208610535
, O O 0.9999618530273438
and O O 0.9999810457229614
positive O O 0.9997344613075256
autoantibodies O O 0.9969948530197144
developed O O 0.9999991655349731
in O O 0.9999996423721313
a O O 0.9999970197677612
43 O O 0.9996902942657471
- O O 0.9999511241912842
year O O 0.9999984502792358
- O O 0.9999432563781738
old O O 0.9998451471328735
man O O 0.9996626377105713
, O O 0.9999935626983643
who O O 0.9999936819076538
was O O 0.9999971389770508
receiving O O 0.9999990463256836
long O O 0.9996722936630249
- O O 0.9977647066116333
term O O 0.9979385733604431
sulfasalazine S-Chemical S-Chemical 0.9996497631072998
therapy O O 0.9998823404312134
for O O 0.9999992847442627
chronic O O 0.9995619654655457
ulcerative O O 0.9990479350090027
colitis O O 0.9998445510864258
. O O 0.9999983310699463

Upon O O 0.9996252059936523
rechallenge O O 0.9998849630355835
with O O 0.9999836683273315
either O O 0.998940646648407
cephalosporin S-Chemical S-Chemical 0.9928056597709656
, O O 0.9999645948410034
the O O 0.9999076128005981
hematologic O O 0.9964408278465271
syndrome O O 0.9995983242988586
was O O 0.9999743700027466
reproduced O O 0.9999861717224121
in O O 0.999997615814209
most O O 0.9999836683273315
dogs O O 0.9988440275192261
tested O O 0.9999759197235107
; O O 0.9999680519104004
cefonicid S-Chemical S-Chemical 0.551193356513977
( O O 0.9821838140487671
but O O 0.9993534684181213
not O O 0.9992493987083435
cefazedone S-Chemical S-Chemical 0.9903280138969421
) O O 0.9915280342102051
- O O 0.9992747902870178
treated O O 0.9998575448989868
dogs O O 0.9988790154457092
showed O O 0.9999933242797852
a O O 0.9999982118606567
substantially O O 0.9999991655349731
reduced O O 0.999839186668396
induction O O 0.9999079704284668
period O O 0.9999960660934448
( O O 0.9999923706054688
15 O O 0.9999294281005859
+ O O 0.9999874830245972
/ O O 0.9999922513961792
- O O 0.9999527931213379
5 O O 0.9999399185180664
days O O 0.9999942779541016
) O O 0.9999905824661255
compared O O 0.9999994039535522
to O O 0.9999988079071045
that O O 0.9999942779541016
of O O 0.9999862909317017
the O O 0.9999974966049194
first O O 0.9999746084213257
exposure O O 0.9999511241912842
to O O 0.9999926090240479
the O O 0.9989670515060425
drug O O 0.9995170831680298
( O O 0.9999701976776123
61 O O 0.9996541738510132
+ O O 0.9999823570251465
/ O O 0.9999899864196777
- O O 0.999923586845398
24 O O 0.9999477863311768
days O O 0.9999959468841553
) O O 0.9999873638153076
. O O 0.999998927116394

During O O 0.999969482421875
an O O 0.9999986886978149
18 O O 0.9998608827590942
- O O 0.9999798536300659
month O O 0.9999986886978149
period O O 0.9999995231628418
of O O 0.9999982118606567
study O O 0.9999629259109497
41 O O 0.9994080066680908
hemodialyzed O O 0.9862356781959534
patients O O 0.9996870756149292
receiving O O 0.9999576807022095
desferrioxamine S-Chemical S-Chemical 0.9984219074249268
( O O 0.9994183778762817
10 O O 0.9581868648529053
- O O 0.983871340751648
40 O O 0.9988545179367065
mg O O 0.9998900890350342
/ O O 0.9999786615371704
kg O O 0.9999434947967529
BW O O 0.9975957274436951
/ O O 0.999983549118042
3 O O 0.9999179840087891
times O O 0.9999960660934448
weekly O O 0.9998974800109863
) O O 0.9999226331710815
for O O 0.9999971389770508
the O O 0.9999995231628418
first O O 0.9999996423721313
time O O 0.9999914169311523
were O O 0.9999991655349731
monitored O O 0.9999960660934448
for O O 0.9999986886978149
detection O O 0.9999901056289673
of O O 0.9999949932098389
audiovisual O O 0.9990277290344238
toxicity O O 0.9999479055404663
. O O 0.999998927116394

Attentional O O 0.9991362690925598
modulation O O 0.9999021291732788
of O O 0.9999887943267822
perceived O O 0.9998775720596313
pain O O 0.9982592463493347
intensity O O 0.9997615218162537
in O O 0.9999501705169678
capsaicin S-Chemical S-Chemical 0.9729365110397339
- O O 0.9970356225967407
induced O O 0.9999755620956421
secondary O O 0.9997093081474304
hyperalgesia O O 0.9988099336624146
. O O 0.9999969005584717

The O O 0.9999418258666992
magnitude O O 0.9999904632568359
and O O 0.9999986886978149
time O O 0.9999966621398926
course O O 0.9999988079071045
of O O 0.999995231628418
the O O 0.9999949932098389
increase O O 0.9999978542327881
in O O 0.9999997615814209
heart O O 0.9999368190765381
rate O O 0.9999643564224243
and O O 0.9999957084655762
the O O 0.999994158744812
decrease O O 0.9999958276748657
in O O 0.999998927116394
systolic O O 0.991734504699707
blood O O 0.9936515092849731
pressure O O 0.9999198913574219
after O O 0.9999892711639404
nitroglycerin S-Chemical S-Chemical 0.6890316009521484
were O O 0.9999113082885742
similar O O 0.9999994039535522
in O O 0.9999986886978149
the O O 0.9999958276748657
normal O O 0.9999692440032959
and O O 0.9999899864196777
diabetic O O 0.9996464252471924
subjects O O 0.9999480247497559
without O O 0.9999991655349731
autonomic O O 0.9996250867843628
neuropathy O O 0.9998188614845276
, O O 0.9999971389770508
whereas O O 0.9999988079071045
a O O 0.9999897480010986
lesser O O 0.9999536275863647
increase O O 0.9999936819076538
in O O 0.9999990463256836
heart O O 0.9999444484710693
rate O O 0.999962568283081
and O O 0.9999974966049194
a O O 0.9999980926513672
greater O O 0.999994158744812
decrease O O 0.9999896287918091
in O O 0.9999969005584717
systolic O O 0.9822307229042053
blood O O 0.9813697338104248
pressure O O 0.9995220899581909
occurred O O 0.9999973773956299
in O O 0.9999990463256836
the O O 0.9999841451644897
diabetic O O 0.9995119571685791
subjects O O 0.9999656677246094
with O O 0.9999995231628418
autonomic O O 0.9991371035575867
neuropathy O O 0.9998430013656616
. O O 0.9999988079071045

Fasciculations O O 0.9974110722541809
in O O 0.9999980926513672
six O O 0.999870777130127
areas O O 0.9999420642852783
of O O 0.9999910593032837
the O O 0.9999767541885376
body O O 0.999997615814209
were O O 0.9999995231628418
scored O O 0.9999983310699463
from O O 0.9999996423721313
0 O O 0.9998537302017212
to O O 0.9999607801437378
3 O O 0.9984867572784424
and O O 0.9999933242797852
summated O O 0.9999964237213135
as O O 0.9999983310699463
a O O 0.9999986886978149
total O O 0.9999614953994751
fasciculation O O 0.9998456239700317
score O O 0.9999563694000244
. O O 0.9999990463256836

Rats O O 0.9909223914146423
were O O 0.9999964237213135
given O O 0.9999983310699463
a O O 0.9999715089797974
single O O 0.9998388290405273
dose O O 0.9999940395355225
of O O 0.9998316764831543
adriamycin S-Chemical S-Chemical 0.9697309136390686
and O O 0.9999363422393799
one O O 0.9999598264694214
month O O 0.999997615814209
later O O 0.9999978542327881
divided O O 0.9999911785125732
into O O 0.9999961853027344
four O O 0.9990531802177429
groups O O 0.9999430179595947
matched O O 0.9999977350234985
for O O 0.9999842643737793
albuminuria O O 0.9775760173797607
, O O 0.9998921155929565
blood O O 0.9978474378585815
pressure O O 0.9998050332069397
, O O 0.9999722242355347
and O O 0.999957799911499
plasma O O 0.999002993106842
albumin O O 0.555529773235321
concentration O O 0.9995693564414978
. O O 0.9999991655349731

BACKGROUND O O 0.9992139339447021
: O O 0.9999963045120239
The O O 0.9999936819076538
widespread O O 0.9994309544563293
use O O 0.9999967813491821
of O O 0.9998226761817932
benzodiazepines S-Chemical S-Chemical 0.949836015701294
has O O 0.9999938011169434
led O O 0.999998927116394
to O O 0.9999992847442627
increasing O O 0.9999817609786987
recognition O O 0.9999973773956299
of O O 0.9999959468841553
their O O 0.9999990463256836
unwanted O O 0.9999594688415527
effects O O 0.9999951124191284
. O O 0.9999983310699463

The O O 0.9989444613456726
t O O 0.950390100479126
( O O 0.9996222257614136
1 O O 0.9997718930244446
/ O O 0.9999839067459106
2 O O 0.9999350309371948
, O O 0.9998677968978882
z O O 0.9991152882575989
) O O 0.9998127818107605
of O O 0.9995256662368774
desipramine S-Chemical S-Chemical 0.9919283390045166
was O O 0.9999839067459106
longer O O 0.9999990463256836
when O O 0.9999334812164307
desipramine S-Chemical S-Chemical 0.9891549944877625
was O O 0.9999327659606934
coadministered O O 0.9998711347579956
with O O 0.9998699426651001
cinacalcet S-Chemical S-Chemical 0.8230016231536865
( O O 0.9983590245246887
21 O O 0.9973490238189697
. O O 0.9998891353607178
0 O O 0.9995367527008057
versus O O 0.9999852180480957
43 O O 0.9998281002044678
. O O 0.9999775886535645
3 O O 0.9998292922973633
hs O O 0.9998729228973389
) O O 0.999937891960144
. O O 0.9999970197677612

Our O O 0.9999345541000366
results O O 0.9999980926513672
suggest O O 0.9999991655349731
that O O 0.9999980926513672
the O O 0.9999618530273438
suppression O O 0.9999754428863525
of O O 0.9999368190765381
gallbladder O O 0.763019859790802
contractility O O 0.9944538474082947
is O O 0.9999985694885254
the O O 0.9999992847442627
cause O O 0.9999991655349731
of O O 0.9999961853027344
the O O 0.9999974966049194
successive O O 0.9999914169311523
formation O O 0.9999819993972778
of O O 0.9999507665634155
bile O O 0.7633582353591919
sludge O O 0.8171332478523254
, O O 0.997748076915741
gallstones O O 0.9852980375289917
, O O 0.999906063079834
and O O 0.9999216794967651
cholecystitis O O 0.9954427480697632
during O O 0.9999815225601196
octreotide S-Chemical S-Chemical 0.9570236206054688
therapy O O 0.9999657869338989
in O O 0.9999970197677612
Chinese O O 0.9967523813247681
acromegalic O O 0.9943654537200928
patients O O 0.9999159574508667
. O O 0.9999990463256836

In O O 0.9999618530273438
addition O O 0.9999957084655762
3D O O 0.9403969645500183
gradient O O 0.9967509508132935
echo O O 0.9998677968978882
data O O 0.9996525049209595
sets O O 0.9999542236328125
from O O 0.9999904632568359
10 O O 0.9997746348381042
healthy O O 0.9999605417251587
male O O 0.9999120235443115
and O O 0.9999889135360718
10 O O 0.9997672438621521
healthy O O 0.9999377727508545
female O O 0.9999468326568604
age O O 0.9997366070747375
- O O 0.9998694658279419
matched O O 0.9999932050704956
volunteers O O 0.9994927644729614
were O O 0.9999978542327881
used O O 0.9999995231628418
to O O 0.999997615814209
compare O O 0.999790370464325
cerebellar O O 0.9074147343635559
volumes O O 0.9995023012161255
. O O 0.9999982118606567

Conformationally O O 0.9993857145309448
restricted O O 0.9964823722839355
analogs O O 0.9877970814704895
of O O 0.998794674873352
BD1008 S-Chemical S-Chemical 0.6085646748542786
and O O 0.9999655485153198
an O O 0.9998406171798706
antisense O O 0.9746424555778503
oligodeoxynucleotide S-Chemical S-Chemical 0.7761034369468689
targeting O O 0.9998770952224731
sigma1 O O 0.935246467590332
receptors O O 0.9968594312667847
produce O O 0.9998775720596313
anti O O 0.9992231130599976
- O O 0.9939868450164795
cocaine S-Chemical S-Chemical 0.6994692087173462
effects O O 0.9999603033065796
in O O 0.9999973773956299
mice O O 0.9998379945755005
. O O 0.9999991655349731

Peritubular O O 0.9648973345756531
capillary O O 0.991859495639801
basement O O 0.9938914775848389
membrane O O 0.995827853679657
reduplication O O 0.9999223947525024
in O O 0.9999914169311523
allografts O O 0.9631196856498718
and O O 0.9999529123306274
native O O 0.999819815158844
kidney O O 0.9996470212936401
disease O O 0.9996222257614136
: O O 0.9999980926513672
a O O 0.9999847412109375
clinicopathologic O O 0.9947189092636108
study O O 0.9999889135360718
of O O 0.9999948740005493
278 O O 0.9999661445617676
consecutive O O 0.9999943971633911
renal O O 0.9996488094329834
specimens O O 0.9982707500457764
. O O 0.9999988079071045

The O O 0.9998666048049927
renal O O 0.9988232254981995
function O O 0.9999946355819702
of O O 0.9999644756317139
74 O O 0.999405026435852
children O O 0.9998506307601929
with O O 0.9999978542327881
malignant O O 0.9994588494300842
mesenchymal O O 0.9976391792297363
tumors O O 0.999736487865448
in O O 0.9999995231628418
complete O O 0.9999788999557495
remission O O 0.9999716281890869
and O O 0.9999959468841553
who O O 0.9999958276748657
have O O 0.9999901056289673
received O O 0.9999984502792358
the O O 0.9995657801628113
same O O 0.9989714622497559
ifosfamide S-Chemical S-Chemical 0.7113661766052246
chemotherapy O O 0.9904076457023621
protocol O O 0.9973340034484863
( O O 0.999990701675415
International O O 0.9993357062339783
Society O O 0.9999414682388306
of O O 0.9999963045120239
Pediatric O O 0.9983211159706116
Oncology O O 0.9975680708885193
Malignant O O 0.9996086955070496
Mesenchymal O O 0.9725524187088013
Tumor O O 0.9954748749732971
Study O O 0.9993197917938232
84 O O 0.9966223239898682
[ O O 0.9993801116943359
SIOP O O 0.8485690951347351
MMT O O 0.9580875039100647
84 O O 0.9880997538566589
] O O 0.9993902444839478
) O O 0.9999725818634033
were O O 0.9999996423721313
studied O O 0.9999992847442627
1 O O 0.9999434947967529
year O O 0.9999997615814209
after O O 0.9999998807907104
the O O 0.9999990463256836
completion O O 0.9999996423721313
of O O 0.9999983310699463
treatment O O 0.9999991655349731
. O O 0.9999995231628418

This O O 0.9998281002044678
difference O O 0.9999978542327881
is O O 0.9999992847442627
explained O O 0.9999995231628418
by O O 0.9999996423721313
patient O O 0.9998505115509033
comorbidities O O 0.9998694658279419
and O O 0.9999990463256836
more O O 0.9999995231628418
frequent O O 0.9999914169311523
use O O 0.9999942779541016
of O O 0.9998444318771362
beta O O 0.7671266794204712
- O O 0.9176293611526489
blockers O O 0.9980472326278687
. O O 0.9999970197677612

The O O 0.9999003410339355
occurrence O O 0.9999977350234985
of O O 0.9999692440032959
infarcts O O 0.9997041821479797
were O O 0.9999988079071045
confirmed O O 0.9999997615814209
by O O 0.9999997615814209
histological O O 0.9987179040908813
methods O O 0.9999651908874512
. O O 0.9999988079071045

Recurarization O O 0.9997772574424744
in O O 0.9999991655349731
the O O 0.9999836683273315
recovery O O 0.999976396560669
room O O 0.9999814033508301
. O O 0.9999985694885254

Valproate S-Chemical S-Chemical 0.9238423705101013
- O O 0.995598316192627
induced O O 0.9999349117279053
encephalopathy O O 0.9998563528060913
is O O 0.9999979734420776
a O O 0.9999961853027344
rare O O 0.9992040991783142
syndrome O O 0.9987145662307739
that O O 0.9999179840087891
may O O 0.9999799728393555
manifest O O 0.999980092048645
in O O 0.999996542930603
otherwise O O 0.9999964237213135
normal O O 0.9999730587005615
epileptic O O 0.9976015686988831
individuals O O 0.9996272325515747
. O O 0.9999982118606567

Moreover O O 0.9999849796295166
, O O 0.9999991655349731
these O O 0.9999948740005493
behaviors O O 0.9999850988388062
are O O 0.9999994039535522
accompanied O O 0.9999997615814209
by O O 0.9999994039535522
biochemical O O 0.999583899974823
changes O O 0.9999910593032837
in O O 0.9999988079071045
brain O O 0.9993500113487244
regions O O 0.9998424053192139
previously O O 0.9999991655349731
identified O O 0.9999992847442627
as O O 0.9999995231628418
relevant O O 0.9999977350234985
to O O 0.9999927282333374
OCD O O 0.9121730327606201
. O O 0.9999853372573853

A O O 0.9996533393859863
previously O O 0.9999797344207764
healthy O O 0.9981951117515564
child O O 0.9994438290596008
who O O 0.9999967813491821
developed O O 0.9999986886978149
acute O O 0.9995959401130676
, O O 0.9999951124191284
severe O O 0.9999873638153076
, O O 0.9999966621398926
rapidly O O 0.9999796152114868
progressive O O 0.9993608593940735
vanishing O O 0.9968597888946533
bile O O 0.9986012578010559
duct O O 0.9992707371711731
syndrome O O 0.999964714050293
shortly O O 0.999998927116394
after O O 0.9999902248382568
Stevens O O 0.7939738631248474
- O O 0.9205181002616882
Johnson O O 0.9917953610420227
syndrome O O 0.9996684789657593
is O O 0.9999910593032837
described O O 0.9999985694885254
; O O 0.9999916553497314
this O O 0.9998855590820312
was O O 0.999992847442627
temporally O O 0.9999969005584717
associated O O 0.9999911785125732
with O O 0.9999568462371826
ibuprofen S-Chemical S-Chemical 0.9633679986000061
use O O 0.9996342658996582
. O O 0.9999970197677612

Infarcts O O 0.9988160133361816
in O O 0.9999972581863403
substantia O O 0.9110636711120605
nigra O O 0.9325582981109619
pars O O 0.9950937032699585
reticulata O O 0.9969971179962158
were O O 0.9999951124191284
evoked O O 0.9999972581863403
by O O 0.9999988079071045
prolonged O O 0.9969934225082397
pilocarpine S-Chemical S-Chemical 0.9975932240486145
- O O 0.9966650605201721
induced O O 0.9999228715896606
status O O 0.9998617172241211
epilepticus O O 0.9969845414161682
. O O 0.999996542930603

The O O 0.9999188184738159
results O O 0.9999984502792358
indicate O O 0.9999983310699463
that O O 0.9999964237213135
rat O O 0.9901319742202759
atrial O O 0.9990860223770142
spontaneous O O 0.9989525079727173
beating O O 0.9997549653053284
is O O 0.9999935626983643
more O O 0.9999970197677612
dependent O O 0.9998518228530884
on O O 0.9998815059661865
[ O O 0.9052401781082153
Na S-Chemical S-Chemical 0.9984307885169983
] O O 0.9942765831947327
o O O 0.9830973148345947
than O O 0.999441921710968
on O O 0.9995775818824768
[ O O 0.995009183883667
Ca S-Chemical S-Chemical 0.9332367181777954
] O O 0.9961372017860413
o O O 0.9990599751472473
in O O 0.9999748468399048
a O O 0.9999775886535645
range O O 0.9999793767929077
of O O 0.9999948740005493
+ O O 0.9999769926071167
/ O O 0.999955415725708
- O O 0.9997851252555847
50 O O 0.9998492002487183
% O O 0.9999916553497314
of O O 0.9999758005142212
their O O 0.9999912977218628
normal O O 0.9997746348381042
concentration O O 0.999915599822998
. O O 0.9999967813491821

Fentanyl S-Chemical S-Chemical 0.9615311026573181
is O O 0.9999880790710449
a O O 0.9999979734420776
commonly O O 0.999119222164154
used O O 0.9995883107185364
supplement O O 0.9971383810043335
that O O 0.9998836517333984
may O O 0.9999933242797852
contribute O O 0.9999979734420776
to O O 0.9999977350234985
this O O 0.9999663829803467
, O O 0.9999934434890747
although O O 0.9999910593032837
it O O 0.999969482421875
may O O 0.9999960660934448
also O O 0.9999980926513672
improve O O 0.9999949932098389
analgesia O O 0.9971189498901367
. O O 0.9999973773956299

Serum O O 0.9941635727882385
creatinine S-Chemical S-Chemical 0.9546043872833252
( O O 0.9994844198226929
SCr O O 0.4715159833431244
) O O 0.9809783697128296
levels O O 0.9999873638153076
and O O 0.9999988079071045
estimated O O 0.9998389482498169
glomerular O O 0.988341748714447
filtration O O 0.9997400641441345
rate O O 0.999976634979248
were O O 0.9999992847442627
assessed O O 0.9999996423721313
at O O 0.9999978542327881
baseline O O 0.9999480247497559
and O O 0.9999991655349731
2 O O 0.9999597072601318
to O O 0.999998927116394
5 O O 0.9999516010284424
days O O 0.9999992847442627
after O O 0.9999997615814209
receiving O O 0.9999978542327881
medications O O 0.9996953010559082
. O O 0.9999970197677612

Pain O O 0.9992895126342773
intensity O O 0.9999881982803345
and O O 0.9999986886978149
pain O O 0.9999563694000244
period O O 0.9999996423721313
were O O 0.9999995231628418
statistically O O 0.9999996423721313
significantly O O 0.9999998807907104
lower O O 0.9999991655349731
for O O 0.9999985694885254
the O O 0.9999825954437256
30 O O 0.9986947178840637
- O O 0.9997103810310364
second O O 0.9999568462371826
injection O O 0.9999908208847046
than O O 0.9999977350234985
for O O 0.9999970197677612
the O O 0.9999797344207764
10 O O 0.9959112405776978
- O O 0.9994921684265137
second O O 0.9999076128005981
injection O O 0.9999963045120239
. O O 0.9999978542327881

Evidence O O 0.9998887777328491
for O O 0.9999990463256836
an O O 0.9999831914901733
involvement O O 0.999995231628418
of O O 0.9998425245285034
D1 O O 0.7550023198127747
and O O 0.9957112073898315
D2 O O 0.9418156743049622
dopamine S-Chemical S-Chemical 0.9597077965736389
receptors O O 0.9997069239616394
in O O 0.9999951124191284
mediating O O 0.9926347136497498
nicotine S-Chemical S-Chemical 0.9990783929824829
- O O 0.9978110194206238
induced O O 0.9999829530715942
hyperactivity O O 0.9999349117279053
in O O 0.9999951124191284
rats O O 0.9993910789489746
. O O 0.9999973773956299

ROIs O O 0.9570406675338745
drawn O O 0.9999927282333374
over O O 0.9999825954437256
the O O 0.9999788999557495
gamma O O 0.8709322810173035
camera O O 0.9994149208068848
images O O 0.999971866607666
showed O O 0.9999982118606567
a O O 0.9999972581863403
ratio O O 0.9999958276748657
of O O 0.9999922513961792
4 O O 0.9997033476829529
. O O 0.9999827146530151
4 O O 0.998970627784729
. O O 0.9999874830245972

CONCLUSION O O 0.9999475479125977
: O O 0.9999980926513672
Activation O O 0.9999754428863525
of O O 0.9998983144760132
pallidal O O 0.8978258967399597
neurotensin S-Chemical O 0.44324028491973877
receptors O O 0.986748218536377
may O O 0.9999926090240479
be O O 0.9999963045120239
involved O O 0.9999990463256836
in O O 0.9999716281890869
neurotensin S-Chemical S-Chemical 0.8766441345214844
- O O 0.9874719977378845
induced O O 0.9999568462371826
antiparkinsonian O O 0.9954230189323425
effects O O 0.9999819993972778
. O O 0.9999988079071045

This O O 0.9999188184738159
is O O 0.9999997615814209
the O O 0.9999998807907104
first O O 0.9999972581863403
report O O 0.9999951124191284
of O O 0.9999934434890747
such O O 0.9999994039535522
an O O 0.9999992847442627
unusual O O 0.9999831914901733
reaction O O 0.9999886751174927
to O O 0.9999107122421265
carbamazepine S-Chemical S-Chemical 0.9996157884597778
. O O 0.9999659061431885

Early O O 0.9998965263366699
onset O O 0.9995145797729492
migraine O O 0.9997503161430359
attacks O O 0.9999607801437378
were O O 0.9999992847442627
induced O O 0.9999979734420776
by O O 0.999995231628418
nitroglycerin S-Chemical S-Chemical 0.9441357254981995
in O O 0.9999780654907227
seven O O 0.9999939203262329
out O O 0.9999986886978149
of O O 0.999993085861206
10 O O 0.999976634979248
patients O O 0.9999692440032959
versus O O 0.9999991655349731
no O O 0.9999985694885254
patient O O 0.9999933242797852
in O O 0.9999990463256836
the O O 0.9999932050704956
placebo O O 0.9997938275337219
group O O 0.9999732971191406
. O O 0.9999988079071045

Many O O 0.9999732971191406
of O O 0.9999939203262329
these O O 0.9999970197677612
patients O O 0.999767005443573
are O O 0.9999955892562866
taking O O 0.998958945274353
pentoxifylline S-Chemical S-Chemical 0.9341617226600647
( O O 0.9979861974716187
Trental S-Chemical S-Chemical 0.5820552110671997
) O O 0.9947600960731506
, O O 0.9999706745147705
a O O 0.9990683197975159
methylxanthine S-Chemical S-Chemical 0.5499827861785889
derivative O O 0.9240872263908386
which O O 0.9995623230934143
may O O 0.9999972581863403
improve O O 0.9999990463256836
intermittent O O 0.9998685121536255
claudication O O 0.9996969699859619
. O O 0.9999980926513672

Thyroid O O 0.8467828035354614
- O O 0.9917872548103333
stimulating O O 0.9999531507492065
hormone O O 0.9974278807640076
, O O 0.9998539686203003
magnesium S-Chemical S-Chemical 0.7886329293251038
, O O 0.9993650317192078
and O O 0.9993095397949219
potassium S-Chemical S-Chemical 0.908535361289978
levels O O 0.9998745918273926
were O O 0.9999980926513672
within O O 0.9999982118606567
normal O O 0.9999932050704956
limits O O 0.9999948740005493
, O O 0.9999972581863403
urine O O 0.9595834016799927
drug O O 0.9996622800827026
screen O O 0.9972193241119385
was O O 0.9999878406524658
negative O O 0.9999867677688599
, O O 0.9999861717224121
and O O 0.9998297691345215
alcohol S-Chemical S-Chemical 0.9771063923835754
use O O 0.9999513626098633
was O O 0.9999969005584717
denied O O 0.9999985694885254
. O O 0.9999963045120239

After O O 0.9998914003372192
administration O O 0.9999840259552002
of O O 0.9996163845062256
phenylephrine S-Chemical S-Chemical 0.9977611303329468
, O O 0.9998670816421509
MAP O S-Chemical 0.7365311980247498
increased O O 0.9999886751174927
( O O 0.9999285936355591
51 O O 0.99986732006073
+ O O 0.9999845027923584
/ O O 0.9999954700469971
- O O 0.9999654293060303
12 O O 0.9999597072601318
to O O 0.999993085861206
81 O O 0.9999279975891113
+ O O 0.9999794960021973
/ O O 0.9999901056289673
- O O 0.9999101161956787
13 O O 0.9999128580093384
mmHg O O 0.9997310042381287
; O O 0.9999463558197021
P O O 0.995439887046814
< O O 0.9999233484268188
0 O O 0.9997726082801819
. O O 0.9999704360961914
001 O O 0.9993007183074951
; O O 0.999990701675415
mean O O 0.9999923706054688
+ O O 0.9999830722808838
/ O O 0.9999830722808838
- O O 0.9996639490127563
SD O O 0.9985036849975586
) O O 0.9999330043792725
. O O 0.9999977350234985

The O O 0.9998983144760132
rats O O 0.9996341466903687
were O O 0.9999994039535522
trained O O 0.9999997615814209
to O O 0.9999979734420776
swim O O 0.9998290538787842
for O O 0.9999991655349731
a O O 0.9999980926513672
specific O O 0.9999425411224365
duration O O 0.999994158744812
and O O 0.999998927116394
for O O 0.9999994039535522
a O O 0.9999998807907104
particular O O 0.9999995231628418
period O O 0.9999996423721313
. O O 0.9999990463256836

Close O O 0.9998905658721924
observation O O 0.9999815225601196
of O O 0.9999759197235107
the O O 0.9999120235443115
response O O 0.9999867677688599
status O O 0.9999874830245972
both O O 0.9999979734420776
clinically O O 0.9999938011169434
and O O 0.9999979734420776
with O O 0.9999934434890747
beta O O 0.6537821292877197
- O O 0.5580641627311707
hCG O O 0.8849663734436035
values O O 0.999669075012207
may O O 0.9999991655349731
indicate O O 0.9999992847442627
whether O O 0.9999986886978149
and O O 0.9999953508377075
when O O 0.9999973773956299
more O O 0.999994158744812
agressive O O 0.9961110949516296
combination O O 0.9997997879981995
chemotherapy O O 0.9980113506317139
should O O 0.9999966621398926
be O O 0.9999961853027344
started O O 0.9999973773956299
. O O 0.9999970197677612
( O O 0.9998874664306641
ABSTRACT O O 0.9911404252052307
TRUNCATED O O 0.9999563694000244
AT O O 0.9999262094497681
250 O O 0.9997866749763489
WORDS O O 0.9998948574066162
) O O 0.9997896552085876

As O O 0.9994858503341675
an O O 0.9999115467071533
alpha O O 0.8444972038269043
- O O 0.9499905109405518
blocker O O 0.9967517852783203
, O O 0.9999810457229614
it O O 0.9998983144760132
also O O 0.9999741315841675
exerts O O 0.9999982118606567
a O O 0.9999983310699463
significant O O 0.9999436140060425
relaxant O O 0.9982073307037354
effect O O 0.9999874830245972
on O O 0.999992847442627
the O O 0.9997945427894592
bladder O O 0.9992828965187073
neck O O 0.9998434782028198
and O O 0.9996694326400757
urethra O O 0.9914950132369995
. O O 0.9999951124191284

In O O 0.9998100399971008
SE O O 0.9938645958900452
survivors O O 0.9999818801879883
, O O 0.9999990463256836
similar O O 0.9999812841415405
stimulation O O 0.9998735189437866
resulted O O 0.9999992847442627
in O O 0.9999978542327881
a O O 0.9998964071273804
population O O 0.999739944934845
spike O O 0.9999170303344727
followed O O 0.9999995231628418
, O O 0.9999978542327881
at O O 0.9999992847442627
a O O 0.9999995231628418
variable O O 0.9999901056289673
latency O O 0.9999958276748657
, O O 0.9999994039535522
by O O 0.9999997615814209
negative O O 0.9998488426208496
DC O O 0.8878966569900513
shifts O O 0.9999289512634277
and O O 0.9999990463256836
repetitive O O 0.9997946619987488
afterdischarges O O 0.9962138533592224
of O O 0.9999648332595825
3 O O 0.9496274590492249
- O O 0.9752217531204224
60 O O 0.9980952143669128
s O O 0.9976032376289368
duration O O 0.9995524287223816
, O O 0.9999344348907471
which O O 0.9999779462814331
were O O 0.9999960660934448
blocked O O 0.9999984502792358
by O O 0.9999980926513672
ionotropic O O 0.8996273875236511
glutamate S-Chemical S-Chemical 0.9695842266082764
receptor O O 0.9997310042381287
antagonists O O 0.9997467398643494
. O O 0.9999969005584717

Propylthiouracil S-Chemical S-Chemical 0.4887177050113678
therapy O O 0.9978017210960388
was O O 0.9999896287918091
withdrawn O O 0.9999953508377075
, O O 0.9999972581863403
and O O 0.999996542930603
she O O 0.9999783039093018
was O O 0.9999934434890747
treated O O 0.9999996423721313
with O O 0.9999992847442627
a O O 0.999983549118042
1 O O 0.9794489145278931
- O O 0.9989799857139587
month O O 0.999994158744812
course O O 0.9999909400939941
of O O 0.9999375343322754
prednisone S-Chemical S-Chemical 0.8418194651603699
, O O 0.9991806149482727
which O O 0.9999854564666748
alleviated O O 0.9999994039535522
her O O 0.999985933303833
symptoms O O 0.999985933303833
. O O 0.999998927116394

Data O O 0.9991264939308167
suggest O O 0.9999979734420776
that O O 0.9999954700469971
this O O 0.9998577833175659
sensitive O O 0.9996048808097839
hemoglobin O O 0.9882981181144714
assay O O 0.9987573623657227
is O O 0.9999934434890747
useful O O 0.9999978542327881
for O O 0.99998939037323
ICH O O 0.7499341368675232
detection O O 0.9999758005142212
, O O 0.9999983310699463
and O O 0.9999936819076538
that O O 0.9999945163726807
a O O 0.9999489784240723
model O O 0.9997005462646484
with O O 0.9999964237213135
a O O 0.9999785423278809
small O O 0.999159574508667
ICH O O 0.9772565364837646
induced O O 0.9999701976776123
with O O 0.9999963045120239
a O O 0.9999794960021973
low O O 0.9998511075973511
- O O 0.9987323880195618
dose O O 0.999840497970581
collagenase O S-Chemical 0.7915927171707153
should O O 0.9999353885650635
be O O 0.9999914169311523
used O O 0.9999983310699463
for O O 0.9999988079071045
evaluation O O 0.9999936819076538
of O O 0.9999433755874634
drugs O O 0.9971969127655029
that O O 0.9997773766517639
may O O 0.9999955892562866
affect O O 0.9999901056289673
ICH O O 0.9922325611114502
. O O 0.9999972581863403

Our O O 0.999758780002594
observations O O 0.9999662637710571
demonstrated O O 0.9999986886978149
an O O 0.9999916553497314
association O O 0.9999948740005493
of O O 0.9999983310699463
hearing O O 0.9998733997344971
loss O O 0.9999983310699463
with O O 0.9999996423721313
a O O 0.9999982118606567
higher O O 0.9999978542327881
incidence O O 0.9999924898147583
of O O 0.9999958276748657
perinatal O O 0.9997925162315369
complications O O 0.9999830722808838
. O O 0.9999994039535522

These O O 0.999886155128479
data O O 0.9999194145202637
were O O 0.9999990463256836
correlated O O 0.9999946355819702
with O O 0.999997615814209
histologically O O 0.999931812286377
scored O O 0.9998186230659485
cervical O O 0.9968356490135193
cord O O 0.998762845993042
damage O O 0.9999563694000244
in O O 0.9999994039535522
a O O 0.9999861717224121
separate O O 0.9998524188995361
group O O 0.9999359846115112
of O O 0.9999786615371704
similarly O O 0.9999905824661255
dosed O O 0.9990279674530029
rats O O 0.9955370426177979
sampled O O 0.9999933242797852
14 O O 0.9898141026496887
- O O 0.9980903267860413
21 O O 0.9998602867126465
days O O 0.9999957084655762
post O O 0.9998329877853394
- O O 0.9985132813453674
exposure O O 0.9999877214431763
. O O 0.9999979734420776

Pharmacokinetic O O 0.9979959726333618
interactions O O 0.9997865557670593
of O O 0.9997150301933289
curcumin S-Chemical S-Chemical 0.5026261806488037
with O O 0.9961070418357849
phenobarbitone S-Chemical S-Chemical 0.9761936664581299
and O O 0.9992400407791138
carbamazepine S-Chemical S-Chemical 0.9932366013526917
were O O 0.9999866485595703
also O O 0.9999966621398926
studied O O 0.9999972581863403
. O O 0.9999985694885254

Finally O O 0.99994957447052
, O O 0.9999717473983765
pruritus O O 0.9633966684341431
disappeared O O 0.9999865293502808
within O O 0.9999990463256836
19 O O 0.9999821186065674
months O O 0.9999972581863403
, O O 0.9999984502792358
and O O 0.9999974966049194
liver O O 0.9999128580093384
tests O O 0.9999902248382568
returned O O 0.9999994039535522
to O O 0.9999994039535522
normal O O 0.9999943971633911
27 O O 0.9999732971191406
months O O 0.9999986886978149
after O O 0.9999997615814209
the O O 0.9999986886978149
onset O O 0.9999995231628418
of O O 0.9999961853027344
hepatitis O O 0.9993791580200195
. O O 0.9999971389770508

Her O O 0.9997257590293884
symptoms O O 0.9999847412109375
totally O O 0.9999940395355225
regressed O O 0.9999953508377075
after O O 0.9999982118606567
drug O O 0.9998006224632263
withdrawal O O 0.9999568462371826
and O O 0.9999908208847046
reappeared O O 0.9999426603317261
when O O 0.9998310804367065
acitretin S-Chemical S-Chemical 0.8794491291046143
was O O 0.9995371103286743
reintroduced O O 0.999987006187439
. O O 0.9999923706054688

MAIN O O 0.9595781564712524
EXPOSURE O O 0.9998852014541626
: O O 0.9999899864196777
Reported O O 0.9999986886978149
maternal O O 0.9999586343765259
use O O 0.9999908208847046
of O O 0.9998575448989868
antibacterials O O 0.4247737526893616
( O O 0.990798830986023
1 O O 0.9964801669120789
month O O 0.9999690055847168
before O O 0.9999971389770508
pregnancy O O 0.9999932050704956
through O O 0.9999994039535522
the O O 0.9999990463256836
end O O 0.9999986886978149
of O O 0.9999982118606567
the O O 0.9999985694885254
first O O 0.999996542930603
trimester O O 0.999988317489624
) O O 0.9999699592590332
. O O 0.9999969005584717

Forty O O 0.9935587048530579
- O O 0.9996086955070496
three O O 0.9999650716781616
ovarian O O 0.9857557415962219
cancer O O 0.9998624324798584
patients O O 0.9999228715896606
were O O 0.9999990463256836
available O O 0.9999991655349731
for O O 0.9999996423721313
analysis O O 0.9999687671661377
following O O 0.9999992847442627
six O O 0.9999573230743408
cycles O O 0.9999490976333618
of O O 0.9999954700469971
the O O 0.9999516010284424
same O O 0.9997305274009705
PAC S-Chemical S-Chemical 0.5901610255241394
- O O 0.9869809746742249
containing O O 0.9998674392700195
regimen O O 0.992302656173706
: O O 0.9999597072601318
23 O O 0.910845160484314
had O O 0.999881386756897
been O O 0.999996542930603
supplemented O O 0.9999862909317017
by O O 0.9999700784683228
glutamate S-Chemical S-Chemical 0.852096438407898
all O O 0.9953442215919495
along O O 0.9999785423278809
the O O 0.9999655485153198
treatment O O 0.9999957084655762
period O O 0.9999986886978149
, O O 0.9999984502792358
at O O 0.999998927116394
a O O 0.9999994039535522
daily O O 0.9999539852142334
dose O O 0.9999974966049194
of O O 0.9999960660934448
three O O 0.9999613761901855
times O O 0.9999971389770508
500 O O 0.9999091625213623
mg O O 0.9994258880615234
( O O 0.9999055862426758
group O O 0.9992995262145996
G O O 0.988062858581543
) O O 0.9998117089271545
, O O 0.9999902248382568
and O O 0.9999861717224121
20 O O 0.9986475110054016
had O O 0.9999967813491821
received O O 0.9999980926513672
a O O 0.9999170303344727
placebo O O 0.9983654618263245
( O O 0.9996696710586548
group O O 0.9991734623908997
P O O 0.9966517090797424
) O O 0.9999046325683594
. O O 0.9999973773956299

CONCLUSIONS O O 0.9999529123306274
: O O 0.9999996423721313
These O O 0.999996542930603
data O O 0.9999493360519409
demonstrate O O 0.9999847412109375
direct O O 0.9994152784347534
and O O 0.9999699592590332
/ O O 0.9990531802177429
or O O 0.9999957084655762
indirect O O 0.9989612102508545
drug O O 0.999267041683197
- O O 0.9994432330131531
induced O O 0.9999090433120728
toxicity O O 0.9999165534973145
. O O 0.9999980926513672

In O O 0.9999375343322754
the O O 0.9999986886978149
absence O O 0.9999973773956299
of O O 0.9996458292007446
caffeine S-Chemical S-Chemical 0.9925127029418945
, O O 0.9991447925567627
acetaminophen S-Chemical S-Chemical 0.9982900023460388
( O O 0.9997532963752747
up O O 0.9986909031867981
to O O 0.9999468326568604
300 O O 0.9997771382331848
mg O O 0.9997754693031311
/ O O 0.9999501705169678
kg O O 0.9996737241744995
) O O 0.9998632669448853
did O O 0.9999892711639404
not O O 0.9999861717224121
modify O O 0.9999686479568481
the O O 0.9999496936798096
seizures O O 0.9996368885040283
induced O O 0.9999970197677612
by O O 0.9999988079071045
maximal O O 0.9382736086845398
electroshock O O 0.8319998979568481
and O O 0.9998856782913208
did O O 0.9999918937683105
not O O 0.9999932050704956
alter O O 0.9999921321868896
the O O 0.9999748468399048
convulsant O O 0.9968949556350708
dose O O 0.9999665021896362
of O O 0.9991330504417419
pentylenetetrezol S-Chemical S-Chemical 0.9854021072387695
in O O 0.9998582601547241
mice O O 0.9965412020683289
( O O 0.9999827146530151
tests O O 0.999946117401123
performed O O 0.9999984502792358
by O O 0.9999982118606567
the O O 0.9975121021270752
Anticonvulsant O O 0.9173742532730103
Screening O O 0.9975161552429199
Project O O 0.9997683167457581
of O O 0.9999102354049683
NINCDS O O 0.9678766131401062
) O O 0.9999017715454102
. O O 0.9999972581863403

After O O 0.9998742341995239
discontinuing O O 0.9991163611412048
isoniazid S-Chemical S-Chemical 0.9692007303237915
therapy O O 0.9999669790267944
a O O 0.9999873638153076
similar O O 0.9999381303787231
pattern O O 0.999955415725708
of O O 0.9999730587005615
behavior O O 0.9999419450759888
was O O 0.9999969005584717
noted O O 0.9999973773956299
that O O 0.9999728202819824
was O O 0.9999868869781494
controlled O O 0.9999918937683105
by O O 0.9999618530273438
pyridoxine S-Chemical S-Chemical 0.9992271661758423
. O O 0.9999794960021973

We O O 0.9998699426651001
conclude O O 0.9999970197677612
that O O 0.9999988079071045
the O O 0.9999477863311768
interpeduncular O O 0.9901902675628662
nucleus O O 0.9952215552330017
mediates O O 0.9999284744262695
nicotinic O O 0.864250659942627
depression O O 0.9979706406593323
of O O 0.9999402761459351
locomotor O O 0.994857668876648
activity O O 0.999894380569458
and O O 0.9999866485595703
dampens O O 0.9998875856399536
nicotinic O O 0.7324390411376953
arousal O O 0.9670180678367615
mechanisms O O 0.999630331993103
located O O 0.9999958276748657
elsewhere O O 0.9999954700469971
in O O 0.9999983310699463
the O O 0.9999717473983765
brain O O 0.9998847246170044
. O O 0.9999985694885254

This O O 0.9998575448989868
case O O 0.9999955892562866
emphasizes O O 0.9999990463256836
the O O 0.9999984502792358
possibility O O 0.9999991655349731
that O O 0.9999942779541016
HUS O O 0.886359453201294
in O O 0.9999812841415405
adults O O 0.9994007349014282
is O O 0.9999942779541016
not O O 0.9999980926513672
invariably O O 0.9999988079071045
irreversible O O 0.999990701675415
and O O 0.9999983310699463
that O O 0.9999984502792358
, O O 0.9999961853027344
despite O O 0.9999988079071045
prolonged O O 0.999893307685852
oliguria O O 0.8997678160667419
, O O 0.9999890327453613
recovery O O 0.9999228715896606
of O O 0.9999613761901855
renal O O 0.9989148378372192
function O O 0.9999545812606812
can O O 0.9999946355819702
be O O 0.9999980926513672
obtained O O 0.9999984502792358
. O O 0.9999945163726807

On O O 0.9998160004615784
two O O 0.9999778270721436
paradoxical O O 0.9998916387557983
side O O 0.9999263286590576
- O O 0.9997081160545349
effects O O 0.999991774559021
of O O 0.9997019171714783
prednisolone S-Chemical S-Chemical 0.9831074476242065
in O O 0.9999439716339111
rats O O 0.9996187686920166
, O O 0.9999747276306152
ribosomal O O 0.8934794664382935
RNA O O 0.9630274772644043
biosyntheses O O 0.9907846450805664
, O O 0.9999772310256958
and O O 0.9999759197235107
a O O 0.9999868869781494
mechanism O O 0.999941349029541
of O O 0.9999892711639404
action O O 0.9998888969421387
. O O 0.9999979734420776

The O O 0.9999839067459106
aim O O 0.9999986886978149
of O O 0.9999986886978149
the O O 0.999991774559021
study O O 0.9999916553497314
was O O 0.9999998807907104
to O O 0.9999980926513672
clarify O O 0.9999942779541016
the O O 0.9999973773956299
incidence O O 0.9999923706054688
and O O 0.9999986886978149
severity O O 0.9999986886978149
of O O 0.9999991655349731
adverse O O 0.9999935626983643
cardiac O O 0.9999241828918457
effects O O 0.9999936819076538
to O O 0.9999992847442627
this O O 0.9998282194137573
treatment O O 0.9999980926513672
. O O 0.9999991655349731

Ticlopidine S-Chemical S-Chemical 0.9906455278396606
- O O 0.9985076785087585
induced O O 0.9999649524688721
aplastic O O 0.9980034232139587
anemia O O 0.9996744394302368
: O O 0.9999924898147583
report O O 0.9999939203262329
of O O 0.9999780654907227
three O O 0.9999414682388306
Chinese O O 0.9992947578430176
patients O O 0.9999282360076904
and O O 0.9999946355819702
review O O 0.9999969005584717
of O O 0.9999485015869141
the O O 0.9999451637268066
literature O O 0.9998157620429993
. O O 0.9999978542327881

Warfarin S-Chemical S-Chemical 0.9407951235771179
- O O 0.9985143542289734
induced O O 0.9999122619628906
iliopsoas O O 0.9952482581138611
hemorrhage O O 0.9999655485153198
with O O 0.9999986886978149
subsequent O O 0.9999940395355225
femoral O O 0.9981914162635803
nerve O O 0.9981820583343506
palsy O O 0.9997772574424744
. O O 0.9999983310699463

Anaesthetists O O 0.992258608341217
' O O 0.9999898672103882
nightmare O O 0.9999774694442749
: O O 0.9999892711639404
masseter O O 0.9977057576179504
spasm O O 0.9995647072792053
after O O 0.9999945163726807
induction O O 0.9999911785125732
in O O 0.9999986886978149
an O O 0.9999934434890747
undiagnosed O O 0.9998966455459595
case O O 0.9999934434890747
of O O 0.9998946189880371
myotonia O O 0.8589907288551331
congenita O O 0.9338183403015137
. O O 0.9999735355377197

Side O O 0.9996601343154907
effects O O 0.9999980926513672
attributable O O 0.9999969005584717
to O O 0.9999583959579468
mazindol S-Chemical S-Chemical 0.9981077909469604
included O O 0.9999752044677734
decreased O O 0.999638557434082
appetite O O 0.7657323479652405
( O O 0.9602085947990417
36 O O 0.9966108202934265
% O O 0.9999852180480957
) O O 0.9999699592590332
, O O 0.9999984502792358
dry O O 0.9797534346580505
mouth O O 0.9941884279251099
( O O 0.9999476671218872
10 O O 0.999829888343811
% O O 0.9999891519546509
) O O 0.9999516010284424
, O O 0.9999940395355225
behavioral O O 0.9999420642852783
change O O 0.9998605251312256
( O O 0.9999823570251465
22 O O 0.9998859167098999
% O O 0.9999866485595703
) O O 0.9999289512634277
, O O 0.9999889135360718
and O O 0.99998939037323
gastrointestinal O O 0.9987444877624512
symptoms O O 0.9999386072158813
( O O 0.9999822378158569
18 O O 0.9998327493667603
% O O 0.9999790191650391
) O O 0.9997062087059021
; O O 0.999969482421875
mazindol S-Chemical S-Chemical 0.5751165747642517
dosage O O 0.9564378261566162
was O O 0.9999700784683228
reduced O O 0.9999974966049194
in O O 0.9999985694885254
43 O O 0.9999638795852661
% O O 0.9999988079071045
of O O 0.9999922513961792
patients O O 0.9999912977218628
. O O 0.999998927116394

Groups O O 0.9988614320755005
1 O O 0.9909466505050659
and O O 0.9998798370361328
2 O O 0.9988143444061279
underwent O O 0.9999958276748657
micropuncture O O 0.9968018531799316
studies O O 0.9999957084655762
after O O 0.9999995231628418
10 O O 0.9999808073043823
days O O 0.9999969005584717
. O O 0.9999972581863403

METHODS O O 0.9988173842430115
: O O 0.9999967813491821
Neonatal O O 0.9968888163566589
rats O O 0.9997978806495667
were O O 0.9999983310699463
treated O O 0.9999988079071045
with O O 0.9999972581863403
the O O 0.9992008805274963
tricyclic O O 0.9578492641448975
antidepressant S-Chemical O 0.6293798685073853
clomipramine S-Chemical S-Chemical 0.9099405407905579
or O O 0.9995658993721008
vehicle O O 0.9953384399414062
between O O 0.9999945163726807
days O O 0.9999877214431763
9 O O 0.9988340735435486
and O O 0.9998915195465088
16 O O 0.9992105960845947
twice O O 0.9999890327453613
daily O O 0.9999610185623169
and O O 0.9999970197677612
behaviorally O O 0.9999884366989136
tested O O 0.999984860420227
in O O 0.999996542930603
adulthood O O 0.9999467134475708
. O O 0.9999988079071045

When O O 0.9996227025985718
the O O 0.9992222785949707
metoclopramide S-Chemical S-Chemical 0.9394638538360596
administration O O 0.9999451637268066
was O O 0.999984860420227
discontinued O O 0.9999905824661255
, O O 0.9999977350234985
the O O 0.9999942779541016
abnormal O O 0.9998762607574463
movements O O 0.9999933242797852
gradually O O 0.9999983310699463
improved O O 0.9999994039535522
to O O 0.9999990463256836
a O O 0.9999992847442627
considerable O O 0.999998927116394
extent O O 0.9999915361404419
. O O 0.9999994039535522

Times O O 0.9998181462287903
to O O 0.9999977350234985
ambulate O O 0.9973745346069336
and O O 0.9999898672103882
to O O 0.9999823570251465
void O O 0.9996728897094727
were O O 0.9999951124191284
similar O O 0.9999980926513672
after O O 0.9999045133590698
lidocaine S-Chemical S-Chemical 0.9988020658493042
and O O 0.9987686276435852
prilocaine S-Chemical S-Chemical 0.9987698197364807
( O O 0.9992203712463379
150 O O 0.9910316467285156
vs O O 0.9992403984069824
. O O 0.9998335838317871
165 O O 0.999729335308075
min O O 0.9996416568756104
and O O 0.9998677968978882
238 O O 0.9996486902236938
vs O O 0.9999011754989624
. O O 0.9999145269393921
253 O O 0.9998599290847778
min O O 0.999875545501709
, O O 0.999975323677063
respectively O O 0.9999969005584717
) O O 0.9999823570251465
but O O 0.9999988079071045
prolonged O O 0.9999951124191284
after O O 0.9999281167984009
bupivacaine S-Chemical S-Chemical 0.9980478286743164
( O O 0.9995633959770203
200 O O 0.9865750670433044
and O O 0.9997653365135193
299 O O 0.9997884631156921
min O O 0.9998212456703186
, O O 0.9999836683273315
respectively O O 0.9999980926513672
; O O 0.9999779462814331
P O O 0.9907642602920532
< O O 0.9999442100524902
0 O O 0.9997965693473816
. O O 0.9999535083770752
05 O O 0.99964439868927
) O O 0.9999022483825684
. O O 0.9999978542327881

Prospective O O 0.9999713897705078
studies O O 0.9999406337738037
on O O 0.9999942779541016
ATT O O 0.9408504962921143
- O O 0.9921739101409912
ALF O O 0.9898653626441956
are O O 0.9999977350234985
lacking O O 0.9999967813491821
. O O 0.9999923706054688

Although O O 0.9998824596405029
responding O O 0.9999810457229614
patients O O 0.9999052286148071
were O O 0.9999982118606567
scheduled O O 0.9999996423721313
to O O 0.9999985694885254
receive O O 0.9999864101409912
consolidation O O 0.9974861145019531
radiotherapy O O 0.9954635500907898
and O O 0.999993085861206
24 O O 0.999231219291687
patients O O 0.9998568296432495
received O O 0.999998927116394
preplanned O O 0.9983396530151367
second O O 0.9999022483825684
- O O 0.9994908571243286
line O O 0.9999699592590332
chemotherapy O O 0.9995529055595398
after O O 0.9999963045120239
disease O O 0.997689962387085
progression O O 0.9999707937240601
, O O 0.9999935626983643
the O O 0.9999706745147705
response O O 0.9999982118606567
and O O 0.9999959468841553
toxicity O O 0.9998784065246582
rates O O 0.9999562501907349
reported O O 0.9999995231628418
refer O O 0.9999994039535522
only O O 0.9999982118606567
to O O 0.9999977350234985
the O O 0.9999780654907227
chemotherapy O O 0.9985484480857849
regimen O O 0.9998241066932678
given O O 0.9999973773956299
. O O 0.9999939203262329

These O O 0.9999380111694336
findings O O 0.9999855756759644
suggest O O 0.9999982118606567
that O O 0.9999958276748657
disruption O O 0.9999943971633911
of O O 0.9999696016311646
the O O 0.9997532963752747
blood O O 0.9728165864944458
- O O 0.9961422085762024
brain O O 0.9994445443153381
barrier O O 0.9999473094940186
during O O 0.999998927116394
acute O O 0.9989711046218872
hypertension O O 0.9992716908454895
is O O 0.9999979734420776
not O O 0.9999988079071045
related O O 0.9999978542327881
to O O 0.9999961853027344
the O O 0.9997168183326721
synthesis O O 0.9899699091911316
/ O O 0.9991243481636047
release O O 0.998818576335907
of O O 0.9985356330871582
bradykinin S-Chemical S-Chemical 0.9810020923614502
to O O 0.9999147653579712
activate O O 0.9862604737281799
B2 O O 0.9882215857505798
receptors O O 0.9998364448547363
. O O 0.9999977350234985

( O O 0.9897964596748352
+ O O 0.9998428821563721
/ O O 0.9999630451202393
- O O 0.9995169639587402
) O O 0.9995515942573547
- O O 0.9950003027915955
PG B-Chemical B-Chemical 0.9954953193664551
- I-Chemical I-Chemical 0.9943413734436035
9 E-Chemical E-Chemical 0.9676451683044434
( O O 0.9985136389732361
10 O O 0.9993916749954224
- O O 0.9991399049758911
40 O O 0.9998886585235596
mg O O 0.9999433755874634
kg O O 0.9996737241744995
- O O 0.9994532465934753
1 O O 0.9997687935829163
i O O 0.9999322891235352
. O O 0.9999352693557739
p O O 0.9997381567955017
. O O 0.9999147653579712
) O O 0.9999024868011475
was O O 0.9999932050704956
able O O 0.9999914169311523
to O O 0.9999719858169556
prevent O O 0.9999566078186035
amnesia O O 0.9991151690483093
induced O O 0.9999861717224121
by O O 0.999860405921936
scopolamine S-Chemical S-Chemical 0.9992029070854187
( O O 0.9994171857833862
1 O O 0.9737386107444763
mg O O 0.997126042842865
kg O O 0.9971351623535156
- O O 0.9984697699546814
1 O O 0.9994327425956726
i O O 0.9999059438705444
. O O 0.9998824596405029
p O O 0.9993718266487122
. O O 0.9996825456619263
) O O 0.999350368976593
and O O 0.9995505213737488
dicyclomine S-Chemical S-Chemical 0.9966338276863098
( O O 0.9996567964553833
2 O O 0.9943441152572632
mg O O 0.9996668100357056
kg O O 0.9989528656005859
- O O 0.9990750551223755
1 O O 0.9996086955070496
i O O 0.999929666519165
. O O 0.9998894929885864
p O O 0.9997376799583435
. O O 0.9999412298202515
) O O 0.9999687671661377
in O O 0.9999986886978149
the O O 0.9999816417694092
mouse O O 0.9992939233779907
passive O O 0.999377429485321
- O O 0.999444305896759
avoidance O O 0.9998264908790588
test O O 0.9999727010726929
. O O 0.9999988079071045

Intracranial O O 0.9967107772827148
aneurysms O O 0.9993124008178711
or O O 0.9999866485595703
arteriovenous O O 0.975554883480072
malformations O O 0.9996166229248047
were O O 0.9999992847442627
present O O 0.9999997615814209
in O O 0.9999996423721313
17 O O 0.99993896484375
of O O 0.9999774694442749
32 O O 0.9999551773071289
patients O O 0.9999793767929077
studied O O 0.9999939203262329
angiographically O O 0.9998562335968018
or O O 0.9999929666519165
at O O 0.9999972581863403
autopsy O O 0.9999861717224121
; O O 0.9999988079071045
cerebral O O 0.9994156360626221
vasculitis O O 0.9989392161369324
was O O 0.9999967813491821
present O O 0.9999995231628418
in O O 0.9999991655349731
two O O 0.9999911785125732
patients O O 0.999983549118042
. O O 0.9999990463256836

Readministration O O 0.9993701577186584
of O O 0.9992130994796753
amantadine S-Chemical S-Chemical 0.9900984168052673
, O O 0.9999163150787354
after O O 0.9999961853027344
a O O 0.9999725818634033
drug O O 0.9994140863418579
- O O 0.999760091304779
free O O 0.999879002571106
overnight O O 0.9998094439506531
period O O 0.9999986886978149
, O O 0.9999991655349731
increased O O 0.9999935626983643
motility O O 0.9983199238777161
from O O 0.9999954700469971
respective O O 0.9998993873596191
saline O O 0.9936250448226929
control O O 0.9998711347579956
in O O 0.9999959468841553
all O O 0.9999778270721436
strains O O 0.9996984004974365
with O O 0.9999984502792358
exception O O 0.9999933242797852
of O O 0.9999479055404663
the O O 0.9999115467071533
BALB O O 0.997468113899231
/ O O 0.9998972415924072
C O O 0.9889208078384399
mice O O 0.999672532081604
where O O 0.9999825954437256
suppression O O 0.9998425245285034
of O O 0.9999196529388428
motility O O 0.9997320771217346
occurred O O 0.9999970197677612
. O O 0.999998927116394

In O O 0.9998165965080261
mice O O 0.999795138835907
, O O 0.9999548196792603
apomorphine S-Chemical S-Chemical 0.9954257607460022
produced O O 0.999993085861206
qualitatively O O 0.9999903440475464
different O O 0.9999918937683105
responses O O 0.9999932050704956
under O O 0.9999988079071045
novel O O 0.9999045133590698
conditions O O 0.9999090433120728
when O O 0.9999983310699463
compared O O 0.9999990463256836
to O O 0.9999973773956299
those O O 0.999982476234436
behaviors O O 0.9999363422393799
elicited O O 0.9999991655349731
in O O 0.9999995231628418
the O O 0.9999953508377075
home O O 0.9998846054077148
test O O 0.9999632835388184
cage O O 0.9991610050201416
. O O 0.9999980926513672

Epidemiological O O 0.9999312162399292
evidence O O 0.9999661445617676
indicates O O 0.999998927116394
that O O 0.9999954700469971
prenatal O O 0.9972586631774902
nutritional O O 0.9997847676277161
deprivation O O 0.999951958656311
may O O 0.9999990463256836
increase O O 0.9999990463256836
the O O 0.9999982118606567
risk O O 0.9999983310699463
of O O 0.9999973773956299
schizophrenia O O 0.999675989151001
. O O 0.9999980926513672

He O O 0.999147891998291
was O O 0.9999955892562866
awake O O 0.9999940395355225
, O O 0.9999991655349731
revealed O O 0.9999996423721313
no O O 0.9999994039535522
changes O O 0.9999979734420776
of O O 0.9999970197677612
mental O O 0.9999669790267944
status O O 0.9999656677246094
and O O 0.9999977350234985
at O O 0.9999990463256836
rest O O 0.9999915361404419
there O O 0.9999995231628418
were O O 0.9999990463256836
no O O 0.9999997615814209
further O O 0.9999994039535522
motor O O 0.999591052532196
symptoms O O 0.9999864101409912
. O O 0.9999979734420776

To O O 0.9999662637710571
directly O O 0.9999879598617554
examine O O 0.9999785423278809
the O O 0.9999971389770508
importance O O 0.999997615814209
of O O 0.9999727010726929
growth O O 0.9998295307159424
to O O 0.9998865127563477
Warfarin S-Chemical S-Chemical 0.9872300028800964
- O O 0.9976958632469177
induced O O 0.9999816417694092
artery O O 0.9981695413589478
calcification O O 0.9997076392173767
in O O 0.9999957084655762
animals O O 0.9991393089294434
of O O 0.9999892711639404
the O O 0.9999916553497314
same O O 0.9999909400939941
age O O 0.9995100498199463
, O O 0.9999902248382568
20 O O 0.9929070472717285
- O O 0.9995299577713013
day O O 0.9999831914901733
- O O 0.999907374382019
old O O 0.9993867874145508
rats O O 0.9996719360351562
were O O 0.9999960660934448
fed O O 0.9990416169166565
for O O 0.9999934434890747
2 O O 0.9994534850120544
weeks O O 0.9999918937683105
either O O 0.9999963045120239
an O O 0.9998750686645508
ad O O 0.9990154504776001
libitum O O 0.99809330701828
diet O O 0.9996622800827026
or O O 0.9999926090240479
a O O 0.9999626874923706
6 O O 0.984528124332428
- O O 0.9948400855064392
g O O 0.9981524348258972
/ O O 0.999717652797699
d O O 0.9995073080062866
restricted O O 0.999427855014801
diet O O 0.9995425939559937
that O O 0.99997878074646
maintains O O 0.9999805688858032
weight O O 0.999866247177124
but O O 0.9999896287918091
prevents O O 0.9999927282333374
growth O O 0.9999891519546509
. O O 0.9999972581863403

Bradycardia O O 0.4006597697734833
( O O 0.9975792765617371
defined O O 0.9999712705612183
as O O 0.999993085861206
a O O 0.9999945163726807
decrease O O 0.9999966621398926
in O O 0.9999992847442627
heart O O 0.9999806880950928
rate O O 0.9999231100082397
to O O 0.9999980926513672
less O O 0.9999889135360718
than O O 0.9999619722366333
50 O O 0.9996781349182129
beat O O 0.9997789263725281
min O O 0.9984523057937622
- O O 0.9982309937477112
1 O O 0.9966031312942505
) O O 0.9997406601905823
was O O 0.9999933242797852
prevented O O 0.999998927116394
when O O 0.9999988079071045
the O O 0.9999955892562866
larger O O 0.9997052550315857
dose O O 0.9999940395355225
of O O 0.9999504089355469
either O O 0.9949299693107605
active O O 0.9286149740219116
drug O O 0.9968613386154175
was O O 0.9996248483657837
used O O 0.9999929666519165
. O O 0.9999972581863403

The O O 0.9998995065689087
drug O O 0.9995381832122803
was O O 0.9999924898147583
withdrawn O O 0.9999957084655762
on O O 0.9999972581863403
presentation O O 0.9999969005584717
to O O 0.9999991655349731
hospital O O 0.9999659061431885
in O O 0.9999963045120239
11 O O 0.9997828602790833
patients O O 0.9999750852584839
, O O 0.999998927116394
with O O 0.9999997615814209
rapid O O 0.9999773502349854
clinical O O 0.9999980926513672
improvement O O 0.9999990463256836
in O O 0.9999995231628418
9 O O 0.9892573952674866
. O O 0.9999808073043823

Thus O O 0.9998956918716431
the O O 0.9999655485153198
mechanism O O 0.9998511075973511
by O O 0.9999803304672241
which O O 0.9995456337928772
acetaminophen S-Chemical S-Chemical 0.9980555772781372
antagonizes O O 0.9998993873596191
the O O 0.9998760223388672
actions O O 0.9999170303344727
of O O 0.9997097849845886
caffeine S-Chemical S-Chemical 0.9941577911376953
in O O 0.9999744892120361
the O O 0.9999599456787109
CNS O O 0.9977549910545349
remains O O 0.9999974966049194
unknown O O 0.9999971389770508
. O O 0.9999988079071045

The O O 0.9998502731323242
proliferation O O 0.9999876022338867
of O O 0.9996354579925537
astrocytes O O 0.6961294412612915
( O O 0.9983647465705872
Bergmann O O 0.6491175889968872
' O O 0.9556567668914795
s O O 0.9897658228874207
in O O 0.9999454021453857
particular O O 0.9999866485595703
) O O 0.9999678134918213
and O O 0.9999974966049194
occasionally O O 0.9999872446060181
of O O 0.9984753727912903
oligodendrocytes O S-Chemical 0.5540766716003418
was O O 0.9998272061347961
found O O 0.9999966621398926
. O O 0.9999966621398926

CONCLUSIONS O O 0.9999457597732544
: O O 0.9999995231628418
We O O 0.9999480247497559
have O O 0.9999672174453735
demonstrated O O 0.9999958276748657
an O O 0.9999953508377075
increased O O 0.9999914169311523
risk O O 0.9999964237213135
of O O 0.9999895095825195
VTE O O 0.9742832779884338
associated O O 0.9999686479568481
with O O 0.9999991655349731
the O O 0.9999077320098877
use O O 0.9999929666519165
of O O 0.9999246597290039
CPA S-Chemical S-Chemical 0.9335650205612183
/ O O 0.9979352951049805
EE S-Chemical S-Chemical 0.9580408930778503
in O O 0.999992847442627
women O O 0.9999597072601318
with O O 0.9999982118606567
acne O O 0.9311901926994324
, O O 0.99981290102005
hirsutism O O 0.9889435768127441
or O O 0.9999622106552124
PCOS O O 0.9587575793266296
although O O 0.9999922513961792
residual O O 0.9999728202819824
confounding O O 0.9998620748519897
by O O 0.9999988079071045
indication O O 0.9998996257781982
cannot O O 0.9999943971633911
be O O 0.9999939203262329
excluded O O 0.9999884366989136
. O O 0.9999984502792358

In O O 0.9999302625656128
independent O O 0.9999048709869385
groups O O 0.9999716281890869
, O O 0.999982476234436
morphine S-Chemical S-Chemical 0.9957501888275146
inhibited O O 0.9999918937683105
the O O 0.9999324083328247
intestinal O O 0.9990733861923218
transit O O 0.9996591806411743
in O O 0.9999990463256836
48 O O 0.9998216032981873
+ O O 0.9999715089797974
/ O O 0.999988317489624
- O O 0.9999450445175171
4 O O 0.9999508857727051
% O O 0.9999978542327881
and O O 0.9999864101409912
38 O O 0.9999032020568848
+ O O 0.9999822378158569
/ O O 0.9999861717224121
- O O 0.9999359846115112
4 O O 0.9999419450759888
% O O 0.9999985694885254
after O O 0.9999988079071045
acute O O 0.9985334873199463
and O O 0.9999825954437256
chronic O O 0.9993627667427063
treatment O O 0.9999966621398926
, O O 0.9999992847442627
respectively O O 0.9999994039535522
, O O 0.9999971389770508
suggesting O O 0.9999979734420776
that O O 0.9999576807022095
tolerance O O 0.9998617172241211
did O O 0.9999943971633911
not O O 0.9999946355819702
develop O O 0.9999700784683228
to O O 0.9999986886978149
the O O 0.9999876022338867
constipating O O 0.9997777342796326
effects O O 0.9999940395355225
. O O 0.9999978542327881

In O O 0.9999672174453735
both O O 0.9999995231628418
instances O O 0.9999991655349731
, O O 0.9999997615814209
suspicion O O 0.9999972581863403
of O O 0.9999902248382568
the O O 0.9999717473983765
presence O O 0.9999949932098389
of O O 0.9999504089355469
carcinoma O O 0.9913142323493958
was O O 0.9999966621398926
aroused O O 0.9999991655349731
by O O 0.9999994039535522
the O O 0.9999510049819946
palpation O O 0.9979031085968018
of O O 0.9998204112052917
a O O 0.9996180534362793
small O O 0.9959450364112854
nodule O O 0.9990707635879517
in O O 0.9999949932098389
the O O 0.999957799911499
vaginal O O 0.9986616373062134
fornix O O 0.9967154264450073
. O O 0.9999960660934448

These O O 0.9999536275863647
results O O 0.9999979734420776
indicate O O 0.9999997615814209
a O O 0.9999992847442627
reliable O O 0.9998264908790588
memory O O 0.9999959468841553
for O O 0.999998927116394
magnitude O O 0.9999812841415405
and O O 0.9999964237213135
duration O O 0.9999963045120239
of O O 0.9999980926513672
experimentally O O 0.9999970197677612
induced O O 0.9999945163726807
pain O O 0.9999426603317261
. O O 0.9999990463256836

Lidocaine S-Chemical S-Chemical 0.9963082075119019
- O O 0.9988370537757874
induced O O 0.9999558925628662
cardiac O O 0.9995032548904419
asystole O O 0.9338930249214172
. O O 0.9999939203262329

Recently O O 0.9999769926071167
, O O 0.9999924898147583
synthetic O O 0.9638862013816833
fibrinolysis O O 0.9787973165512085
inhibitors O O 0.9977854490280151
such O O 0.9999935626983643
as O O 0.999159574508667
tranexamic B-Chemical B-Chemical 0.9873983860015869
acid E-Chemical E-Chemical 0.9985249638557434
( O O 0.9979100823402405
tAMCA S-Chemical S-Chemical 0.9630864262580872
) O O 0.9996931552886963
have O O 0.9999834299087524
been O O 0.9999990463256836
considered O O 0.9999978542327881
as O O 0.999995231628418
substitutes O O 0.9993032217025757
for O O 0.999981164932251
aprotinin O S-Chemical 0.9109318852424622
. O O 0.9999935626983643

In O O 0.9998998641967773
conclusion O O 0.9999992847442627
, O O 0.9999982118606567
treatment O O 0.9999967813491821
with O O 0.9999890327453613
BMCs O S-Chemical 0.5060131549835205
can O O 0.99988853931427
prevent O O 0.999994158744812
the O O 0.9999966621398926
development O O 0.9999992847442627
of O O 0.9999979734420776
chronic O O 0.999882698059082
seizures O O 0.9998134970664978
, O O 0.9999974966049194
reduce O O 0.9999971389770508
neuronal O O 0.9999672174453735
loss O O 0.9999972581863403
, O O 0.999996542930603
and O O 0.9999970197677612
influence O O 0.9999885559082031
the O O 0.9999898672103882
reorganization O O 0.9999693632125854
of O O 0.9999620914459229
the O O 0.9998325109481812
hippocampal O O 0.9767978191375732
neuronal O O 0.9996205568313599
network O O 0.9998937845230103
. O O 0.9999982118606567

However O O 0.9998648166656494
, O O 0.9999963045120239
increased O O 0.9998935461044312
dyspnoea O S-Chemical 0.9497547149658203
and O O 0.9997852444648743
bronchospasm O S-Chemical 0.8922322392463684
necessitated O O 0.9999691247940063
reintubation O O 0.9988345503807068
. O O 0.9999972581863403

CONCLUSION O O 0.9998111128807068
: O O 0.9999580383300781
Raloxifene S-Chemical S-Chemical 0.924045205116272
was O O 0.9999408721923828
associated O O 0.9999916553497314
with O O 0.9999992847442627
an O O 0.9999979734420776
increased O O 0.9999959468841553
risk O O 0.9999979734420776
for O O 0.9999996423721313
venous O O 0.9971098303794861
thromboembolism O O 0.9989394545555115
, O O 0.999993085861206
but O O 0.9999973773956299
there O O 0.9999992847442627
was O O 0.9999991655349731
no O O 0.9999996423721313
increased O O 0.9999966621398926
risk O O 0.9999970197677612
for O O 0.9999990463256836
cataracts O O 0.999806821346283
, O O 0.9999932050704956
gallbladder O O 0.9998433589935303
disease O O 0.9999761581420898
, O O 0.999995231628418
endometrial O O 0.9995386600494385
hyperplasia O O 0.9999620914459229
, O O 0.9999793767929077
or O O 0.9999880790710449
endometrial O O 0.999909520149231
cancer O O 0.9999406337738037
. O O 0.9999990463256836

There O O 0.999976634979248
was O O 0.9999998807907104
a O O 0.9999988079071045
close O O 0.9999104738235474
parallel O O 0.9999713897705078
between O O 0.9999990463256836
the O O 0.9999964237213135
effect O O 0.9999988079071045
of O O 0.9999712705612183
vitamin B-Chemical B-Chemical 0.9990585446357727
D E-Chemical E-Chemical 0.9024474024772644
dose O O 0.9990806579589844
on O O 0.999988317489624
artery O O 0.9699642658233643
calcification O O 0.9982849955558777
and O O 0.9999974966049194
the O O 0.9999970197677612
effect O O 0.9999971389770508
of O O 0.9999203681945801
vitamin B-Chemical B-Chemical 0.9986082911491394
D E-Chemical E-Chemical 0.9596167802810669
dose O O 0.9995207786560059
on O O 0.9999866485595703
the O O 0.9999693632125854
elevation O O 0.9999834299087524
of O O 0.9999244213104248
serum O O 0.9124962091445923
calcium S-Chemical S-Chemical 0.9833332896232605
, O O 0.9998714923858643
which O O 0.9998691082000732
suggests O O 0.9999948740005493
that O O 0.9999567270278931
vitamin B-Chemical B-Chemical 0.9995174407958984
D E-Chemical E-Chemical 0.9933078289031982
may O O 0.9999611377716064
induce O O 0.9999916553497314
artery O O 0.999570906162262
calcification O O 0.9996989965438843
through O O 0.9999992847442627
its O O 0.9999978542327881
effect O O 0.9999961853027344
on O O 0.9999936819076538
serum O O 0.9917416572570801
calcium S-Chemical S-Chemical 0.9959589838981628
. O O 0.9999946355819702

Remission O O 0.9997193217277527
induction O O 0.9999911785125732
of O O 0.9999841451644897
meningeal O O 0.8103863596916199
leukemia O O 0.9861233234405518
with O O 0.9999885559082031
high O O 0.999942421913147
- O O 0.9987047910690308
dose O O 0.9999595880508423
intravenous O O 0.9629495739936829
methotrexate S-Chemical S-Chemical 0.997852087020874
. O O 0.9999858140945435

Graded O O 0.9962485432624817
dobutamine S-Chemical S-Chemical 0.9939397573471069
infusions O O 0.9999134540557861
of O O 0.9999905824661255
0 O O 0.9962902069091797
. O O 0.9999618530273438
5 O O 0.9988824725151062
, O O 0.9998801946640015
2 O O 0.999657154083252
. O O 0.9999762773513794
5 O O 0.9994055032730103
, O O 0.9999024868011475
5 O O 0.9989957213401794
and O O 0.9999356269836426
10 O O 0.9998779296875
micrograms O O 0.9998314380645752
/ O O 0.9999712705612183
kg O O 0.9995445609092712
per O O 0.9999462366104126
min O O 0.9988260865211487
were O O 0.999984860420227
administered O O 0.9999974966049194
. O O 0.9999978542327881

In O O 0.9999347925186157
this O O 0.9999773502349854
model O O 0.9999802112579346
of O O 0.9999967813491821
chronic O O 0.999853253364563
renal O O 0.9990079998970032
failure O O 0.9999867677688599
the O O 0.9999972581863403
decline O O 0.9999923706054688
in O O 0.999991774559021
GFR O O 0.8789791464805603
is O O 0.9999548196792603
not O O 0.9999988079071045
accompanied O O 0.9999984502792358
by O O 0.999998927116394
a O O 0.9999847412109375
corresponding O O 0.9998544454574585
fall O O 0.9999765157699585
in O O 0.9999996423721313
effective O O 0.9999725818634033
renal O O 0.9968047142028809
plasma O O 0.9980635046958923
flow O O 0.9963216781616211
, O O 0.9999752044677734
which O O 0.9999607801437378
may O O 0.9999979734420776
be O O 0.9999995231628418
the O O 0.9999988079071045
functional O O 0.9998107552528381
expression O O 0.9998313188552856
of O O 0.9999390840530396
the O O 0.9999721050262451
formation O O 0.9999889135360718
of O O 0.9999915361404419
nonfiltrating O O 0.9975570440292358
atubular O O 0.935274064540863
glomeruli O O 0.9151254296302795
. O O 0.9999818801879883

In O O 0.9998902082443237
contrast O O 0.9999760389328003
, O O 0.9999946355819702
dosages O O 0.9996669292449951
of O O 0.9991436004638672
Mipafox S-Chemical S-Chemical 0.9814526438713074
( O O 0.9997979998588562
less O O 0.9999661445617676
than O O 0.9999585151672363
or O O 0.9999581575393677
equal O O 0.9999916553497314
to O O 0.999988317489624
5 O O 0.9998599290847778
mg O O 0.9998829364776611
/ O O 0.9999470710754395
kg O O 0.9996848106384277
) O O 0.9997751116752625
which O O 0.9999362230300903
inhibited O O 0.9998672008514404
mean O O 0.9997343420982361
NTE O O 0.9614266157150269
activity O O 0.9999681711196899
in O O 0.9999977350234985
spinal O O 0.9960885047912598
cord O O 0.9988172054290771
less O O 0.999994158744812
than O O 0.9999916553497314
or O O 0.9999791383743286
equal O O 0.9999964237213135
to O O 0.9999918937683105
61 O O 0.9998071789741516
% O O 0.9999867677688599
and O O 0.9999821186065674
brain O O 0.9996488094329834
less O O 0.9999924898147583
than O O 0.9999932050704956
or O O 0.9999918937683105
equal O O 0.9999991655349731
to O O 0.9999955892562866
60 O O 0.9999005794525146
% O O 0.9999974966049194
produced O O 0.999988317489624
this O O 0.9999973773956299
degree O O 0.9999936819076538
of O O 0.9999972581863403
cord O O 0.994688868522644
damage O O 0.9999464750289917
in O O 0.9999992847442627
only O O 0.9999967813491821
9 O O 0.9998086094856262
% O O 0.9999966621398926
of O O 0.9999856948852539
the O O 0.9999772310256958
animals O O 0.9996681213378906
. O O 0.9999984502792358

This O O 0.999839186668396
approach O O 0.9999918937683105
allowed O O 0.9999990463256836
investigating O O 0.9999725818634033
the O O 0.9999884366989136
efficacy O O 0.9999839067459106
of O O 0.999488115310669
alpha B-Chemical B-Chemical 0.9528130292892456
- I-Chemical I-Chemical 0.9768564105033875
lipoic I-Chemical I-Chemical 0.9186495542526245
acid E-Chemical E-Chemical 0.9982742071151733
in O O 0.9999810457229614
preventing O O 0.9999744892120361
axonal O O 0.9895556569099426
damage O O 0.9999016523361206
and O O 0.9999773502349854
apoptosis O O 0.9970223307609558
and O O 0.9999916553497314
the O O 0.9999830722808838
function O O 0.9999803304672241
and O O 0.9999942779541016
ultrastructural O O 0.9996440410614014
morphology O O 0.999693751335144
of O O 0.9999285936355591
mitochondria O O 0.9989896416664124
after O O 0.9999929666519165
exposure O O 0.9999761581420898
to O O 0.9999866485595703
toxic O O 0.6336532831192017
agents O O 0.7164599299430847
and O O 0.9964635968208313
alpha B-Chemical B-Chemical 0.6896827816963196
- I-Chemical I-Chemical 0.8280216455459595
lipoic I-Chemical I-Chemical 0.92194002866745
acid E-Chemical E-Chemical 0.9944881796836853
. O O 0.999967098236084

In O O 0.9999808073043823
the O O 0.9999997615814209
present O O 0.9999982118606567
work O O 0.9999983310699463
we O O 0.9999878406524658
assessed O O 0.9999992847442627
the O O 0.999997615814209
effect O O 0.9999977350234985
of O O 0.9999927282333374
treatment O O 0.9999964237213135
of O O 0.9999512434005737
rats O O 0.9952009916305542
with O O 0.9999775886535645
gum B-Chemical B-Chemical 0.9817370176315308
Arabic E-Chemical E-Chemical 0.9537848234176636
on O O 0.9999676942825317
acute O O 0.9998410940170288
renal O O 0.9999024868011475
failure O O 0.9999973773956299
induced O O 0.9999988079071045
by O O 0.9999898672103882
gentamicin S-Chemical S-Chemical 0.5479917526245117
( O O 0.9535176753997803
GM S-Chemical S-Chemical 0.9304102659225464
) O O 0.9936980605125427
nephrotoxicity O O 0.9972924590110779
. O O 0.9999977350234985

Two O O 0.9995023012161255
patients O O 0.9999487400054932
developed O O 0.9999994039535522
acute O O 0.9991816878318787
tubular O O 0.9989631175994873
necrosis O O 0.9989238381385803
, O O 0.9999918937683105
characterized O O 0.9999991655349731
clinically O O 0.9999986886978149
by O O 0.9999997615814209
acute O O 0.9997711777687073
oliguric O O 0.9751615524291992
renal O O 0.9998496770858765
failure O O 0.9999958276748657
, O O 0.9999985694885254
while O O 0.9999985694885254
they O O 0.9999964237213135
were O O 0.9999969005584717
receiving O O 0.9999991655349731
a O O 0.999936580657959
combination O O 0.9999455213546753
of O O 0.9998680353164673
cephalothin B-Chemical B-Chemical 0.9734393954277039
sodium E-Chemical E-Chemical 0.9976139068603516
and O O 0.998863697052002
gentamicin B-Chemical B-Chemical 0.8144139051437378
sulfate E-Chemical E-Chemical 0.9933434724807739
therapy O O 0.9997251629829407
. O O 0.9999983310699463

We O O 0.9997144341468811
describe O O 0.9999961853027344
a O O 0.9999990463256836
case O O 0.999996542930603
of O O 0.9999898672103882
transient O O 0.9992515444755554
neurological O O 0.9999648332595825
deficit O O 0.9999675750732422
that O O 0.9999908208847046
occurred O O 0.9999982118606567
after O O 0.9999992847442627
unilateral O O 0.999488115310669
spinal O O 0.9993335604667664
anaesthesia O O 0.9998314380645752
with O O 0.9999963045120239
8 O O 0.9959012866020203
mg O O 0.9994851350784302
of O O 0.9998219609260559
1 O O 0.9928405284881592
% O O 0.9998799562454224
hyperbaric O O 0.4980786144733429
bupivacaine S-Chemical S-Chemical 0.888622522354126
slowly O O 0.999790608882904
injected O O 0.9996979236602783
through O O 0.9999912977218628
a O O 0.9997932314872742
25 O O 0.9824995994567871
- O O 0.9881160259246826
gauge O O 0.9956219792366028
pencil O O 0.9955780506134033
- O O 0.9988717436790466
point O O 0.9996480941772461
spinal O O 0.9964487552642822
needle O O 0.9991762042045593
. O O 0.9999948740005493

Totals O O 0.9998914003372192
of O O 0.9999743700027466
128 O O 0.9999388456344604
cases O O 0.9999723434448242
and O O 0.9999902248382568
650 O O 0.998803973197937
controls O O 0.9994879961013794
were O O 0.9999947547912598
analysed O O 0.9999909400939941
for O O 0.9999932050704956
repeat O O 0.9996607303619385
use O O 0.9999730587005615
and O O 0.9999957084655762
135 O O 0.9999220371246338
cases O O 0.9998577833175659
and O O 0.9999938011169434
622 O O 0.9982940554618835
controls O O 0.9997053742408752
for O O 0.9999972581863403
switching O O 0.9998231530189514
patterns O O 0.9999675750732422
. O O 0.9999983310699463

The O O 0.9999439716339111
incidence O O 0.9999701976776123
of O O 0.9999678134918213
mood O O 0.9975447058677673
switches O O 0.9999467134475708
seemed O O 0.9999995231628418
not O O 0.9999997615814209
to O O 0.9999992847442627
differ O O 0.9999990463256836
between O O 0.9999988079071045
patients O O 0.9999362230300903
receiving O O 0.9999960660934448
an O O 0.9985018968582153
anticonvulsant O O 0.917291522026062
and O O 0.9999921321868896
those O O 0.9999988079071045
receiving O O 0.9999982118606567
no O O 0.999980092048645
mood O O 0.9981189370155334
stabilizer O O 0.9998794794082642
. O O 0.9999972581863403

Sulpiride S-Chemical S-Chemical 0.9005191922187805
is O O 0.9999818801879883
a O O 0.9999946355819702
selective O O 0.9725366234779358
D2 O O 0.8384808301925659
- O O 0.9597345590591431
receptor O O 0.9985332489013672
antagonist O O 0.9993890523910522
with O O 0.9999886751174927
antipsychotic O O 0.9977737069129944
and O O 0.9998828172683716
antidepressant S-Chemical O 0.779430627822876
properties O O 0.9996860027313232
. O O 0.9999984502792358

These O O 0.9999538660049438
findings O O 0.9999936819076538
reveal O O 0.9999995231628418
the O O 0.9999983310699463
differential O O 0.999984622001648
impact O O 0.9999985694885254
of O O 0.9999876022338867
immune O O 0.9918252229690552
escape O O 0.995792031288147
variants O O 0.999601423740387
on O O 0.9999963045120239
the O O 0.9999293088912964
replication O O 0.9999598264694214
and O O 0.9999947547912598
drug O O 0.9999336004257202
susceptibility O O 0.9999958276748657
of O O 0.9999819993972778
complex O O 0.9968564510345459
HBV O O 0.9974642992019653
mutants O O 0.9991735816001892
, O O 0.9999986886978149
supporting O O 0.9999970197677612
the O O 0.9999979734420776
need O O 0.9999978542327881
of O O 0.9999984502792358
close O O 0.9999810457229614
surveillance O O 0.9999642372131348
and O O 0.9999979734420776
treatment O O 0.9999872446060181
adjustment O O 0.9999921321868896
in O O 0.9999994039535522
response O O 0.9999988079071045
to O O 0.9999994039535522
the O O 0.9999920129776001
selection O O 0.9999802112579346
of O O 0.9999910593032837
distinct O O 0.9997621178627014
mutational O O 0.9999682903289795
patterns O O 0.9999818801879883
. O O 0.9999991655349731

This O O 0.9998251795768738
paper O O 0.9993033409118652
presents O O 0.9999985694885254
the O O 0.999998927116394
results O O 0.9999995231628418
of O O 0.9999996423721313
treating O O 0.999977707862854
IST O O 0.9674111604690552
by O O 0.9999973773956299
intratympanic O O 0.7742501497268677
instillation O O 0.9830840229988098
of O O 0.9920754432678223
lignocaine S-Chemical S-Chemical 0.9916037917137146
( O O 0.9919416904449463
lidocaine S-Chemical S-Chemical 0.9987258315086365
) O O 0.9971334934234619
2 O O 0.9874405860900879
per O O 0.9999707937240601
cent O O 0.9999877214431763
through O O 0.9999984502792358
a O O 0.9997660517692566
grommet O O 0.9625455141067505
, O O 0.9999191761016846
for O O 0.9999980926513672
five O O 0.9999803304672241
weekly O O 0.9999399185180664
courses O O 0.9999523162841797
. O O 0.9999992847442627

NO S-Chemical S-Chemical 0.9987581968307495
- O O 0.999444305896759
induced O O 0.9999744892120361
migraine O O 0.9996850490570068
attack O O 0.9998145699501038
: O O 0.9999961853027344
strong O O 0.9999772310256958
increase O O 0.9999957084655762
in O O 0.9999955892562866
plasma O O 0.9955191612243652
calcitonin B-Chemical S-Chemical 0.7420307397842407
gene I-Chemical O 0.9764636754989624
- I-Chemical O 0.9947675466537476
related I-Chemical O 0.9999274015426636
peptide E-Chemical O 0.8781257271766663
( O O 0.9987712502479553
CGRP S-Chemical O 0.8007974028587341
) O O 0.9978563189506531
concentration O O 0.9998027682304382
and O O 0.9999963045120239
negative O O 0.9999760389328003
correlation O O 0.9999799728393555
with O O 0.9999938011169434
platelet O O 0.9177064895629883
serotonin S-Chemical S-Chemical 0.9409197568893433
release O O 0.9999758005142212
. O O 0.9999977350234985

AIM O O 0.9486632347106934
: O O 0.9999933242797852
This O O 0.9999943971633911
study O O 0.999992847442627
was O O 0.9999998807907104
carried O O 0.9999997615814209
out O O 0.9999990463256836
to O O 0.9999991655349731
determine O O 0.9999639987945557
the O O 0.9999970197677612
effect O O 0.9999972581863403
of O O 0.9999823570251465
injection O O 0.9993104934692383
duration O O 0.9997186064720154
on O O 0.999998927116394
bruising O O 0.9997678399085999
and O O 0.9999959468841553
pain O O 0.9999629259109497
following O O 0.9999996423721313
the O O 0.9999974966049194
administration O O 0.9999946355819702
of O O 0.9999877214431763
the O O 0.9999209642410278
subcutaneous O O 0.9993239641189575
injection O O 0.9999701976776123
of O O 0.99928879737854
heparin S-Chemical S-Chemical 0.9904043674468994
. O O 0.9999788999557495

Taking O O 0.9998273849487305
these O O 0.9999737739562988
in O O 0.9999825954437256
vitro O O 0.9994159936904907
and O O 0.9999910593032837
in O O 0.9999953508377075
vivo O O 0.998730480670929
results O O 0.9999830722808838
together O O 0.9999985694885254
, O O 0.999997615814209
our O O 0.9999536275863647
study O O 0.999981164932251
suggests O O 0.9999983310699463
that O O 0.9998841285705566
maltolyl B-Chemical B-Chemical 0.9880870580673218
p I-Chemical I-Chemical 0.9814961552619934
- I-Chemical I-Chemical 0.9969404935836792
coumarate E-Chemical E-Chemical 0.9721217751502991
is O O 0.9998593330383301
a O O 0.9999964237213135
potentially O O 0.9999796152114868
effective O O 0.9999185800552368
candidate O O 0.9998759031295776
against O O 0.999997615814209
Alzheimer O O 0.9980216026306152
' O O 0.9997805953025818
s O O 0.995555579662323
disease O O 0.9996064305305481
that O O 0.9999493360519409
is O O 0.9999860525131226
characterized O O 0.9999992847442627
by O O 0.9999986886978149
wide O O 0.9998856782913208
spread O O 0.9999403953552246
neuronal O O 0.9998904466629028
death O O 0.9999102354049683
and O O 0.9999988079071045
progressive O O 0.9999412298202515
decline O O 0.9999876022338867
of O O 0.9999960660934448
cognitive O O 0.9999631643295288
function O O 0.9999735355377197
. O O 0.9999991655349731

These O O 0.9999465942382812
data O O 0.9999345541000366
might O O 0.9999986886978149
indicate O O 0.9999978542327881
that O O 0.999997615814209
the O O 0.9999265670776367
generation O O 0.9998412132263184
of O O 0.999923586845398
reactive O O 0.9953027963638306
oxygen S-Chemical S-Chemical 0.6186708211898804
species O O 0.9813360571861267
and O O 0.9999430179595947
activation O O 0.9989053010940552
of O O 0.9988676309585571
NF O O 0.5009312033653259
- O O 0.675554633140564
kappaB O O 0.7662425637245178
plays O O 0.999678373336792
a O O 0.9999992847442627
more O O 0.9999979734420776
central O O 0.9999818801879883
role O O 0.9999984502792358
in O O 0.9999973773956299
seizure O O 0.998817503452301
- O O 0.9997707009315491
associated O O 0.9999874830245972
neuronal O O 0.9998714923858643
damage O O 0.9999655485153198
in O O 0.9999982118606567
the O O 0.9999641180038452
temporal O O 0.9998472929000854
cortex O O 0.9993292093276978
as O O 0.9999895095825195
compared O O 0.9999951124191284
to O O 0.9999901056289673
the O O 0.9998977184295654
hippocampal O O 0.9724175930023193
hilus O O 0.991091251373291
. O O 0.9999971389770508

Less O O 0.9998797178268433
frequent O O 0.9998747110366821
toxic O O 0.9934093952178955
effects O O 0.9999630451202393
included O O 0.9999978542327881
thrombocytopenia O O 0.9991046786308289
, O O 0.9999926090240479
anemia O O 0.9999690055847168
, O O 0.9999933242797852
nausea O O 0.9999232292175293
, O O 0.9999978542327881
mild O O 0.9992546439170837
alopecia O O 0.9953033924102783
, O O 0.9999560117721558
phlebitis O O 0.9428182244300842
, O O 0.9993250370025635
and O O 0.9999487400054932
mucositis O O 0.9991422891616821
. O O 0.9999971389770508

RESULTS O O 0.9998691082000732
: O O 0.9999979734420776
Head O O 0.997978150844574
- O O 0.9994087219238281
up O O 0.9997269511222839
tilt O O 0.9994654059410095
caused O O 0.9999985694885254
systolic O O 0.9978606104850769
orthostatic O O 0.998237133026123
hypotension O O 0.9993528723716736
which O O 0.9999628067016602
was O O 0.9999890327453613
marked O O 0.9999948740005493
in O O 0.9999984502792358
six O O 0.999968409538269
of O O 0.9999375343322754
20 O O 0.9998220801353455
PD O O 0.9892019033432007
patients O O 0.9989809393882751
on O O 0.9998548030853271
selegiline S-Chemical S-Chemical 0.9751240611076355
, O O 0.9999557733535767
one O O 0.9999852180480957
of O O 0.9999873638153076
whom O O 0.9999831914901733
lost O O 0.9999947547912598
consciousness O O 0.9999659061431885
with O O 0.9999991655349731
unrecordable O O 0.9997273087501526
blood O O 0.9922423362731934
pressures O O 0.9999257326126099
. O O 0.9999990463256836

There O O 0.9999679327011108
was O O 0.9999997615814209
no O O 1.0
significant O O 0.999998927116394
difference O O 0.9999995231628418
in O O 0.9999998807907104
the O O 0.9999988079071045
frequency O O 0.9999980926513672
of O O 0.9999986886978149
signs O O 0.9999915361404419
or O O 0.9999986886978149
symptoms O O 0.9999969005584717
between O O 0.9999994039535522
the O O 0.9999898672103882
two O O 0.9999549388885498
groups O O 0.99998939037323
although O O 0.999998927116394
neurotoxicity O O 0.9997183680534363
symptoms O O 0.9999951124191284
presented O O 0.9999996423721313
mostly O O 0.9999996423721313
with O O 0.9999997615814209
lower O O 0.9999992847442627
scores O O 0.9999895095825195
of O O 0.9999973773956299
severity O O 0.9999959468841553
in O O 0.9999990463256836
group O O 0.9999778270721436
G O O 0.9714395403862
. O O 0.999991774559021

She O O 0.9994640946388245
was O O 0.9999980926513672
admitted O O 0.9999997615814209
to O O 0.9999977350234985
the O O 0.9999785423278809
medical O O 0.9999978542327881
intensive O O 0.9999972581863403
care O O 0.9999964237213135
unit O O 0.9999263286590576
, O O 0.9999603033065796
venlafaxine S-Chemical S-Chemical 0.985842764377594
was O O 0.9999754428863525
discontinued O O 0.9999982118606567
, O O 0.9999979734420776
and O O 0.9999988079071045
no O O 0.999997615814209
further O O 0.999997615814209
sequelae O O 0.9987849593162537
were O O 0.9999929666519165
seen O O 0.9999980926513672
. O O 0.999995231628418

RESULTS O O 0.9999281167984009
: O O 0.9999990463256836
For O O 0.9999990463256836
the O O 0.9999977350234985
60 O O 0.9999641180038452
patients O O 0.9999867677688599
who O O 0.9999983310699463
completed O O 0.9999904632568359
phase O O 0.9980582594871521
A O O 0.9897558093070984
, O O 0.9999903440475464
standard O O 0.9997982382774353
- O O 0.9989621639251709
dose O O 0.9999130964279175
haloperidol S-Chemical S-Chemical 0.9944446682929993
was O O 0.999976634979248
efficacious O O 0.9999539852142334
and O O 0.9999977350234985
superior O O 0.9999978542327881
to O O 0.9999978542327881
both O O 0.9999947547912598
low O O 0.9998903274536133
- O O 0.9990664124488831
dose O O 0.9999403953552246
haloperidol S-Chemical S-Chemical 0.9953142404556274
and O O 0.9998558759689331
placebo O O 0.9978814721107483
for O O 0.9999926090240479
scores O O 0.9998980760574341
on O O 0.9999988079071045
the O O 0.9999949932098389
Brief O O 0.9998941421508789
Psychiatric O O 0.9998975992202759
Rating O O 0.999751627445221
Scale O O 0.9996370077133179
psychosis O O 0.999910831451416
factor O O 0.9999963045120239
and O O 0.9999964237213135
on O O 0.9999972581863403
psychomotor O O 0.9956949949264526
agitation O O 0.9999105930328369
. O O 0.9999991655349731

The O O 0.9999445676803589
temporal O O 0.9999903440475464
relationship O O 0.9999990463256836
between O O 0.9999988079071045
lipid O O 0.8709149360656738
peroxidation O O 0.966331422328949
in O O 0.9999783039093018
the O O 0.999625563621521
kidney O O 0.9956021308898926
and O O 0.9999120235443115
proteinuria O O 0.9619110822677612
was O O 0.999977707862854
examined O O 0.9999983310699463
in O O 0.9999994039535522
this O O 0.999991774559021
study O O 0.9999948740005493
. O O 0.9999992847442627

Rats O O 0.9964746832847595
treated O O 0.999997615814209
with O O 0.9998830556869507
L B-Chemical B-Chemical 0.9826613068580627
- I-Chemical I-Chemical 0.985123336315155
DOPA E-Chemical E-Chemical 0.9874423146247864
were O O 0.9999886751174927
allocated O O 0.999998927116394
to O O 0.9999954700469971
two O O 0.999901294708252
groups O O 0.9999778270721436
based O O 0.9999996423721313
on O O 0.9999995231628418
the O O 0.9999982118606567
presence O O 0.9999990463256836
or O O 0.999998927116394
absence O O 0.9999949932098389
of O O 0.9999643564224243
LID O O 0.9617469310760498
. O O 0.9999914169311523

Older O O 0.9997983574867249
age O O 0.9994301199913025
was O O 0.9999978542327881
significantly O O 0.9999997615814209
correlated O O 0.9999984502792358
with O O 0.9999992847442627
the O O 0.9999579191207886
CHF O O 0.9742676615715027
development O O 0.9999988079071045
; O O 0.9999996423721313
with O O 0.9999994039535522
median O O 0.9972411394119263
ages O O 0.9993224143981934
for O O 0.9999977350234985
the O O 0.9999951124191284
entire O O 0.999915361404419
group O O 0.9999650716781616
and O O 0.9999979734420776
for O O 0.9999986886978149
patients O O 0.9999920129776001
developing O O 0.9999958276748657
CHF O O 0.9934684038162231
of O O 0.9999885559082031
45 O O 0.9994839429855347
and O O 0.9999833106994629
59 O O 0.9997784495353699
, O O 0.9999980926513672
respectively O O 0.9999995231628418
. O O 0.999998927116394

Using O O 0.9997966885566711
this O O 0.9999637603759766
rationale O O 0.9998691082000732
, O O 0.9999953508377075
the O O 0.9984318614006042
8 B-Chemical B-Chemical 0.7928155064582825
- I-Chemical I-Chemical 0.9605030417442322
aminoquinoline E-Chemical E-Chemical 0.9825045466423035
WR242511 S-Chemical S-Chemical 0.7798675894737244
, O O 0.9999375343322754
a O O 0.9999840259552002
potent O O 0.9996825456619263
long O O 0.9997381567955017
- O O 0.9994722008705139
lasting O O 0.9999512434005737
MHb O O 0.9810248613357544
former O O 0.9998950958251953
in O O 0.9999707937240601
rodents O O 0.9786686897277832
and O O 0.9998201727867126
beagle O O 0.9171044826507568
dogs O O 0.9939733147621155
, O O 0.9999717473983765
was O O 0.9999791383743286
studied O O 0.9999953508377075
in O O 0.9999973773956299
the O O 0.9999299049377441
rhesus O O 0.9903456568717957
monkey O O 0.9978606104850769
for O O 0.9999964237213135
advanced O O 0.9997939467430115
development O O 0.9999711513519287
as O O 0.9999982118606567
a O O 0.9999979734420776
potential O O 0.9998917579650879
CN O O 0.9603442549705505
pretreatment O O 0.9999239444732666
. O O 0.9999994039535522

INTRODUCTION O O 0.9998145699501038
: O O 0.9997904896736145
Cyclophosphamide S-Chemical S-Chemical 0.9899477958679199
is O O 0.9999741315841675
an O O 0.999836802482605
alkylating O O 0.5205971002578735
agent O O 0.8463070392608643
given O O 0.9999101161956787
frequently O O 0.9999775886535645
as O O 0.9999972581863403
a O O 0.9999904632568359
component O O 0.9999856948852539
of O O 0.9999922513961792
many O O 0.9999885559082031
conditioning O O 0.9998824596405029
regimens O O 0.9999358654022217
. O O 0.9999992847442627

Cimetidine S-Chemical S-Chemical 0.9806582927703857
clearance O O 0.9999650716781616
decreased O O 0.9999997615814209
with O O 0.9999995231628418
age O O 0.9998698234558105
. O O 0.9999991655349731

Atypical O O 0.9996870756149292
sensations O O 0.9999697208404541
following O O 0.999995231628418
the O O 0.9999216794967651
use O O 0.9999951124191284
of O O 0.9998365640640259
subcutaneous O O 0.9237020015716553
sumatriptan S-Chemical S-Chemical 0.7052615284919739
are O O 0.9999850988388062
common O O 0.9999854564666748
, O O 0.9999973773956299
but O O 0.9999978542327881
of O O 0.999996542930603
uncertain O O 0.9999643564224243
origin O O 0.9999780654907227
. O O 0.999998927116394

Age O O 0.9830554723739624
- O O 0.9996238946914673
dependent O O 0.9999752044677734
sensitivity O O 0.999958872795105
of O O 0.9998749494552612
the O O 0.9998362064361572
rat O O 0.997848629951477
to O O 0.9999977350234985
neurotoxic O O 0.9855067729949951
effects O O 0.999908447265625
of O O 0.9992863535881042
streptomycin S-Chemical S-Chemical 0.989194393157959
. O O 0.9999725818634033

Alterations O O 0.9999575614929199
in O O 0.9999992847442627
the O O 0.9999840259552002
structural O O 0.9998859167098999
elements O O 0.9999873638153076
of O O 0.9999842643737793
the O O 0.9999146461486816
BBB O O 0.9967226386070251
coexisted O O 0.9999942779541016
with O O 0.9999971389770508
marked O O 0.9992519021034241
lesions O O 0.9997928738594055
of O O 0.9998899698257446
neurons O O 0.9969960451126099
of O O 0.9995039701461792
the O O 0.9985270500183105
cerebellum O O 0.9088267087936401
( O O 0.9997879862785339
Purkinje O O 0.654632568359375
cells O O 0.9099862575531006
are O O 0.9997479319572449
earliest O O 0.9999582767486572
) O O 0.9999724626541138
. O O 0.9999985694885254

Administration O O 0.9999052286148071
of O O 0.9999446868896484
THP S-Chemical S-Chemical 0.6365132331848145
( O O 0.9962896108627319
3 O O 0.9928171634674072
. O O 0.9999133348464966
75 O O 0.9996777772903442
, O O 0.9999436140060425
7 O O 0.9997803568840027
. O O 0.9999654293060303
5 O O 0.9996405839920044
and O O 0.9999829530715942
15 O O 0.9999549388885498
mg O O 0.9999662637710571
/ O O 0.9999932050704956
kg O O 0.9999679327011108
i O O 0.9999030828475952
. O O 0.9999604225158691
p O O 0.9997512698173523
. O O 0.9999300241470337
) O O 0.9998787641525269
1 O O 0.999286949634552
h O O 0.9939129948616028
prior O O 0.999923586845398
to O O 0.9997325539588928
haloperidol S-Chemical S-Chemical 0.9958295226097107
resulted O O 0.9999938011169434
in O O 0.9999970197677612
a O O 0.9999591112136841
dose O O 0.9999793767929077
- O O 0.9996241331100464
dependent O O 0.9998993873596191
increase O O 0.9999912977218628
in O O 0.9999991655349731
the O O 0.999994158744812
catalepsy O O 0.9998145699501038
times O O 0.9999862909317017
( O O 0.9999918937683105
P O O 0.9960766434669495
< O O 0.9999736547470093
0 O O 0.9998712539672852
. O O 0.9999691247940063
05 O O 0.9997386336326599
) O O 0.9999322891235352
. O O 0.9999984502792358

The O O 0.9999319314956665
similarities O O 0.9999889135360718
between O O 0.9999990463256836
the O O 0.9999943971633911
effects O O 0.9999994039535522
of O O 0.9999980926513672
structural O O 0.9999043941497803
lesions O O 0.9997096657752991
and O O 0.9999980926513672
pharmacological O O 0.9984032511711121
depression O O 0.9988203644752502
of O O 0.9999135732650757
the O O 0.9998370409011841
brain O O 0.9981426000595093
stem O O 0.9782025218009949
reticular O O 0.9994803071022034
formation O O 0.9999552965164185
are O O 0.999998927116394
discussed O O 0.9999995231628418
. O O 0.9999992847442627

Cardiovascular O O 0.99989914894104
complications O O 0.9999924898147583
associated O O 0.9999982118606567
with O O 0.9999803304672241
terbutaline S-Chemical S-Chemical 0.9971043467521667
treatment O O 0.9999653100967407
for O O 0.9999991655349731
preterm O O 0.9996753931045532
labor O O 0.9999687671661377
. O O 0.9999992847442627

Palpebral O O 0.5140689015388489
twitching O O 0.9928298592567444
in O O 0.9999942779541016
a O O 0.9999785423278809
depressed O O 0.9985519051551819
adolescent O O 0.9976682066917419
on O O 0.99991774559021
citalopram S-Chemical O 0.5882272124290466
. O O 0.9999771118164062

Serial O O 0.9997919201850891
studies O O 0.9999951124191284
of O O 0.9999971389770508
auditory O O 0.9956670999526978
neurotoxicity O O 0.9997468590736389
in O O 0.9999985694885254
patients O O 0.9999798536300659
receiving O O 0.9999831914901733
deferoxamine S-Chemical S-Chemical 0.9987961053848267
therapy O O 0.9999288320541382
. O O 0.9999959468841553

None O O 0.999927282333374
of O O 0.9999868869781494
these O O 0.9999986886978149
current O O 0.9999297857284546
models O O 0.9999599456787109
demonstrate O O 0.9999889135360718
multiple O O 0.9998998641967773
OCD O O 0.9411919713020325
- O O 0.9980006814002991
like O O 0.9999767541885376
behaviors O O 0.9999536275863647
. O O 0.9999979734420776

Metabolic O O 0.9978612065315247
studies O O 0.9999840259552002
suggested O O 0.9999985694885254
a O O 0.9999561309814453
block O O 0.9999728202819824
in O O 0.9999821186065674
the O O 0.9996799230575562
kynurenine S-Chemical S-Chemical 0.4173882007598877
pathway O O 0.9973272085189819
of O O 0.9998466968536377
tryptophan S-Chemical S-Chemical 0.7515496015548706
metabolism O O 0.998566210269928
. O O 0.9999977350234985

Cardiac O O 0.9961268305778503
marker O O 0.9985699653625488
enzymes O O 0.9984036087989807
and O O 0.9999902248382568
antioxidative O O 0.9793224930763245
parameters O O 0.9974367022514343
in O O 0.9999949932098389
serum O O 0.9990541338920593
and O O 0.9999510049819946
heart O O 0.9992245435714722
tissues O O 0.9988535642623901
were O O 0.9999988079071045
measured O O 0.999998927116394
. O O 0.9999991655349731

Two O O 0.9998181462287903
weeks O O 0.9999985694885254
after O O 0.9999997615814209
the O O 0.9999970197677612
initiation O O 0.9999865293502808
of O O 0.9999896287918091
therapy O O 0.9999661445617676
, O O 0.9999983310699463
her O O 0.9996868371963501
hematocrit O O 0.9220767617225647
had O O 0.9999616146087646
decreased O O 0.9999990463256836
from O O 0.999995231628418
44 O O 0.9998868703842163
. O O 0.9999973773956299
1 O O 0.9999790191650391
% O O 0.9999991655349731
to O O 0.999996542930603
20 O O 0.9999587535858154
. O O 0.9999982118606567
4 O O 0.9999861717224121
% O O 0.9999985694885254
, O O 0.9999947547912598
and O O 0.9999953508377075
she O O 0.9999626874923706
had O O 0.9999994039535522
a O O 0.9999909400939941
positive O O 0.9998131394386292
direct O O 0.9930220246315002
Coombs O O 0.9905046820640564
antiglobulin O O 0.9857972264289856
test O O 0.9994677901268005
and O O 0.9999796152114868
an O O 0.9999765157699585
elevated O O 0.9996738433837891
indirect O O 0.9969601631164551
bilirubin S-Chemical S-Chemical 0.9607968926429749
. O O 0.9999876022338867

The O O 0.9999665021896362
present O O 0.9999316930770874
study O O 0.9999953508377075
aimed O O 0.9999992847442627
to O O 0.9999990463256836
investigate O O 0.9999884366989136
the O O 0.999976396560669
anticonvulsant O O 0.9917022585868835
activity O O 0.9999891519546509
as O O 0.9999969005584717
well O O 0.9999980926513672
as O O 0.9999991655349731
the O O 0.9999974966049194
effects O O 0.9999991655349731
on O O 0.9999990463256836
the O O 0.9999701976776123
level O O 0.9999971389770508
of O O 0.9999830722808838
hippocampal O O 0.7824894785881042
amino B-Chemical B-Chemical 0.918060302734375
acid E-Chemical E-Chemical 0.8395781517028809
neurotransmitters O O 0.9132757186889648
( O O 0.9972948431968689
glutamate S-Chemical S-Chemical 0.5277301669120789
, O O 0.9053629636764526
aspartate S-Chemical S-Chemical 0.8955639600753784
, O O 0.9959163069725037
glycine S-Chemical S-Chemical 0.981153130531311
and O O 0.9984708428382874
GABA S-Chemical S-Chemical 0.9758037328720093
) O O 0.9995936751365662
of O O 0.99982088804245
N B-Chemical B-Chemical 0.9918842315673828
- I-Chemical I-Chemical 0.9952309727668762
( I-Chemical I-Chemical 0.9926474094390869
2 I-Chemical I-Chemical 0.9953833222389221
- I-Chemical I-Chemical 0.999607264995575
propylpentanoyl I-Chemical I-Chemical 0.9723968505859375
) I-Chemical I-Chemical 0.9595882296562195
urea E-Chemical E-Chemical 0.8229758143424988
( O O 0.9903774857521057
VPU S-Chemical S-Chemical 0.7213349342346191
) O O 0.9997208714485168
in O O 0.9999970197677612
comparison O O 0.9999951124191284
to O O 0.9999986886978149
its O O 0.9999481439590454
parent O O 0.9995692372322083
compound O O 0.9992237091064453
, O O 0.9999829530715942
valproic B-Chemical B-Chemical 0.9695863723754883
acid E-Chemical E-Chemical 0.9900429248809814
( O O 0.9982378482818604
VPA S-Chemical S-Chemical 0.9079264998435974
) O O 0.999760091304779
. O O 0.999997615814209

Methamphetamine S-Chemical S-Chemical 0.9976624250411987
( O O 0.999818742275238
10 O O 0.9795660376548767
mg O O 0.9986937642097473
/ O O 0.9999368190765381
kg O O 0.9988194108009338
sc O O 0.8624070882797241
) O O 0.9959194660186768
, O O 0.9999557733535767
administered O O 0.9999972581863403
five O O 0.9999908208847046
times O O 0.9999969005584717
, O O 0.9999946355819702
reduced O O 0.9999983310699463
the O O 0.999968409538269
levels O O 0.9999911785125732
of O O 0.9998328685760498
dopamine S-Chemical S-Chemical 0.9981003403663635
and O O 0.9998433589935303
its O O 0.9998180270195007
metabolites O O 0.9925717711448669
in O O 0.999996542930603
striatal O O 0.9984330534934998
tissue O O 0.9995417594909668
when O O 0.9999974966049194
measured O O 0.9999964237213135
72 O O 0.9997726082801819
h O O 0.9994031190872192
after O O 0.9999990463256836
the O O 0.9999967813491821
last O O 0.9999876022338867
injection O O 0.9999984502792358
. O O 0.9999980926513672

Twelve O O 0.9990265369415283
patients O O 0.99997878074646
with O O 0.9999990463256836
liver O O 0.9998358488082886
disease O O 0.9999895095825195
related O O 0.9999986886978149
to O O 0.9999279975891113
methyldopa S-Chemical S-Chemical 0.802463173866272
were O O 0.9967607855796814
seen O O 0.9999990463256836
between O O 0.9999990463256836
1967 O O 0.9999943971633911
and O O 0.9999969005584717
1977 O O 0.9999879598617554
. O O 0.9999988079071045

Eosinophilic O O 0.6400787830352783
infiltrations O O 0.9990463852882385
were O O 0.9999988079071045
found O O 0.9999990463256836
around O O 0.9999926090240479
the O O 0.999934196472168
vessels O O 0.9996802806854248
. O O 0.9999979734420776

Associations O O 0.9997981190681458
between O O 0.9999992847442627
use O O 0.9999959468841553
of O O 0.999909520149231
benzodiazepines S-Chemical S-Chemical 0.9800888895988464
or O O 0.9999730587005615
related O O 0.9993257522583008
drugs O O 0.9995365142822266
and O O 0.9999943971633911
health O O 0.9999830722808838
, O O 0.9999983310699463
physical O O 0.9999710321426392
abilities O O 0.9997372031211853
and O O 0.9999969005584717
cognitive O O 0.9996880292892456
function O O 0.9999194145202637
: O O 0.999997615814209
a O O 0.9999908208847046
non O O 0.9997811913490295
- O O 0.9997629523277283
randomised O O 0.9998564720153809
clinical O O 0.9999920129776001
study O O 0.9999808073043823
in O O 0.9999994039535522
the O O 0.9999942779541016
elderly O O 0.9998468160629272
. O O 0.999998927116394

Therefore O O 0.99996018409729
, O O 0.9999924898147583
conversion O O 0.9999256134033203
should O O 0.9999980926513672
be O O 0.9999992847442627
considered O O 0.9999995231628418
for O O 0.9999953508377075
patients O O 0.9999628067016602
who O O 0.9999986886978149
have O O 0.9999920129776001
not O O 0.999994158744812
developed O O 0.9999899864196777
advanced O O 0.9831801652908325
CAN O O 0.849593460559845
and O O 0.9994717240333557
proteinuria O O 0.9891355037689209
. O O 0.9999924898147583

The O O 0.9998865127563477
effect O O 0.9999957084655762
of O O 0.99993896484375
PDTC S-Chemical S-Chemical 0.9625877737998962
on O O 0.999901294708252
status O O 0.9957411289215088
epilepticus O O 0.9102699160575867
- O O 0.9942071437835693
associated O O 0.999954104423523
cell O O 0.9997543692588806
loss O O 0.9999876022338867
in O O 0.9999957084655762
the O O 0.999763548374176
hippocampus O O 0.9538905620574951
and O O 0.9998257756233215
piriform O O 0.5644125938415527
cortex O O 0.8374099731445312
was O O 0.9997827410697937
evaluated O O 0.9999970197677612
in O O 0.9999973773956299
the O O 0.9999699592590332
rat O O 0.9961743354797363
fractionated O O 0.9995023012161255
pilocarpine S-Chemical S-Chemical 0.8755572438240051
model O O 0.9997729659080505
. O O 0.9999967813491821

TRI S-Chemical S-Chemical 0.5983718037605286
given O O 0.9994233846664429
repeatedly O O 0.9999294281005859
to O O 0.9999408721923828
rats O O 0.9924518465995789
increases O O 0.9999985694885254
the O O 0.9999853372573853
locomotor O O 0.9845649003982544
hyperactivity O O 0.9999516010284424
induced O O 0.999985933303833
by O O 0.9997650980949402
d B-Chemical B-Chemical 0.9144995212554932
- I-Chemical I-Chemical 0.9872024655342102
amphetamine E-Chemical E-Chemical 0.975203275680542
, O O 0.9945566654205322
quinpirole S-Chemical S-Chemical 0.994212806224823
and O O 0.9992960691452026
( O B-Chemical 0.9102510809898376
+ O I-Chemical 0.8779248595237732
) O I-Chemical 0.9080828428268433
- O I-Chemical 0.8433045148849487
7 O I-Chemical 0.563747763633728
- O I-Chemical 0.6741572618484497
hydroxy O I-Chemical 0.6627441048622131
- O I-Chemical 0.8447195887565613
dipropyloaminotetralin O E-Chemical 0.8440393209457397
( O O 0.9915472865104675
dopamine S-Chemical S-Chemical 0.8632151484489441
D2 O O 0.8222268223762512
and O O 0.9963066577911377
D3 O O 0.8493313789367676
effects O O 0.997556209564209
) O O 0.9998877048492432
. O O 0.9999958276748657

One O O 0.998497724533081
patient O O 0.9999901056289673
died O O 0.9999980926513672
, O O 0.9999974966049194
having O O 0.9999926090240479
presented O O 0.9999938011169434
in O O 0.9999983310699463
hepatic O O 0.9998918771743774
failure O O 0.9999951124191284
, O O 0.9999978542327881
and O O 0.9999963045120239
another O O 0.9999946355819702
, O O 0.9999886751174927
who O O 0.9999948740005493
had O O 0.9999943971633911
been O O 0.9999970197677612
taking O O 0.9991686344146729
methyldopa S-Chemical S-Chemical 0.941646933555603
for O O 0.9998621940612793
7 O O 0.9985253214836121
years O O 0.9999847412109375
, O O 0.9999963045120239
showed O O 0.999996542930603
slower O O 0.9999970197677612
clinical O O 0.999962329864502
and O O 0.9999980926513672
biochemical O O 0.9998759031295776
resolution O O 0.9999910593032837
over O O 0.9999996423721313
a O O 0.9999996423721313
period O O 0.9999998807907104
of O O 0.9999996423721313
several O O 0.999998927116394
months O O 0.9999971389770508
. O O 0.9999986886978149

The O O 0.9996763467788696
EEG O O 0.7598106265068054
shows O O 0.9999233484268188
characteristic O O 0.9999454021453857
triphasic O O 0.9913327097892761
waves O O 0.9997884631156921
in O O 0.9999986886978149
most O O 0.9999974966049194
patients O O 0.9999761581420898
with O O 0.9999996423721313
this O O 0.9999891519546509
complication O O 0.9999924898147583
. O O 0.9999990463256836

By O O 0.9994250535964966
contrast O O 0.9992064833641052
, O O 0.9995661377906799
apomorphine S-Chemical S-Chemical 0.9924702644348145
- O O 0.9972172975540161
induced O O 0.9998388290405273
locomotion O O 0.9992687106132507
was O O 0.9999986886978149
more O O 0.9999995231628418
prominent O O 0.9999958276748657
in O O 0.9999982118606567
the O O 0.999993085861206
novel O O 0.999845027923584
exploratory O O 0.9989573955535889
box O O 0.9997005462646484
. O O 0.999996542930603

In O O 0.9999226331710815
contrast O O 0.9999940395355225
with O O 0.9999992847442627
other O O 0.9999927282333374
beta O O 0.7961304783821106
blockers O O 0.9719746708869934
, O O 0.9979788661003113
flestolol S-Chemical S-Chemical 0.9957517385482788
- O O 0.993716299533844
induced O O 0.999915599822998
effects O O 0.9999778270721436
reverse O O 0.9999617338180542
rapidly O O 0.9999918937683105
( O O 0.9999880790710449
within O O 0.999995231628418
30 O O 0.999908447265625
minutes O O 0.9999912977218628
) O O 0.9999912977218628
following O O 0.999998927116394
discontinuation O O 0.9999852180480957
because O O 0.9999988079071045
of O O 0.999988317489624
its O O 0.9999983310699463
short O O 0.9999812841415405
half O O 0.9998726844787598
- O O 0.9998778104782104
life O O 0.9999923706054688
. O O 0.9999982118606567

The O O 0.9995958209037781
semi O O 0.9956725835800171
- O O 0.9998424053192139
quantitative O O 0.9999521970748901
scoring O O 0.9995086193084717
was O O 0.9999992847442627
significantly O O 0.9999998807907104
worst O O 0.9999995231628418
in O O 0.9999990463256836
the O O 0.9999902248382568
group O O 0.9999179840087891
treated O O 0.9999970197677612
with O O 0.9999762773513794
CsA S-Chemical S-Chemical 0.6474918127059937
plus O O 0.9873114824295044
SRL S-Chemical S-Chemical 0.9500048160552979
( O O 0.9997550845146179
P O O 0.7428303360939026
< O O 0.9974144697189331
0 O O 0.9986703395843506
. O O 0.9999567270278931
001 O O 0.996846616268158
compared O O 0.9999949932098389
with O O 0.9999891519546509
controls O O 0.9992233514785767
) O O 0.9999436140060425
and O O 0.9999970197677612
the O O 0.9999942779541016
analysis O O 0.9999629259109497
of O O 0.9999910593032837
the O O 0.9999945163726807
total O O 0.9999603033065796
grade O O 0.9999294281005859
of O O 0.9999505281448364
fibrosis O O 0.9978415966033936
also O O 0.9999834299087524
showed O O 0.9999986886978149
the O O 0.9999997615814209
highest O O 0.999997615814209
proportion O O 0.9999969005584717
in O O 0.9999996423721313
the O O 0.9999985694885254
same O O 0.9999690055847168
group O O 0.9999420642852783
and O O 0.9999959468841553
was O O 0.9999995231628418
significantly O O 1.0
different O O 0.9999996423721313
from O O 0.9999973773956299
controls O O 0.9998559951782227
( O O 0.9999834299087524
P O O 0.9952793121337891
< O O 0.9999649524688721
0 O O 0.9998378753662109
. O O 0.999962329864502
02 O O 0.9997654557228088
) O O 0.9999334812164307
. O O 0.9999985694885254

The O O 0.9998576641082764
systemic O O 0.9999090433120728
, O O 0.9999947547912598
central O O 0.9999090433120728
venous O O 0.9997143149375916
, O O 0.9999927282333374
pulmonary O O 0.9994458556175232
capillary O O 0.9935046434402466
wedge O O 0.9912235736846924
pressures O O 0.9999327659606934
, O O 0.9999908208847046
and O O 0.9999971389770508
heart O O 0.9999279975891113
rates O O 0.9998736381530762
, O O 0.9999970197677612
were O O 0.9999988079071045
similar O O 0.9999997615814209
in O O 0.9999992847442627
the O O 0.9999939203262329
two O O 0.99994957447052
groups O O 0.9999924898147583
. O O 0.9999992847442627

